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Pituitary adenomas are benign tumours of the pituitary gland. The estimated prevalence 
of pituitary adenomas is 78 to 94 cases per 100,000 individuals, with an incidence of four 
cases per 100,000 individuals (1). These rare, usually slow growing adenomas can be either 
functional e.g. hormone producing resulting in excessive endocrine activity and classical 
endocrine syndromes, or non-functional e.g. non-hormone producing resulting in clinical 
symptoms only in case of significant mass effects. Furthermore, they can be categorized into 
microadenomas (< 1 cm) and macroadenomas (> 1 cm). Pituitary adenomas can be treated 
by transsphenoidal surgery, additional radiotherapy or medical treatment and sometimes an 
expectative approach. The local mass effect of the tumour and/or the treatment can result 
in pituitary insufficiency, i.e. hypopituitarism, which can be treated by hormone replacement 
therapy (2). However, despite optimal medical treatment several physical, psychological 
and social complaints may persist, despite long-term remission (3). This chapter provides 
an overview of the functioning of the hypothalamic-pituitary axes and the consequences of 
defects in this system, in particular the effect of dysfunctions of the pituitary-adrenal axis on 
the central nervous system. Furthermore, the challenges related to these dysfunctions and 
the long-term clinical outcomes are discussed. Given the biopsychosocial approach adopted 
in this thesis, psychological and social aspects are described in detail including illness per-
ceptions, beliefs about medicine, quality of life, as well as self-management approaches for 
dealing with chronic illness directed to improve patient well-being.  
Hypothalamic-pituitary axes
The functional links between the hypothalamus, the pituitary, and related endocrine glands 
are known as the hypothalamic-pituitary-end organ axes. The hypothalamus secretes 
releasing hormones, i.e. corticotropin-releasing hormone (CRH), growth hormone releasing 
hormone (GHRH), thyrotropin-releasing hormone (TRH), gonadotropin-releasing hormone 
(GnRH), and inhibitory hormones, i.e. somatostatin and dopamine. In addition to the hypo-
thalamus playing a role in the neuroendocrine system, it is also involved in the regulation of 
body temperature, thirst, appetite and sleep (2).
The pituitary gland lies at the base of the skull in a cavity of the sphenoid bone, also known 
as the hypophysial fossa which is a part of the sella turcica (4). The pituitary is connected to 
the hypothalamus by the pituitary stalk, and consists of a posterior lobe and an anterior lobe. 
The posterior lobe secretes:
•	 Vasopressin (also known as anti-diuretic hormone (ADH)) is the key regulator of sodium 
and water balance and plays a role in cardiovascular function;
•	 Oxytocin has a role in the contraction of smooth muscles. 
The anterior lobe of the pituitary is stimulated by the releasing hormones secreted by the 
hypothalamus in order to secrete the following hormones (2): 
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•	 Adrenocorticotropic hormone (ACTH) targets the adrenal cortex to secrete cortisol;
•	 Growth hormone (GH) acts mainly on the liver to produce insulin-like growth factor-1 
(IGF-1) which stimulates growth of bone and muscle. GH also has a direct effect on tissues 
stimulating growth;
•	 Prolactin which acts on breast tissue and stimulates lactation;
•	 Thyroid-stimulating hormone (TSH) stimulates the thyroid gland to produce thyroid 
hormones (T3 and T4);
•	 Follicle-stimulating hormone (FSH) and luteinising hormone (LH) act on the gonadal 
glands to regulate the secretion of testosterone in males, and oestrogen and progester-
one in females.
Under normal conditions the hypothalamic-pituitary axes are highly regulated. However, 
dysfunctions can occur at the level of the end organ (primary disorder), at the level of the pi-
tuitary (secondary disorder), or at the level of the hypothalamus (tertiary disorder), resulting 
in dysregulation of the hypothalamic-pituitary axes. In case of a pituitary adenoma, classical 
syndromes can develop:
Cushing’s disease
ACTH secreting pituitary adenomas result in excessive adrenal cortisol, which leads to 
Cushing’s disease. Clinical features of Cushing’s disease are (central) obesity, rounded face 
(i.e. moon face), easy bruising, stretch marks, hirsutism (Figure 1), high blood pressure, 
diabetes mellitus, irregular menstrual periods in women, erectile dysfunction in men, easy 
fractures of bones, muscle weakness, acne, poor wound healing, infections and psychologi-
cal disturbances (e.g. psychosis, depression). Cushing’s disease is treated by removal of the 
pituitary adenoma by transsphenoidal surgery. Several approaches can be used in case of 
residual adenoma, i.e. reoperation, conventional radiotherapy or bilateral adrenalectomy. 
Blockers of steroidogenesis, i.e. metyrapone and ketoconazole are available for (temporary) 
reduction of cortisol secretion. New medical therapies are emerging including treatment 
with a somatostatin analogs with a high affinity for the somatostatin receptor subtype 5 
(i.e. Pasireotide), a glucocorticoid receptor blocker (i.e. Mifepristone), and a new generation 
steroid synthesis inhibitors (5). Since hypercortisolism is a lethal condition, removal of both 
adrenals (bilateral adrenalectomy) is a viable option to establish cure of hypercortisolism, 
when surgery and radiotherapy have not led to the desired outcome (2;6). Although physi-
cal and psychological symptoms improve after correction for hypercortisolism, persistent 
morbidity is often observed in patients with long-term remission of Cushing’s disease, such 
as increased cardiovascular morbidity, osteoporosis (7), impairments in cognitive functioning 





GH producing pituitary adenomas result in exposure to elevated GH and IGF-I levels. Exces-
sive GH levels during childhood or adolescence will lead to gigantism, while elevated GH 
levels during adulthood will lead to the classical syndrome of acromegaly. Clinical manifesta-
tions of acromegaly include changes in appearance including soft tissue overgrowth with 
increased size of hands and feet, and coarsening of facial features (Figure 2), deepening of 
voice, visual field defects, headaches, excessive sweating, weight gain, oiliness of the skin, 
fatigue, joint pain, menstrual disorders, erectile dysfunction in men, and decreased libido. 
Other symptoms frequently seen in patients with acromegaly are sleep apnoea syndrome, 
carpal tunnel syndrome, athropathy, diabetes mellitus, colonic polyps, and heart failure. Ac-
romegaly is usually treated by removal of the pituitary adenoma by transsphenoidal surgery, 
which can be curative when the adenoma is not invasive, or by medical treatment with so-
matostatin analogs (i.e. Octreotide) or a GH receptor antagonist (i.e. Pegvisomant). Treatment 
http://jamanetwork.com/data/Journals/JAMA/22480/jpg15029fa.png[02-07-2017 14:02:00]figure 1. Signs in Cushing’s disease, derived from Pluta et al. (11)
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with somatostatin analogs consists of (lifelong) monthly subcutaneous or intramuscular 
injections of sustained-release somatostatin analogs (i.e. Octreotide LAR or lanreotide) and 
pegvisomant consists of daily injections. Also a combination therapy with pegvisomant and 
somatostatin analogs can be used. Most frequently reported side effects (>10%) of soma-
tostatin analogs are gastrointestinal complaints, headache, cholelithiasis, and hyperglycemia 
(12). Conventional radiotherapy is one of the alternative treatment options (2;6). 
Although symptoms improve after normalisation of GH and IGF-I levels, long-term 
morbidity in patients with biochemically cured acromegaly is seen, characterized by joint 
complaints, hypertension, myocardial infarction, diabetes mellitus (13), psychopathology 
(14), and increased mortality (15). 
figure 2. Signs in acromegaly, derived from Levy & Howlett (6).
Prolactinoma
Prolactin secreting pituitary adenomas are named prolactinomas and are the most common 




tures of prolactinomas are galactorrhea, amenorrhea or oligomenorrhoea in women, erectile 
dysfunction in men, decreased libido, and subfertility (2;6). Prolactinomas are treated by 
medical therapy with dopamine agonists (e.g. Cabergoline) which consists of an orally taken 
dose once or twice a week. Most frequently reported side effects (>10%) are headache, dizzi-
ness, dyspepsia, gastritis, nausea, stomach ache, asthenia, and fatigue (16). Transsphenoidal 
surgery is a good alternative in case of side effects or resistance to the therapy . Conventional 
radiotherapy is reserved for patients who have persistent hyperprolactinemia after surgery 
or medical treatment (2;6). 
Non-functioning pituitary adenoma
Non-functioning pituitary adenomas (NFAs) are named as such because they do not secrete 
any hormones, consequently they are usually large when the diagnosis is established. The 
mass effects of the adenoma can result in pressure on the pituitary itself or to adjacent struc-
tures, such as the optic nerve or optic chiasm. Clinical features of NFAs are visual field defects, 
hypopituitarism and headache. Since these adenomas are generally large, transsphenoidal 
surgical resection is usually required to relieve mass effects. Conventional radiotherapy may 
be used to reduce tumour progression or recurrence of the tumour (2). Even after long-term 
remission of NFA, patients may suffer from persistent visual field defects (17). 
Hypopituitarism 
For all pituitary adenomas counts that due to damage to the pituitary as a result of the mass 
effect of the tumour, the surgical treatment or the radiotherapy, it could be that one or more 
pituitary hormones are not (or not sufficiently) produced. This is known as hypopituitarism. 
The majority of the patients with hypopituitarism need lifelong treatment with hormone 
replacement therapy (Table 1), aiming to mimic the physiology of end organ hormones. 
Replacement therapy for adrenal insufficiency is of particular relevance, since too low cortisol 
levels can lead to an acute adrenal crisis (i.e. Addison’s crisis) which is a life threatening situ-
ation. On the other hand, when replacement therapy consists of too high hydrocortisone 
dosages this may lead to exposure to hypercortisolism resulting into symptoms similar to 
Cushing’s disease. Furthermore, replacement dose adjustments are required in stressful situ-
ations, i.e. physical and psychological stressors or illness. Considering these serious effects, 
adequate replacement therapy in adrenal insufficiency as well as, adaptation of the dose 
during stress, is crucial (18). 
Adrenal insufficiency can be caused by an ACTH insufficiency due to damage to the pitu-
itary, also known as secondary adrenal insufficiency (SAI), it can also be the result of damage 
to the adrenal glands, known as primary adrenal insufficiency (PAI) or Addison’s disease. PAI 
is most frequently caused by auto-immunity or following bilateral adrenalectomy after for 
instance a persisting Cushing’s disease.
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Table 1. Hormone replacement therapy in case of hypopituitarism
Insufficiency of replacement therapy
Cortisol Hydrocortisone: 15-40 mg per day divided into two to three doses
Thyroid hormones Levothyroxine: 1.6 µg/kg per day (100-200 µg usually adequate)
Gonadotropic hormones Adrogel: 50-100 mg per day (males)
Combination estrogen/progestin (females)
Growth hormone Growth hormone: 2-5 µg/kg per day
Titration of the hydrocortisone dose 
Hydrocortisone replacement therapy needs to be balanced between over- and underreplace-
ment. It aims at achieving the normal circadian rhythm of cortisol secretion, with high cortisol 
levels in the morning and lower cortisol levels in the afternoon and evening. Furthermore, 
it is recommended that hydrocortisone intake should be individualized, since it is likely that 
there is large individual variation in hydrocortisone requirements taking into consideration 
differences in cortisol sensitivity due to polymorphisms of the glucocorticoid receptor gene 
(19). For the determination of the required individual hydrocortisone dosage it is advocated 
to take into account blood pressure, metabolic derangements and patient perceived sense 
of well-being (20). Furthermore, clinicians can rely on cortisol levels as measured in saliva, 
serum and plasma. However, limitations of these measurements are that cortisol levels are 
measured at one time point and that they do not reflect cortisol action at tissue level. Appar-
ently, a recently developed method enables to retrospectively assess cortisol levels for longer 
time periods, namely the assessment of cortisol in scalp hair (21). Scalp hair grows with one 
cm per month (22), so a hair sample of for example the proximal three cm represents the 
cortisol concentration of the last three months.
Long-term effects of cortisol on the central nervous system
It postulated that the causes for persistent morbidity in patients with dysfunctions of the 
pituitary-adrenal axis are multi-factorial, including imperfections of surgical treatment of 
the pituitary gland or intrinsic imperfections in hormone replacement therapy. Furthermore, 
patients who are previously exposed to hypercortisolism, such as in Cushing’s disease, may 
also suffer from potential irreversible effects of the cortisol excess on the central nervous 
system and peripheral tissue. 
In the human brain, the effect of cortisol is mediated via two types of receptors: the min-
eralocorticoid receptor (MR) and the glucocorticoid receptor (GR). MR is highly expressed in 
the hippocampus, a brain structure involved in memory and learning processes, while GR is 
widely expressed throughout the whole brain. Cortisol has a tenfold higher binding affinity 
for the MR than for the GR. Consequently, MRs are activated first when cortisol levels increase, 




The negative effects of cortisol excess on the central nervous system are well-recognized in 
animal brains, but less well established in the human brain. In 1992 Starkman and colleagues 
were the first to report on hippocampal volumes obtained from routine pituitary magnetic 
resonance imaging (MRI) diagnostics of patients with active Cushing’s disease, and compared 
these with healthy control data derived from the literature. It was observed that hippocam-
pal volume was decreased during active Cushing’s disease (24), but a partial recovery was 
observed after successful  biomedical treatment (25;26). The field of neuroimaging has been 
rapidly expanding and currently available neuroimaging techniques enable a more precise 
evaluation of the brain. Besides the evaluation of brain structures, also brain function can 
be currently examine i.e. functional MRI (fMRI). fMRI is based on the assumption that when a 
brain region is active more oxygen is needed and therefore a higher blood flow is achieved. 
By measuring changes in oxygen consumption during processing of a task, it can be inferred 
what areas are activated during a particular task (27). The currently available neuroimaging 
techniques can be used to provide more (new) insight into brain characteristics of patients 
exposed to hypercortisolism such as in Cushing’s disease.
Quality of life
In clinical studies the umbrella term ‘patient reported outcome’ (PRO) is frequently used, 
referring to a measure of a patient’s health status directly derived from the patient, without 
interpretation of clinicians or anyone else (28). Thereby, the term PRO indicates the impor-
tance of the patient’s own perspective on their health status. ‘Quality of life’ (QoL) can be seen 
as one type of PRO. 
Although it is established that QoL should cover physical-, psychological-, and social 
well-being (in accordance with the biopsychosocial model) (29), one concrete definition of 
QoL is lacking, which poses major challenges for the evaluation and interpretation of QoL 
(30). A model that is frequently used to conceptualise QoL and whose validity is supported 
by empirical evidence over the years (31) and has been widely applied to different patient 
populations (32-34) is the conceptual model proposed by Wilson and Cleary (1995) (35). This 
model establishes the biopsychosocial model (29) by integrating the clinical paradigm i.e. 
the biomedical paradigm and the quality of life model (i.e. social science paradigm). Where 
the biomedical paradigm focusses on pathological processes, and biological, physiological, 
and clinical outcomes, the social science paradigm focusses on dimensions of functioning 
and overall well-being. This models states that health can be thought of as a continuum of in-
creasing biological, psychological and social complexity, with on the one end pure biological 
measures, and on the other measures of general health perceptions (Figure 3). It explicates 
the proposed dominant causal relationships (bold) and mediating factors. From left to right, 
it goes from cell-level to the individual to the interaction of the individual in its social context. 
The arrows used in figure 3 do not imply that there are no reciprocal relations, just as the ab-
sence of arrows does not imply that there are no such relationships. Furthermore, it should be 
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noted that the relation between symptom status and biological and physiological variables 
is rather complex. In other words biological and physiological variables can be profoundly 
abnormal without the patient perceiving symptoms, or the other way around with the pa-
tient perceiving profound symptoms for which no biological or physiological abnormalities 





perceptions Symptom status Functional status 
Overall  



















figure 3. Wilson-Cleary model of QoL (35).
Biological and Physiological variables: function of cell, organs, and organ systems e.g., diagnoses, laboratory 
values, measures of physiological function, and physical examination findings.
Symptom status: a patient’s perception of an abnormal physical, emotional or cognitive state.
Functional status: ability of the individual to perform particular tasks. The main domains of functioning are 
physical functioning, social functioning, role function, and psychological functioning.
General Health perceptions: subjective rating of health, and represents and integrates all of the previous 
health concepts.
Quality of life in pituitary disease
In patients with pituitary disease QoL is traditionally assessed by the use of questionnaires. 
QoL can be assessed by validated questionnaires and it is usually recommended that a ge-
neric questionnaire (assesses general QoL domains, valid for healthy respondents or patients 
with any medical condition) is combined with a disease-specific questionnaire (assesses QoL 
aspects relevant to a specific disease), in order to assess both the general perspective of QoL 
and disease-specific aspects (36). Disease-specific QoL questionnaires for patients with pitu-
itary disease have been developed e.g. the ACROQoL for acromegaly (37-39), the QoL-AGHDA 
for growth hormone deficiency (GHD) (40), and the Tuebingen CD-25 and the CushingQoL 
for Cushing’s disease (41-43). Unfortunately, no questionnaires are available for patients with 




QoL questionnaires (e.g. generic, disease-specific questionnaires) it is difficult to compare 
QoL between studies. However, in general it can be observed that patients with pituitary 
disease report impairments in QoL during active disease, which improves somewhat after 
surgery (44), medical treatment (i.e. somatostatine analogs, GH receptor antagonists in acro-
megaly or a glucocorticoid receptor blocker in Cushing’s disease) (45-47) or growth hormone 
replacement therapy (48). However, QoL evaluations after long-term remission demonstrate 
persistent impairments in QoL. For example, patients report musculoskeletal pain (49), sexual 
dysfunction (50), worse mental health (51), and fatigue (52). Furthermore, disease-specific 
differences were observed between various pituitary diseases, with patients with acromegaly 
reporting impairment characterized by worse physical performance and bodily pain (3), and 
patients with Cushing’s disease reporting impairment characterized by worse psychological 
well-being and psychological and social adjustment (53).  Unfortunately, prospective QoL 
studies with long-term follow-up including treatment naïve patients are lacking resulting 
a lack of insight into the time course of QoL impairments, as well as the effectiveness of 
treatment in terms of QoL. 
Illness perceptions and beliefs about medicine
Illness perceptions are conceptualized in the Common-Sense Model of Self-Regulation (CSM) 
(54). This model views the patient as an active problem solver who makes sense of his/her 
illness. It also conceptualizes how patients develop emotional and cognitive representations 
of their illness and how they develop coping strategies to manage their illness e.g. self-
management behaviour. Three stages are specified in this model (Figure 4). First, patients de-
velop illness perceptions in response to stimuli, i.e. information from the social environment 
such as friends, family, medical doctors and (social) media, but also information derived from 
previous or current experience with illness.  Both emotional illness perceptions (e.g., anxiety, 
anger) and cognitive illness perceptions are formed. These cognitive illness perceptions can 
be organized around five content domains: 
•	 Identity: the label that is used to describe the condition and the associated symptoms;
•	 Cause: the perceived cause of the illness;
•	 Timeline: the expected duration of the illness; 
•	 Consequences: the perceived effect of the illness on physical, psychological, and social 
well-being;
•	 Cure/control: the perceived extent to which the illness can be controlled or cured through 
treatment and behaviour.
Illness perceptions then influence the coping strategies patients use to manage their illness 
and their emotional well-being. The used coping strategies will influence outcome. Finally, 
the patient appraises the used coping strategies and outcomes, and decides to continue with 
the same strategy or to adapt their coping behaviour. A central aspect of this model is the 
assumption that emotional and cognitive responses are processed in parallel. Furthermore, 
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the presence of a feedback loop illustrates the self-regulation process, in which individuals 
use coping strategies, appraise progress and adapt coping strategies when needed (55). 
In patients with pituitary disease it was demonstrated that these patients reported more 
negative illness perceptions compared to patients with acute and chronic conditions. For 
instance, it was demonstrated that patients with Cushing’s disease or acromegaly perceived 
more negative consequences of the disease compared to patients with acute pain and they 
perceived less personal control than patients with chronic obstructive pulmonary disease 
(56;57). Furthermore, patients reported to use less effective coping strategies, including 
performing less active coping, seeking less social support, and using more avoidant coping 
strategies compared to an a-select sample of the Dutch population (58).
Patients not only have certain perceptions about their illness, they also have certain beliefs 
about their treatment i.e. beliefs about medicine. These beliefs can be categorized into beliefs 
about the necessity of taking medication and concerns about negative effects of medication. 
Similar to illness perceptions as conceptualized in the CSM, beliefs about medicines also 
contain emotional and cognitive aspects which are processed in parallel. Therefore, it can 
be postulated that beliefs about medicine can be incorporated into the CSM (Figure 4) (59), 
resulting in the extended CSM in which  beliefs about medicine are related to illness percep-
tions and to coping strategies. Previous research already provided evidence for the existence 
of these associations in patients with other chronic conditions (60;61). 
Cognitive response to 
illness 











Perceptions of treatment (e.g., needs and concerns) 
Emotional response to treatment (e.g., worry, fear) 
figure 4. The Common-Sense Model of Self-Regulation (black) extended with beliefs about medicine 
(grey). Adapted from Horne (59).
self-management 
For several chronic diseases self-management interventions (SMIs) have been developed 




(2002) as “the individual’s ability to manage the symptoms, treatment, physical, psychologi-
cal, and social consequences and life style changes inherent in living with a chronic condition. 
Efficacious self-management encompasses ability to monitor one’s condition and to effect 
the cognitive, behavioural and emotional responses necessary to maintain a satisfactory 
quality of life” (63). This definition further stresses the importance of psychological and social 
management, besides the management of medical treatment. Between existing SMIs great 
diversity in composition exists which can be explained by the fact that SMIs may be based on 
different theoretical models (e.g. the CSM), but also to differences between diseases, as well 
as differences in self-management aims. For instance, SMIs can focus on managing medica-
tion intake, lifestyle changes, or managing emotional aspects of having a chronic disease. 
Nevertheless, widely used components in SMIs are: 
•	 Information provision; 
•	 Self-monitoring: systematic recording of information (e.g. symptoms) to increase aware-
ness and recognise potential patterns;
•	 Skills training: illness-related skills (e.g. adjusting medication in response to symptoms);
•	 Behaviour change: adopting new behaviours and/or changing pre-existing behaviours;
•	 Changing unhelpful beliefs (e.g. beliefs about themselves, self-efficacy beliefs, illness 
perceptions, beliefs about medicine);
•	 Managing emotions: e.g. stress management, training in coping strategies, managing 
anxiety and depressive symptoms;
•	 Enhancing communication skills and social support: supportive environment of the self-
management group, enhancing communication and support by relatives, friends, family, 
but also health care professionals (64).
An example of a SMI which includes these components is the Patient and Partner Education 
Programme for patients with Parkinson’s disease (65). This programme comprises techniques 
from cognitive behavioural therapy, such as cognitive restructuring, systematic relaxation, 
situational behavioural analysis, and social skills training. The programme consists of eight 
weekly session of 90 minutes (Figure 5). Although this SMI was originally developed, and 
found to be effective for patients with Parkinson’s disease (65-67), it has also been adapted 
and found to be effective for patients with Huntington’s disease (68). Recently, a manual for 
using this SMI in patients with chronic disease in general (PPEP4ALL) was published (69). 
ouTlIne of THe THesIs
Pituitary adenomas are benign tumours of the pituitary gland. Despite optimal medical 
treatment several physical, psychological, and social complaints may persist, even after long-
term remission (3). This thesis aims to describe health outcomes in these patients by using 
a biopsychosocial approach covering the continuum with on the one hand biological and 
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physiological measures and on the other measures of general health perceptions and QoL as 
described by the Wilson-Cleary model (Figure 3) (35). 
figure 5. Themes and aims of the patient education programme. Figure derived from A’Campo et al. (66)
In part I biological and physiological variables will be described at the level of the brain (e.g. 
grey matter, neuronal processing) in patients with long-term remission of Cushing’s disease, 
as well as whether brain characteristics are associated with patient reported psychological 
morbidity (Symptom status). Part II will again focus on biological and physiological variables, 
but this time on long-term cortisol levels measured in scalp hair in patients with adrenal 
insufficiency treated with replacement therapy. Associations will be assessed between hair 
cortisol levels and anthropometrics (Symptom status), and QoL. In addition, psychological 
morbidity (Symptom status) and cognitive functioning (Functional status) will be examined 
in patients with primary adrenal insufficiency. Finally, in part III QoL in patients with pitu-
itary disease will be discussed based on studies using QoL questionnaires, as well as QoL as 
formulated by patients during focus group conversations. Furthermore, illness perceptions 
and beliefs about medication will be examined. In addition, the impact of pituitary disease 




development of a patient reported outcome measure (PROM) to assess whether patients are 
bothered by complaints and whether they need (specific) support from their environment. 
Finally, the evaluation of a SMI for patients with pituitary disease and their partners will be 
described which potentially positively influence characteristics of the environment and 
characteristics of the patient aiming to improve overall QoL of patients and their partners. 
Part I: long-term effects of cushing’s disease on the human brain
Considering the persistent impairments in psychological and cognitive functioning in pa-
tients with long-term remission of Cushing’s disease and the fact that the brain is a major 
target area for cortisol, the first part of this thesis was aimed to assess whether the persistent 
impairments might be explained by structural and/or functional alterations in the brain. For 
this research question, first, an overview is provided of the outcome of (functional) MRI stud-
ies of the brain in patients with Cushing’s disease (chapter 2). Then in chapter 3 grey matter 
volumes in patients after long-term remission of Cushing’s disease were examined, as well as 
whether potential brain alterations were associated with patient reported psychological and 
cognitive dysfunction, and clinical severity. Besides this structural evaluation, a functional 
evaluation was performed in the same cohort of patients by measuring brain activation dur-
ing emotion processing using an emotional faces paradigm (chapter 4). 
Part II: clinical implications of adrenal insufficiency
Part II focusses on patients with adrenal insufficiency treated with hydrocortisone replace-
ment therapy. In these patients replacement therapy is aiming to mimic the circadian rhythm 
of cortisol secretion. It is recommended that hydrocortisone intake should be individualized 
and clinicians can currently rely on saliva, serum and plasma which measures cortisol levels 
at one time point. In chapter 5 a new tool to measure cortisol levels in patients with adre-
nal insufficiency was used and evaluated, namely measuring cortisol in scalp hair. For this 
evaluation hair cortisol levels of patients with adrenal insufficiency treated with replacement 
therapy were compared with patients with pituitary disease without adrenal insufficiency 
and healthy controls. Furthermore, associations were examined between hair cortisol levels, 
hydrocortisone intake and anthropometrics. In the same patient population it was also exam-
ined whether long-term cortisol levels as measured in scalp hair were associated with patient 
reported QoL (chapter 6).
As previously mentioned, the brain is a major target area for cortisol and therefore it plays 
an important role in psychological and cognitive functioning. Considering the HPA-axis 
dysregulation in patients with adrenal insufficiency it can be suggested that their psycho-
logical and cognitive functioning is affected. Therefore, in chapter 7 cognitive functioning 
was examined in patients with adrenal insufficiency. For this evaluation cognitive function-
ing of patient with adrenal insufficiency was compared to cognitive functioning of healthy 
matched controls. Furthermore, we aimed to examine the direct effect of low cortisol levels 
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on cognitive functioning. Therefore, patients with normal hydrocortisone intake were also 
compared to patients with postponed hydrocortisone intake. The last chapter of this part 
describes psychological symptoms and functioning in patients with adrenal insufficiency. 
Psychological morbidity, personality traits, and QoL in patients with adrenal insufficiency 
were evaluated by using validated questionnaires. In addition, it was examined whether psy-
chological morbidity, personality traits, and QoL were associated with hydrocortisone intake.
Part III: The next step in improving quality of life in pituitary disease
The persistent impairments in QoL seen in patients with pituitary disease might be explained 
by issues in the preceding domains of the Wilson-Cleary model i.e., biological variables, 
symptom status, functional status, but they might also be influenced by patient character-
istics (e.g. their values and beliefs) and environmental characteristics (e.g. partner, social 
support), i.e. psychological and social aspects. In order to further elaborate QoL and determi-
nants of QoL in patients with pituitary disease, we first provided an overview of the available 
QoL studies in patients with pituitary disease (chapter 9). Considering the fact that the 
majority of the patients with pituitary disease may need lifelong medical treatment, as well 
as that illness perceptions and treatment beliefs are potentially influencing factors of self-
management behaviour, beliefs about medicine and their relation to illness perceptions and 
QoL were examined in chapter 10. The patient perspective of QoL in patients with pituitary 
disease was further elucidated by the use of focus group conversations. Besides the patient 
perspective, the perspective of potential partners of patients with pituitary disease was also 
explored by the use of focus group conversations. The results of these focus group studies 
were reported in chapter 11 and chapter 12. Then, we developed a disease-specific patient 
reported outcome measure (PROM) in order to assess whether patients are bothered by cer-
tain consequences of the disease, as well as whether they need support for these issues i.e., 
the Leiden Bother and Needs Questionnaire for patients with pituitary disease (LBNQ-Pituitary). 
The process of development and validation of the LBNQ-Pituitary is described in chapter 13. 
chapter 14 describes how the Patient and Partner Education Programme was adapted for 
patients with pituitary disease (PPEP-Pituitary) and evaluates the effectiveness of this SMI by 
using a multi-centre randomized controlled trial.
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Cushing’s syndrome causes irreversible effects 
on the human brain: a systematic review of 
structural and functional MRI studies
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background: Cushing’s syndrome is characterized by excessive exposure to cortisol, and 
is associated with both metabolic and behavioral abnormalities. Symptoms improve sub-
stantially after biochemical cure, but may persist during long-term remission. The causes 
for persistent morbidity are probably multi-factorial, including a profound effect of cortisol 
excess on the brain, a major target area for glucocorticoids.
objective: To review publications evaluating brain characteristics in patients with Cushing’s 
syndrome using magnetic resonance imaging (MRI). 
Methods: Systematic review of literature published in Pubmed, Embase, Web of Knowledge, 
and Cochrane databases. 
results:  Nineteen studies using MRI in patients with Cushing’s syndrome were selected, 
including studies in patients with active disease, patients in long-term remission and longi-
tudinal studies, covering a total of 339 unique patients. Patients with active disease showed 
smaller hippocampal volumes, enlarged ventricles, and cerebral atrophy as well as alterations 
in neurochemical concentrations and functional activity. After abrogation of cortisol excess, 
the reversibility of structural and neurochemical alterations was incomplete after long-term 
remission. MRI findings were related to clinical characteristics (i.e. cortisol levels, duration of 
exposure to hypercortisolism, current age, age at diagnosis, triglyceride levels) and behav-
ioral outcome (i.e. cognitive and emotional functioning, mood, and quality of life).
conclusion: Patients with active Cushing’s syndrome demonstrate brain abnormalities, 
which only partly recover after biochemical cure, since these still occur even after long-term 
remission. Cushing’s syndrome might be considered as a human model of nature that pro-
vides a keyhole perspective of the neurotoxic effects of exogenous glucocorticoids on the 
brain.




Cushing’s syndrome (CS) is a rare clinical syndrome characterized by excessive endogenous 
exposure to cortisol due to various etiologies. The majority of patients have ACTH-producing 
pituitary tumors (i.e. Cushing’s disease (CD)); other causes include adrenal tumors or ectopic 
ACTH secreting tumors. CS manifests all characteristic features of excessive stress hormone 
exposure, i.e. psychopathology, gonadal dysfunction, hirsutism, abnormal (central) fat distri-
bution, thin skin with easy bruisability, hypertension, muscle weakness, and osteoporosis (1). 
Patients are treated with surgery, and in case surgical remission is not obtained, radiotherapy 
and/or with medical treatment (2). Although symptoms improve substantially after bio-
chemical cure, cardiovascular morbidity and mortality remained elevated (3-5). Furthermore, 
despite long-term remission, patients with CS reported impaired quality of life (6), higher 
prevalence of psychopathology, and demonstrated impairments in cognitive functioning 
(7;8). It is likely that the causes for persistent morbidity are multi-factorial, including intrinsic 
imperfections of surgical or endocrine replacement therapy, and the impact of living with a 
chronic disease, but also irreversible effects of cortisol excess on the central nervous system 
during remission that may affect personality, behavior, and metabolism cannot be neglected. 
Whereas the attention for the presence of psychopathology and impairments in cognitive 
functioning in patients with active, as well as remitted CS is self-evident, the number of stud-
ies evaluating brain structures and activity in patients with CS has been rather limited. 
The detrimental effects of hypercortisolism, such as in CS, on the human brain were first 
highlighted in autopsy reports, describing a lighter brain and enlarged ventricles in deceased 
CS patients (9). The first in vivo studies in the human evaluating these brain characteristics 
were performed in patients with CS using pneumoencephalography. In 1971, Momose 
and colleagues used pneumoencephalography in 31 patients with CD, and demonstrated 
cerebral cortical atrophy in 90% of the patients and cerebellar cortical atrophy in 74% of the 
patients compared to normal references derived from the literature (10). The introduction 
of the magnetic resonance imaging (MRI) scanner in 1977 enabled the assessment of brain 
volumes and brain structures more accurately and in more detail. In 1992, Starkman and 
colleagues were the first to report on hippocampal volumes obtained from routine pituitary 
MRI diagnostics of patients with active CS, and compared these with healthy control data 
derived from the literature. Hippocampal volume was decreased during active CS (11), but a 
partial recovery could be observed after successful  treatment (12;13). However, new imaging 
techniques are emerging that enable to better evaluate brain structures and functioning. 
The aim of the present study was to systematically review the literature on structural and 
functional changes in the brain identified with (MRI) in patients with CS. The secondary aim 
was to review potential associations between brain characteristics and disease status, cogni-




search strategy and data extraction
The following electronic databases were searched: Pubmed, Embase, Web of Knowledge, 
and Cochrane. The search was performed on August 5 2014. We composed a search strategy 
focusing on MRI studies in patients with Cushing’s disease and Cushing’s syndrome (see 
Supplement 1 for the complete search strategy). Studies on patients with CS due to the use 
of exogenous corticosteroids were excluded. Data extraction and eligibility were assessed by 
two independent investigators (C.D.A. and A.M.P.). Inconsistencies were resolved by consen-
sus.  All references were checked for additional papers. The following data were extracted: 
1) sample size, 2) gender distribution, 3) mean age of included patients, 4) disease status 
(active/remission), 5) estimated duration of exposure to hypercortisolism, 6) methods used, 
and 7) results. 
Quality assessment 
Due to different designs and methods in the studies that were identified, it was not possible 
to use a pre-existing quality assessment tool. Therefore, we formulated a quality assessment 
list adapted from the list used in a systematic review on neuroimaging studies in patients 
with multiple sclerosis (14). Sixteen items were defined: clear study objective, inclusion/exclu-
sion criteria, population demographics, diagnostic criteria and/or remission criteria, estimation 
of disease duration, composition of patient group (i.e. heterogeneous or homogenous regard-
ing to origin of CS (pituitary-adrenal) and disease status (active-remission)), sample size, 
design (retrospective assessment based on scans obtained from routine pituitary evaluation, 
or prospective or cross-sectional), inclusion of a control group assessed in the same manner 
as the patient group, assessment of cognitive and psychological functioning, imaging protocol, 
scanner type (1T, 1.5T or 3T), strength of effect reported, multivariate analysis, and discussion 
of limitations. Total individual quality scores ranged from 0 to 20 points (see Table 1). The 
quality of each study was assessed by two independent reviewers (C.D.A. and A.M.P) and 
discrepancies were discussed and resolved by consensus. Total scores were calculated as 
percentages (“individual total score” / 20 x 100%). The median of the quality scores was 75% 
and was used as cut-off point, with papers with quality scores ≥75% being considered as 
high quality papers. Given the low number of studies, studies were not excluded based on 
the quality assessment.
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Table 1. List of criteria used for the quality assessment
1 Research objective Yes=1 / No=0
2 Inclusion/exclusion criteria Yes=1 / No=0
3 Population demographics 
(at least gender, age, education*)
Yes=1 / No=0
4 Diagnostic criteria and/or remission criteria Yes=1 / No=0
5 Estimation of disease duration Yes=1 / No=0




8 Sample size n<20 =0
n>20 =1
9 Design Retrospective=0 
Prospective =1
Cross-sectional=1




(including cognitive tasks during fMRI)
Yes=1 / No=0
12 Psychological measures Yes=1 / No=0
13 Imaging protocol Yes=1 / No=0
14 Scanner 1T=1 / 1.5T=2 / 3T=3
15 Strength of effect Yes=1 / No=0
16 Multivariate analysis Yes=1 / No=0
17 Limitations discussed Yes=1 / No=0
Total score
*Or IQ in case of studies in children.
resulTs
literature overview
The literature search identified 142 publications, of which 16 were eligible for inclusion. By 
scanning references of included articles, three articles were added to the selection. Therefore, 
the final selection consisted of 19 articles including a total number of 339 unique patients 
(Table 3, Figure 1). This selection consisted of six longitudinal studies, 11 cross-sectional 
studies, and two studies using both designs. The majority of the studies used structural 
MRI (n=14), three studies used proton magnetic resonance spectroscopy (H-MRS), and two 
studies used functional MRI. Nine studies combined MRI outcome with the assessment of 
cognitive functioning. Further information on the MRI techniques, neuropsychological tests, 
and behavioral measures are provided in the Supplementary file 2.
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16 references were eligible for 
inclusion
142 potentially relevant references 
identified from electronic search
126 references excluded based on 
title and abstract
3 references were added by 
screening reference lists from 
included articles
19 references were finally included
figure 1. Flow-diagram of selection and exclusion stages.
Table 2. Quality assessment




Starkman, 1992 1 1 1 1 1 0 1 0 0 0 1 0 1 2 1 0 1 12 60%
Starkman, 1999 1 1 0 1 1 1 1 1 1 0 0 0 1 2 1 1 1 14 70%
Khiat, 1999 1 1 0 1 0 0 1 0 1 1 0 0 1 2 1 0 1 11 55%
Khiat, 2000 1 1 0 1 0 0 1 0 1 1 0 0 1 2 1 0 0 10 50%
Simmons, 2000 1 0 0 0 0 1 1 1 0 1 0 0 0 0 1 0 0 6 30%
Bourdeau, 2002 1 1 0 1 0 1 1 1 1 1 0 0 1 2 1 0 1 13 65%
Starkman, 2003 1 1 0 1 1 1 1 1 1 0 1 1 1 2 1 1 0 15 75%
Merke, 2005 1 1 1 1 1 0 1 0 1 2 1 1 1 2 1 0 1 16 80%
Hook, 2007 1 1 1 1 1 1 1 1 1 0 1 1 1 2 1 1 1 17 85%
Starkman, 2007 1 1 0 1 1 1 1 1 1 0 0 1 1 2 1 1 1 15 75%
Maheu, 2008 1 1 1 1 1 0 1 0 1 1 1 0 1 3 1 1 1 16 80%
Resmini, 2011 1 1 1 1 1 0 0 1 1 2 1 0 1 3 1 1 1 17 85%
Toffanin, 2011 1 1 1 1 1 1 1 0 1 0 0 0 1 1 1 1 1 13 65%
Langenecker, 2012 1 1 1 1 1 0 1 1 1 1 0 1 1 3 1 1 1 17 85%
Andela, 2013 1 1 1 1 1 1 1 1 1 2 1 1 1 3 1 1 1 20 100%
Resmini, 2013 1 1 1 1 1 0 1 0 1 2 0 0 1 3 1 0 1 15 75%
Crespo, 2014 1 1 1 1 1 0 0 1 1 2 1 0 1 3 1 1 1 17 85%
Santos, 2014 1 1 1 1 1 0 1 1 1 2 1 1 1 3 1 0 1 18 90%
Van der Werff, 2014 1 1 1 1 1 1 1 1 1 2 1 1 1 3 1 1 1 20 100%
The 17 quality items were scored following the criteria listed in table 1. bold: quality score≥75%.




The individual quality scores of the studies ranged from 30 to 100%, with a median of 75%. 
Overall, the more recent articles had higher quality scores, which can partly be explained by 
the transition from using 1.5T scanners to 3T scanners, and the absence of applying multivari-
ate analysis in the earlier studies. Furthermore, 53% of the studies (n=10) included patients 
with CS of both pituitary and adrenal origin, and approximately half of the studies did not 
include psychological (n=11) and/or cognitive measures (n=9).
endocrine evaluation 
Diagnostic criteria for CS were clearly defined in thirteen studies (68%).  Five studies (26%) 
did not describe diagnostic criteria, but mentioned criteria of remission (15-19). One study 
did neither describe diagnostic nor remission criteria (20). 
Described diagnostic criteria were clinical features (truncal obesity, skin and muscle ar-
thophy, moon facies) (11-13;21), elevated urinary free cortisol (UFC) (11-13;21-29), elevated 
cortisol secretion rates (11-13;21;23-25;30), elevated midnight salivary cortisol (29;31), 
absence of blunted circadian rhythm of cortisol secretion (11-13;21;26;27;30;32;33), elevated 
ACTH levels (in CD only) (12;13;21;23;24), lack of suppression after low dose dexamethasone 
((1 mg) (22;25;29;33), (2mg) (12;13;21), dose not mentioned (23;24)) or 50% suppression after 
high dose (8mg) (12;13;21), and abnormal response to CRH (30). 
Described remission criteria were normal UFC (15-19), adrenal insufficiency, morning 
cortisol suppression after low dose dexamethasone overnight (1mg) (17-19), or less than 30 
mg hydrocortisone per day (15).
All studies (except four (15;20;23;24)) reported on the estimated duration of hypercorti-
solism, which was based on patient’s history and old photographs. In studies that included 
pediatric patients with CS, the onset of decreased growth velocity was used (26;27). The 
mean estimated duration of hypercortisolism ranged from 2.6 to 7.9 years. 
MrI outcome in patients with active cushing’s syndrome
The first studies evaluating brain volume with MRI in patients with active CS used MRI scans 
obtained from routine pituitary evaluation. In 1992, Starkman et al. reported hippocampal 
volume to be outside the 95% confidence interval of healthy control data derived from the 
literature in 27% of the patients (total sample size n=12) (11).  In a  larger cohort (n=63), 
patients with CS were reported to have more brain atrophy compared to controls (Figure 2) 
(20). In agreement, Bourdeau and colleagues demonstrated that patients with active CS had 
increased third ventricle diameter, bicaudate diameter, and cerebral atrophy, compared to 
control patients with no sellar tumors (15). A recent study found smaller grey matter volumes 
of the bilateral cerebellum in patients with active CS compared to controls (19). When inves-
tigating the effect of CS on the developing brain, children with CS were found to have smaller 
cerebral volumes, larger ventricles and smaller amygdala than controls (27).
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Khiat et al. (1999) used proton magnetic resonance spectroscopy (H-MRS), a non-invasive 
tool that can be used to evaluate changes in cerebral metabolites. Patients with active CS 
had decreased ratios of creatine and phosphocreatine ratios (markers of energy metabolism) 
and decreased choline-containing compounds (a membrane marker) in frontal and thalamic 
areas, indicating persistent alterations in the cholinergic system (23).
Only two studies have investigated patients with active CS with functional magnetic 
resonance imaging (fMRI). Using an emotional faces task, adult patients demonstrated less 
activation in the left anterior superior temporal gyrus, and higher activation in the frontal, 
medial, and subcortical regions during the identification of emotional faces. These findings 
indicated alterations in brain activity in regions used for emotion processing (25). Further-
more, adolescents with active CS demonstrated increased activation in the left amygdala 
and right anterior hippocampus in response to successful encoding during the performance 
of a facial memory task. These results point toward alterations in brain activity in substrates 
related to depressive symptoms and emotional memory. Interestingly, none of the adoles-
cents suffered from psychiatric disease, therefore the authors postulated that the exagger-
ated amygdala activity and exposure to elevated cortisol levels is not sufficient for initiating 
depression in adolescents (26). 
longitudinal studies assessing the potential reversibility of brain abnormalities
Eight studies evaluated the potential reversibility of alterations in the brain after correction of 
hypercortisolism (mean duration of follow-up between 6 to 40 months). 
Correction of hypercortisolism increased hippocampal volume (12), and decreased third 
ventricle- and bicaudate diameter, and regressed brain atrophy (15). Toffanin et al. reported 
figure 2. Brain atrophy in a patient with active CD vs. healthy control. 
T1-weighted sagittal MRIs of a 32-year-old patient with Cushing’s disease (A) and age- and sex-matched control 
(B) (20).
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a significant increase in right and left hippocampus head volumes in CD patients after trans-
sphenoidal surgery, with no significant increase in the body and tail of the hippocampus, 
suggesting that the head of the hippocampus is more sensitive to excessive cortisol exposure 
(33). Recovery in metabolite concentrations was also accompanied by an increase in thalamic 
and frontal choline levels up to six months after correction of hypercortisolism, indicating 
improvement in cholinergic system function (23). Children with CS demonstrated an increase 
in cerebral volumes and a decrease in ventricular volumes after surgery and total cerebral 
volume and ventricular size after one year of follow-up were comparable to age-matched 
controls (27).
MrI outcome in patients in long-term remission of cushing’s syndrome
Six studies evaluated patients in remission of CS using a cross-sectional design and identi-
fied structural, functional and biochemical abnormalities. The average duration of remission 
ranged from 3.4-11.9 years. 
Resmini et al. found no differences between patients with active disease and patients in 
remission, and therefore analyzed these patients as one group. They found no differences in 
hippocampal volume between patients and healthy matched controls, but total grey mat-
ter (cortical and subcortical) and cortical grey matter were smaller in patients compared 
to controls (17). In 2013, Andela et al. found a smaller grey matter volumes of the anterior 
cingulate cortex and larger grey matter volumes of the left posterior lobe of the cerebellum 
in CD patients in long-term remission compared to healthy matched controls (figure 3) (22), 
whereas Santos and colleagues found no differences in cerebellar volumes between patients 
in remission and controls (19). Recently, Crespo et al. evaluated cortical thickness in medically 
treated eucortisolemic patients and patients in remission and demonstrated that patients 
with CS had decreased cortical thickness when compared to controls (16).
At present, only one study has evaluated white matter integrity in patients with long-term 
remission of CD and demonstrated widespread reductions of integrity in white matter tracts 
throughout the brain (29). 
Finally, using H-MRS, Resmini et al. demonstrated lower N-Acetyl-Aspartate ratios (marker 
of neuronal density, integrity, and variability) in the bilateral hippocampus in patients in 
remission of CS compared to controls, reflecting neuronal damage. Furthermore, patients 
demonstrated higher Glutamate (excitatory neurotransmitter) and Glutamine (glial marker) 
levels in both hippocampi, indicating proliferation as a repair mechanism. The authors postu-
lated that these persisted alteration in biochemical markers in the brain could be related to 
glucocorticoid neurotoxicity (18).
associations between brain abnormalities and clinical characteristics
Several studies found associations between structural and functional brain abnormalities 
and clinical and laboratory characteristics in patients with CS.
38
Chapter 2
In patients with active disease, hippocampal volumes were negatively correlated with 
plasma cortisol levels, but not with UFC, current age and cortisol levels multiplied by the 
estimated duration of disease (11). In functional MRI studies in active disease dorsal anterior 
cingulate activation during emotional task was positively associated with percent decline 
figure 3. Grey matter volumes in patients after long-term remission of CD.
(A) Results of regions of interest analysis, with lesser grey matter volumes in patients than in controls (P<0.05; 
617 voxels, 2 mm isotropic). (B) Results of whole brain analysis with lesser grey matter volumes in patients than in 
controls (P<0.05; 37 voxels, 2 mm isotropic). (C) Results of whole brain analysis with greater grey matter volumes 
in patients than in controls (P<0.05; 323 voxels, 2 mm isotropic). The left hemisphere corresponds with the right 
side of the image (22).
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in ACTH from morning peak to afternoon nadir, but not with percent cortisol decline from 
morning peak to afternoon nadir (25). On the other hand, in adolescents with active disease 
left amygdala activation and right anterior hippocampal activation during a facial memory 
task was not correlated with 24-hr UFC levels (26). Bicaudate diameter was correlated with 
UFC in patients with active CD, whereas no associations were found with degree of cerebral 
atrophy. In patients with adrenal CS, UFC did correlate with the degree of cerebral atrophy 
(15). Duration of hypercortisolism was negatively associated with subcortical grey matter 
volume (17), and significant differences in brain atrophy were found between subsets of pa-
tients with a long disease duration compared to patients with  shorter disease duration (20). 
Furthermore, grey matter volume of the bilateral cerebellum, was negatively associated with 
age at diagnosis and triglyceride levels, but not with current age, level of cholesterol, glucose, 
UFC, duration of exposure to hypercortisolism (19). Furthermore, cortical thickness was not 
associated with duration of eucortisolism, duration of prior hypercortisolism and UFC (16). 
Increase in hippocampal volume after correction of hypercortisolism was negatively as-
sociated with current age (12), and significant differences in degree of brain atrophy were 
found between subsets of patients  of different age (20). In contrast, Bourdeau et al. found 
no correlation between brain volume and current age, although this could be related to 
the relatively young sample of patients included (15). An increase in hippocampal volume 
was associated with a decrease in UFC after treatment (12;13;21), but not with reduction 
in plasma cortisol, duration of disease or the number of months relapsed since treatment 
(21;30). Increase in right caudate head volume (CHV) was also associated with decrease in 
UFC, while increase in left CHV and right and left CHV together were not associated with 
change in UFC (13;21). 
In patients with long-term remission no correlations were found between grey matter 
volumes of the ACC and cerebellum and white matter integrity, and estimated duration of 
hypercortisolism, duration of remission and clinical severity (22;29), nor between NAA and 
GLX ratios and duration of hypercortisolism and duration of remission (18).
associations between brain abnormalities and behavioral outcome/measures
In several studies associations between structural and functional brain abnormalities and 
behavioral measures, especially in memory and mood domains, were found.
In patients with active disease, hippocampal volumes were positively associated with 
verbal learning and verbal recall (11). Increased activation of the left lateral posterior/
pulvinar nuclei of the thalamus and the left middle frontal gyrus were positively correlated 
with accuracy in emotion identification in patients with active disease, whereas activation 
in the left superior parietal lobule was not significantly correlated with accuracy of emotion 
identification (25). In adolescents with active CS, left amygdala activation and right anterior 
hippocampal activation did not correlate with the performance of a facial memory task (26). 
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ated with improvement in learning (13;30), but change in CHV was not (13;30). An increase in 
right caudate volume was associated with improvement in mood (depression, anxiety) and 
related ideation (obsessive-compulsive and paranoid ideation), whereas change in left CHV 
and hippocampal volume were not correlated with mood or ideation (21). 
Recently, Crespo et al. demonstrated that cortical thickness was not associated with deci-
sion making in medically treated eucortisolemic patients and patients in remission (16). Fur-
thermore, in a group of patients with active disease, as well as patients in remission, patients 
with severe memory impairment showed smaller hippocampal volumes than controls (17), 
and grey matter volumes of the left lobe of the cerebellum were positively associated with 
visual memory, and grey matter volumes of the right lobe of the cerebellum were positively 
associated with reported disease-specific quality of life (19). 
In patients with long-term remission reductions in white matter integrity in the left uncinate 
fasciculus were associated with severity of depressive symptoms, whereas no correlations 
were found between white matter integrity in other brain regions, grey matter volumes in 
the ACC and cerebellum, and behavioral outcome (i.e. depressive symptoms, anxiety, apathy, 
irritability, cognitive failure) (22;29).
dIscussIon
This systematic review shows that endogenous glucocorticoid excess in Cushing’s syndrome 
has profound effects on the human brain. This includes structural grey matter, possibly 
white matter abnormalities and neurochemical and functional alterations. After correction 
of hypercortisolism, the structural and neurochemical alterations improve substantially and 
correlate with improvements in clinical and behavioral outcomes. Nevertheless, abnormali-
ties in both grey- and white matter are not completely reversible at long-term remission and 
are accompanied by psychological symptoms and impairments in cognitive functioning 
(7;22;29;34).
The brain, and in particular the limbic system, is a major target area for cortisol consider-
ing the high density of both the mineralo- and glucocorticoid receptor (35). The neurotoxic 
effects of corticosteroid excess on the central nervous system are well-recognized in experi-
mental animal studies: i.e. reduction of apical dendrites of hippocampal pyramidal neurons 
(36), hippocampal volume reduction (37), and reduction volume of the left anterior cingulate 
gyrus (38). Furthermore, experimental models of chronic stress have clearly shown neurotoxic 
effects that appeared to be reversible by anti-glucocorticoid treatment (39). However, long-
term experimental histopathological data after abrogation of corticosteroid overexposure 
are not available to our knowledge. It is tempting to speculate that the observed psychologi-
cal morbidity and cognitive impairment in patients with active CS (40;41) could be explained, 
at least in part, by the findings of MRI studies. In support of this, brain abnormalities and 
behavioral outcomes are clearly correlated. The anterior cingulate cortex, hippocampus and 
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amygdala together constitute the neurocircuitry of stress (42). Therefore, psychopathology 
and cognitive impairment in patients with active CS might be related to structural alterations 
within this circuitry, but also to alterations in functional activity and connectivity within it. In 
accordance, changes in functional activity were reported during a facial emotion task in adult 
patients (25), and a facial memory task in adolescents (26). FMRI studies on other emotional 
and cognitive tasks (e.g. executive function, memory) in adult patients with CS, or studies as-
sessing functional connectivity during rest, have not been reported. Also, there were no fMRI 
studies in patients in remission of CS published in the time window of our literature search. 
At present, brain characteristics in CS patients who are in long-term remission have been 
reported in only six cross-sectional MRI studies, with an average duration of remission rang-
ing from 3.4-11.9 years. These studies showed smaller grey matter volumes in the anterior 
cingulate cortex, larger grey matter volumes in the cerebellum, widespread reductions in 
white matter integrity (22;29), and alterations in specific neuronal metabolites in the hip-
pocampus (18). The behavioral phenotype of patients in remission of CS (7;34) might also be, 
at least in part, explained by these findings. This is supported by the observed correlations 
between reductions in white matter integrity in the left uncinate fasciculus and severity 
of depressive symptoms in one DTI study. However, no other correlations were identified 
between the structural brain abnormalities and behavioral outcomes in patients in remission 
of CS, which might be due to a limited power or to the fact that behavioral outcomes may 
show stronger associations with functional brain abnormalities (22;29). 
The actual course of the residual alterations in patients in long-term remission is hard to 
capture, since longitudinal studies with long-term follow-up are lacking (i.e. mean duration 
of follow-up in available studies ranging from 6 to 40 months). Furthermore, previous stud-
ies in patients with active CS mainly evaluated the hippocampus, and the first MRI studies 
in patients with CS did not have access to modern and more sophisticated analytical tools. 
Therefore, it is plausible to assume that previous studies have been unable to document 
abnormalities at least in active patients. For instance, white matter integrity as assessed with 
diffusion tensor imaging (29) has not been evaluated in patients with active disease, which 
retains us from drawing conclusions about the development of these reductions in white 
matter integrity. 
It is tempting to speculate that the brain abnormalities found in patients with CS during 
active disease, as well as during remission, also apply for patients with iatrogenic CS due to 
glucocorticoid treatment. This is supported by findings of similar brain abnormalities in pa-
tients while on long-term corticosteroid therapy as in patients with CS (smaller hippocampal, 
amygdala volumes, cerebral atrophy, alterations in neurochemical concentrations) (43-46).
A considerable amount of between-study heterogeneity was observed. First of all, hetero-
geneity was present regarding sample composition, with some studies analyzing homog-
enous groups of patients with pituitary CD or patients with adrenal CS, whereas other studies 
analyzed a more heterogeneous group of patients with pituitary as well adrenal CS. In addi-
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tion, some studies analyzed homogenous groups of patients with active disease or patients 
in remission, whereas other studies analyzed patients with active, as well as patients with 
remitted disease. Secondly, studies demonstrated a great variety in analyzed brain regions of 
interest and in the methodology used. Consequently, no meta-analysis could be performed. 
Furthermore, it should be acknowledged that CS is associated with multisystem morbidity 
(47) and pituitary hormone deficiencies, which all can affect the brain (48-52).
In conclusion, patients with CS demonstrate structural brain abnormalities, as well as 
neurochemical and functional abnormalities, which only partly recover during long-term 
remission, since these still occur even after long-term remission. Cushing’s syndrome might 
be considered as a human model of nature that provides a keyhole perspective of the neuro-
toxic effects of exogenous glucocorticoids on the brain.
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suPPleMenT 1. searcH sTraTeGy
PubMed (1 query):
(“cushing disease”[All Fields] OR “cushing’s disease”[All Fields] OR “cushings disease”[All Fields] OR “Cush-
ing Syndrome”[Mesh] OR “Cushing’s Syndrome”[all fields] OR “Cushing Syndrome”[all fields] OR “Cushings 
Syndrome”[all fields] OR “cushing”[tiab] OR “cushings”[tiab] OR “cushing’s”[tiab] OR “ACTH-Secreting Pituitary 
Adenoma”[Mesh] OR “ACTH-Producing Pituitary Adenoma”[all fields] OR “ACTH Producing Pituitary Adenoma” OR 
“ACTH-Producing Pituitary Adenomas”[all fields]  OR “ACTH Producing Pituitary Adenomas”[all fields] OR “ACTH 
Secreting Pituitary Adenoma”[all fields] OR “ACTH-Secreting Pituitary Adenomas”[all fields] OR “ACTH-Secreting 
Pituitary Adenoma”[all fields] OR “ACTH Secreting Pituitary Adenomas”[all fields]) AND (“functional mri”[All Fields] 
OR “fMRI”[all fields] OR “fmr”[all fields] OR “f mr”[all fields] OR “functional magnetic”[all fields] OR “functional mr”[all 
fields] OR ((“Magnetic Resonance Imaging”[Mesh] OR “mri”[All Fields] OR “MRIs”[All Fields] OR “magnetic reso-
nance imaging”[all fields]) AND (“functional”[all fields] OR “Mental Processes”[Mesh] OR “cognition”[all fields] OR 
“cognitive”[all fields] OR “task”[all fields] OR “tasks”[all fields] OR “learning”[all fields] OR “memory”[all fields]))) AND 
(“brain”[all fields] OR “Brain”[Mesh] OR “hippocampus”[all fields] OR “hippocampal”[all fields] OR “hippocampi”[all 
fields] OR hippocamp*[all fields] OR “amygdala”[all fields] OR “amygdalae”[all fields] OR “lymbic system”[all fields] 
OR “cerebellar”[all fields] OR “cerebellum”[all fields] OR cerebel*[all fields] OR cerebr*[all fields] OR “grey matter”[all 
fields] OR “gray matter”[all fields] OR “Mesencephalon”[all fields] OR “Locus Coeruleus”[all fields] OR “Raphe 
Nuclei”[all fields] OR “Tectum Mesencephali”[all fields] OR “Inferior Colliculi”[all fields] OR “Superior Colliculi”[all 
fields] OR “Tegmentum Mesencephali”[all fields] OR “Cerebral Aqueduct”[all fields] OR “Pedunculopontine Teg-
mental Nucleus”[all fields] OR “Periaqueductal Gray”[all fields] OR “Red Nucleus”[all fields] OR “Substantia Nigra”[all 
fields] OR “Ventral Tegmental Area”[all fields] OR “Reticular Formation”[all fields] OR “Rhombencephalon”[all 
fields] OR “Medulla Oblongata”[all fields] OR “Area Postrema”[all fields] OR “Olivary Nucleus”[all fields] OR “Soli-
tary Nucleus”[all fields] OR “Metencephalon”[all fields] OR “Cerebellum”[all fields] OR “Cerebellar Cortex”[all fields] 
OR “Purkinje Cells”[all fields] OR “Cerebellar Nuclei”[all fields] OR “Cerebellopontine Angle”[all fields] OR “Pons”[all 
fields] OR “Cochlear Nucleus”[all fields] OR “Locus Coeruleus”[all fields] OR “Vestibular Nuclei”[all fields] OR “Ra-
phe Nuclei”[all fields] OR “Trigeminal Nuclei”[all fields] OR “Trigeminal Nucleus”[all fields] OR “Trigeminal Caudal 
Nucleus”[all fields] OR “Cerebral”[all fields] OR “Choroid Plexus”[all fields] OR “Ependyma”[all fields] OR “Fourth 
Ventricle”[all fields] OR “Lateral Ventricles”[all fields] OR “Septum Pellucidum”[all fields] OR “Third Ventricle”[all 
fields] OR “Limbic System”[all fields] OR “Amygdala”[all fields] OR “Epithalamus”[all fields] OR “Habenula”[all fields] 
OR “Pineal Gland”[all fields] OR “Gyrus Cinguli”[all fields] OR “Dentate Gyrus”[all fields] OR “Pyramidal Cells”[all 
fields] OR “Hypothalamus”[all fields] OR “Olfactory Pathways”[all fields] OR “Islands of Calleja”[all fields] OR “Ol-
factory Bulb”[all fields] OR “Parahippocampal Gyrus”[all fields] OR “Entorhinal Cortex”[all fields] OR “Perforant 
Pathway”[all fields] OR “Substantia Innominata”[all fields] OR “Mesencephalon”[all fields] OR “Locus Coeruleus”[all 
fields] OR “Raphe Nuclei”[all fields] OR “Tectum Mesencephali”[all fields] OR “Inferior Colliculi”[all fields] OR “Superi-
or Colliculi”[all fields] OR “Tegmentum Mesencephali”[all fields] OR “Cerebral Aqueduct”[all fields] OR “Pedunculo-
pontine Tegmental Nucleus”[all fields] OR “Periaqueductal Gray”[all fields] OR “Red Nucleus”[all fields] OR “Substan-
tia Nigra”[all fields] OR “Ventral Tegmental Area”[all fields] OR “Prosencephalon”[all fields] OR “Diencephalon”[all 
fields] OR “Epithalamus”[all fields] OR “Habenula”[all fields] OR “Pineal Gland”[all fields] OR “Hypothalamus”[all 
fields] OR “Hypothalamic”[all fields] OR “Subthalamus”[all fields] OR “Entopeduncular Nucleus”[all fields] OR “Sub-
thalamic Nucleus”[all fields] OR “Thalamus”[all fields] OR “Thalamic Nuclei”[all fields] OR “Septal Nuclei”[all fields] 
OR “Septum Pellucidum”[all fields] OR “Telencephalon”[all fields] OR “Cerebrum”[all fields] OR “Basal Ganglia”[all 
fields] OR “Cerebral Cortex”[all fields] OR “Corpus Callosum”[all fields] OR “Diagonal Band of Broca”[all fields] OR 
“Internal Capsule”[all fields] OR “Olfactory Pathways”[all fields] OR “Islands of Calleja”[all fields] OR “Olfactory 
Bulb”[all fields] OR “Septum of Brain”[all fields] OR “Septal Nuclei”[all fields] OR “Septum Pellucidum”[all fields] OR 
“Rhombencephalon”[all fields] OR “Amygdala”[all fields] OR “Corpus Striatum”[all fields] OR “Globus Pallidus”[all 
fields] OR “Neostriatum”[all fields] OR “Nucleus Accumbens”[all fields] OR “Substantia Innominata”[all fields] 
OR “Basal Nucleus of Meynert”[all fields] OR “Caudate Nucleus”[all fields] OR “High Vocal Center”[all fields] OR 
“Putamen”[all fields] OR “Frontal Lobe”[all fields] OR “Motor Cortex”[all fields] OR “Prefrontal Cortex”[all fields] OR 
“Hippocampus”[all fields] OR “Dentate Gyrus”[all fields] OR “Pyramidal Cells”[all fields] OR “Neocortex”[all fields] OR 
“Occipital Lobe”[all fields] OR “Visual Cortex”[all fields] OR “Parietal Lobe”[all fields] OR “Somatosensory Cortex”[all 
fields] OR “Pyramidal Cells”[all fields] OR “Temporal Lobe”[all fields] OR “Auditory Cortex”[all fields] OR “Parahippo-
campal Gyrus”[all fields] OR “Entorhinal Cortex”[all fields] OR “Metencephalon”[all fields] OR “Myelencephalon”[all 
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fields] OR “Raphe Nuclei”[all fields] OR “Medulla Oblongata”[all fields] OR “Area Postrema”[all fields] OR “Olivary 
Nucleus”[all fields] OR “Solitary Nucleus”[all fields] OR “white matter”[all fields])
EMBASE (2 queries):
1: (cushing disease/ OR cushing syndrome/ OR “cushing disease”.mp OR “cushing’s disease”.mp OR “cushings dis-
ease”.mp OR “Cushing’s Syndrome”.mp OR “Cushing Syndrome”.mp OR “Cushings Syndrome”.mp OR “cushing”.mp 
OR “cushings”.mp OR “cushing’s”.mp OR ACTH secreting adenoma/ OR “ACTH-Producing Pituitary Adenoma”.mp OR 
“ACTH Producing Pituitary Adenoma”.mp OR “ACTH-Producing Pituitary Adenomas”.mp  OR “ACTH Producing Pitu-
itary Adenomas”.mp OR “ACTH Secreting Pituitary Adenoma”.mp OR “ACTH-Secreting Pituitary Adenomas”.mp OR 
“ACTH-Secreting Pituitary Adenoma”.mp OR “ACTH Secreting Pituitary Adenomas”.mp) AND (functional magnetic 
resonance imaging/ OR “functional mri”.mp OR “fMRI”.mp OR “fmr”.mp OR “f mr”.mp OR “functional magnetic”.mp 
OR “functional mr”.mp OR ((exp nuclear magnetic resonance imaging/ OR “mri”.mp OR “MRIs”.mp OR “magnetic 
resonance imaging”.mp) AND (“functional”.mp OR exp mental function/ OR “cognition”.mp OR “cognitive”.mp OR 
“task”.mp OR “tasks”.mp OR “learning”.mp OR “memory”.mp))) AND (“brain”.mp OR exp Brain/ OR “hippocampus”.mp 
OR “hippocampal”.mp OR “hippocampi”.mp OR hippocamp*.mp OR “amygdala”.mp OR “amygdalae”.mp OR “lymbic 
system”.mp OR “cerebellar”.mp OR “cerebellum”.mp OR cerebel*.mp OR cerebr*.mp OR “grey matter”.mp OR “gray 
matter”.mp OR “Mesencephalon”.mp OR “Locus Coeruleus”.mp OR “Raphe Nuclei”.mp OR “Tectum Mesencephali”.
mp OR “Inferior Colliculi”.mp OR “Superior Colliculi”.mp OR “Tegmentum Mesencephali”.mp OR “Cerebral Aque-
duct”.mp OR “Pedunculopontine Tegmental Nucleus”.mp OR “Periaqueductal Gray”.mp OR “Red Nucleus”.mp OR 
“Substantia Nigra”.mp OR “Ventral Tegmental Area”.mp OR “Reticular Formation”.mp OR “Rhombencephalon”.mp 
OR “Medulla Oblongata”.mp OR “Area Postrema”.mp OR “Olivary Nucleus”.mp OR “Solitary Nucleus”.mp OR “Met-
encephalon”.mp OR “Cerebellum”.mp OR “Cerebellar Cortex”.mp OR “Purkinje Cells”.mp OR “Cerebellar Nuclei”.mp 
OR “Cerebellopontine Angle”.mp OR “Pons”.mp OR “Cochlear Nucleus”.mp OR “Locus Coeruleus”.mp OR “Vestibular 
Nuclei”.mp OR “Raphe Nuclei”.mp OR “Trigeminal Nuclei”.mp OR “Trigeminal Nucleus”.mp OR “Trigeminal Caudal 
Nucleus”.mp OR “Cerebral”.mp OR “Choroid Plexus”.mp OR “Ependyma”.mp OR “Fourth Ventricle”.mp OR “Lateral 
Ventricles”.mp OR “Septum Pellucidum”.mp OR “Third Ventricle”.mp OR “Limbic System”.mp OR “Amygdala”.mp OR 
“Epithalamus”.mp OR “Habenula”.mp OR “Pineal Gland”.mp OR “Gyrus Cinguli”.mp OR “Dentate Gyrus”.mp OR “Pyra-
midal Cells”.mp OR “Hypothalamus”.mp OR “Olfactory Pathways”.mp OR “Islands of Calleja”.mp OR “Olfactory Bulb”.
mp OR “Parahippocampal Gyrus”.mp OR “Entorhinal Cortex”.mp OR “Perforant Pathway”.mp OR “Substantia Innomi-
nata”.mp OR “Mesencephalon”.mp OR “Locus Coeruleus”.mp OR “Raphe Nuclei”.mp OR “Tectum Mesencephali”.mp 
OR “Inferior Colliculi”.mp OR “Superior Colliculi”.mp OR “Tegmentum Mesencephali”.mp OR “Cerebral Aqueduct”.mp 
OR “Pedunculopontine Tegmental Nucleus”.mp OR “Periaqueductal Gray”.mp OR “Red Nucleus”.mp OR “Substantia 
Nigra”.mp OR “Ventral Tegmental Area”.mp OR “Prosencephalon”.mp OR “Diencephalon”.mp OR “Epithalamus”.mp 
OR “Habenula”.mp OR “Pineal Gland”.mp OR “Hypothalamus”.mp OR “Hypothalamic”.mp OR “Subthalamus”.mp 
OR “Entopeduncular Nucleus”.mp OR “Subthalamic Nucleus”.mp OR “Thalamus”.mp OR “Thalamic Nuclei”.mp OR 
“Septal Nuclei”.mp OR “Septum Pellucidum”.mp OR “Telencephalon”.mp OR “Cerebrum”.mp OR “Basal Ganglia”.mp 
OR “Cerebral Cortex”.mp OR “Corpus Callosum”.mp OR “Diagonal Band of Broca”.mp OR “Internal Capsule”.mp OR 
“Olfactory Pathways”.mp OR “Islands of Calleja”.mp OR “Olfactory Bulb”.mp OR “Septum of Brain”.mp OR “Septal Nu-
clei”.mp OR “Septum Pellucidum”.mp OR “Rhombencephalon”.mp OR “Amygdala”.mp OR “Corpus Striatum”.mp OR 
“Globus Pallidus”.mp OR “Neostriatum”.mp OR “Nucleus Accumbens”.mp OR “Substantia Innominata”.mp OR “Basal 
Nucleus of Meynert”.mp OR “Caudate Nucleus”.mp OR “High Vocal Center”.mp OR “Putamen”.mp OR “Frontal Lobe”.
mp OR “Motor Cortex”.mp OR “Prefrontal Cortex”.mp OR “Hippocampus”.mp OR “Dentate Gyrus”.mp OR “Pyramidal 
Cells”.mp OR “Neocortex”.mp OR “Occipital Lobe”.mp OR “Visual Cortex”.mp OR “Parietal Lobe”.mp OR “Somatosen-
sory Cortex”.mp OR “Pyramidal Cells”.mp OR “Temporal Lobe”.mp OR “Auditory Cortex”.mp OR “Parahippocampal 
Gyrus”.mp OR “Entorhinal Cortex”.mp OR “Metencephalon”.mp OR “Myelencephalon”.mp OR “Raphe Nuclei”.mp OR 
“Medulla Oblongata”.mp OR “Area Postrema”.mp OR “Olivary Nucleus”.mp OR “Solitary Nucleus”.mp OR “white mat-
ter”.mp)
2: (cushing disease/ OR cushing syndrome/ OR “cushing disease”.mp OR “cushing’s disease”.mp OR “cushings dis-
ease”.mp OR “Cushing’s Syndrome”.mp OR “Cushing Syndrome”.mp OR “Cushings Syndrome”.mp OR “cushing”.mp 
OR “cushings”.mp OR “cushing’s”.mp OR ACTH secreting adenoma/ OR “ACTH-Producing Pituitary Adenoma”.mp 
OR “ACTH Producing Pituitary Adenoma” OR “ACTH-Producing Pituitary Adenomas”.mp  OR “ACTH Producing Pitu-
itary Adenomas”.mp OR “ACTH Secreting Pituitary Adenoma”.mp OR “ACTH-Secreting Pituitary Adenomas”.mp OR 
“ACTH-Secreting Pituitary Adenoma”.mp OR “ACTH Secreting Pituitary Adenomas”.mp) AND (functional magnetic 
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resonance imaging/ OR “functional mri”.mp OR “fMRI”.mp OR “fmr”.mp OR “f mr”.mp OR “functional magnetic”.mp 
OR “functional mr”.mp)
Web of Science (2 queries):
1: TS=((cushing disease OR cushing syndrome OR “cushing disease” OR “cushing’s disease” OR “cushings disease” OR 
“Cushing’s Syndrome” OR “Cushing Syndrome” OR “Cushings Syndrome” OR “cushing” OR “cushings” OR “cushing’s” 
OR ACTH secreting adenoma OR “ACTH-Producing Pituitary Adenoma” OR “ACTH Producing Pituitary Adenoma” 
OR “ACTH-Producing Pituitary Adenomas”  OR “ACTH Producing Pituitary Adenomas” OR “ACTH Secreting Pituitary 
Adenoma” OR “ACTH-Secreting Pituitary Adenomas” OR “ACTH-Secreting Pituitary Adenoma” OR “ACTH Secreting 
Pituitary Adenomas”) AND (functional magnetic resonance imaging OR “functional mri” OR “fMRI” OR “fmr” OR “f 
mr” OR “functional magnetic” OR “functional mr” OR ((nuclear magnetic resonance imaging OR “mri” OR “MRIs” OR 
“magnetic resonance imaging”) AND (“functional” OR mental function OR “cognition” OR “cognitive” OR “task” OR 
“tasks” OR “learning” OR “memory”))) AND (“brain” OR Brain OR “hippocampus” OR “hippocampal” OR “hippocampi” 
OR hippocamp* OR “amygdala” OR “amygdalae” OR “lymbic system” OR “cerebellar” OR “cerebellum” OR cerebel* 
OR cerebr* OR “grey matter” OR “gray matter” OR “Mesencephalon” OR “Locus Coeruleus” OR “Raphe Nuclei” OR 
“Tectum Mesencephali” OR “Inferior Colliculi” OR “Superior Colliculi” OR “Tegmentum Mesencephali” OR “Cerebral 
Aqueduct” OR “Pedunculopontine Tegmental Nucleus” OR “Periaqueductal Gray” OR “Red Nucleus” OR “Substantia 
Nigra” OR “Ventral Tegmental Area” OR “Reticular Formation” OR “Rhombencephalon” OR “Medulla Oblongata” OR 
“Area Postrema” OR “Olivary Nucleus” OR “Solitary Nucleus” OR “Metencephalon” OR “Cerebellum” OR “Cerebellar 
Cortex” OR “Purkinje Cells” OR “Cerebellar Nuclei” OR “Cerebellopontine Angle” OR “Pons” OR “Cochlear Nucleus” 
OR “Locus Coeruleus” OR “Vestibular Nuclei” OR “Raphe Nuclei” OR “Trigeminal Nuclei” OR “Trigeminal Nucleus” 
OR “Trigeminal Caudal Nucleus” OR “Cerebral” OR “Choroid Plexus” OR “Ependyma” OR “Fourth Ventricle” OR “Lat-
eral Ventricles” OR “Septum Pellucidum” OR “Third Ventricle” OR “Limbic System” OR “Amygdala” OR “Epithalamus” 
OR “Habenula” OR “Pineal Gland” OR “Gyrus Cinguli” OR “Dentate Gyrus” OR “Pyramidal Cells” OR “Hypothalamus” 
OR “Olfactory Pathways” OR “Islands of Calleja” OR “Olfactory Bulb” OR “Parahippocampal Gyrus” OR “Entorhinal 
Cortex” OR “Perforant Pathway” OR “Substantia Innominata” OR “Mesencephalon” OR “Locus Coeruleus” OR “Raphe 
Nuclei” OR “Tectum Mesencephali” OR “Inferior Colliculi” OR “Superior Colliculi” OR “Tegmentum Mesencephali” OR 
“Cerebral Aqueduct” OR “Pedunculopontine Tegmental Nucleus” OR “Periaqueductal Gray” OR “Red Nucleus” OR 
“Substantia Nigra” OR “Ventral Tegmental Area” OR “Prosencephalon” OR “Diencephalon” OR “Epithalamus” OR “Ha-
benula” OR “Pineal Gland” OR “Hypothalamus” OR “Hypothalamic” OR “Subthalamus” OR “Entopeduncular Nucleus” 
OR “Subthalamic Nucleus” OR “Thalamus” OR “Thalamic Nuclei” OR “Septal Nuclei” OR “Septum Pellucidum” OR 
“Telencephalon” OR “Cerebrum” OR “Basal Ganglia” OR “Cerebral Cortex” OR “Corpus Callosum” OR “Diagonal Band 
of Broca” OR “Internal Capsule” OR “Olfactory Pathways” OR “Islands of Calleja” OR “Olfactory Bulb” OR “Septum of 
Brain” OR “Septal Nuclei” OR “Septum Pellucidum” OR “Rhombencephalon” OR “Amygdala” OR “Corpus Striatum” 
OR “Globus Pallidus” OR “Neostriatum” OR “Nucleus Accumbens” OR “Substantia Innominata” OR “Basal Nucleus 
of Meynert” OR “Caudate Nucleus” OR “High Vocal Center” OR “Putamen” OR “Frontal Lobe” OR “Motor Cortex” OR 
“Prefrontal Cortex” OR “Hippocampus” OR “Dentate Gyrus” OR “Pyramidal Cells” OR “Neocortex” OR “Occipital Lobe” 
OR “Visual Cortex” OR “Parietal Lobe” OR “Somatosensory Cortex” OR “Pyramidal Cells” OR “Temporal Lobe” OR “Au-
ditory Cortex” OR “Parahippocampal Gyrus” OR “Entorhinal Cortex” OR “Metencephalon” OR “Myelencephalon” OR 
“Raphe Nuclei” OR “Medulla Oblongata” OR “Area Postrema” OR “Olivary Nucleus” OR “Solitary Nucleus” OR “white 
matter”))
2: TS=((“cushing disease” OR “cushing syndrome” OR chsing OR cushing*  OR “cushing disease” OR “cushing’s dis-
ease” OR “cushings disease” OR “Cushing’s Syndrome” OR “Cushing Syndrome” OR “Cushings Syndrome” OR “cush-
ing” OR “cushings” OR “cushing’s” OR ACTH secreting adenoma OR “ACTH-Producing Pituitary Adenoma” OR “ACTH 
Producing Pituitary Adenoma” OR “ACTH-Producing Pituitary Adenomas”  OR “ACTH Producing Pituitary Adeno-
mas” OR “ACTH Secreting Pituitary Adenoma” OR “ACTH-Secreting Pituitary Adenomas” OR “ACTH-Secreting Pi-
tuitary Adenoma” OR “ACTH Secreting Pituitary Adenomas”) AND (“functional magnetic” OR “functional mri” OR 
“fMRI” OR “fmr” OR “f mr” OR “functional magnetic” OR “functional mr” OR “functional imaging”))
Cochrane (1 query):
((cushing disease OR cushing syndrome OR cushing disease OR cushing’s disease OR cushings disease OR Cush-
ing’s Syndrome OR Cushing Syndrome OR Cushings Syndrome OR cushing OR cushings OR cushing’s OR ACTH 
secreting adenoma OR ACTH-Producing Pituitary Adenoma OR ACTH Producing Pituitary Adenoma OR ACTH-
Producing Pituitary Adenomas  OR ACTH Producing Pituitary Adenomas OR ACTH Secreting Pituitary Adenoma 
OR ACTH-Secreting Pituitary Adenomas OR ACTH-Secreting Pituitary Adenoma OR ACTH Secreting Pituitary Ad-
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enomas) AND (functional magnetic resonance imaging OR functional mri OR fMRI OR fmr OR f mr OR functional 
magnetic OR functional mr OR ((nuclear magnetic resonance imaging OR mri OR MRIs OR magnetic resonance 
imaging) AND (functional OR mental function OR cognition OR cognitive OR task OR tasks OR learning OR mem-
ory))) AND (brain OR Brain OR hippocampus OR hippocampal OR hippocampi OR hippocamp* OR amygdala OR 
amygdalae OR lymbic system OR cerebellar OR cerebellum OR cerebel* OR cerebr* OR grey matter OR gray matter 
OR Mesencephalon OR Locus Coeruleus OR Raphe Nuclei OR Tectum Mesencephali OR Inferior Colliculi OR Supe-
rior Colliculi OR Tegmentum Mesencephali OR Cerebral Aqueduct OR Pedunculopontine Tegmental Nucleus OR 
Periaqueductal Gray OR Red Nucleus OR Substantia Nigra OR Ventral Tegmental Area OR Reticular Formation OR 
Rhombencephalon OR Medulla Oblongata OR Area Postrema OR Olivary Nucleus OR Solitary Nucleus OR Meten-
cephalon OR Cerebellum OR Cerebellar Cortex OR Purkinje Cells OR Cerebellar Nuclei OR Cerebellopontine Angle 
OR Pons OR Cochlear Nucleus OR Locus Coeruleus OR Vestibular Nuclei OR Raphe Nuclei OR Trigeminal Nuclei 
OR Trigeminal Nucleus OR Trigeminal Caudal Nucleus OR Cerebral OR Choroid Plexus OR Ependyma OR Fourth 
Ventricle OR Lateral Ventricles OR Septum Pellucidum OR Third Ventricle OR Limbic System OR Amygdala OR Epi-
thalamus OR Habenula OR Pineal Gland OR Gyrus Cinguli OR Dentate Gyrus OR Pyramidal Cells OR Hypothalamus 
OR Olfactory Pathways OR Islands of Calleja OR Olfactory Bulb OR Parahippocampal Gyrus OR Entorhinal Cortex OR 
Perforant Pathway OR Substantia Innominata OR Mesencephalon OR Locus Coeruleus OR Raphe Nuclei OR Tectum 
Mesencephali OR Inferior Colliculi OR Superior Colliculi OR Tegmentum Mesencephali OR Cerebral Aqueduct OR 
Pedunculopontine Tegmental Nucleus OR Periaqueductal Gray OR Red Nucleus OR Substantia Nigra OR Ventral 
Tegmental Area OR Prosencephalon OR Diencephalon OR Epithalamus OR Habenula OR Pineal Gland OR Hypo-
thalamus OR Hypothalamic OR Subthalamus OR Entopeduncular Nucleus OR Subthalamic Nucleus OR Thalamus 
OR Thalamic Nuclei OR Septal Nuclei OR Septum Pellucidum OR Telencephalon OR Cerebrum OR Basal Ganglia OR 
Cerebral Cortex OR Corpus Callosum OR Diagonal Band of Broca OR Internal Capsule OR Olfactory Pathways OR Is-
lands of Calleja OR Olfactory Bulb OR Septum of Brain OR Septal Nuclei OR Septum Pellucidum OR Rhombenceph-
alon OR Amygdala OR Corpus Striatum OR Globus Pallidus OR Neostriatum OR Nucleus Accumbens OR Substantia 
Innominata OR Basal Nucleus of Meynert OR Caudate Nucleus OR High Vocal Center OR Putamen OR Frontal Lobe 
OR Motor Cortex OR Prefrontal Cortex OR Hippocampus OR Dentate Gyrus OR Pyramidal Cells OR Neocortex OR 
Occipital Lobe OR Visual Cortex OR Parietal Lobe OR Somatosensory Cortex OR Pyramidal Cells OR Temporal Lobe 
OR Auditory Cortex OR Parahippocampal Gyrus OR Entorhinal Cortex OR Metencephalon OR Myelencephalon OR 
Raphe Nuclei OR Medulla Oblongata OR Area Postrema OR Olivary Nucleus OR Solitary Nucleus OR white matter))
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suPPleMenT 2. exPlanaTIon of used MeTHods
Method explanation
Imaging techniques
Functional MRI (fMRI) Functional  neuroimaging procedure measuring brain 
activity by detecting changes in blood flow and oxygen 
response (BOLD response).
     Face Memory Task Consists of two phases encoding of facial emotional 
expression within the scanner, and the surprise 
recognition after the scan.
     Facial Emotion Perception Test (FEPT) Assesses accuracy and speed of identification of facial 
expressions, with categorization of animals used as 
a control for visual processing ability and fine motor 
speed. Participants are asked to categorize faces into four 
categories (happy, sag, fearful, angry) and animals into 
four categories (dogs, cats, primates, birds) outside the 
scanner and within the scanner.
Proton Magnetic Resonance Spectroscopy 
(H-MRS)
Analytical technique that uses signals from hydrogen 
protons to determine the relative concentrations of target 
brain metabolites.
neuropsychological test
Rey Auditory Verbal Learning Test (RAVLT) Evaluates verbal learning and memory and consists of 15 
words which are visually presented in three trials and a 
fourth delayed trial. The amount of words recalled after 
each trial is counted. The more words produced, the better 
the learning capability. 
Rey-Osterrieth Complex Figure (ROCF) Assesses visual memory. Participants are asked to copy 
the figure, and draw it immediately or after 3 minutes 
(depending on the test version), and after 20 minutes 
again without seeing the figure.
Wisconsin Card Sorting Test (WCST) Assesses cognitive flexibility. Four models are shown to 
participants. Participants are asked to match their cards 
with one of the model, aiming to find the correct criteria, 
while criteria change over time.
Grooved Pegboard (GP) Assesses fine motor skills. Participants are asked to insert 
some pegs in a pegboard, as quick as possible, with both 
the dominant and non-dominant hand.
Iowa Gambling Task (IGT) Assesses decision making. Participants see four cards (A, 
B, C, D) on a computer screen. A-B are considered riskier, 
but subjects win more money on the short-term, but 
lose more in the long-term. C-D are considered safer, but 
subjects win less money in the short-term, but lose less 
money in the long-term. An increase in both the amount 
of lost money and the number of riskier cards reflect 
poorer decision making.
Selective Reminding Task (SRT) Consists of a six-trial word-list learning task of unpaired 
words. After the first trial participants are asked to state 
the words they remembered, without regard to order. In 
the five next trials, after being asked to state all 12 words, 
participants were selectively reminded only the words 
they did not remember from the previous trial.
Trail Making Test A (TMT-A) Assesses motor functions. Participants are asked to 
connect numbers in the right order.
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Trail Making Test B (TMT-B) Assesses dived attention. Participants are asked to 
connect numbers and letters in ascending order.
Wechsler Intelligence Scale for Children (WISC) Measures intelligence in children aged 6-16 years.
Wechsler Adult Intelligence Scale (WAIS) Measures intelligence in adults and older adolescents.
Boston Naming Test (BNT) Assesses denomination. Participants are asked to name 
a picture.
Symbol Digit Modality Test (SDMT) Assesses information processing speeds (attention, visual 
scanning, tracking). A model with symbols and numbers 
are shown to participants. In the presence of these 
models, participants are asked to fill out the numbers at 
the corresponding symbols, as quickly as possible.
Verbal fluency - FAS Assesses phonetic fluency. Participants are asked to call 
all the words they can within one minute. Words should 
begin with a specific letter, i.e. F-A-S.
Verbal fluency (D) Assesses phonetic fluency. Participants are asked to call 
all the words they can within one minute beginning with 
letter “D”.
California Verbal Learning Test – Children (CVLT-C) Assess learning and recall abilities as well as verbal 
learning and memory deficits.
Woodcock-Johnson Psychoeducational Battery Revised: 
Test of Achievement
Assesses cognitive abilities, scholastic aptitude, and 
achievement in the areas of reading, mathematics, and 
written language.
Cognitive Failure Questionnaire (CFQ) Assesses ones failures in perception, memory, and motor 
function. On this 25-item questionnaire each question can 
be answered on a 5-point Likert scale. A higher sum score 
indicates that an individual experiences greater cognitive 
failure.
Physical questionnaires
Physical and Neurologic Examination of Subtle Signs 
(PANESS)
Assesses subtle deficits of gross and fine motor function.
Cushing Severity Index (CSI) Assesses severity of symptoms and to retrospectively 
estimate (clinical severity) at the time of active disease. 
It contains eight clinical features and can be scored on a 
3-point scale. A higher score indicates greater severity.
Psychological measures
Beck Depression Inventory (BDI) 21-item inventory measuring severity of depression. Each 
question is scored on a scale from 0 to 3. Total higher 
scores indicate more severe depressive symptoms.
State-Trait Anxiety Inventory (STAI) 40-item inventory measuring state anxiety and trait 
anxiety. Higher scores indicate higher levels of anxiety.
Montgomery-Asberg Depression Rating Scale (MADRS) 10-item questionnaire which focuses on the most 
commonly occurring symptoms of depressive illness 
(i.e. apparent sadness, reported sadness, inability to feel, 
difficulty in concentration, inner tension, pessimistic 
thoughts, suicidal thoughts, lassitude, reduced sleep, 
reduced appetite). A higher total score indicates more 
severe depression.
Inventory of Depression Symptomatology (IDS) 28-item multiple-choice questionnaire, which is designed 
to measure severity of depressive symptoms. A higher 
total score indicates greater severity of depressive 
symptoms.
MRI studies in Cushing’s syndrome
59
2
Beck Anxiety Inventory (BAI) 21-item inventory which evaluates anxiety.  Each question 
can be answered on a 4-point Likert scale. A higher sum 
score indicates greater severity of anxiety.
Fear Questionnaire (FQ) 24-item questionnaire assessing phobic anxiety. Each 
question can be answered on an 8-point Likert scale. This 
total phobia score can be divided into three subscales: the 
agoraphobia subscale, the blood injury phobia subscale 
and the social phobia subscale. Higher scores indicate 
greater severity of phobias.
Irritability Scale (IS) Consists of 14 items on a 4-point scale, with higher scores 
indicating greater irritability. A total score of 14 point or 
more is being used to characterize subjects as irritable.
Apathy Scale (AS) Consists of 14 questions on a 4-point scale, with higher 
scores indicating greater apathy. A total score of 14 
points or more is being used to characterize subjects as 
apathetic.
Symptom Checklist (SCL-90-R) Consists of 90 items and assesses physical and 
psychological complaints.
Behavioral Assessment System for Children (BASC) Multidimensional system used to evaluate the behavior 
and self-perceptions of children, adolescents and young 
adults.
Kiddie Schedule for Affective Disorders and 
Schizophrenia-Present and Lifetime (KSADS-PL)
Semi-structured interview designed to generate DSM-IV 
psychiatric diagnoses in children of 6-18 years.
Quality of life
CushingQoL Assess Cushing-related QoL and consists of 12 questions 
on a 5-point Likert scale ranging from always to never, 
with a lower score indicating a greater impact on QoL.
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objective: Patients with long-term remission of Cushing’s disease (CD) have persistent 
psychological and cognitive impairments. It is unknown whether, and to what extent, these 
impairments are accompanied by structural abnormalities in the brain. We aim to investigate 
structural changes in the brain in a sample of patients with predominantly long-term remis-
sion of CD and to examine whether these changes are associated with psychological and 
cognitive dysfunction, and clinical severity.
design: A cross-sectional, case control study.
Methods: In 25 patients with predominantly long-term remission of CD and 25 matched 
healthy controls, grey matter volumes in the regions of interest (hippocampus, amygdala, an-
terior cingulate cortex) and in the whole brain were examined, using 3T Magnetic Resonance 
Imaging and a voxel-based morphometry approach. Psychological and cognitive functioning 
were assessed using validated questionnaires and clinical severity was assessed using the 
Cushing’s syndrome Severity Index.
results: Compared to controls, patients had smaller grey matter volumes of areas in the 
anterior cingulate cortex (on average 14%, P<0.05) and greater volume of the left posterior 
lobe of the cerebellum (on average 34%, P<0.05). As expected, patients with remitted CD 
reported more depressive symptoms (P=0.005), more anxiety (P=0.003), more social phobia 
(P=0.034), more apathy (P=0.002) and more cognitive failure (P=0.023) compared to controls, 
but the differences in grey matter volumes were not associated with psychological or cogni-
tive measures, nor with clinical severity. 
conclusion: Patients with predominantly long-term remission of CD showed specific struc-
tural brain abnormalities, in the presence of psychological dysfunction. Our data form a basis 
for future work aimed at elucidating the relation of the structural brain abnormalities and the 
sustained psychological deficits after long-term exposure to high cortisol levels.




Cushing’s disease (CD) is caused by excessive endogenous cortisol exposure (1). After suc-
cessful surgical correction of hypercortisolism, the physical, psychological and cognitive 
symptoms improve substantially (2;3). However, despite curative treatment of the adenomas 
per se, multiple physical, psychological and cognitive complaints may persist and morbidity 
and mortality remain increased, even in case of long-term remission (4;5). 
Cortisol is the main hormonal mediator of the stress response and acts via stimulation of 
both the mineralocorticoid (MR) and glucocorticoid receptors (GR) in the central nervous 
system. HPA-axis activity is regulated by limbic structures such as the hippocampus and 
amygdala and the anterior cingulate cortex (ACC) (6). These areas are also important target 
areas for glucocorticoid hormones via activation of MR and GR. In accordance, long-term 
exposure to elevated cortisol levels has been linked to functional and structural changes of 
these limbic structures both in humans and preclinical studies (7;8). For example, prolonged 
cortisol elevations predict memory dysfunction and reduced volume of the hippocampus 
and ACC during aging (9;10). Moreover, in patients with Cushing’s syndrome, hypercorti-
solism was associated with smaller hippocampal volumes and overall brain atrophy (11-13), 
with increasing hippocampal volumes and improving emotional and cognitive functioning 
after correction of hypercortisolism (11;14-18). 
To date, the long-term effects of  chronic overexposure to cortisol, such as in CD, on the 
brain has been evaluated in only one study (19). In that study, focusing on memory function 
and hippocampal volume in 33 patients with Cushing’s syndrome and 34 matched healthy 
controls, no overall differences in hippocampal volume between patients and controls were 
found (19). However, there was a considerable heterogeneity within the patient group in 
terms of disease status and treatment. Both patients with active CD and patients with CD in 
remission, with either pituitary or adrenal disease, were included and analyzed as one group 
(19), precluding definite conclusions. Furthermore, volumetric analyses were limited to the 
hippocampus and did not include other brain regions known to be important in emotional 
and cognitive functioning.
Recently, we performed a large cross-sectional study in a well-characterized cohort of 
patients with long-term biochemical remission, i.e. successful treatment for CD. We found 
a decreased quality of life (20;21), a higher prevalence of psychopathology (e.g. depression, 
anxiety, apathy) (22), maladaptive personality traits (22) and subtle cognitive impairments 
(23) despite long-term cure. The results of these studies suggest irreversible effects of longer 
periods with  glucocorticoid excess on brain function and possibly brain structure. These 
findings were associated with clinical characteristics (e.g. hydrocortisone dependency). 
The primary aim of the present cross-sectional study was to investigate whether this cohort 
of patients with predominantly long-term biochemical remission of pituitary-dependent 
CD shows structural brain abnormalities, using a voxel-based morphometry approach. In 
particular, given the results of our previous study, we aimed to evaluate structural changes in 
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important cerebral regions of the limbic system, i.e. the hippocampus, the amygdala, but also 
in a cerebral key region for both cognitive and emotional functioning: the ACC. Furthermore, 
we performed an explorative whole brain analysis to detect possible structural changes in 
areas outside this a priori defined regions of interest. In addition, we aimed to explore associa-
tions between structural changes and measures of psychological and cognitive dysfunction 
and to take clinical characteristics, such as hydrocortisone dependency into account. 
subjecTs and MeTHods 
subjects
All patients in long-term remission of CD of pituitary origin monitored at our institute (N=49) 
and between 18 and 60 years of age, were invited by letter and those who did not respond 
were contacted by phone. The response rate was 96% and 31 patients were screened for 
eligibility. Exclusion criteria were (history of ) drug- or alcohol abuse, neurological problems, 
contraindications for undergoing a MRI scan and left-handedness. 25 CD patients and 25 
matched healthy controls were included in the present study. All CD patients had been 
treated by transsphenoidal surgery, two patients (8%) additionally underwent bilateral ad-
renalectomy, whereas six patients (24%) had received additional radiotherapy. One patient 
(4%) used antidepressants. Healthy controls were pair-wise matched for gender, age, and 
education and recruited by advertisements in grocery stores and via Internet. Inclusion 
criteria for healthy controls were age between 18 and 60 years, right handedness, no current 
or prior drug- or alcohol abuse, no present and past history of  psychiatric or neurological 
disorders, no use of psychotropic medication and no contraindications for MRI scanning.   
The diagnosis of CD had been confirmed in all patients. ACTH dependent Cushing’s 
syndrome had been diagnosed based on internationally agreed guidelines, with clinical 
manifestations and positive biochemical tests, including increased urinary excretion rates 
of free cortisol, decreased overnight suppression by dexamethasone (1 mg) and elevated 
midnight salivary cortisol values. Cure of CD had been achieved by transsphenoidal surgery 
and, if necessary, followed by repeated surgery and/or postoperative radiotherapy. Cure 
of CD was defined by normal overnight suppression of plasma cortisol levels (< 50 nmol/ 
liter) after administration of dexamethasone (1 mg) and normal 24-h urinary excretion 
rates of cortisol (<220 nmol/24 h). Hydrocortisone independency was defined as a normal 
cortisol response to CRH or insulin tolerance test (> 500 nmol/L). Patients were followed at 
our department with yearly intervals, and pituitary hormone substitution was prescribed in 
accordance with the results of  the yearly evaluation. In patients who were glucocorticoid 
dependent after treatment, recovery of the pituitary-adrenal axis was tested twice a year. The 
dose of hydrocortisone was on average 20mg/d divided into 2-3 dosages. After withdrawal 
of hydrocortisone replacement for 24 hours, a fasting morning blood sample was taken for 
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the measurement of serum cortisol concentrations. Patients with serum cortisol concentra-
tion <120 nmol/liter were considered to have ongoing glucocorticoid dependency, and 
hydrocortisone treatment was restarted. Patients with serum cortisol levels of 120-500nmol/
liter were tested by ACTH stimulation tests (250µg). A normal response to ACTH stimulation 
was defined as a stimulated cortisol >550nmol/liter. When the cortisol response to ACTH 
was normal, patients were tested by ITT or CRH stimulation test. When cortisol responses 
to these tests were <550nmol/liter, hydrocortisone treatment was restarted. Evaluation of 
growth hormone (GH) deficiency was done by insulin-tolerance test or arginine-GHRH test 
only in patients under the age of 70 years and only after at least 2 years of remission. Patients 
with an inadequate stimulation of GH by one of these tests were treated with recombinant 
human GH, aiming at IGF-1 levels between 0 and +2 SD values. In addition, the twice yearly 
evaluation consisted of measurement of free T4 and testosterone levels (in male patients). 
If results were below the lower limit of the respective reference ranges, substitution with L-
thyroxin and/or testosterone was started. In the case of amenorrhea and low estradiol levels 
in premenopausal women, estrogen replacement was provided. Persistent cure of CD was 
documented by normal values of a dexamethasone (1 mg) suppression test, urinary cortisol 
excretion rates, and midnight salivary cortisol levels before participation in the current study. 
The estimated duration of disease was determined through patients’ history by looking for 
the earliest physical/somatic signs. Duration of remission was calculated from the date of cu-
rative transsphenoidal surgery, or in case of persistent disease, from the date of normalization 
of biochemical tests after postoperative radiotherapy. Patient and treatment characteristics 
were collected from the patient records. 
Written informed consent was obtained from all participants prior to the clinical assess-
ment and the MRI-scan session. Our institutional review board approved the study protocol.
This study was in accordance with the principles of the declaration of Helsinki.
study design
We scheduled a single study visit of approximately two hours for MRI scanning (60 minutes) 
and an interview for the evaluation of the clinical data and the assessment of psychological 
and cognitive functioning. Scan sessions took place between 9.00 am and 12.00 am. After 
the examination, participants were asked to complete several self-rating questionnaires at 
home for the assessment of psychopathology and cognitive functioning and to return them 
within a week.
assessment of psychopathology and cognitive functioning (appendix 1)
Presence and severity of depressive symptoms were evaluated using the Montgomery-
Åsberg Depression Rating Scale (MADRS) (24;25), which was the only scale that was assessed 
by the interviewer, and the Inventory of Depression Symptomatology (IDS) (26). Anxiety was 
evaluated using the Beck Anxiety Inventory (BAI) (27) and the Fear Questionnaire (FQ) (28). 
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Apathy and irritability were assessed using the Apathy Scale (AS) and the Irritability Scale (IS), 
respectively (29;30). The Cognitive Failures Questionnaire (CFQ) was used to assess failures in 
perception, memory, and motor function (31).   
cushing’s syndrome severity Index (csI) 
The Cushing’s syndrome Severity Index (CSI) (32) was used to assess current severity of symp-
toms and to retrospectively estimate (clinical) severity at the time of active disease. The CSI 
contains eight clinical features and can be scored on a 3-point scale, ranging from 0 to 2. A 
higher total score on the CSI indicates greater severity, with a range of 0–16. The information 
necessary for completing this index was derived from clinical history and medical files. Two 
raters, who reached consensus on each feature in case of discrepancy, scored the CSI. For 
the active phase, the CSI was scored retrospectively. The current score was evaluated based 
on the last yearly evaluation. The total score of the active phase and the total score of the 
remission phase were used in the analyses. 
MrI data acquisition
Images were acquired on a Philips 3T magnetic resonance imaging system (Philips Health-
care, Best, The Netherlands), (software version 3.2.1). A SENSE-32 channel head coil was used 
for radio frequency transmission and reception. For each subject, anatomical images were 
obtained using a sagittal 3-dimensional gradient-echo T1-weighted sequence (repetition 
time (TR) = 9.8 ms, echo time (TE) = 4.6 ms, matrix size 256 x 256, voxel size 1,17 x 1,17 
x 1,2 mm, 140 slices, scan duration 4:56 minutes) as part of a larger imaging protocol. A 
neuroradiologist, blinded for the clinical details of the subjects, examined all anatomical 
images. Apart from incidental age-related white matter hyperintensities and effects of the 
post-transsphenoidal surgeryin the perisellar area, no other macroscopic abnormalities were 
observed in the patients and controls. 
statistical analyses and data preprocessing
The first analysis comprised the voxel-based comparison of grey matter volumes in the 
regions of interest (ROI) (i.e. hippocampus, amygdala, ACC) and across the whole brain be-
tween patients with predominantly  long-term remission of CD and their matched healthy 
controls. Structural data was analyzed with FSL-VBM, a voxel-based morphometry style 
analysis (FMRIB’s Software Library) (33). First, structural images were brain-extracted and grey 
matter-segmented (34). The resulting grey matter partial volume images were then aligned 
to MNI152 (T1 standard brain average over 152 subjects; Montreal Neurological Institute, 
Montreal, QC, Canada) standard space, using affine registration (35), followed by nonlinear 
registration. The resulting images of all participants were averaged to create a study-specific 
template, to which the native grey matter images were then non-linearly re-registered. 
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The Jacobian of the warp field obtained in this registration reflects the voxel-wise relative 
volume change between the original and the study specific template (i.e. a Jacobian of 5 
indicates that a volume in the original image has been shrunk by a factor of 5). In order to 
correct for local expansion or contraction, the registered partial volume images were then 
modulated by dividing by the Jacobian of the warp field. The modulated segmented images 
were then smoothed with an isotropic Gaussian kernel with a sigma of 3 mm. The Gaussian 
outputs a weighted average of each voxel’s neighborhood, with the average weighted more 
towards the value of the centrally located voxels. The application of this type of smoothing 
reduces the noise in the data substantially.
The Harvard-Oxford Cortical and Subcortical Structural Atlases implemented in FSL were 
used to create masks for our regions of interest: the bilateral hippocampus, the bilateral 
amygdala and the ACC. Probability range was set to 50-100% for all three structures. The 
study-specific template was then applied to this mask to create a study specific template 
of the grey matter values in the regions of interest only. Finally, groups were compared us-
ing a general linear model (GLM) including age, gender and level of education as confound 
regressors. A voxel-wise GLM was applied using permutation-based (5000 permutations) 
non-parametric testing, correcting for multiple comparisons across space. First, groups 
were compared in our regions of interest, using the created mask. Second, an exploratory 
whole brain VBM analysis was done, using the study-specific grey matter image as a mask to 
investigate whether any unpredicted differences existed between CD patients and controls. 
To explore possible differences between patients with hydrocortisone substitution (n=13) 
and patients without substitution (n=12), these two steps were repeated contrasting these 
two groups. Threshold-free Cluster Enhancement was used for finding clusters in the data 
(36), with thresholds for both the regions of interest comparison as well as the whole brain 
analysis  set on P<0.05, corrected. In addition to the VBM analysis, we used FMRIB’s integrated 
registration and segmentation tool (FIRST) to perform an automated segmentation of the 
amygdala and the hippocampus, allowing both shape and volume analyses.
The second analysis compared patients with predominantly  long-term remission of CD 
and their matched healthy controls, on measures of psychological and cognitive function-
ing. Data from questionnaires were analyzed using SPSS for Windows version 20.0 (SPSS Inc., 
Chicago, IL). All data are presented as numbers and percentages, means and standard devia-
tions (SD) or median and interquartile range (IQR). The assumption of normal distribution 
was tested using the Kolmogorov-Smirnov Test and the assumption of equal variances with 
a Levene’s Test. With respect to psychological and cognitive functioning, normally distrib-
uted continuous variables between patients and matched controls were compared using 
t-tests, and non-normally distributed continuous variables (MADRS, IDS, BAI, FQ, AS, CFQ) 
using Mann-Whitney U tests. Considering the overlap in phenomenology assessed by the 
questionnaires, a strict correction for multiple testing might be too conservative, therefore 
all tests were two-sided with P<0.05 uncorrected. 
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A third analysis was conducted in the patient group. In this analysis, we examined voxel-
wise correlations of behavioural and clinical characteristics with grey matter volume in the 
areas resulting from  the ROI analysis and the whole brain analysis. The possible influence of 
radiotherapy could not be properly examined, considering the small number of patients that 
had received radiotherapy. The level of significance was set at P<0.05. 
resulTs
Patient characteristics
As expected, patients and matched healthy controls did not differ in age, gender and educa-
tion. The mean estimated duration of active disease was 7.9 ± 7.9 years (range 0.8 - 37.0). The 
mean duration of remission was 11.2 ± 8.2 years (range 0.8 - 29.4). Hydrocortisone replace-
ment therapy was given to 13 patients (52%). The mean CSI score during active disease was 
8.1 ± 2.0, and 2.5 ± 1.5 at the time of evaluation (i.e. long-term remission) (Table 1).







Gender (male/female) 4/21 4/21 1.000a
Age (years) 45 ± 8 47±7 0.471b
Education 0.946a
     Low 6 (24%) 6 (24%)
     Medium 12 (48%) 11 (44%)
     High 7 (28%) 8 (32%)
Surgery
Transsphenoidal  adenomectomy 25 (100%)
Bilateral adrenalectomy 2 (8%)
Radiotherapy 6 (24%)
Disease duration (years) 7.9 ± 7.9
Duration of remission (years) 11.2 ± 8.2
Hypopituitarism
      Any axis 14 (56%)
      GH 10 (40%)
      LH/FSH 9 (36%)
      TSH 10 (40%)
      ADH 3 (12%)
      Hydrocortisone substitution 13 (52%)
      Hydrocortisone dose (mg/d) 20.0 (0.0 – 20.0)
Clinical severity index
      Active phase, total 8.1 ± 2.0
      Remission phase, total 2.5 ± 1.5
P values were tested with: aChi-square test, bindependent-sample t-test. 
Data are presented as mean ± SD or number (%) or by median IQR.




Region of interest analyses 
The VBM-analysis, in patients in with predominantly long-term remission of CD showed 
smaller grey matter volumes in a large part of the bilateral ACC in comparison with controls. 
Closer examination of the data revealed that the patients had an average of 14% smaller grey 
matter volumes in the ACC compared to matched healthy controls. There were no grey mat-
ter volume differences in the bilateral hippocampus and amygdala (Figure 1A). We observed 
no greater grey matter volumes in any of the ROIs in CD patients, compared to controls. 
Furthermore, within the patient group no differences were found in grey matter volumes 
between patients with hydrocortisone substitution and patients without substitution. The 
FIRST analysis showed similar results, with no differences in both shape and volume of the 
bilateral amygdala and bilateral hippocampus, between patients and controls. 
Whole brain analysis
Patients with predominantly long-term remission of CD showed smaller grey matter volumes 
in the left perigenual region (Brodman’s area between BA 32 and BA 12) of the ACC, compared 
to controls (Figure 1B). Greater grey matter volumes were found in the posterior lobe of the 
left cerebellum in CD patients compared to controls (Figure 1C). On average patients showed 
34% larger grey matter volumes in the left posterior lobe of the cerebellum compared to 
controls (P<0.05). When the threshold was lowered to P<0.10 an additional similar effect 
was observed in grey matter volumes of the right posterior lobe of the cerebellum. Within 
the patient group, no differences were found in grey matter volumes between patients with 
hydrocortisone substitution and patients without substitution.
Psychopathology and cognitive functioning among patients and controls
Table 2 shows that patients with predominantly long-term remission of CD had more depres-
sive symptoms (P<0.005) compared to controls, as assessed with the MADRS and the IDS. The 
mean total score on the MADRS was 6.3, indicating mild depressive symptoms. Furthermore, 
CD patients experienced more anxiety (P=0.003), more social phobia (P=0.034), and a greater 
degree of apathy (P=0.002), with 44% of patients having a score of 14 or higher, which is 
indicative of clinically relevant apathy. On the Irritability scale, 36 % of the patients had 
a score of 14 or higher, which is indicative of clinically relevant irritability. In addition, CD 
patients reported more cognitive failure (P=0.023) compared to controls. No other significant 
between-group differences were found. Within the patient group, no significant differences 
were found in psychopathology and cognitive functioning between patients with hydrocor-
tisone substitution and patients without substitution.
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figure 1. VBM analysis results.
A): Results of regions of interest analysis, with grey matter volumes in patients < controls (P < 0.05; 617 voxels, 
2mm isotropic). 
B): Results of whole brain analysis with grey matter volumes in patients < controls (P < 0.05; 37 voxels, 2mm iso-
tropic). 
C): Results of whole brain analysis with grey matter volumes in patients > controls (P < 0.05; 323 voxels, 2mm 
isotropic). Effects are presented on the MNI-152 1mm standard brain at a threshold of P < 0.05. Coordinates are x 
= -4, y = 42, z = 0 for Fig. 1a and 1b and x = -29, y = -66, z = -56 for Fig. 1C. The left hemisphere corresponds with 
the right side of the image.
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Furthermore, in the patient group no significant associations between grey matter volumes 
in the ACC and cerebellum, and scores on the distinguishing psychometric instruments 
(MADRS, IDS, BAI, AS, CFQ) were found using a voxel-wise correlation approach. Also, no 
significant associations between grey matter volumes of the areas of effect and clinical char-
acteristics (i.e. estimated disease duration, duration of remission, Clinical Severity Indexes; 
active and remission subscale) (data not shown) were found.
dIscussIon
The present study demonstrates that structural abnormalities in the brain are present in 
patients cured from CD, despite long-term remission. The data indicate that in comparison 
to matched healthy controls, volumes of areas in the ACC were smaller, whereas grey matter 
volumes of the left posterior lobe of the cerebellum were larger in patients. There were no 
significant differences in grey matter volumes in  the hippocampus or amygdala between 
the two groups. These findings may support the hypothesis that the increased prevalence of 
depressive symptoms, anxiety, apathy and cognitive impairments observed in patients with 
long-term cured CD (22;23) is associated with structural brain changes. However, in these pa-
tients no significant correlations were found between psychological dysfunction and clinical 
characteristics on the one hand, and  the grey matter volumes of the ACC and left posterior 
lobe of the cerebellum on the other hand.
Table 2. Psychopathology and cognitive failure questionnaires: patients with predominantly long-term re-






MADRS 6.3 ± 5.5 1.4 ± 1.8 0.000b
Inventory depression scale (IDS) 46.8 ± 13.0 36.3 ± 5.8 0.005b
Beck Anxiety inventory (BAI) 28.4 ± 5.7 24.0 ± 3.1 0.003b
Fear Questionnaire (FQ) 24.5 ± 17.4 14.2 ± 10.0 0.051b
      agoraphobia subscale 6.1 ± 7.9 3.4 ± 4.7 0.477b
      blood injury phobia subscale 6.2 ± 8.3 3.2 ± 4.1 0.118a
      social phobia subscale 12.2 ± 8.0 7.6 ± 4.9 0.034b
Irritability scale (IS) 12.1 ± 8.7 8.0 ± 6.1 0.066a
      Total score > 14 9 (36%) 6 (24%)
Apathy scale (AS) 13.6 ± 6.6 7.8± 3.8 0.002b
      Total score > 14 11 (44%) 2 (8%)
Cognitive failure questionnaire (CFQ) 38.0 ± 16.5 27.6 ± 9.7 0.023b
P values were tested with: a independent-sample t-test, b Mann-Whitney U test. 
Level of significance was set at P<0.05 and significant values are in bold. 
Data are presented as mean ± SD or number (%).
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We confirmed our hypothesis that the ACC would be affected in cured CD. The amygdala 
and hippocampus are connected to the anterior regions of the ACC and constitute a neural 
circuitry for stress reactivity and modulation (37). Dysfunction of this circuitry is implicated in 
mood and anxiety disorders (38). In addition, patients with stress-related psychopathology 
show a reduced volume of the ACC (39;40). In accordance, reduction of ACC volume is also 
found in animals exposed to hypercortisolism (8) and in elderly humans with dysregula-
tion of the HPA-axis (10). Importantly, the ACC is involved in cognitive-affective processes 
such as assessing the projection of emotional and motivational stimuli and the regulation 
of emotional responses (41), and mediates ongoing behavioral adaptation (42).  Therefore, 
the identified abnormalities of the ACC may be involved in disturbances of cognitive and 
emotional functioning identified in CD (43) and in patients after long-term remission of CD 
(4;22;23). However, in the current study we were not able to demonstrate a  correlation be-
tween the observed brain changes and quantitative estimates of psychopathology. This may 
be due to power problems or limitations of the clinical rating scales for psychopathology. An 
alternative hypothesis could be that the identified structural abnormalities may also underlie 
or reflect abnormalities in functional or structural connectivity. 
In the exploratory whole brain analysis we found an enlarged volume of the left cerebellum 
in patients with predominantly  long-term remission of CD. When we lowered the threshold, 
grey matter volumes of the right cerebellum were also found to be enlarged in patients 
with predominantly long-term remission of CD, indicating that this effect might be bilateral. 
Interestingly, the cerebellum is susceptible to increased cortisol levels (44) and it is involved 
in motor functioning, as well as cognitive and emotional functioning (45). Intriguingly, a 
study by Spinelli et al. (2009), reported that individuals exposed to an extremely stressful 
environment developed a larger cerebellum (46). Another research group investigated the 
effect of chronic stress on cortical and striatal circuits (required for goal-directed behavior 
and habits) in rats. They found global hypertrophy of the dorsolateral striatum and atrophy of 
the dorsomedial striatum and suggested that the reorganization of the corticostriatal circuits 
after chronic stress is bidirectional, based on hypertrophy and atrophy of neuronal dendritic 
trees (47). This mechanism of bidirectional reorganization could also provide an explanation 
for the larger volume of the cerebellum in our patients treated for CD.  
Contrary to our hypotheses, we did not find alterations in the hippocampus and amygdala. 
However, it might be that these brain structures were affected during active disease (11-13), 
but that grey matter volumes increased after biochemical cure. This would be in accordance 
with the previously found increase in hippocampal volume in CD patients after correction 
of hypercortisolism (11;14-16) and the well-documented plasticity of hippocampal neurons 
in animal models (48). Nevertheless, children experienced cognitive decline despite reversal 
of brain atrophy one year after surgical remission (49) and adult patients with long-term 
remission of CD still demonstrated impaired memory function (23). Recently, a potential 
mechanism was provided for this persisted memory impairment, by demonstrating that 
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in comparison to healthy matched controls, patients in remission of CD show biochemical 
abnormalities in the hippocampus, without hippocampal volume reduction (50). Studies in 
animals have documented that other brain areas also show structural changes in response to 
increased cortisol levels (47). However, the plasticity (in this case the extent of reversibility) 
of these non-hippocampal structures in CD is still unknown. Since there are no studies that 
have focused on other brain structures in patients with active CD, like the ACC or amygdala, it 
is not clear when these structural changes occur and how they develop over time. 
For direct effects of glucocorticoids on a brain area, either the MR or GR  has to be pres-
ent in this area. Using data on human brain tissue arrays available from  ‘The Allen Institute 
for Brain Science’, a high expression was demonstrated of both MR and/or GR,  not only in 
the hippocampus, ACC and amygdala, but also in the cerebellum (51).  Taken into account 
the effects found in our study, which were limited to the ACC and cerebellum, one can con-
clude that  expression of MR and/or GR in a brain area is necessary, but not predictive of 
structural changes following chronic overexposure to glucocorticoids. A possible alternative 
explanation is that structural changes may also occur via transsynaptic mechanisms. Such 
mechanisms have been suggested for (transient) morphological changes in the hippocampal 
CA3 area, which itself expresses very low numbers of GRs, but receives input from the cortisol 
sensitive dentate gyrus (52).
To our knowledge, our study is the first to show that structural abnormalities in the brain 
are present in patients cured from CD, despite long-term remission. Strengths of our study 
are the homogeneity of our patient cohort with regard to treatment (i.e. all patients had been 
treated with transsphenoidal surgery)  and the careful selection of controls. Nevertheless, 
heterogeneity still existed in the patient group with regard to disease duration and duration 
of remission, which may have decreased the power of this study. Although a sample size 
of 25 in both groups is appropriate for the evaluation of structural changes with MRI (53), 
our study might have been underpowered to detect possible correlations between clinical 
data, psychological and cognitive measures, and grey matter volumes within the patient 
group, and to detect grey matter differences between patients with or without hydrocorti-
sone substitution. In addition, cognitive functions were assessed using a questionnaire (i.e. 
CFQ), and although this questionnaire has been validated repeatedly, it is no substitute for 
extensive neuropsychological testing, which gives a more accurate representation of cogni-
tive functioning. Furthermore, because of our cross-sectional design it cannot be excluded 
that structural abnormalities were already present in patients before onset of CD. The use of 
a longitudinal design in future research could provide more insight into the course of the 
found abnormalities. 
In general, alterations in grey matter volume in adults with pathology have been found to 
be associated with dysfunctions of specific areas or related circuitry. However, the absence of 
volumetric differences does not exclude functional alterations in brain areas and circuits. It 
should also be acknowledged that a volumetric VBM approach does not reveal the underly-
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ing changes or pathology in grey matter microstructure, i.e. at the level of neurons or glia 
cells. Subsequently, at present there are no data available on abnormalities at the level of 
neurons or glia cells after chronic overexposure to glucocorticoids that may shed more light 
on the nature of the observed structural abnormalities. Therefore, conclusions about func-
tional alterations in the specific brain areas cannot be drawn based solely on our findings. 
Exploring functional brain characteristics in our sample would be an important next step 
to further elucidate the neurobiological basis of psychological dysfunction in patients with 
remitted CD. 
The data presented in this study provide a further perspective towards detailed pheno-
typing of patients after treatment of CD, who have always been considered cured  after 
long-term remission of hypercortisolism. In agreement with others, CD and possibly Cush-
ing’s syndrome as well, could be a unique model to study the apparently prolonged, or even 
irreversible, effects of increased cortisol exposure on the brain. It is tempting to speculate 
that these findings, to a certain extent, could also apply to patients with chronic or recurrent 
forms of highly prevalent stress-related disorders, and, in addition, to patients chronically 
treated with exogenous corticosteroids, that are commonly prescribed to suppress the im-
mune system (54). 
In summary, the present study demonstrates that patients with long-term cure after treat-
ment for CD have profound structural alterations in the brain, with smaller volumes of an 
area in the ACC and greater volumes of the left posterior lobe of the cerebellum, and report 
more depressive symptoms, anxiety, social phobia, apathy,  and cognitive failure, compared 
to healthy controls. The findings suggest possible structural substrates for long-term psycho-
logical effects of hypercortisolemia in CD. Clearly, more research is needed to increase our 
insight in the underlying mechanisms and the trajectory of changes, which may also lead to 
the identification of ‘critical time windows’ or potential targets for prevention. 
references
 (1)  Newell-Price J, Bertagna X, Grossman AB, Nieman LK. Cushing’s syndrome. Lancet 2006 May 
13;367(9522):1605-17.
 (2)  Dorn LD, Burgess ES, Friedman TC, Dubbert B, Gold PW, Chrousos GP. The longitudinal course of 
psychopathology in Cushing’s syndrome after correction of hypercortisolism. J Clin Endocrinol 
Metab 1997 Mar;82(3):912-9.
 (3)  Starkman MN, Schteingart DE, Schork MA. Cushing’s syndrome after treatment: changes in 
cortisol and ACTH levels, and amelioration of the depressive syndrome. Psychiatry Res 1986 
Nov;19(3):177-88.
 (4)  Pereira AM, Tiemensma J, Romijn JA. Neuropsychiatric disorders in Cushing’s syndrome. Neuroen-
docrinology 2010;92 Suppl 1:65-70.
 (5)  Feelders RA, Pulgar SJ, Kempel A, Pereira AM. MANAGEMENT OF ENDOCRINE DISEASE: The bur-
den of Cushing’s disease: clinical and health-related quality of life aspects. Eur J Endocrinol 2012 
Sep;167(3):311-26.
Brain abnormalities after Cushing’s disease
75
3
 (6)  De Kloet ER, Joels M, Holsboer F. Stress and the brain: from adaptation to disease. Nat Rev Neuro-
sci 2005 Jun;6(6):463-75.
 (7)  McEwen BS, Eiland L, Hunter RG, Miller MM. Stress and anxiety: structural plasticity and epigen-
etic regulation as a consequence of stress. Neuropharmacology 2012 Jan;62(1):3-12.
 (8)  Cerqueira JJ, Catania C, Sotiropoulos I, Schubert M, Kalisch R, Almeida OF, et al. Corticosteroid 
status influences the volume of the rat cingulate cortex - a magnetic resonance imaging study. J 
Psychiatr Res 2005 Sep;39(5):451-60.
 (9)  Lupien SJ, de LM, de SS, Convit A, Tarshish C, Nair NP, et al. Cortisol levels during human aging 
predict hippocampal atrophy and memory deficits. Nat Neurosci 1998 May;1(1):69-73.
 (10)  MacLullich AM, Ferguson KJ, Wardlaw JM, Starr JM, Deary IJ, Seckl JR. Smaller left anterior cingu-
late cortex volumes are associated with impaired hypothalamic-pituitary-adrenal axis regulation 
in healthy elderly men. J Clin Endocrinol Metab 2006 Apr;91(4):1591-4.
 (11)  Bourdeau I, Bard C, Noel B, Leclerc I, Cordeau MP, Belair M, et al. Loss of brain volume in en-
dogenous Cushing’s syndrome and its reversibility after correction of hypercortisolism. J Clin 
Endocrinol Metab 2002 May;87(5):1949-54.
 (12)  Starkman MN, Gebarski SS, Berent S, Schteingart DE. Hippocampal formation volume, memory 
dysfunction, and cortisol levels in patients with Cushing’s syndrome. Biol Psychiatry 1992 Nov 
1;32(9):756-65.
 (13)  Simmons NE, Do HM, Lipper MH, Laws ER, Jr. Cerebral atrophy in Cushing’s disease. Surg Neurol 
2000 Jan;53(1):72-6.
 (14)  Toffanin T, Nifosi F, Follador H, Passamani A, Zonta F, Ferri G, et al. Volumetric MRI analysis of 
hippocampal subregions in Cushing’s disease: a model for glucocorticoid neural modulation. Eur 
Psychiatry 2011 Jan;26(1):64-7.
 (15)  Starkman MN, Giordani B, Gebarski SS, Berent S, Schork MA, Schteingart DE. Decrease in cortisol 
reverses human hippocampal atrophy following treatment of Cushing’s disease. Biol Psychiatry 
1999 Dec 15;46(12):1595-602.
 (16)  Hook JN, Giordani B, Schteingart DE, Guire K, Giles J, Ryan K, et al. Patterns of cognitive change 
over time and relationship to age following successful treatment of Cushing’s disease. J Int Neu-
ropsychol Soc 2007 Jan;13(1):21-9.
 (17)  Starkman MN, Giordani B, Gebarski SS, Schteingart DE. Improvement in learning associated with 
increase in hippocampal formation volume. Biol Psychiatry 2003 Feb 1;53(3):233-8.
 (18)  Starkman MN, Giordani B, Gebarski SS, Schteingart DE. Improvement in mood and ideation as-
sociated with increase in right caudate volume. J Affect Disord 2007 Aug;101(1-3):139-47.
 (19)  Resmini E, Santos A, Gomez-Anson B, Vives Y, Pires P, Crespo I, et al. Verbal and visual memory 
performance and hippocampal volumes, measured by 3-Tesla magnetic resonance imaging, in 
patients with Cushing’s syndrome. J Clin Endocrinol Metab 2012 Feb;97(2):663-71.
 (20)  van Aken MO, Pereira AM, Biermasz NR, van Thiel SW, Hoftijzer HC, Smit JW, et al. Quality of life 
in patients after long-term biochemical cure of Cushing’s disease. J Clin Endocrinol Metab 2005 
Jun;90(6):3279-86.
 (21)  Tiemensma J, Kaptein AA, Pereira AM, Smit JW, Romijn JA, Biermasz NR. Negative illness percep-
tions are associated with impaired quality of life in patients after long-term remission of Cushing’s 
syndrome. Eur J Endocrinol 2011 Oct;165(4):527-35.
 (22)  Tiemensma J, Biermasz NR, Middelkoop HA, van der Mast RC, Romijn JA, Pereira AM. Increased 
prevalence of psychopathology and maladaptive personality traits after long-term cure of Cush-
ing’s disease. J Clin Endocrinol Metab 2010 Oct;95(10):E129-E141.
76
Chapter 3
 (23)  Tiemensma J, Kokshoorn NE, Biermasz NR, Keijser BJ, Wassenaar MJ, Middelkoop HA, et al. Subtle 
cognitive impairments in patients with long-term cure of Cushing’s disease. J Clin Endocrinol 
Metab 2010 Jun;95(6):2699-714.
 (24)  Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J 
Psychiatry 1979 Apr;134:382-9.
 (25)  Snaith RP, Harrop FM, Newby DA, Teale C. Grade scores of the Montgomery-Asberg Depression 
and the Clinical Anxiety Scales. Br J Psychiatry 1986 May;148:599-601.
 (26)  Rush AJ, Gullion CM, Basco MR, Jarrett RB, Trivedi MH. The Inventory of Depressive Symptomatol-
ogy (IDS): psychometric properties. Psychol Med 1996 May;26(3):477-86.
 (27)  Beck AT, Epstein N, Brown G, Steer RA. An inventory for measuring clinical anxiety: psychometric 
properties. J Consult Clin Psychol 1988 Dec;56(6):893-7.
 (28)  Marks IM, Mathews AM. Brief standard self-rating for phobic patients. Behav Res Ther 
1979;17(3):263-7.
 (29)  Starkstein SE, Petracca G, Chemerinski E, Kremer J. Syndromic validity of apathy in Alzheimer’s 
disease. Am J Psychiatry 2001 Jun;158(6):872-7.
 (30)  Chatterjee A, Anderson KE, Moskowitz CB, Hauser WA, Marder KS. A comparison of self-report and 
caregiver assessment of depression, apathy, and irritability in Huntington’s disease. J Neuropsy-
chiatry Clin Neurosci 2005;17(3):378-83.
 (31)  Broadbent DE, Cooper PF, FitzGerald P, Parkes KR. The Cognitive Failures Questionnaire (CFQ) and 
its correlates. Br J Clin Psychol 1982 Feb;21 (Pt 1):1-16.
 (32)  Sonino N, Boscaro M, Fallo F, Fava GA. A clinical index for rating severity in Cushing’s syndrome. 
Psychother Psychosom 2000 Jul;69(4):216-20.
 (33)  Smith SM, Jenkinson M, Woolrich MW, Beckmann CF, Behrens TE, Johansen-Berg H, et al. Advances 
in functional and structural MR image analysis and implementation as FSL. Neuroimage 2004;23 
Suppl 1:S208-S219.
 (34)  Zhang Y, Brady M, Smith S. Segmentation of brain MR images through a hidden Markov ran-
dom field model and the expectation-maximization algorithm. IEEE Trans Med Imaging 2001 
Jan;20(1):45-57.
 (35)  Jenkinson M, Bannister P, Brady M, Smith S. Improved optimization for the robust and accurate 
linear registration and motion correction of brain images. Neuroimage 2002 Oct;17(2):825-41.
 (36)  Smith SM, Nichols TE. Threshold-free cluster enhancement: addressing problems of smoothing, 
threshold dependence and localisation in cluster inference. Neuroimage 2009 Jan 1;44(1):83-98.
 (37)  Shin LM, Liberzon I. The neurocircuitry of fear, stress, and anxiety disorders. Neuropsychopharma-
cology 2010 Jan;35(1):169-91.
 (38)  Bremner JD. Neuroimaging in posttraumatic stress disorder and other stress-related disorders. 
Neuroimaging Clin N Am 2007 Nov;17(4):523-38, ix.
 (39)  Woodward SH, Kaloupek DG, Streeter CC, Martinez C, Schaer M, Eliez S. Decreased anterior cingu-
late volume in combat-related PTSD. Biol Psychiatry 2006 Apr 1;59(7):582-7.
 (40)  van Tol MJ, van der Wee NJ, van den Heuvel OA, Nielen MM, Demenescu LR, Aleman A, et 
al. Regional brain volume in depression and anxiety disorders. Arch Gen Psychiatry 2010 
Oct;67(10):1002-11.
 (41)  Bush G, Luu P, Posner MI. Cognitive and emotional influences in anterior cingulate cortex. Trends 
Cogn Sci 2000 Jun;4(6):215-22.
 (42)  Sheth SA, Mian MK, Patel SR, Asaad WF, Williams ZM, Dougherty DD, et al. Human dorsal an-
terior cingulate cortex neurons mediate ongoing behavioural adaptation. Nature 2012 Aug 
9;488(7410):218-21.
Brain abnormalities after Cushing’s disease
77
3
 (43)  Starkman MN, Schteingart DE. Neuropsychiatric manifestations of patients with Cushing’s syn-
drome. Relationship to cortisol and adrenocorticotropic hormone levels. Arch Intern Med 1981 
Feb;141(2):215-9.
 (44)  Teicher MH, Andersen SL, Polcari A, Anderson CM, Navalta CP, Kim DM. The neurobiological 
consequences of early stress and childhood maltreatment. Neurosci Biobehav Rev 2003 Jan;27(1-
2):33-44.
 (45)  Baumann O, Mattingley JB. Functional topography of primary emotion processing in the human 
cerebellum. Neuroimage 2012 Jul 16;61(4):805-11.
 (46)  Spinelli S, Chefer S, Suomi SJ, Higley JD, Barr CS, Stein E. Early-life stress induces long-term mor-
phologic changes in primate brain. Arch Gen Psychiatry 2009 Jun;66(6):658-65.
 (47)  Dias-Ferreira E, Sousa JC, Melo I, Morgado P, Mesquita AR, Cerqueira JJ, et al. Chronic stress causes 
frontostriatal reorganization and affects decision-making. Science 2009 Jul 31;325(5940):621-5.
 (48)  Schubert MI, Kalisch R, Sotiropoulos I, Catania C, Sousa N, Almeida OF, et al. Effects of altered 
corticosteroid milieu on rat hippocampal neurochemistry and structure--an in vivo magnetic 
resonance spectroscopy and imaging study. J Psychiatr Res 2008 Sep;42(11):902-12.
 (49)  Merke DP, Giedd JN, Keil MF, Mehlinger SL, Wiggs EA, Holzer S, et al. Children experience cognitive 
decline despite reversal of brain atrophy one year after resolution of Cushing syndrome. J Clin 
Endocrinol Metab 2005 May;90(5):2531-6.
 (50)  Resmini E, Santos A, Gomez-Anson B, Lopez-Mourelo O, Pires P, Vives-Gilabert Y, et al. Hippo-
campal dysfunction in cured Cushing’s syndrome patients, detected by 1H-MR-spectroscopy. Clin 
Endocrinol 2013 May 1;79(5):700-7.
 (51)  Hawrylycz MJ, Lein ES, Guillozet-Bongaarts AL, Shen EH, Ng L, Miller JA, et al. An anatomically 
comprehensive atlas of the adult human brain transcriptome. Nature 2012 Sep 20;489(7416):391-
9.
 (52)  Fuchs E, Flugge G, Czeh B. Remodeling of neuronal networks by stress. Front Biosci 2006;11:2746-
58.
 (53)  Pell GS, Briellmann RS, Chan CH, Pardoe H, Abbott DF, Jackson GD. Selection of the control 
group for VBM analysis: influence of covariates, matching and sample size. Neuroimage 2008 Jul 
15;41(4):1324-35.




aPPendIx 1. descrIPTIon of used PsycHoPaTHoloGy and coGnITIVe 
faIlure QuesTIonnaIres.
Inventory of Depression Symptomatology (IDS) is a 28-item multiple-choice questionnaire, 
which is designed to measure severity of depressive symptoms. A higher total score indicates 
greater severity of depressive symptoms (24). 
Montgomery-Åsberg Depression Rating Scale (MADRS) is a 10-item questionnaire which 
focuses on the most commonly occurring symptoms of depressive illness (i.e. apparent sad-
ness, reported sadness, inability to feel, difficulty in concentration, inner tension, pessimistic 
thoughts, suicidal thoughts, lassitude, reduced sleep, reduced appetite). A higher total score 
indicates more severe depression (22), with severity grades: 0-6 = absent, 7-19 = mild, 20-34 
= moderate, 35-60 = severe (23).
Beck Anxiety Inventory (BAI) is a 21-question inventory which evaluates anxiety. For each 
question the participant was asked to chose between 4 answers, ranging from 1 = not al all, 
to 4 = severely. A higher sum score indicates greater severity of anxiety (25). 
Fear questionnaire (FQ) is a 24-item questionnaire assessing phobic anxiety. Each question 
can be answered on an 8-point Likert scale, ranging from 0 = would not avoid it, to 8 = always 
avoid it. For the present study, we only used the items necessary for the total phobia score 
(item 2-16). This total phobia score can be divided into three subscales: the agoraphobia 
subscale, the blood injury phobia subscale and the social phobia subscale. Higher scores 
indicate greater severity of phobias (26).
Apathy Scale (AS) consists of 14 questions on a 4-point scale. The items ranges from 0 = no 
apathetic behavior, to 3 = maximum intensity of apathetic behavior. A total score can range 
from 0 to 42 points, with higher scores indicating greater apathy. A total score of 14 points or 
more is being used to characterize subjects as apathetic (27;28).
Irritability Scale (IS) consists of 14 items on a 4-point scale. The items ranges from 0 = no 
irritable behavior, to 3 = maximum intensity of irritable behavior. Sum scores can range from 
0 to 42, with higher scores indicating greater irritability. A total score of 14 point or more is 
being used to characterize subjects as irritable (28).
Cognitive Failures Questionnaire (CFQ) measure ones failures in perception, memory, and 
motor function. On this 25-item questionnaire each question can be answered on a 5-point 
Likert scale, ranging from 0 = never, to 4 = very often. A higher sum score indicates that an 
individual experiences greater cognitive failure (29).   
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Patients with long-term remission of Cushing’s disease (CD) demonstrate residual psycho-
logical complaints. At present, it is not known how previous exposure to hypercortisolism 
affects psychological functioning in the long-term. Earlier Magnetic Resonance Imaging 
(MRI) studies demonstrated abnormalities of brain structure and resting-state connectivity in 
patients with long-term remission of CD, but no data are available on functional alterations in 
the brain during the performance of emotional or cognitive tasks in these patients. 
We performed a cross-sectional functional MRI study, investigating brain activation during 
emotion processing in patients with long-term remission of CD. Processing of emotional 
faces versus a non-emotional control condition was examined in 21 patients and 21 matched 
healthy controls. Analyses focused on activation and connectivity of two a priori determined 
regions of interest: the amygdala and the medial prefrontal - orbitofrontal cortex (mPFC-OFC). 
We also assessed psychological functioning, cognitive failure, and clinical disease severity. 
Patients showed less mPFC activation during processing of emotional faces compared to 
controls, whereas no differences were found in amygdala activation. An exploratory psycho-
physiological interaction analysis demonstrated decreased functional coupling between the 
ventromedial PFC and posterior cingulate cortex (a region structurally connected to the PFC) 
in CD-patients. 
The present study is the first to show alterations in brain function and task-related 
functional coupling in patients with long-term remission of CD relative to matched healthy 
controls. These alterations may, together with abnormalities in brain structure, be related to 
the persisting psychological morbidity in patients with CD after long-term remission.




Cushing’s disease (CD) is characterized by elevated endogenous cortisol levels and is re-
lated to physical and psychological morbidity in more than 70% of the patients (1). After 
correction of hypercortisolism, physical and psychological symptoms improve substantially. 
However, patients with long-term remission of CD still demonstrate residual physical and 
psychopathological morbidity (2,3), impairments in cognitive functioning (4–7) and reduced 
quality of life (8). A recent study provided evidence for a role of specific genetic polymor-
phisms in the etiology of cognitive impairments in these patients (9), but the persistent 
symptoms in patients with long-term remission of CD are still ill-understood. Cortisol acts in 
the central nervous system by stimulation of mineralocorticoid receptors and glucocorticoid 
receptors. An appropriate balance in activation of these two receptor systems is required for 
adequate stress responses. Hyperactivation of the hypothalamic-pituitary-adrenal (HPA)-axis 
during active CD not only induces overactivation of the receptors, but also an imbalance 
in mineralocorticoid- and glucocorticoid receptor activation, both of which might result 
in inadequate stress responses and enhanced vulnerability to psychopathology (10). The 
residual psychological and cognitive morbidity after long-term remission of CD suggests 
that exposure to hypercortisolism not only has acute effects, but might also be related to 
persistent changes in the brain. 
Several neuroimaging studies have observed changes in morphology and function of 
the brain during the active phase of CD (11). Using functional Magnetic Resonance Imag-
ing (fMRI), less activation in the left anterior superior temporal gyrus and higher activation 
in frontal, medial, and subcortical regions during the identification of emotional faces was 
measured, indicating altered activity of brain structures relevant to the perception, process-
ing and regulation of emotion (12). In addition, adolescents with active CD demonstrated 
increased activation in the left amygdala and right anterior hippocampus during a memory 
task involving emotional faces (13). Moreover, patients with active CD showed structural 
brain abnormalities, including hippocampal volume reduction and cerebral atrophy (14,15). 
Mainly short term follow-up studies (duration of follow-up: 6-40 months) demonstrated at 
least partly reversibility of these structural brain abnormalities (14,16), although no firm 
conclusions can be drawn about the completeness of reversibility since long-term follow-up 
studies are lacking. Recently, we and others have shown that patients with long-term remis-
sion of CD (mean duration of remission: 11.2 years) still have abnormalities in brain structure, 
as evidenced by smaller grey matter volumes in the anterior cingulate cortex, larger grey 
matter volumes in the left lobe of the cerebellum (17) and widespread reductions in white 
matter integrity (18). In addition, these patients showed increased resting-state functional 
connectivity of the anterior cingulate cortex (19). Furthermore, a spectroscopy study by 
Resmini and colleagues demonstrated persistent biochemical alterations in both the left and 
right hippocampus in cured CD patients (20). Taken together, these findings indicate that 
patients with long-term remission of CD have persisting structural and biochemical brain 
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abnormalities, as well as changes in functional connectivity at rest, after cure of previous 
hypercortisolism (11). However, it is presently unknown whether these alterations appear 
in conjunction with altered brain activity patterns during the performance of cognitive or 
emotional tasks. 
Given the link between hypercortisolism and disturbances in the stress response (10), 
and the irritability, anxiety, and depressive symptoms reported by patients with long-term 
remission of CD (2), we decided to examine brain activity during the processing of emotional 
faces in these patients. Patients were part of the sample described previously (17–19). Focus 
was on two regions of interest (ROIs): the amygdala and the medial prefrontal – orbitofrontal 
cortex (mPFC-OFC) (21). The amygdala and the mPFC, including the orbitofrontal cortex, are 
both part of the limbic system and involved in the regulation of the HPA-axis (22). Previous 
neuroimaging studies in patients with stress-related psychiatric disorders demonstrated 
hyperactivation of the amygdala and hypoactivation of the mPFC in response to emotional 
stimuli (23,24), and it has been suggested that disturbances in the amygdala – mPFC circuitry 
lead to symptoms of anxiety (22). Considering the similarity in psychopathology between 
patients with CD and patients suffering from stress-related psychiatric disorders, we hypoth-
esized that patients with long-term remission of CD would also show hypoactivaton of the 
mPFC combined with hyperactivation of the amygdala, relative to matched controls. 
In addition to the ROI analyses, we performed a whole-brain analysis to examine task-
related activation in other brain regions. Furthermore, we investigated potential associa-
tions between brain activity and psychological and cognitive measures, and several clinical 
characteristics (e.g. hydrocortisone dependency and disease severity). In addition, we used 
psychophysiological interaction analyses (25) to explore group differences in functional con-
nectivity during processing of emotional faces. 
MaTerIal and MeTHods
Participants 
Patients with long-term remission of CD of pituitary origin, monitored yearly at our institute, 
were invited by letter to participate in this study (n=49; age 18-60 years). Patients who did 
not respond to the invitation letter were contacted by phone. Thirty-one CD-patients were 
willing to participate and were screened for eligibility. Exclusion criteria were past or present 
drug- or alcohol abuse, neurological disorders, general contraindications for undergoing a 
magnetic resonance imaging (MRI) scan and left-handedness. Healthy control participants 
were recruited by advertisements in grocery stores and via Internet and were included based 
on the following inclusion criteria: no neurological or psychiatric disorders (past or present), 
no psychotropic medication, right-handedness and no contraindications for MRI-scanning. 
A total of 25 CD-patients and 30 controls took part in this study. Three CD-patients and 
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eight controls were excluded from the final analyses because of behavioral data indicating 
insufficient task participation (see Analysis behavioral data). Next, the remaining CD-patients 
and controls were matched on gender, age and education, resulting in a final sample of 21 
CD-patients and 21 controls.
The diagnosis of CD had been confirmed in all patients. Criteria for diagnosis as well as for 
biochemical cure were applied as previously described (4). Duration of disease was estimated 
by looking for the earliest physical/somatic signs in the patient’s history. The duration of 
remission was calculated from the date of curative transsphenoidal surgery, or in case of 
persistent disease, from the date of normalization of biochemical tests after postoperative 
radiotherapy. Written informed consent was obtained from all participants prior to the clini-
cal assessment and the MRI-scan. The study protocol was approved by the medical ethical 
committee of the Leiden University Medical Center. 
study procedure
Each participant visited the Leiden University Medical Center for a two-hour session consist-
ing of an interview for the evaluation of clinical data, assessment of psychopathology and 
cognitive functioning, and an MRI-scan. At the end of the session, participants were asked to 
complete several self-rating questionnaires at home for the assessment of psychopathology 
and cognitive functioning and to return them within a week. One CD-patient did not return 
the questionnaires. 
assessment of psychopathology and cognitive functioning 
The assessment of psychopathology and cognitive functioning took place as described 
earlier (17,18). Presence and severity of depressive symptoms was assessed using the 
Montgomery-Åsberg Depression Rating Scale (MADRS; (26)) and the Inventory of Depression 
Symptomatology (IDS; (27)). Anxiety was evaluated using the Beck Anxiety Inventory (BAI; 
(28)) and the Fear Questionnaire (FQ; (29)). Apathy and irritability were assessed using the 
Apathy Scale (AS; (30)) and the Irritability Scale (IS; (31)). Failures in perception, memory, and 
motor function were evaluated using the Cognitive Failures Questionnaire (CFQ; (32)).  
cushing’s syndrome severity Index (csI) 
The Cushing’s syndrome Severity Index (CSI; (33)) was used to evaluate current severity of 
symptoms and to retrospectively estimate clinical severity at the time of active disease. A 
higher total score on the CSI indicates greater disease severity. The information necessary 
for completing this index was derived from clinical history and medical files. Two raters, who 
reached consensus on each feature in case of discrepancy, scored the CSI. 
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The faces task 
The fMRI Faces task was based on the event-related emotional faces paradigm reported by 
(34); the task described here has been employed earlier (35,36). The task presents 120 color 
photographs of faces with angry, fearful, happy, neutral and sad expressions (task-condition) 
and 80 scrambled faces (control-condition). Photographs were selected from the Karolinska 
Directed Emotional Faces System (37) and represented standardized facial expressions of 
emotions expressed by amateur actors. For each facial expression, 24 photographs were 
selected (12 male faces, 12 female faces). Duration of stimulus presentation (both of faces 
and scrambled faces) was 2.5 s. Between stimuli, a black screen was presented with a random 
duration between 0.5 and 1.5 s. An event-related design was used to reduce anticipatory 
effects. During the task-condition, participants were instructed to indicate the gender of the 
presented face by pressing buttons of magnet-compatible button boxes attached to their 
legs. During the control-condition, participants were instructed to press the button cor-
responding to the direction of an arrow presented over the scrambled face. Reaction time 
and accuracy were recorded. The task was presented using E-prime software (Psychology 
Software Tools, Pittsburgh, PA). Images were projected onto a translucent screen, which was 
visible for participants by means of a mirror above their head. Average duration of the task 
was 11.8 minutes. 
analysis behavioral data 
Behavioral data of the Faces task were processed using custom-written scripts in Matlab 
(Mathworks). Data were filtered for each participant by removing trials with reaction times 
≤ 300 ms and trials with reaction times more than three standard deviations apart from 
the mean individual reaction time, following the procedure described by (38). This filtering 
procedure was applied to remove extreme outlier trials from the subsequent analysis of per-
formance, and eliminated on average 13.21% of trials (CD-patients: 13.24%; controls: 13.18%; 
no difference between groups (independent-samples t-test: t(53)=0.06, P=0.94)). Participants 
with a percentage of missing trials exceeding the upper bound of the 95% confidence inter-
val for the mean percentage of missing trials for each group were excluded. This was the case 
for two CD-patients and three controls. Subsequently, performance (accuracy and reaction 
time) was determined for each participant, for all trials and for particular task conditions 
(scrambled faces; facial expressions; separate for the five different facial expressions: angry, 
fearful, happy, neutral and sad). Participants with an overall accuracy ≤ 80% (one CD-patient; 
five controls) were excluded from the dataset. After matching on age, gender and education, 
21 CD-patients and 21 controls formed the final sample of this study.
Statistical analyses of performance were performed using IBM SPSS Statistics for Windows 
(Version 21.0. Armonk, NY: IBM Corp). Repeated measures ANOVAs with condition (facial 
expressions vs scrambled faces) as within-subjects factor and group (CD-patients vs controls) 
as between-subjects factor were used to investigate group differences in performance (ac-
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curacy and reaction time). In addition, repeated measures ANOVAs with facial expression 
(angry, fearful, happy, neutral, sad) as within-subjects factor and group (CD-patients vs con-
trols) as between-subjects factor were used to examine whether facial expression influenced 
performance of the groups. Significance level was set at P≤0.05. 
MrI data acquisition 
Imaging data were collected using a Philips 3.0T Achieva MRI scanner (Philips Medical Sys-
tems, Best, The Netherlands), equipped with a 32-channel SENSE (Sensitivity Encoding) head 
coil and located at the Leiden University Medical Centre. During the Faces task, functional 
scans were acquired using T2* weighted echo-planar imaging (repetition time (TR)=2200 ms, 
echo time (TE)=30 ms, 38 axial slices, descending acquisition, 2.75 mm x 2.75 mm x 2.75 mm 
+ 10% interslice gap, field of view 220 x 115 x 220 mm). The first two volumes of the scan were 
dummy scans and were removed to allow for equilibration of T1 saturation effects. A 3D T1-
weighted anatomical scan and a high-resolution EPI-image were acquired for within-subject 
registration purposes (T1 scan: TR=9.734 ms, TE=4.59 ms, flip angle = 8°, 140 slices, 0.875 x 
0.875 x 1.2 mm, FOV = 224 x 168 x 177.333 mm; EPI high-resolution scan: TR = 2200 ms, TE 
= 30 ms, flip angle = 80°, 84 axial slices, 1.964 x 1.964 x 2 mm).  The task was part of a larger 
scanning session (17-19).
fMrI data analysis
Data analysis was performed using FEAT (FMRI Expert Analysis Tool; version 6.00) (39,40). Pre-
statistics processing consisted of motion correction, slice-timing correction using Fourier-
space time-series phase-shifting, non-brain removal, spatial smoothing using a Gaussian 
kernel of FWHM 6.0 mm, grand-mean intensity normalization of the entire 4D dataset by 
a single scaling factor in order to enable higher-level analyses, and high-pass temporal 
filtering (Gaussian-weighted least-squares straight line fitting, with σ=30.0 s). Functional 
scans of each participant were registered to the individual high-resolution EPI-image, which 
was in turn registered to the individual 3D T1-weighted anatomical scan and subsequently 
registered to the Montreal Neurological Institute (MNI) T1-template brain (resolution 2 mm). 
Next, event-related statistical analysis of the time-series was carried out in native space. For 
each participant, six explanatory variables with their temporal derivatives were included in 
the general linear model, representing the presentation of 1) a scrambled face, 2) an angry 
face, 3) a fearful face, 4) a happy face, 5) a neutral face and 6) a sad face. Each EV had a dura-
tion of 2.5 s and was convolved with a double gamma haemodynamic response function. 
Subsequently, six contrasts of interest were defined: 1) all emotional faces > scrambled faces 
(referred to as “viewing faces”, representing main effect of task); 2) angry faces > scrambled 
faces; 3) fearful faces > scrambled faces; 4) happy faces > scrambled faces; 5) neutral faces > 
scrambled faces and 6) sad faces > scrambled faces. We verified whether the individual scans 
were registered correctly and confirmed that relative motion parameters did not exceed 2.5 
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mm. Subsequently, the individual contrast images were submitted to higher-level mixed-
effects group analyses. 
Whole-brain analysis: main effect of task  
A whole-brain analysis was performed to determine activity related to the main effect of 
task (emotional faces > scrambled faces). Clusters were tested for significance using a height 
threshold of z>2.3 and a cluster-corrected significance threshold of P<0.05 (41). 
Region Of Interest (ROI) analyses: differences between groups
Given our a priori hypotheses about the amygdala and mPFC, we applied a ROI approach 
in order to maximize statistical power to detect differences in brain activation between the 
CD-patients and controls in these areas. To that aim, we performed two separate higher-level 
analyses, restricted respectively to the amygdala and the mPFC-OFC by applying pre-thresh-
old masking. Masks were created in standard space with a resolution of 2x2x2 mm. The amyg-
dala ROI was defined using the Harvard-Oxford Subcortical Structural Atlas implemented in 
FSLView (version 3.2.0) and consisted of voxels with a probability of at least 50% of belonging 
to the left or right amygdala (total size of mask: 505 voxels). The mPFC-OFC ROI was created 
using the Harvard-Oxford Cortical Structural Atlas implemented in FSLView (version 3.2.0) 
and consisted of voxels with a probability of at least 10% of belonging to the subcallosal 
cortex, the frontal medial cortex or the frontal orbital cortex. In addition, we included those 
voxels of the anterior division of the cingulate gyrus (probability threshold: 10%) positioned 
anterior of the y-coordinate of 30 mm (total size of mask: 10738 voxels). Masks are shown in 
Figure 1.  
Within these masks, we investigated activation related to the main effect of task (emotional 
faces > scrambled faces) for each group separately, and report regions with a height thresh-
old of z>2.3 and a cluster-corrected significance threshold of P<0.05 (41).  Subsequently, we 
x = -30 y = 29 z= -16
figure 1. Regions of interest: medial prefrontal  – orbitofrontal cortex  (mPFC-OFC) (blue; 10738 voxels) 
and amygdala (red; 505 voxels), superimposed on the template MNI_T1_152_1mm_brain. All images are 
displayed according to radiological convention: right in image is left in brain.
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investigated group-differences related to the main effect of task. Significant group-differ-
ences within the ROIs were further explored by extracting individual mean z-scores from 
the lower-level contrast images of the contrast ‘emotional faces > scrambled faces’ with the 
Featquery-tool (implemented in FSL 5.0.4). Correlation analyses on these individual z-scores 
were performed using Pearson’s r or, when data violated assumptions for parametric tests, 
with Kendall’s tau. In addition, individual mean z-scores for the other contrasts (each facial 
expression > scrambled faces) were extracted from significant clusters.  
Whole-brain analysis: differences between groups
In addition to the ROI analyses, we performed an exploratory whole-brain analysis to 
investigate task-related group-differences in brain activation outside the predefined ROIs. 
Clusters were tested for significance using a height threshold of z>2.3 and a cluster-corrected 
significance threshold of P<0.05 (41). 
Post-hoc exploratory psychophysiological interaction (PPI) analyses 
In order to investigate whether group-differences in activation were accompanied by differ-
ences in functional connectivity specific to the task, we performed exploratory psychophysi-
ological interaction (PPI) analyses for significant clusters resulting from our ROI analyses. A 
PPI analysis investigates whether a task-condition (psychological component) influences 
the co-variation in activity (physiological component) between a certain seed region and 
other brain regions (25). For each individual, a first-level PPI analysis was performed using 
FEAT. Individual timecourses (physiological component) were extracted from a seed region 
based on the significant cluster obtained in the ROI-analyses. The psychological regressor 
denoted the task-condition of interest (emotional faces > scrambled faces). We convolved 
this regressor with a double gamma haemodynamic response function, applied temporal 
filtering and added a temporal derivative. The product of the demeaned physiological regres-
sor and the zero-centered psychological regressor represented the PPI regressor of interest. 
In addition, a confound regressor (faces + scrambled faces) was included in the model, to 
explain shared variance between trial types (regressor convolved with a double gamma hae-
modynamic response function, temporal filtering applied and a temporal derivative added). 
Higher-level PPI analyses were used to test for differences between groups in task-related 
functional connectivity. In order to avoid false-positive results in this exploratory analysis, 
clusters were tested for significance using a rather stringent height threshold of z>3.1 and 
a cluster-corrected significance threshold of P<0.05 (41). Significant clusters were further 





Characteristics of CD-patients and matched healthy controls are presented in Table 1. Patients 
had a mean estimated duration of disease of 8.2 years (standard deviation (SD): 8.5; range 0.8 
– 37.0 y), while the mean duration of remission at the time of evaluation was 10.8 years (SD: 
7.9; range 1.9 – 10.8 y). CSI scores during active disease and at the time of evaluation were 8.3 
(SD: 2.0, range 5.0-12.0) and 2.5 (SD: 1.6, range 0.0 – 5.0), respectively. Eleven patients (52%) 
received hydrocortisone replacement. CD-patients had more depressive symptoms than con-
trols on the MADRS (P<0.001). Scores on the other questionnaires were not different between 
groups when correcting for multiple comparisons (Bonferroni-corrected significance level: 
P<0.005; Table 1). However, when a less conservative threshold (P<0.05) was applied, patients 
appeared to have more depressive symptoms as measured with the IDS self-report question-
naire (P=0.017) and higher anxiety levels as assessed by both the BAI (P=0.008) and the FQ 
(P=0.007). Specifically, patients reported increased levels of social anxiety (P=0.006), while 
scores on agoraphobia and blood-injury phobia did not differ between groups. In addition, 
patients had higher scores on the Apathy Scale (P=0.006) and mentioned higher levels of 
cognitive failure (P=0.023) (Table 1). Patients with and without hydrocortisone replacement 
did not differ on any of these scores (data not shown).
behavioral data 
Performance scores (accuracy and reaction time) on the Faces task are presented in Figure 2 
(see for detailed scores Supplementary Table 1). There were no group-differences with respect 
to the percentage of missing trials (i.e. trials in which no response was given; independent-
samples t-test:  t(40)=-1.06, P=0.29). Repeated Measures ANOVAs (condition (facial expres-
sions vs scrambled faces) x group) revealed a significant effect of condition on both accuracy 
(F(1,40)=4.09, P=0.05) and reaction time (F(1,40)=9.89, P=0.003). However, there was no ef-
fect of group on performance (accuracy: F(1,40)=0.01, P=0.91; reaction time: F(1,40)=0.13, 
P=0.72) nor an interaction between group and condition (accuracy: F(1,40)=0.20, P=0.66; 
reaction time: F(1,40) = 3.02, P=0.09). Post-hoc paired-sample t-tests revealed that all par-
ticipants reacted slower (t(41)=3.1, P=0.004), but were more accurate (t(41)=-2.0, P=0.047) in 
trials with facial expressions compared to trials with scrambled faces.  
Additional repeated measures ANOVAs investigating the effect of facial expression on 
performance (facial expression x group) revealed no significant effect of facial expression 
on either accuracy (F(4,160)=1.64, P=0.17) or reaction time (F(4,160)=1.17, P=0.33). In addi-
tion, there was no significant effect of group (accuracy: F(1,40)=2.84, P=0.10 ; reaction time: 
F(1,40)=1.30, P=0.26) nor a significant interaction between facial expression and group (ac-
curacy: F(4,160)=0.58, P= 0.68; reaction time: F(4,160)=0.17, P=0.95) (Figure 2). 
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Whole-brain analysis: main effect of task  
The whole-brain analysis revealed task-related (emotional faces > scrambled faces) activa-
tion clusters in line with those reported in earlier work (34–36). In both patients and controls, 
significant brain activation was present in the bilateral occipital cortex and fusiform gyrus, 
bilateral amygdala and hippocampus, and several prefrontal areas (Figure 3A and 3B; Supple-
mentary Table 2). 
Table 1 Characteristics of participants and results of psychopathology and cognitive performance. Data are 
presented as mean ± standard deviation or as numbers 
cd-patients 
(n =21) Healthy controls (n=21)
P value
Age (years) 45.0  ± 7.9 45.9  ± 6.7 0.693 a 
Gender (male/female) 4 / 17 4 / 17 1.000 b 
Education (n)
Low 5 5 1.000 b
Medium 10 10 1.000 b
High 6 6 1.000 b
Surgery (n)
Transsphenoidal adenomectomy 21 (100%)
Bilateral adrenalectomy 1 (5%)
Radiotherapy (n) 5 (24 %)
Disease duration (years) 8.2 ± 8.5
Duration of remission (years) 10.8 ± 7.9
Clinical severity index (total score)
Active phase 8.3 ± 2.0
Remission phase 2.5 ± 1.6
Hydrocortisone substitution (n)
Mean dose: 18.4 mg/day (± 10.3 mg)
11 (52 %)
Montgomery-Åsberg Depression Rating 
Scale (MADRS)
5.9 ± 5.7 1.3 ± 1.5 0.000 c  **
Inventory of Depression Symptomatology 
(IDS) #  
46.2 ± 13.8 34.9 ± 3.3 0.017 c  *
Beck Anxiety Inventory (BAI) # 28.2 ± 6.1 23.6 ± 2.8 0.008 c  *
Fear Questionnaire (FQ) # 
Total Score 26.8 ± 17.5 13.6 ± 10.5 0.007 a *
Agoraphobia Subscale 6.8 ± 8.4 2.9 ± 4.9 0.242 c
Blood Injury Phobia Subscale 6.8 ± 8.9 3.5 ± 4.4 0.327 c
Social Phobia Subscale 13.2 ± 7.8 7.2 ± 5.1 0.006 a * 
Apathy Scale (AS) # 13.2 ± 6.7 8.2 ± 3.8 0.006 a *
Irritability Scale (IS) # 11.7 ± 9.5 7.3 ± 4.8 0.147 c
Cognitive Failures Questionnaire (CFQ) # 37.9 ± 17.8 25.4 ± 8.0 0.023 c *
Differences between groups were tested with an independent-samples t–test (a), χ2 –test (b) or Mann-Whitney U 
test (c).
#: Scores based on data from 20 CD patients. 
*: Group-difference at uncorrected significance level P <0.05. 
**: Group-difference at Bonferroni-corrected significance level P < 0.005.
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region of Interest (roI) analyses: differences between groups
Amygdala
In line with our hypothesis and the results of the whole-brain analysis, viewing faces was 
associated with significant bilateral amygdala activation, both in patients with CD and con-
trols (Supplementary Figure 1; Supplementary Table 3). There was, however, no significant 
difference in brain activation levels between groups at the predefined threshold (z>2.3, 
cluster-corrected significance threshold of P<0.05). Also when we applied a more liberal 
voxel threshold of P<0.01 (uncorrected), no significant activation differences between groups 
emerged.   
mPFC-OFC 
Within the predefined mPFC-OFC ROI, viewing faces was associated with activation in bilat-




























































figure 2. Performance on Faces task. Error bars represent standard error of the mean. *: P<0.05, **: P<0.005.
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Group-comparisons showed decreased activation of the ventromedial PFC (vmPFC) in CD-
patients relative to controls (clustersize: 274 voxels, P=0.021; Figure 4A and Supplementary 
Table 4). To further illustrate the group-difference in brain activation within the vmPFC, mean 
z-scores were extracted from the lower-level contrast images for each individual, using a 
mask including those voxels showing a significant group-difference (z>2.3) within the vmPFC 
ROI (from now on referred to as ‘vmPFC group-difference mask’). Results are presented in 
Figure 4B. 
In addition, the vmPFC group-difference mask was used to extract individual mean 
z-scores for the five lower-level contrasts representing activation related to the separate 
facial expressions (angry, fearful, happy, neutral, sad) relative to scrambled faces, in order to 
investigate whether the difference in vmPFC activation between the groups was influenced 
by specific facial expressions. A repeated measures ANOVA (facial expression x group) con-
CD
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figure 3. Significant activation clusters related to viewing faces (emotional faces > scrambled faces) at 
whole-brain level in CD-patients with long-term remission (CD; Figure 3A) and control participans (HC; 
Figure 3B). Significant clusters are superimposed on the template MNI_T1_152_1mm_brain. All images are 
displayed according to radiological convention: right in image is left in brain. 
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firmed the effect of group (F(1,40)=8.65, P=0.005), but revealed no effect of facial expression 
(F(4,160)=1.61, P=0.19); in addition, there was no interaction between facial expression and 
group (F(4,160)=0.57, P=0.65) (Figure 4C). These findings indicate that the vmPFC-hypoacti-
vation in CD-patients is not driven by viewing a face with a specific emotional expression, but 
rather represents an overall effect of viewing faces. 
relation between vmPfc activation and clinical characteristics
Within the group of patients, there was no relation between activation (contrast emotional 
faces > scrambled faces) in the vmPFC cluster and scores on the MADRS (Kendall’s tau=0.22, 
x = 0 y = 46 z = -12 











































figure 4. Significant group difference in activation related to viewing faces (emotional faces > scrambled 
faces) within the mPFC-OFC ROI (Figure 4A). CD-patients with long-term remission (CD) had significantly 
lower activation levels in the vmPFC when compared to control participants (HC). Significant clusters are 
superimposed on the template MNI_T1_152_1mm_brain. All images are displayed according to radiologi-
cal convention: right in image is left in brain. Blue colors indicate decreased activation levels in CD-patients 
relative to control participants. For illustrative purposes, individual z-scores were extracted from the vmPFC 
cluster and presented in Figure 4B (emotional faces > scrambled faces) and Figure 4C (separate facial ex-
pressions). Analyses confirmed significantly decreased activation levels in CD-patients with long-term re-
mission compared to controls, but no effect of facial expression.
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P=0.18). In addition, there was no difference in vmPFC activation levels between patients 
who received radiotherapy (n=5) and patients who did not receive radiotherapy (n=16; 
t(19) =-0.38, P=0.71), neither was there a difference between patients with hydrocortisone 
replacement (n=11) and those who were not glucocorticoid dependent (n=10; t(19)=-1.5, 
P=0.15). Furthermore, there was no relation between vmPFC activation and disease duration 
(Kendall’s tau=0.13, P=0.40) or the severity of symptoms as measured with the CSI during 
active disease (Pearson’s r=-0.03, P=0.89) or during remission (Kendall’s tau = 0.15, P=0.37). 
The relation between the duration of remission and vmPFC activation was significant at trend 
level (Pearson’s r =-0.41, P= 0.06), indicating that a longer duration of remission is associated 
with more activation in the vmPFC.
Whole-brain analysis: differences between groups
Comparison of whole-brain activation levels (contrast emotional faces > scrambled faces) 
between the groups revealed decreased brain activation in CD-patients relative to controls 
in a cluster in the mPFC (Supplementary Table 2). This cluster extended into the left frontal 
pole (clustersize: 578 voxels, P=0.021). There were no clusters where CD-patients showed 
increased activation relative to controls. 
Post-hoc exploratory PPI analyses
We performed a post-hoc exploratory PPI analysis with the hypoactive cluster in the vmPFC 
as seed region. Using the vmPFC group-difference mask, we extracted for each participant 
the mean time course from this region. This time course constituted the physiological regres-
sor in the model, while the psychological regressor denoted the task-condition of interest 
(emotional faces > scrambled faces). Comparison of the groups revealed no significant 
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figure 5. Significant group difference in functional connectivity during the faces vs scrambled task condi-
tion (PPI) between the vmPFC (red) and the posterior cingulate cortex (PCC; blue colors indicate decreased 
functional connectivity in CD- patients relative to control participants) (Figure 5A). CD-patients with long-
term remission had significantly decreased positive functional coupling when compared to control partici-
pants (HC). For illustrative purposes, individual z-scores were extracted from the PCC cluster and presented 
in Figure 5B. Significant clusters superimposed on the template MNI_T1_152_1mm_brain. All images are 
displayed according to radiological convention: right in image is left in brain.   
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tional connectivity between the vmPFC cluster and the amygdala. Exploratory analyses at 
the whole-brain level revealed a significant group difference in task-condition associated 
changes in connectivity at the whole brain level (Figure 5): CD-patients showed a decreased 
positive functional coupling related to the task (emotional faces > scrambled faces) between 
the vmPFC cluster and the posterior cingulate cortex (PCC) relative to controls (cluster size: 
139 voxels, P=0.049; maximum z-value 4.19 at MNI coordinate (X,Y,Z) -12, -34, 42).  
dIscussIon
The present study is the first to demonstrate task-related functional brain abnormalities in 
patients with long-term remission of CD relative to matched healthy control participants. We 
found hypoactivation of the ventromedial prefrontal cortex (vmPFC) during processing of 
facial expressions (versus scrambled faces), without alterations in amygdala activation. This 
vmPFC hypoactivation was not elicited by a specific facial expression. The post-hoc explor-
atory psychophysiological interaction (PPI) analysis, investigating task-related correlations in 
brain activity between regions, revealed decreased functional coupling between the vmPFC 
and the posterior cingulate cortex (PCC). These functional brain abnormalities may, at least in 
part, underlie the long-term psychological morbidity as is observed after successful correc-
tion of hypercortisolism (4).
The vmPFC hypoactivation reported here (Figure 3 and Figure 4) is in line with the results 
of earlier work on prefrontal functioning during emotional processing in stress-related dis-
orders. The vmPFC is functionally and structurally connected to the amygdala and is, due to 
its role in fear learning and fear extinction, implicated in the pathogenesis of anxiety and 
mood disorders (22). Decreased mPFC activation has been reported during emotional tasks 
in patients with specific phobia and panic disorder (42), women with generalized anxiety 
disorder (43), men with posttraumatic stress disorder (PTSD) (24) and individuals reporting 
emotional maltreatment during their childhood (44). However, the present results are in 
striking contrast with earlier findings in patients with active CD, since patients with active 
disease demonstrated higher activation levels in frontal, medial, and subcortical regions 
during the identification of emotional faces (12). It should, however, be noted that this hy-
peractivation was accompanied by lower accuracy in task performance in patients compared 
to controls (12), while we did not find any group differences in task performance in our 
study (Figure 2; Supplementary Table 1). These findings tentatively suggest that correction 
of hypercortisolism may induce a switch in vmPFC activation levels from hyperactivation to 
hypoactivation in response to emotional stimuli. Future longitudinal research is needed to 
study the time course of dynamic changes that occur after correction of hypercortisolism. 
We speculate that the hypoactivation in the vmPFC, in combination with the earlier 
described alterations in brain structure and white matter integrity in the same sample of pa-
tients (17,18), underlies the persisting psychopathology previously reported in patients with 
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long-term remission of CD (2,7). In line with these results, the patient sample investigated 
here showed an increased prevalence of depressive symptoms, anxiety levels and symptoms 
of apathy (Table 1). Although patients had clear symptoms and differed significantly from 
controls, it should be noted that their scores on depression scales were still within the normal 
range (26), indicating that the patients would not have been classified as having a clinical 
depression. This observation suggests that the functional brain changes in patients with 
long-term remission of CD reported here are not the result of suffering from a depressive 
disorder. Alternatively, this null-effect could be caused by insufficient power due to the 
relatively small sample size or reflect the limited sensitivity of questionnaires to measure 
specific elements of psychopathology. Furthermore, it is possible that the hypoactivation of 
the vmPFC only enhances the sensitivity to develop psychopathology, but that the actual 
expression of psychopathology is also dependent on other factors, such as environmental 
factors and personality traits. Future studies with a larger sample size could provide more 
insight into this relationship, as well as into the influence of other factors such as duration 
of remission or glucocorticoid dependency. These factors showed weak and insignificant 
relationships with vmPFC activation in our study, but are potentially confounding factors 
that should be taken into account. 
As expected, we observed robust amygdala activation in response to facial expressions 
(Supplementary Figure 1).  Contrary to our hypothesis, we did not find any group differences 
in amygdala activation. We expected amygdala hyperactivation in this sample of patients 
compared to healthy controls, based on studies reporting increased amygdala activation 
in patients with other stress-related disorders, such as PTSD (45), social anxiety disorder 
(SAD) (46), and participants with previous childhood maltreatment (35); for a review see 
(21). However, our results coincide with those from other studies reporting no difference in 
amygdala activation levels between patients and healthy controls, for example in women 
with generalized anxiety disorder (43), patients with generalized SAD (47) and patients with 
depression and anxiety (36). The absence of alterations in amygdala activity might also relate 
to the specifics of our task-paradigm, since the results of various experiments, reviewed by 
(22), suggest that task-related factors like the amount of attention and the level of awareness 
of the stimuli could possibly influence the level of amygdala activation in anxiety. However, 
more research is needed to explore this relationship between task specifics and amygdala 
activation levels into more detail. Alternatively, the lack of detection of a group difference 
in amygdala activation could possibly be caused by differences in baseline amygdala blood 
flow and blood oxygenation level-dependent (BOLD) responses between patients and con-
trols, which could not be measured with the methods used in this study. 
Additional post-hoc PPI analyses revealed decreased functional coupling in patients 
between the vmPFC and the posterior cingulate cortex (PCC) during the task-condition 
(emotional faces > scrambled faces) (Figure 5). The PCC is suggested to play an important role 
in directing attention, regulating cognition, memory-related processes and self-referential 
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tasks, but it’s exact function is still a matter of debate (48). The mPFC and PCC are structur-
ally connected by the cingulum tract and are functionally connected as part of the so-called 
default mode network (DMN) (49,50). Earlier research by our group showed decreased white 
matter integrity in the cingulum tract in the same group of CD patients (18). Here, we expand 
this finding by showing decreased functional coupling between the areas that are structur-
ally connected by the cingulum tract. To the best of our knowledge, we are the first to report 
on changes in task-condition associated functional connectivity in patients with CD after 
long-term remission. Although this finding is preliminary due to the exploratory nature of the 
analysis, it is in line with the results of earlier work on stress-related disorders. For example, a 
recent review reported decreased functioning of the DMN in patients with anxiety disorders 
in tasks in which they were supposed to regulate their emotions without explicit instruc-
tions (51). In addition, Bluhm and colleagues showed decreased connectivity between the 
mPFC and the PCC in women with PTSD (52). However, these studies determined functional 
connectivity during rest, while we observed changes in task-condition dependent functional 
connectivity. Future research is needed to elaborate on the aberrant functional coupling 
between the vmPFC and the PCC in patients with long-term remission of CD, in order to 
investigate the direction of these changes.   
The findings of this study provide new insight into the functional brain alterations underly-
ing the persisting psychological morbidity seen in patients after treatment of CD, who have 
always been considered cured after correction of cortisol excess. Although no formal conclu-
sions can be drawn about causal relations between the effects of previous exposure to exces-
sive cortisol levels and functional brain alterations given the cross-sectional design of this 
study, the results presented here strongly suggest that hypercortisolism induces persistent 
changes in brain activation. The use of a longitudinal design in future research enables to 
provide more insight into the course of the described functional abnormalities. 
In conclusion, the present study clearly shows long-term changes in brain activation pat-
terns in patients with CD despite long-term remission of cortisol excess. Thereby, we have 
provided insight in the effects of past hypercortisolism on the brain. These functional altera-
tions may, together with the previously reported structural abnormalities in cerebral grey 
and white matter, underlie the long-term psychological morbidity in patients with CD after 
correction of hypercortisolism. Prospective studies with a long-term follow-up could provide 
more insight into the longitudinal changes that occur after correction of cortisol excess.  
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supplementary Table 1. Performance on Faces Task 
cd-patients (n =21) Healthy controls (n=21) P-value a 
Missings (%) 3 ± 2 3 ±  2 0.29
accuracy (%)
Scrambled faces 96 ± 10 95 ± 10.0 0.78
Facial expressions 99 ± 1 99 ± 1 0.09
Angry 99 ± 3 100 ± 2
Fearful 99 ± 2 99 ± 2
Happy 99 ± 2 100 ± 2 
Neutral 98 ± 3 98 ± 3 
Sad 99 ± 2 100 ± 1
reaction time (ms)
Scrambled faces 726 ± 76 742 ± 178 0.71
Facial expressions 807 ± 114 766. ± 124 0.27
Angry 798 ± 135 764 ± 147 
Fearful 793 ± 106 755 ± 126 
Happy 814 ± 130 763 ± 140
Neutral 817 ± 125 772 ± 133
Sad 814 ± 127 772 ± 102










x y Z Max. Z 
value # voxels P-value
Hc Bilateral amygdala and hippocampus 20 -4 -16 5.41 6729 <0.001
Right IFG, extending into right MFG 52 22 22 4.67 4118 <0.001
Bilateral SFG 8 14 52 4.45 1814 <0.001
Right Temporal Occipital Fusiform Cortex, extending into 
LOC
38 -50 -22 6.17 1023 <0.001
Left Temporal Fusiform Cortex, extending into ITG -38 -42 -26 5.39 623 0.014
Postcentral Gyrus 56 -12 46 3.38 495 0.045
cd Right MFG, extending into right IFG 54 26 30 4.7 2880 <0.001
Bilateral amygdala and hippocampus 20 -4 -16 5.25 2699 <0.001
Right Occipital Fusiform Gyrus, extending into Temporal 
Occipital Fusiform Cortex
36 -78 -12 5.46 2627 <0.001
Left Temporal Fusiform Gyrus, extending into Occipital 
Fusiform Cortex
-38 -44 -22 5.69 1664 <0.001
Left IFG, extending into left MFG -44 16 28 4.08 748 0.005
Hc > cd mPFC, extending into left Frontal Pole -22 40 -12 3.37 578 0.021
There were no activation clusters CD > HC.
HC: healthy controls; CD: patients with long-term remission of Cushing’s Disease.
IFG: Inferior Frontal Gyrus; MFG: Middle Frontal Gyrus; SFG: Superior Frontal Gyrus; LOC: Lateral Occipital Cortex; 
ITG: Inferior Temporal Gyrus; mPFC: medial Prefrontal Cortex. 




region x y Z
Max. Z 
value # voxels P-value
Hc Right amygdala 20 -4 -16 5.41 256 0.002
Left amygdala -18 -4 -14 4.86 219 0.002
cd Right amygdala 20 -4 -16 5.25 248 0.002
Left amygdala -16 -6 -16 4.94 206 0.003
There were no group differences in activation levels within this ROI.
HC: healthy controls; CD: patients with long-term remission of Cushing’s Disease.
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x y Z Max. Z 
value
# voxels P-value
Hc Bilateral OFC, extending into 
subcallosal cingulate gyrus
28 6 -16 4.07 926 < 0.001
Right Insular Cortex 36 22 0 4.26 769 < 0.001
Left Insular Cortex -30 26 4 3.94 277 0.020
cd Right OFC, extending into right IFG 48 26 -2 4.04 498 0.002
Left OFC -38 32 -16 3.36 213 0.044
cd < Hc vmPFC 0 42 -12 3.2 274 0.021
There were no activation clusters CD > HC within this ROI.
HC: healthy controls; CD: patients with long-term remission of Cushing’s Disease.
OFC: Orbitofrontal Cortex; IFG: Inferior Frontal Gyrus; vmPFC: ventromedial Prefrontal Cortex. 
x = 22 y = -4 z = -18 





supplementary figure 1. Signifi cant activation clusters related to viewing faces (emotional faces > scram-
bled faces) within the amygdala ROI. There were no diff erences in activation levels between CD-patients 
with long- term remission (CD) and control participants (HC). Signifi cant clusters are superimposed on the 
template MNI_T1_152_1mm_brain. All images are displayed according to radiological convention: right in 
image is left in brain.
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x = 0 y = 46 z = -12 





supplementary figure 2. Significant activation clusters related to viewing faces (emotional faces > scram-
bled faces) within the mPFC ROI. Significant clusters are superimposed on the template MNI_T1_152_1mm_
brain. All images are displayed according to radiological convention: right in image is left in brain.
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background: Intrinsic imperfections and lack of reliable biomarkers preclude optimal 
individual dosing of hydrocortisone replacement in adrenal insufficiency (AI). However, 
the clinical relevance of optimal dosing is exemplified by frequently occurring side effects 
of over-replacement and the dangers of under-replacement. Cortisol in scalp hair has been 
identified as a retrospective biomarker for long-term cortisol exposure. We compared hair 
cortisol concentrations (CORThair) of patients with primary or secondary AI on replacement 
therapy with those of patient controls with a pituitary disease without AI (PC) and of healthy 
controls (HC).
Methods: In this cross-sectional study, hair samples and anthropometric data were collected 
in 132 AI patients (52 males), 42 PC (11 males), and 195 HC (90 males). The proximal 3 cm of 
hair were used. CORThair were measured using ELISA.
findings: CORThair were higher in AI patients than in HC and PC (P < 0.001), and hydrocorti-
sone dose correlated with CORThair (P = 0.04). Male AI patients demonstrated higher CORThair 
than female patients (P < 0.001). AI patients had higher body mass index (BMI) than HC (P < 
0.001), and BMI correlated with CORThair in the whole sample (P < 0.001).
Interpretation: Physiological hydrocortisone replacement is associated with increased 
COR Thair. The association between CORThair and BMI could suggest a mild overtreatment that 
may lead to adverse anthropomorphic side effects, especially in males. CORThair measurements 
may be a promising additional tool to monitor cumulative hydrocortisone replacement in AI.




Adrenal insufficiency (AI) in which the adrenal corticosteroid synthesis, i.e. cortisol produc-
tion, is insufficient can be primary in case of pathology of the adrenal glands, or secondary 
in case of hypopituitarism. Patients with AI need replacement therapy with exogenous 
glucocorticoids, preferably hydrocortisone, which is synthetically produced cortisol (1). In 
persons with intact adrenal function around 5 to 10 mg of cortisol per m² of body surface 
area per day is produced (2), with increased requirements during stress. The corresponding 
chronic oral replacement dosage is 15–25 mg per day, usually divided in three dosages in 
an attempt to mimic the circadian rhythm of natural cortisol secretion, with a peak in the 
morning and a gradual decrease during the day and evening (1, 3). It is recommended that 
hydrocortisone replacement should be individualized, taking into account blood pressure, 
metabolic derangements and sense of well-being (4). Various maintenance dosing strategies 
have been published (5). However, it is likely that there will be large individual variation in 
substitution requirements in view of differences in cortisol sensitivity due to  polymorphisms 
of the glucocorticoid receptor gene (6). Currently available cortisol measurements in plasma, 
urine or saliva do not reflect cortisol action at tissue level. In accordance, plasma and sali-
vary cortisol concentrations vary considerably between patients receiving hydrocortisone 
replacement, limiting the possibility to titrate individual hydrocortisone doses upon single 
plasma, or salivary measurements (7). A method to retrospectively assess cortisol for longer 
periods of time is the analysis of cortisol in scalp hair (8). As hair grows approximately one 
cm per month (9), a hair sample of for example three cm represents the long-term cortisol 
concentration of three months. Hydrocortisone is identical to human cortisol and has been 
shown to be measureable in scalp hair (8, 10). 
Hair cortisol levels (CORThair) have repeatedly been associated with body mass index (BMI) 
and increased risk of metabolic syndrome and cardiovascular disease in populations with 
endogenous cortisol metabolism (11-15). Until now, there is very limited data on the clinical 
utility of CORThair measurements in patients with hydrocortisone replacement as is the case 
in AI. A recent study by Gow et al. demonstrated that hydrocortisone dose was significantly 
positively associated with CORThair in patients with primary AI (10). Furthermore, they demon-
strated a significant difference in CORThair in male subjects between patients and controls, but 
no statistically significant difference in females. In addition, they did not observe a difference 
between male and female patients’ CORThair. Thus, this study provided data indicative of a 
potential gender dependent effect in CORThair in patients on hydrocortisone replacement. 
However, it should be acknowledged that this study included only 13 male patients vs. 80 
female patients, which limits the generalizability of the results.
Therefore, we aimed to compare CORThair in a large cohort of patients with primary and 
secondary AI on hydrocortisone replacement therapy (AI patients) with CORThair of control 
patients with a pituitary disease but no hydrocortisone replacement therapy (PC) and healthy 
controls (HC). Furthermore, we aimed to explore possible determinants of CORThair in hydro-
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cortisone treated AI patients, i.e. self-reported hydrocortisone intake, sex, age, and weight. 
We hypothesized that AI patients would have higher CORThair than PC and HC, and that AI 
patients show side effects associated with high cortisol levels. Moreover, we hypothesized 
that CORThair are associated with doses of hydrocortisone replacement and BMI.
subjecTs and MeTHods
study design
This study was designed as a cross-sectional assessment of patients seen at the outpatient 
clinic of the department of Endocrinology of the Leiden University Medical Center. This 
study was conducted between July 2012 and January 2014. Hair samples were collected and 
patients were asked to fill out two short self-developed questionnaires: one questionnaire 
about their hair treatment, and one questionnaire about their hydrocortisone intake (i.e. self-
reported daily dose, time of intake, frequency of increasing/decreasing hydrocortisone dose) 
and/or the potential usage of other exogenous glucocorticoids. Clinical data of patients were 
obtained from their medical records.
Participants
Patients 
We included two groups of patients: group I) patients with primary or secondary adrenal 
insufficiency using hydrocortisone (AI patients), and group II) patient controls (PC) with a 
pituitary disease not using hydrocortisone. A total of 184 patients were willing to participate. 
Patients could not participate in case of insufficient hair growth at the posterior vertex of 
the scalp. Ten patients were excluded from the analysis because of interpretative difficulty 
of their chronic steroid replacement scheme; three had high levels probably due to a hy-
drocortisone stress scheme for Addison’s crisis in the three months prior to hair collection, 
three patients were excluded because of CORThair >3 SD with no clear explanation, and four 
patients were excluded due to debatable AI diagnosis and inconsistent hydrocortisone use. 
The final sample comprised a total of 174 patients (i.e. 132 AI patients and 42 PC). Primary 
AI had been diagnosed by very low early morning cortisol concentrations (<120 nmol/l) or 
insufficient stimulation following ACTH test (below 550 nmol/l) usually in the presence of 
positive adrenal auto-antibodies or an alternative explanation. Secondary adrenal insuffi-
ciency was preferably diagnosed using an insulin tolerance test (ITT), or if contra-indicated, a 
CRH test using the same cut-off as for ACTH stimulation. Pituitary hormone replacement was 
prescribed dependent on the results of the annual evaluation of pituitary functions. In case of 
AI, hydrocortisone was prescribed (usually 20 mg/d divided into 3 dosages, with adjustments 
if clinically judged necessary by the treating physician) together with advices to increase the 
Hair cortisol levels in adrenal insufficiency
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hydrocortisone dose in case of exposure to severe somatic and/or psychological stressors. In 
case of other hormone deficiencies, patients were substituted accordingly.
Healthy controls
To compare CORThair between patients and healthy individuals, we used a group of 195 
healthy controls (HC) previously described elsewhere (8). 
The study was approved by the local ethics committee. All patients and controls gave written 
informed consent.
Hair cortisol assessment
A lock of approximately 150 hairs was cut as close to the scalp as possible from the posterior 
vertex. For analysis, the most proximal three cm of hair were used, corresponding to the most 
recent three months. Hair sample preparation and analysis has been described previously 
(8). In short, a minimum of 10 mg of hair was weighed and cut into small pieces in a glass 
vial. Extraction of cortisol took place in 1 mL of methanol for 16h at 52⁰C while gently shak-
ing. After extraction, the methanol was transferred to another vial and evaporated under a 
constant stream of nitrogen. The samples were dissolved in 250 μL of phosphate buffered 
saline (PBS, pH 8.0) for analysis. A commercially available ELISA Kit for salivary cortisol (DRG 
GmbH, Marburg, Germany) was used to measure cortisol levels. A correction factor was 
applied to the results to account for the potential influence of different hair weights. Cross 
reactivity of other steroids with the kit’s antibodies was reported as follows: Corticosterone 
(29.00%), Cortisone (3.00%), 11-Deoxycortisol (<1.00%), 17-OH Progesterone (<0.50%), other 
hormones (<0.10%). Intra-assay variation was below 5% and the inter-assay variation below 
8% as reported by the supplier. The recovery of the assay was described previously (8). 
statistical analysis
SPSS 20.0 for Windows was used for statistical analysis. Differences in demographic informa-
tion between groups were tested with One-Way-ANOVAs and Pearson Chi Square tests. After 
logarithmic transformation, CORThair were normally distributed. Analyses on CORThair and 
differences between groups were performed by means of univariate general linear models. 
If groups differed on age, sex, BMI, or hair treatment (see Table 1 and Table 2), analyses on 
group differences were adjusted accordingly. For analyses of the etiologies of hydrocortisone 
use, post-hoc tests were applied. Pearson and spearman correlations were used for correla-
tion analyses, depending on normality of the distribution. CORThair are provided in pg/mg 




Participant characteristics (Table 1)
132 AI patients, 42 PC, and 195 HC were included in the analysis. The frequency of using 
glucocorticoid containing medication (other than hydrocortisone or maintenance dose) 
was 14.9% and did not differ between AI patients and PC (P = 0.26). Of these, 12.6% used 
one, and 2.3% used two kinds of glucocorticoid containing medication. The most frequent 
used products were ointments (n = 8) and inhalation aerosols (n = 8). Five patients used 
nasal spray, and one patient had received an injection into a joint.  Patients that used ex-
ternally applied glucocorticoid containing medication did not show different CORThair than 
non-applying patients and were therefore not excluded (P = 0.75). The mean disease duration 
was not significantly different between AI patients (18.33 ± 13.54 years) and PC (15.06 ± 10.30 
years), P = 0.16). Presence of hypertension (defined as either blood pressure above 140/90 
or use of antihypertensive medication) and presence of diabetes mellitus (defined as use of 
oral medication and/or insulin injection) was not different between AI patients and PC, and 
in AI patients, frequencies of hypertension and diabetes mellitus were comparable between 
genders. Both AI and PC showed higher frequencies of diabetes mellitus than HC (both P < 
0.05). Hypertension data were not available for HC.








Age 54.84 (14.99) 49.07 (12.94) 36.17 (12.23) 0.05 0.001 0.001
Sex (male) 52 (39.4%) 11 (26.2%) 90 (46.2%) 0.12 0.23 0.02
BMI 27.80 (5.12) 28.70 (7.45) 24.34 (3.85) 0.95 0.001 0.001
Use of exogenous 
glucocorticoids#
15 (11.5%) 2 (4.9%) NA 0.21 NA NA
Hypertension 56 (43.8%) 24 (60.0%) NA 0.07 NA NA
Diabetes mellitus 21 (9.2%) 4 (9.8%) 5 (2.6 %) 0.92 0.008 0.029
Hair dyed 42 (36.2%) 16 (42.1%) 37 (19.0%) 0.52 0.001 0.002
Hair bleached 13 (9.9%) 9 (22.0%) 13 (6.7%) 0.04 0.29 0.002
Hair permed 2 (1.5%) 3 (7.3%)    2 (1.0%) 0.05 0.69 0.01
Use hairproduct 66 (50.0%) 22 (53.7%) 90 (46.4%) 0.68 0.52 0.40
Frequency hair wash    > 
3 times/week
46 (35.1%) 17 (41.5%) 143 (74.1%) 0.46 0.001 0.001
P-value1: comparison between AI patients and PC, P-value2: comparison between AI patients and HC, 
P-value3: comparison between PC and HC
Data are presented as mean (standard deviation), and as n (valid percentage). AI, adrenal insufficiency; PC, patient 
control group; HC, healthy control group; BMI, Body Mass Index; NA, not applicable; #, use of other external gluco-
corticoids (besides hydrocortisone).
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corThair in aI patients, Pc, and Hc (figure 1a-b)
Analyses showed a significant difference in CORThair between the three groups, F(2, 343) = 
35.39, P < 0.001, adjusted for age, gender, and dyeing of the hair. Post-hoc tests indicated that 
AI patients had higher CORThair (33.89, 14.82 – 89.29) than PC (13.66, 6.22 – 26.58), P= 0.001, 
and HC (10.07, 3.52 – 17.83), P < 0.001, and that PC had higher CORThair than HC, P= 0.04.  In AI 
figure 1. Median and IQR of CORThair. AI, adrenal insufficiency; PC, patient control group; HC, healthy con-
trol group. Untransformed data are shown. 1a) CORThair of AI patients, PC, and HC. 1b) CORThair for AI pa-
tients, PC, and HC, stratified for sex.  *** = P < 0.001; ** = P < 0.01; * = P < 0.05, ○ = P < 0.1. Black lines 
represent differences between the participant groups, whereas grey lines represent sex differences within 
each participant group.
Table 2. Baseline characteristics of male and female AI patients
Males (n = 52) Females (n = 80) P-value
Age 55.94 (16.01) 54.13 (14.35) 0.50
BMI 27.57 (3.85) 27.95 (5.80) 0.68
Duration of follow-up (years) 17.87 (12.69) 18.62 (14.11) 0.76
Daily hydrocortisone dose (mg) 21.58 (4.98) 20.39 (4.21) 0.15
Daily hydrocortisone dose mg/kg 0.25 (0.07) 0.27 (0.07) 0.12
Daily hydrocortisone dose mg/BSA 10.35(2.54) 10.84 (2.27) 0.26
Use of external glucocorticoids # 5 (10.0%) 10 (12.5%) 0.66 
Hypertension 23 (46.9%) 33 (41.8%) 0.57
Diabetes Mellitus 4 (8.0%) 8 (10.0%) 0.70
Hair dyed 0 42 (58.3%) 0.001
Hair bleached 0 13 (16.5%) 0.002
Hair permed 1 (1.9%) 1 (1.3%) 0.76
Use hairproduct 19 (36.5%) 47 (58.8%) 0.01
Frequency hair wash      
   < 2 times/week  








Data are presented as mean (standard deviation), and as n (valid percentage). #: use of other external glucocorti-
coids (besides hydrocortisone); BMI, Body Mass Index; BSA, body surface area.
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patients, 35.6% (61.5% males, 18.8% females) presented with CORThair above our lab-internal 
cut-off for normal, as did 7.1% (9.1% males, 6.5% females) of PC and 3.1% (5.6% males, 1.0% 
females) of HC. Our lab-internal upper limit of normal is 52 pg/mg. For determination, we 
restricted our group of healthy controls to the ones with a BMI between 18.5 and 30.0, and 
used the 97.5 percentile as cut-off value.
In AI patients, men had significantly higher CORThair (75.25, 28.91 – 159.81) than women 
(19.59, 11.49 – 38.49), F(1, 112) = 8.17, P = 0.005), adjusted for age and dyeing of the hair. No 
gender differences were observed in CORThair in PC. In HC, females showed higher CORThair 
than males, F(1, 191) = 5.45, P = 0.02. Stratified analysis for gender revealed that male AI 
patients had higher CORThair than male PC and HC (P = 0.02 and P < 0.001, respectively), 
whereas for female AI patients, CORThair was trend-significantly higher than in female PC (P= 
.07) and significantly higher than in female HC (P < 0.001). Males in the PC group did not show 
different CORThair from males in the HC group, and females in the PC group had not different 
CORThair compared to females in the HC group (all P > 0.1). Within AI patients, no difference in 
CORThair was found for the various etiologies of AI. 
correlation between hydrocortisone dose and hair cortisol levels (figure 2)
Self-reported daily hydrocortisone maintenance dose correlated with CORThair (ρ = 0.18, 
P= 0.04). Stratification for gender showed that this correlation was primarily driven by the 
female AI patients (ρ = 0.24, P = 0.04), whereas the correlation was not significant in male AI 
patients. Neither incidental higher and/or lower hydrocortisone dosages nor the morning 
(peak) dose of hydrocortisone (ρ = 0.15, P = 0.09) were related to CORThair. The self-reported 
figure 2. The relationship between daily hydrocortisone dose (mg/day) and CORThair (pg/mg), ρ = 0.18, P = 
0.04, as indicated with the black solid line, which is the regression line of the group analysis. Analyses strati-
fied for sex show that this effect was driven by the female AI patients (grey; ρ = 0.24, P = 0.04), whereas no 
effect was observed for the male AI patients (black; ρ = -0.04, P = 0.79). CORThair are shown on a log scale.
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daily hydrocortisone dose in mg/kg or mg/m2 was not related to CORThair and stratification for 
sex did not render different results.
correlations between anthropometrics and hair cortisol levels (figure 3)
As indicated in Table 1, BMI differed significantly between AI patients, PC and HC (F2, 327) = 
23.90, P < 0.001. Post-hoc tests revealed that the BMI of AI and PC patients was significantly 
higher compared to HC (P < 0.001), but there was no significant difference between AI and 
PC. For the whole group of participants, BMI showed a significant correlation with CORThair 
(ρ = 0.24, P < 0.001). Stratification for sex and participant group revealed a significant cor-
relation between BMI and CORThair for male AI patients (ρ = 0.34, P = 0.02), but not for female 
AI patients nor for male or female PC or HC. Waist-to-hip ratio (WHR) information was only 
available in a subset of 50 AI patients, 12 PC, and 45 HC. WHR was not different between the 
groups. In the whole sample of participants, WHR and CORThair correlated significantly (r = 
0.20, P = 0.04). WHR and waist circumference were related to self-reported dose in mg/kg (r 
= -0.3, P = 0.04, and r = -0.58, P < 0.001, respectively) and to self-reported dose in mg/BSA 
(r = -0.36, P = 0.01, and r = -0.64, P < 0.001, respectively), but were not related to the total 
self-reported daily hydrocortisone maintenance dose (r = 0.11, P = 0.46, and r = 0.19, P = 0.17, 
respectively). 
figure 3. The relationship between BMI and CORThair. 3a) The association between BMI and CORThair for all 
participants was significant (ρ = 0.24, P < 0.001, black solid line); stratification for sex did not change the re-
sults (ρ = 0.35, p < 0.001 for male participants (black); ρ = 0.18, P = 0.02 for female participants (grey). 3b) In 
only the adrenal insufficiency (AI) patients, the association between BMI and CORThair was not significant; ρ 
= 0.11, P = 0.23 (black solid line). Stratification for sex rendered a significant correlation for male AI patients 
(ρ = 0.34, P = 0.02, black) but no association for female AI patients (ρ = 0.04, P = 0.73, grey). 3c) In the con-
trol persons, the association did reach significance (ρ = 0.14, P = 0.04, black solid line). Stratified analyses 
showed that this effect was driven by the male controls (ρ = 0.24, P = 0.02, black) but was not significant for 




The present study showed that patients using hydrocortisone replacement for AI demon-
strate higher CORThair than pituitary patients and healthy controls with an intact HPA-axis. 
Furthermore, a gender-effect was identified, with male patients with AI demonstrating higher 
CORThair than females, without differences in self-reported hydrocortisone intake. Intrigu-
ingly, this gender effect seems to be specific for hydrocortisone use, since it is not present 
in controls with an intact HPA-axis. In female patients, higher self-reported hydrocortisone 
intake was associated with higher CORThair, whereas this association was not found in male 
patients who demonstrated on average higher CORThair even in the lower dose range. 
In male, but not female AI patients, higher CORThair were associated with higher BMI. This 
relation suggests that high CORThair may reflect chronic overexposure to hydrocortisone, at 
least in male patients. However, further study is required to understand the role of gender 
in the determination of cortisol levels in hair and to confirm whether CORThair are indeed 
representative for corticosteroid exposure in the rest of the organs. Furthermore, it is still 
unclear how exactly cortisol, and hence hydrocortisone, is incorporated into scalp hair (16). 
Therefore, the question remains whether it is the cumulative amount of cortisol or the corti-
sol peak that is most influential on CORThair. In our study, total dose appears to be associated 
with CORThair, and not a single/maximum dose. In contrast, the three patients who received a 
hydrocortisone bolus for an Addison crisis had extremely high values and were excluded from 
the study (data not shown), suggesting a role for a supraphysiological peak in determination 
of CORThair. In contrast to the positive correlation between the absolute hydrocortisone dose 
and CORThair, we found no relation between body weight-adjusted dose and CORThair,. This is 
an interesting finding, since previous research has reported that clearance of hydrocortisone 
in serum is faster in obese patients, and that adjusting the dose for body weight may be 
beneficial for the patient (5, 17). However, the current study may imply that tissue exposure 
following ingestion of hydrocortisone (at a physiological level) is independent of distribution 
volume, i.e. weight, at least for these patient groups as measured by CORThair, and thus ques-
tions the need to increase the hydrocortisone dose in obese patients. This is in accordance 
with recent guidelines pointing to no adjustment for weight (except for children) (3). Male 
patients reached higher CORThair with considerably lower hydrocortisone dosages than 
female patients. This “higher sensitivity” to hydrocortisone is in accordance with the positive 
association between CORThair and BMI in male patients. A possible explanation for this higher 
sensitivity in male patients might be that men seem to have lower corticosteroid binding 
globulin (CBG) levels while total cortisol levels are comparable to women’s total cortisol 
(18). This may result in higher free cortisol levels in men upon hydrocortisone intake. As free 
cortisol is thought to be the cortisol fraction which is incorporated in hair (19), this might 
explain the sex difference found in our study and in the study of Gow and colleagues (10).
However, the clearly increased CORThair suggest that in general patients with AI are chronically 
over-replaced, despite prescribed hydrocortisone replacement dosages aiming at mimicking 
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a “physiological” level. A higher daily hydrocortisone dose has been previously linked to a 
more adverse cardiometabolic risk profile, characterized by higher BMI (20). Steroid excess-
related morbidity is well known from AI cohorts treated with higher doses, resulting in the 
awareness to replace hydrocortisone with the lowest dose possible, generally regarded to as 
a daily hydrocortisone dose of 20 mg (21-22). It is intriguing that AI patients treated with the 
currently advised low hydrocortisone dose have clearly increased CORThair and additionally 
present with steroid-related side effects, such as increased BMI.
It appears unlikely that an increased perceived stress of being a patient influences CORThair 
in this study. Some AI patients are known to occasionally increase their hydrocortisone doses 
in situations of increased psychological stress (23), which might result in higher CORThair. In 
population studies, CORThair has been associated with perceived stress (24-26), but if this was 
the case in the present study, the increased stress of being a patient should then also be 
present in our PC group. However, CORThair between PC and HC were comparable. 
Several strengths and limitations of the present cross-sectional study need to be men-
tioned. In total, we included a considerable number of patients, which enabled us to examine 
CORThair of patient groups with pituitary diseases due to different etiologies. Furthermore, we 
included a patient control group with a pituitary disease and normal adrenal function. All 
concurrent pituitary insufficiencies were treated, but we do acknowledge that, such as hydro-
cortisone replacement therapy, intrinsic imperfections of hormone replacement are also an 
important issue for gonadal steroids, thyroid hormone, and growth hormone replacement. 
Besides the demonstrated association between CORThair and anthropometrics, a consider-
able amount of studies demonstrated the association between high CORThair and psycho-
logical symptoms (25). Furthermore, in a recent study it was demonstrated that a higher 
hydrocortisone intake in patients with primary adrenal insufficiency was associated with 
more impairments in quality of life, psychological morbidity, and maladaptive personality 
traits (27). For future research, it would be interesting to assess patients’ perceived well-being 
in relation to CORThair.
In conclusion, patients on hydrocortisone replacement therapy have elevated CORThair, a 
finding which is predominantly present in male patients. Despite a low dose of on average 
21 mg/day only 64.4% of patients had CORThair in the normal range. This study provides 
important data on the fact that contemporary steroid replacement still results in clear supra-
physiological (hair) cortisol levels, especially in males. However, it needs to be confirmed that 
CORThair reflects cortisol (over)exposure in other organs of the body in exogenously treated 
patients, or that the incorporation of CORThair is different from the reference population with 
normal HPA-axis. Next, it needs to be established which are safe, gender-specific CORThair for 
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In patients with adrenal insufficiency (AI) a higher hydrocortisone intake has been associated 
with more impairment in Quality of Life (QoL). Irrespective of age, sex and severity of AI the 
dosage of hydrocortisone is titrated around 20 mg/D in all patients with AI based on physical 
and mental signs and symptoms. However, until now it is unknown whether these QoL im-
pairments are related to increased systemic cortisol exposure. Measurement of hair cortisol 
levels (CORThair) can be used to assess chronic systemic cortisol exposure. This study aimed to 
explore whether QoL in patients with AI is associated with CORThair and daily hydrocortisone 
intake. We performed a cross-sectional study in 120 patients with AI on stable hydrocortisone 
replacement, in whom hair samples and QoL data were collected. CORThair were measured 
with ELISA, and QoL was assessed with validated questionnaires (SF-36, EQ-5D, HADS, MFI-
20). Patients reported impairments in 14 of 15 QoL subscales (P < .001). More impairments 
in physical aspects of QoL correlated with higher CORThair and higher daily hydrocortisone 
intake (P < .05), an effect that was more pronounced in female patients. Regression analyses 
including both CORThair and hydrocortisone intake revealed a significant negative contri-
bution of higher hydrocortisone intake on physical aspects of QoL (P ≤ .046), whereas no 
significant contribution was found for CORThair.
The present study showed that patients with AI report several impairments in QoL which 
are associated with hydrocortisone intake, and to a lesser extent reflected by chronic sys-
temic cortisol exposure as measured by hair cortisol. This suggests that QoL impairments in 
patients with AI are not per se the effect of prolonged exposure to elevated systemic cortisol 
levels. 




Adrenal insufficiency (AI) is treated with glucocorticoid replacement therapy, usually 20 to 30 
mg of hydrocortisone daily, divided into three dosages (10-15 mg in the morning, 5-10 mg 
in the afternoon, 4-5 mg in the evening), in order to mimic the natural circadian secretion 
of cortisol (1). However, even when patients with primary AI are in a stable medical condi-
tion, they report impaired quality of life (QoL) (2-6). In addition, in patients with secondary 
AI due to pituitary disease, hypopituitarism was found to be an important predictor of QoL 
impairments (7-9). It has been suggested that these QoL impairments are associated with 
intrinsic imperfections in glucocorticoid replacement therapy, and therefore, it is advised 
that hydrocortisone replacement should be individualized (10). For instance, there is large 
individual variation in sensitivity to cortisol, which is partly explained by polymorphisms 
of the glucocorticoid receptor gene (11). However, determining an optimal hydrocortisone 
replacement dose is complicated by the lack of reliable chronic parameters, and as a result 
many patients may be chronically under- or overtreated with potential paramount conse-
quences for well-being and health. 
Until now, it is not well established whether QoL is affected by the degree of cortisol ex-
posure (i.e. adequacy of hydrocortisone replacement) in patients with AI. In a single study, 
authors investigated plasma cortisol day curves and well-being in a small sample of seven 
patients with AI and demonstrated that subphysiological cortisol levels correlated with lower 
well-being (12). Other studies examined the relation between the dosage and intake scheme 
of glucocorticoid replacement therapy and QoL, and demonstrated that in patients with AI, 
QoL was inversely correlated with the hydrocortisone dose (5;13). Importantly, associations 
between hydrocortisone intake and QoL do not provide any information about causality, 
since it might be that high cortisol levels cause QoL impairments, but it might also be that 
patients with worse QoL need more hydrocortisone. 
Addressing this relationship is further complicated by the difficulty of adequately mea-
suring cortisol levels throughout the day, since cortisol levels vary depending on different 
treatment regimens (i.e. varying hydrocortisone doses, as well as differences in timing, ab-
sorption, and metabolism of hydrocortisone), and currently available cortisol measurements 
(i.e. plasma, urinary, salivary) are limited to short-term assessments. 
A promising method to assess cortisol for prolonged periods of time is the analysis of 
cortisol levels in scalp hair (CORThair) (14;15). We (and others) recently assessed the use of 
this measure in AI patients treated with exogenous hydrocortisone. Patients with AI have 
increased levels and hydrocortisone intake has been found to correlate with CORThair (16;17). 
A significant gender effect has been reported in CORThair in patients with AI treated with 
glucocorticoid replacement therapy, with male patients demonstrating higher CORThair than 
females while using the same dose of hydrocortisone (16;17). 
In the present study, we aimed to explore whether CORThair is correlated with QoL. We first 
compared QoL in patients with stable treatment for AI with QoL in healthy controls. Second, 
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we examined potential correlations between QoL, CORThair, and daily hydrocortisone intake 
as another parameter to assess cortisol exposure. 
PaTIenTs and MeTHods
Patients
Scalp hair samples were collected of 132 patients with primary or secondary AI on hydro-
cortisone replacement from the Endocrinology out-patient clinic of the Leiden University 
Medical Center (cohort previously described in (17)). Of this group, nine patients did not 
fill out QoL questionnaires and three patients filled out less than 75% of the questionnaires 
and were therefore excluded from the analysis. Thus, 120 patients with longstanding AI on 
a stable dose were included in the present study. Primary AI had been diagnosed by very 
low early morning cortisol concentrations (<120 nmol/l) or insufficient stimulation following 
ACTH test (below 550 nmol/l) usually in the presence of positive adrenal auto-antibodies or 
an alternative explanation. Secondary adrenal insufficiency was preferably diagnosed using 
an insulin tolerance test, or if contra-indicated, a CRH test using the same cut-off as for ACTH 
stimulation. Pituitary hormone replacement was prescribed dependent on the results of the 
annual evaluation of pituitary functions. In case of AI, hydrocortisone was prescribed (usually 
20 mg per day divided into three dosages, adjusted at the discretion of the treating physi-
cians) together with the advice to increase the hydrocortisone dose in case of exposure to 
severe somatic and psychological stressors.
Comparison QoL data of 437 healthy controls were derived from a previous study from our 
department (18). 
The local ethics committee approved this study. All patients gave written informed consent.
Qol assessment
QoL was assessed with the following four validated questionnaires: 
The Short-Form 36 (SF-36) assesses functional status and general well-being  and consists of 
36 items covering nine health concepts: 1) physical functioning, 2) social functioning, 3) role 
limitation (physical), 4) role limitation (emotional), 5) mental health, 6) vitality, 7) pain, 8) gen-
eral health perception, and 9) general perception of change in health. Scores are expressed 
on a 0–100 scale, and higher scores indicate better QoL (19). 
The EuroQoL-5D (EQ-5D) assesses the current health status reflected in five health 
dimensions; 1) mobility, 2) self-care, 3) usual activities, 4) pain/discomfort, and 5) anxiety/
depression. Scores are expressed on a 1-3 scale per dimension, with higher scores indicating 
worse QoL. Also a visual analogue scale is included ranging from 0 to 100 for recording an 
individual’s rating for their current health-related well-being, with higher scores indicating a 
better health status (20). 
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The Hospital Anxiety and Depression Scale (HADS) assesses both anxiety and depressive 
symptoms and consists of 14 items on a 4-point scale. Higher scores indicate more severe 
anxiety and depressive symptoms (21;22). 
The Multidimensional Fatigue Inventory (MFI-20) consists of 20 statements assessing fatigue 
on a five-point scale covering five dimensions; 1) general fatigue, 2) physical fatigue, 3) 
reduced activity, 4) reduced motivation, and 5) mental fatigue. Scores vary from 0-20; with 
higher scores indicating greater fatigue (23). 
Qol of healthy controls
QoL data of healthy controls were previously collected at our department (18). The EuroQoL-
5D and two subscales of the Short-Form 36 (i.e. mental health, vitality) were not assessed in 
this group of healthy controls. QoL data of 437 healthy controls (136 males) with a mean age 
of 50.9 ± 13.6 years were available and the total group was used for comparison. 
Hair collection, preparation, and analysis
A lock of approximately 150 hairs from the posterior vertex was cut as close to the scalp as 
possible. The hair samples were taped to paper and stored in the dark at room temperature 
until further analysis. One cm represents the average cortisol concentrations of one month 
(15), since it is assumed that hair grows one cm per month, with a range of 0.6 – 1.4 cm/
month (24).
Hair samples are specifically taken from the vertex region of the scalp because its most 
uniform growth pattern and phase (25;26), and importantly, has been specifically been 
validated for cortisol with the lowest mean coefficient of intra-individual variation (27). 
For analyses, the most proximal 3 cm of hair was used, corresponding to the most recent 3 
months. A minimum of 10 mg of hair was weighed and cut into small pieces. For extraction, 1 
mL of methanol was added and the samples were incubated for 16h at 52⁰C. After extraction, 
the methanol was transferred to another vial and evaporated under a constant stream of 
nitrogen. The samples were dissolved in 250 μL of phosphate buffered saline (PBS, pH 8.0). 
A commercially available ELISA Kit for salivary cortisol (DRG GmbH, Marburg, Germany) was 
used to measure cortisol levels. The procedure has been described in detail elsewhere (14). 
Our laboratory internal upper limit of normal is 52 pg/mg.
statistical analyses
Data were analyzed using PASW Statistics version 20.0 (SPSS Inc., Chicago, IL). CORThair were 
reported as median and interquartile ranges (IQR). Other data were presented as mean±SD, 
unless mentioned otherwise. After logarithmic transformation, CORThair were normally 
distributed. The primary analysis comprised the comparison of QoL of patients with AI to 
healthy controls by using independent sample t-tests when data were normally distributed 
and Mann-Whitney U tests when data were not normally distributed. In order to evaluate 
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whether the previously found gender effect in CORThair is reflected in QoL, this analysis was 
also performed after stratification for gender.
The secondary analysis comprised the assessment of the potential association between 
QoL, CORThair, and daily hydrocortisone intake. Partial correlations were calculated between 
QoL and CORThair and daily hydrocortisone intake, adjusted for age and gender. Subsequently, 
groups were stratified for gender and partial correlations were calculated between QoL and 
CORThair and daily hydrocortisone intake, adjusted for age. Regression analyses including 
linear and quadratic terms were used to examine possible u-shaped associations. Further-
more, regression analyses including both CORThair and daily hydrocortisone intake were used 
to differentiate between the contributions of these two factors. Because of the exploratory 
nature of these analyses, adjustment of the level of significance for multiple testing was not 
performed, and the level of significance was set at P < .05.
resulTs
Patient characteristics 
A total of 120 patients with longstanding AI (46 males) with a mean age of 55.0 ± 14.7 years 
were included in the analyses. The duration of follow-up was on average 18.5±13.3 years, 
with a median of 15.8 years (IQR: 8.1-28.9). Patients used a mean daily dose of 21.1 ± 4.5 mg. 
In the whole group of patients, 34% presented with CORThair above our lab-internal cut-off 
for normal (52 pg/mg). Of the males, 59% demonstrated CORThair higher than the lab-internal 
cut-off, in contrast to 19% of the females (P < .001). As previously reported (17), also in the 
present study male patients demonstrated higher CORThair than female patients (75.3 (26.2 
- 150.1) vs. 19.7 (11.6 - 38.5), P < .001). Furthermore, female patients dyed or bleached their 
hair more and used hair products more frequently than male patients (all P ≤ .03) (Table 1). 
Daily hydrocortisone intake and CORThair showed a significant, but modest correlation (r = 
0.185, P = .047).
To evaluate whether there were differences in CORThair between different etiologies of AI, 
five groups were formed: 1) AI due to previous treatment for Cushing’s disease (n = 18), 2) other 
functioning pituitary adenomas (n = 14, including acromegaly (n = 5), prolactinoma (n = 8), and 
FSH producing adenoma (n = 1)), 3) nonfunctioning pituitary adenoma+craniopharyngioma 
(n = 48, nonfunctioning pituitary adenoma (n = 35) and craniopharyngioma (n = 13)), 4) 
primary AI (n = 18), and 5) other causes of hypopituitarism (n=22, including congenital hy-
popituitarism (n = 6), hypopituitarism after radiotherapy/surgery/traumatic brain injury (n = 
7), and other causes such as pituitary inflammation or Sheehan’s syndrome (n = 9)). CORThair 
was lowest in patients with CD, but group differences did not reach statistical significance (P 
= .126) (Figure 1). The self-reported hydrocortisone dose was significantly different between 
groups (P = .003), with patients with primary AI using a higher dose (24.7 ± 4.5 mg) compared 
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to patients with CD (20.0 ± 4.8), NFA+CP (20.9 ± 3.8) or other causes of hypopituitarism (19.2 
± 5.4).








Age (years) 55.0 ± 14.7 57.2 ± 14.8 53.6 ± 14.6 .167b
BMI (kg/m2) 28.0 ± 5.1 27.5 ± 3.5 28.3 ± 5.9 .799b
Duration of follow-up (years) 18.5 ± 13.3 18.2 ± 12.6 18.7 ± 13.8 .995b
Use of external glucocorticoids # 15 (13%) 5 (11%) 10 (14%) .702c
Hair cortisol levels* 23.7 (14.0 – 84.7) 75.3 (26.2 – 150.1) 19.7 (11.6 - 38.5) <.001a
Hair cortisol above our lab-internal 
cut-off (52 pg/mg)
41 (34%) 27 (59%) 14 (19%) <.001c
Daily hydrocortisone dose (mg) 21.1 ± 4.5 21.5 ± 5.1 20.8 ± 4.2 .334b
Daily hydrocortisone dose (mg/kg) 0.26 ± 0.07 0.2 ± 0.07 0.3 ± 0.07 .065b
Daily hydrocortisone dose (mg/BSA) 10.7 ± 2.4 10.3 ± 2.5 11.0 ± 2.3 .077b
Hair dyed 44 (37%) 0 (0%) 44 (60%) <.001c
Hair bleached 18 (15%) 0 (0%) 18 (24%) <.001c
Hair permed 3 (3%) 1 (2%) 2 (3%) .848c
Use of hair product 60 (50%) 17 (37%) 43 (58%) .024c
Frequency hair wash 
> 3 times/week
42 (35%) 21 (46%) 21 (28%) .061c
Data are presented as mean (standard deviation), and as n (valid percentage). a Independent samples t-test, b 
Mann-Whitney U-test, c Chi-square test. AI, adrenal insufficiency; BMI, body mass index; BSA, body surface area; #: 
use of other external glucocorticoids (in addition to their regular  hydrocortisone substitution). P value: AI males 
vs. AI females.
figure 1. Comparison of CORThair between pa-
tient groups.
Mean hair cortisol levels (CORThair) +/- standard error to 
the mean, stratified per patient category as follows: 1. 
CD: AI due to previous treatment for Cushing’s disease 
(n = 18); 2. FA: other functioning pituitary adenomas (n 
= 14, including acromegaly (n = 5), prolactinoma (n = 
8), FSH producing adenoma (n = 1)); 3. NFA+CP: non-
functioning pituitary adenomas (n = 48, including 
craniopharyngeoma (n = 13) and NFA (n = 35)); 4. PAI: 
primary adrenal insufficiency (n = 18); 5. Other: other 
causes of hypopituitarism (n = 22, including congenital 
hypopituitarism (n = 6), hypopituitarism after radio-
therapy/surgery/traumatic brain injury (n = 7), other 
causes such as pituitary inflammation or Sheehan’s syn-
drome (n = 9)). The figure shows a difference in CORThair 
between patients with AI due to previous treatment for 
CD and the other groups, but this difference was not 




Compared to healthy controls, patients with AI reported worse QoL on all subscales (except 
general health perception, SF-36) (P < .05). After stratifying for gender, male patients reported 
worse QoL on 12 of the 15 subscales (P < .05) and female patients reported worse QoL on 14 
of the 15 subscales (P < .001) in comparison to controls (Table 2). 
Comparing QoL between the different etiology groups revealed significantly more depres-
sive symptoms (HADS) in patients with CD (7.3 ± 4.0) relative to patients with NFA+CP (4.3 ± 
3.5) (P = .022) (Figure 2). Furthermore, patients with CD reported more physical fatigue (14.7 
± 2.0), more reduced activity (12.9 ± 1.2) (MFI-20), and worse mental health (58.9 ± 20.2) 
(SF-36) compared to patients with PAI (11.7 ± 4.7; 10.7 ± 4.2; 77.7 ± 18.2) (P = .004, P = .009, P 
= .044, respectively). Considering that only patients with CD differed from the other groups, 
QoL analyses were corrected for etiology of CD. 
relations between corThair and Qol (Table 3) 
Correlations between CORThair and QoL, adjusted for age, gender, and etiology CD revealed 
that in the whole group, higher CORThair correlated at trend level with more limitations in 
daily activities (EQ-5D) (r = 0.180, P = .059). After stratification for gender, it was observed that 
in male patients higher CORThair was associated with more physical fatigue (r = .355, P = .018). 
In female patients higher CORThair was associated with more limitations in daily activities (r = 
0.239, P = .046) and more pain (r = 0.269, P = .024) (EQ-5D). 
In the whole group, QoL of patients with CORThair above the lab-internal cut-off for normal 
was not different from patients with CORThair in the normal range (P > .05). However, female 
patients with CORThair levels above the lab-internal cut-off (n = 14 (19%)) reported lower 
physical functioning (52.9 ± 28.7, P = .025) and more pain on the SF-36 (52.8 ± 29.7, P = 
.033), as well as on the EQ-5D (2.2 ± 0.8, P = .049) relative to females with CORThair within the 
figure 2. Comparison of depressive symptoms 
(HADS) between patient groups.
Mean Depressive and Anxiety symptoms as measured 
by the Hospital Anxiety and Depression Scale (HADS) 
+/- standard error to the mean, stratified by the follow-
ing patient categories: 1. CD: AI due to previous treat-
ment for Cushing’s disease (n = 18); 2. FA: functioning 
pituitary adenomas (n = 14, including acromegaly (n 
= 5), prolactinoma (n = 8), FSH producing adenoma (n 
= 1)); 3. NFA+CP: non-functioning pituitary adenomas 
(n=48, including craniopharyngeoma (n = 13) and 
NFA (n = 35)); 4. PAI: primary adrenal insufficiency (n = 
18) 5. Other: other causes of hypopituitarism (n = 22, 
including congenital hypopituitarism (n = 6), hypopi-
tuitarism after radiotherapy/surgery/traumatic brain 
injury (n = 7), other causes such as pituitary inflamma-
tion or Sheehan’s syndrome (n = 9).


































































































































































































































































































































































































































































































































































































































































































































































































































































































































normal range. No differences in QoL were found between male patients with CORThair above 
the lab-internal cut-off (n = 27 (59%)), and male patients with CORThair within the normal 
range (P > .05). Regression analyses including age, gender, and etiology CD, as well as CORThair 
as a quadratic term did not render significant results.  
relationships between daily hydrocortisone intake and Qol (Table 3)
Correlations between hydrocortisone intake and QoL, adjusted for age, gender, and etiology 
CD, revealed that in the whole group, higher hydrocortisone intake was associated with more 
impairments in physical functioning (r = -0.208, P = .027), less vitality (r = -0.251, P = .007), 
a greater decrease in perceived health (change in health) (r = -0.317, P = .001) (SF-36), more 
limitations in daily activities (r = 0.206, P = .032), and a worse perceived health status (r = 
-0.297, P = .002) (EQ-5D). After stratification for gender, it was observed that higher hydro-
cortisone intake was associated with a worse perceived health status in male patients (r = 
-0.319, P = .048). In female patients, higher hydrocortisone intake was associated with less 
vitality (r = -0.334, P = .005), a greater change in health (r = -0.349, P = .003) (SF-36), more 
limitations in daily activities (r = 0.264, P = .028), and a worse perceived health status (r = 
-0.307, P = .012) (EQ-5D). Regression analyses including age, gender, and etiology CD, as well 
as daily hydrocortisone dose as a quadratic term revealed a significant quadratic contribution 
of hydrocortisone dose to depressive symptoms (HADS) (β = 1.150, P = .019), mental fatigue 
(MFI-20) (β = -1.079, P = .033), physical functioning (β = -0.946, P = .046), social functioning (β 
= -1.232, P = .012), change in health (SF-36) (β = -1.031, P = .039), pain (β = 1.413, P = .004) and 
perceived health status (EQ-5D) (β = -1.022, P = .036), indicating that relatively low, as well as 
relatively high hydrocortisone intake was associated with more depressive symptoms, more 
limitations in physical functioning and social functioning, more pain, and lower perceived 
health, but less mental fatigue.
Table 3. Correlations between QoL, CORThair and hydrocortisone dose
Patients with AIa Males with AIb Females with AIb
CORThair HC dose CORThair HC dose CORThair HC dose
SF-36 Physical functioning -.097 -.208* -.019 -.200 -.122 -.164
Vitality -.068 -.251** .067 -.085 -.164 -.334***
Change in health .015 -.317*** .011 -.258 .031 -.349***
MFI-20 Physical fatigue .120 .136 .335* .203 -.028 .066
EQ-5D Activity .180 .206* .016 .153 .239* .264*
Pain .131 .134 -.054 .013 .269* .215
VAS -.071 -.297*** .171 -.319* -.164 -.307*
a partial correlations correcting for age and gender; b partial correlations correcting for age. *P < .05; **P< .01; *** P< 
.005. AI: adrenal insufficiency. CORThair (pg/mg); hydrocortisone dose (mg). Only significant correlations are shown.
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regression analysis including corThair and hydrocortisone intake
Regression analysis including both CORThair and daily hydrocortisone dose, as well as age, 
gender, and etiology CD, revealed a significant contribution of daily hydrocortisone dose to 
physical functioning (β = -0.182, P = .046) change in health (SF-36) (β = -0.254, P = .008), 
limitations in physical activities (β = 0.204, P = .034) perceived health status (EQ-5D) (β = 
-0.277, P = .004). No significant contribution of CORThair was found in this by using this regres-
sion model. Post-hoc analyses on these significant results using the same regression analyses, 
but without CORThair, resulted in slightly increased beta’s (increases ranging from .008 to 
.022), indicating that part of the variation of CORThair was explained by hydrocortisone intake, 
which is not surprising considering the association between daily hydrocortisone intake and 
CORThair  (r = 0.185, P = .047).
dIscussIon
The present exploratory study confirmed that patients with AI report more impairments in 
QoL compared to healthy controls (2-5), which is dependent on the cause of AI and demon-
strated that daily hydrocortisone intake was inversely correlated with QoL (physical aspects). 
This is in accordance with some (5;13;28), but not all studies (2;4;29). Interestingly, this as-
sociation was not found with systemic cortisol exposure, since only a few aspects of QoL 
were associated with CORThair, suggesting that QoL impairments are not per se due to chronic 
overtreatment with hydrocortisone. Nevertheless, CORThair did explain a part of the variation 
of the observed associations between daily hydrocortisone intake and QoL, indicating that 
the actual cumulative cortisol exposure should also be taken into account.
Previous QoL studies in patients with AI identified several influencing factors, such as au-
toimmune co-morbidity (30), delay of diagnosis (30), higher age at manifestation, and female 
gender (30). Furthermore, it is suggested that intrinsic imperfections in replacement therapy 
also play a role (10). The present study is the first to examine the relation between actual 
chronic cortisol tissue exposure and QoL in patients with AI as measured by CORThair. Based 
on this first explorative study it seems that associations between hydrocortisone intake and 
QoL are not (directly) influenced by cortisol exposure. This suggests that QoL impairments in 
patients with AI are not per se related to higher cortisol exposure, but it might be more obvi-
ous that the relation between hydrocortisone intake and QoL is (at least partly) explained by 
that patients who take more hydrocortisone basically need more hydrocortisone. Further-
more, assessing the potential effect of occasionally taking higher hydrocortisone doses did 
not reveal a significant effect (data not shown). Cortisol acts in the central nervous system by 
binding to mineralocorticoid- and glucocorticoid receptors. The current notion is that the ef-
fects of cortisol binding to mineralocorticoid and glucocorticoid receptors follow an inverted 
u-shaped dose response curve, with both pathological low and high cortisol levels negatively 
affecting the mediating function of these receptors (31). This mechanism might underlie the 
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observed impairments in QoL in female patients with CORThair above the lab-internal cut-off. 
Since there is no explicit lower limit of CORThair, there is no evidence that underreplacement 
negatively affects QoL. Interestingly, this inverted u-shaped dose response curve was identi-
fied in the quadratic associations found between hydrocortisone intake and physical, mental 
and social aspects of QoL. 
Despite the heterogeneous origin of AI in this cross-sectional analysis, we found that 
CORThair correlated with two physical aspects of QoL (physical activities and pain) in female 
patients, and one physical aspect in male patients (physical fatigue). In addition, female pa-
tients with CORThair above the lab-internal cut-off reported more impairment in QoL relative 
to females with CORThair below the lab-internal cut-off. This difference was not found for male 
patients. The found gender difference in CORThair in the present sample with males dem-
onstrating higher CORThair than females, was previously described (17) and may be due to, 
among other factors,  sex-specific differences in levels of circulating cortisol binding globulin. 
Therefore, analyses of the present study were stratified for gender. Furthermore, in male pa-
tients higher CORThair was associated with higher BMI (17), suggesting a metabolic effect of 
overexposure. Recently, Quinkler et al. demonstrated in patients with AI using conventional 
hydrocortisone replacement that switching to once-daily hydrocortisone dual release tablets 
did not ameliorate QoL, although BMI and HbA1c improved (32). Together with the results of 
the present study, this would suggest that more adequate cortisol exposure predominantly 
affect somatic outcome, and to a lesser extent patient-perceived well-being, in particular in 
males. Furthermore, it was observed that patients with CD showed lower CORThair relative to 
the other groups (although not significant). We postulate that this observation is also related 
to the gender effect since ninety-four percent of the patients with CD were females, and 
comparing CORThair between female patients with CD and other female patients revealed 
no significant results (data not shown). Furthermore, it can be speculated that low CORThair 
found in patients with CD might be explained by irreversible changes in cortisol metabolism 
(e.g. more efficient breakdown of cortisol) related to the previous exposure to elevated 
cortisol levels.
In addition, the observation that patients with AI due to previous treatment for CD re-
ported more QoL impairments compared to the other diagnostic groups, while also having 
the lowest CORThair (not significant), could potentially be explained by the fact that these 
patients have been exposed to excessive cortisol levels in the past. Previous literature re-
ported that potential damage caused by this excessive exposure to cortisol might only be 
party reversible (33;34). Therefore, it might be that QoL impairments in the CD group are to a 
larger extent explained by the previous hypercortisolism, than due to current cortisol levels 
as measured by CORThair.
As previous studies show, assessment of CORThair is a useful tool in the diagnosis of Cush-
ing’s syndrome and potentially also for  AI (16;35) or as indicator of somatic disease and 
distress (36-38). Furthermore, the assessment of CORThair in the present study enabled us to 
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discriminate between cause and consequences, since impairments in QoL were associated 
with a higher hydrocortisone intake, but were not reflected by higher CORThair. Several small 
studies on the relation between CORThair and depressive symptoms, anxiety or general well-
being in subjects without AI have been published, however at present no other study primar-
ily focused to this extent on QoL in relation to CORThair in AI (38-41). Younge and colleagues 
assessed CORThair, as well as QoL and psychological parameters (i.e., SF-36, HADS) in patients 
with structural heart disease. They demonstrated that higher CORThair was correlated with 
lower self-reported physical functioning, which remained significant after adjustment for 
age, gender and BMI. No significant correlations were found on other aspects (42). Similarly, 
in the present study, physical aspects of QoL were associated with hair cortisol levels, while 
no correlations were found with other aspects of QoL. 
In the present study, CORThair and some physical aspects of QoL were associated with each 
other in a heterogeneous group of patients with AI.  It is important to acknowledge that we 
studied correlations within a group of patients with AI with impairments in QoL (2-6). This 
group is potentially yielding a relatively small variation of QoL, thereby impeding finding as-
sociations between CORThair and QoL. Other aspects that should be taken into account while 
interpreting the results are the multidimensional character of QoL (43), and the possibility 
that  the used generic and domain-specific QoL questionnaires might have been not sensi-
tive enough. Although a disease-specific QoL questionnaire for primary adrenal insufficiency 
(i.e. AddiQoL (44;45)) could have been more sensitive and suitable, it was not used because 
it has not yet been translated and validated into the Dutch language. In addition, it should 
be acknowledged that although the present sample was heterogeneous regarding etiology 
of AI and that both patients with primary and secondary AI were included, it provides a rep-
resentative sample of everyday clinical practice. Finally, no conclusions can be drawn about 
causality due to the cross-sectional design of this study. Future studies using a longitudinal 
design could provide more information about the time course of QoL impairments, as well as 
the contribution of CORThair.  
In conclusion, this is the first report that further explored the relation between QoL, hy-
drocortisone intake and actual cortisol exposure in AI patients by measuring hair cortisol, 
a marker of long-term systemic cortisol exposure. Patients with AI demonstrated several 
impairments in QoL which were sex-specifically associated with hydrocortisone intake, but 
were to a lesser extent reflected by chronic cortisol exposure as measured by hair cortisol, 
suggesting that QoL impairments in patients with AI are not explained by the effect of pro-
longed exposure to elevated systemic cortisol levels.
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Chapter 7
Mild cognitive deficits in patients with primary 
adrenal insufficiency 







background: The brain is a major target organ for cortisol considering its high density of 
glucocorticoid receptors. Several states of hypothalamus-pituitary-adrenal dysregulation 
point towards impairments in cognitive functioning. However, there is a very limited body of 
research on the effects of hypocortisolism on cognitive functioning. 
aim: To evaluate cognitive functioning in patients with hypocortisolism (i.e. primary adrenal 
insufficiency (PAI)) and to examine the possible effect of postponing early-morning hydro-
cortisone intake on cognitive functioning. 
Methods: Thirty-one patients with PAI on regular morning hydrocortisone intake and 31 
healthy matched controls underwent nine neuropsychological tests evaluating memory 
and executive functioning. In addition, the effect of normal timing and postponement of 
morning hydrocortisone intake on neuropsychological tests were assessed in an additional 
29 patients with PAI. 
results: Compared to controls, patients with PAI performed worse on auditory and visual 
memory tasks (all P≤.024) and executive functioning tasks (all P≤.012). In contrast, patients 
performed better on a concentration and an attention task (both P<.05). Postponement of 
hydrocortisone intake in the morning did not affect the outcomes of neuropsychological 
tests.
conclusion: Patients on long-term hydrocortisone replacement for PAI show mild cognitive 
deficits compared to controls. There was no effect of postponement of regular hydrocorti-
sone intake on cognition.




In the human brain, the effect of cortisol is mediated via two types of receptors: the miner-
alocorticoid receptors (MRs) and the glucocorticoid receptors (GRs). MR is highly expressed 
in the hippocampus, a brain structure involved in memory and learning processes, while 
GR is widely expressed throughout the whole brain. Cortisol has a tenfold higher binding 
affinity for the MR than for the GR. Consequently, MRs are activated first when cortisol levels 
increase, followed by GRs activation when cortisol levels increase further (1). Activation of the 
MR leads to retrieval of previously learned tasks and behavioural responses to new situations, 
while GR activation is responsible for the consolidation of new information (2). 
The mediating functions of MR and GR activation regarding behaviour have been studied 
in animal models. Long-term-potentiation (LTP, reinforcement of synaptic contacts contribut-
ing to storage of information) is enhanced when cortisol levels are mildly elevated, resulting 
in activation of all MRs and some of the GRs. When GRs are extensively activated because of 
high levels of cortisol, LTP was impaired while long-term-depression  (reduction of synaptic 
contacts causing the opposite effect of LTP) was enhanced (3). In accordance, it has been 
postulated that cortisol levels follow an inverted u-shaped dose response curve, with very 
low cortisol levels (predominantly activating the MRs), as well as very high cortisol levels (ac-
tivating MRs and a large amount of GRs) negatively affecting the mediating function of these 
receptors on information processing. This work has been elaborated further in humans by 
Lupien et al. (4), who showed that memory performance can be modulated by pharmacologi-
cal manipulations of glucocorticoid levels, with too low, as well as too high glucocorticoid 
levels resulting in impaired memory function.
The negative effects of exposure to cortisol excess on the human brain and cognition have 
been shown in patients with Cushing’s disease (CD). Patients with active CD suffer from hyper-
cortisolism and demonstrate cognitive impairment and abnormal brain characteristics (5-8), 
which partly persist even after long-term remission (9-12). In contrast to the large amount of 
data on the effects of hypercortisolism on the human brain and cognitive functioning, limited 
data are available on cognitive functioning in patients with hypocortisolism (see Table 1 for 
an overview of studies). Primary adrenal insufficiency (PAI) or Addison’s disease is caused by 
damage to the adrenal gland, most frequently caused by auto-immunity or following bilateral 
adrenalectomy. As a result, cortisol and aldosterone secretion is reduced dramatically or even 
completely absent. Patients are treated with hydrocortisone (HC) replacement in order to 
mimic the circadian rhythm of cortisol secretion as best as possible. However, even on stable 
treatment for PAI, patients reported impairments in QoL (13-15). Interestingly, Tytherleigh et 
al. (2004) investigated the role of MR versus GR activation in information processing in nine 
patients with PAI. In accordance with findings of animal studies, it was demonstrated that 
in comparison with GR activation only, working memory and episodic declarative memory 
performance was better when both receptors were activated. This study further supports 































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































in humans (16). Furthermore, Harbeck et al. (17) investigated the effects of hydrocortisone 
infusion during the night on cognitive functioning in patients with PAI, and concluded that 
higher cortisol levels were associated with worse short-term memory performance. Recently, 
Werumeus Buning and colleagues (18) explored the effect of low versus high dose HC on 
cognition in patients with secondary adrenal insufficiency. The researchers found no signifi-
cant effect on cognition after 10 weeks of treatment with a high dose of HC compared with 
patients on a lower dose of HC. 
The number of studies on cognitive functioning in patients with PAI is limited. Therefore, 
the aim of the present study was to investigate cognitive functioning, including memory and 
executive functioning, in patients with PAI on regular morning HC intake. Furthermore, we 
aimed to investigate the direct effect of very low cortisol levels on cognitive functioning by 
examining the effect of postponement of HC intake in patients with PAI. We hypothesized 
that patients with PAI have cognitive impairments, which would be in line with the inverted 
u-shaped dose response curve of cortisol. Furthermore, we hypothesize that postponement 
of habitual HC intake will lead to more impaired cognitive functioning. 
MaTerIal and MeTHods 
Participants
Patients with PAI were recruited via the outpatient clinic of the department Endocrinology at 
the Leiden University Medical Center (LUMC) and by advertisement via the Dutch Adrenal Pa-
tient Society for Addison and Cushing Patients (NVACP; www.nvacp.nl). Thirty-nine patients 
were derived from the patient network and 21 patients from the LUMC outpatient clinic. A 
final number of 60 participants were included in the present study (23 men and 37 women, 
mean age 49.0 ± 12.4 years). Patients were excluded in case of present or previous drug or 
alcohol abuse, any neurological diagnosis such as CVA, cerebral trauma, or dementia. PAI 
had been diagnosed based on the classical clinical symptoms and biochemical confirmation 
of adrenal insufficiency in the presence of increased ACTH concentrations. Adrenal insuf-
ficiency was diagnosed when basal early morning cortisol concentrations were below the 
reference range of normal (<0.12umol/l) or below 500 nmol/l after stimulation with ACTH. 
Thirty-eight patients (63%) had been diagnosed with PAI due to autoimmune disease with 
positive autoantibodies against the adrenal cortex, 5 patients (8%) had been diagnosed with 
PAI due to non-autoimmune causes (e.g. congenital adrenal aplasia, adrenal calcification), 
and 2 patients (3%) after bilateral adrenalectomy for pheochromocytomas. The origin of PAI 
was unknown in 15 patients (25%). 
All patients were on hydrocortisone replacement with a mean duration of 9.7 ± 8.2 years 
(range 2-38 years), as prescribed by their individual physicians. Eighty-three percent of the 
patients also used fludrocortisone in addition to hydrocortisone. Additional medical therapy 
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included DHEA (23%), levothyroxine for concomitant Hashimoto’s disease (43%), anti-hyper-
tensive drugs (12%), and oral contraceptives (8% of the female patients). Forty-one percent 
of female patients were postmenopausal.
The controls were obtained from online advertisements and advertisements in grocery 
stores and were matched for gender, age, and education. Exclusion criteria were present or 
previous drug or alcohol abuse, any neurological diagnosis or endocrine disease. The Medical 
Ethics Committee of the LUMC approved the protocol and written informed consent was 
obtained from all subjects. 
study procedure
All patients were invited to the LUMC for the neuropsychological examination. Patients were 
randomly assigned to condition 1: taking their regular morning HC dosage on the day of the 
neuropsychological assessment, or condition 2: postponing their regular morning HC dosage 
on the day of the neuropsychological assessment. All patients were instructed to rise, take 
their HC substitution (condition 1), and eat a standardized breakfast between 6 and 7 a.m. 
Both patients and controls were asked to take a standardized breakfast, which consisted of 
a cup of tea without sugar, and one slice of bread. Before the neuropsychological evaluation 
started, blood pressure, heart rate, and glucose levels were measured. The neuropsychologi-
cal examination started at 9.00 a.m. and took approximately 90 minutes. Patients in condition 
2 who postponed their regular morning HC intake were asked to take their medication in the 
presence of the examiner directly after the neuropsychological evaluation. 
cognitive evaluation
In order to assess cognitive functioning, nine neuropsychological tests were completed. A 
functional classification was used to subdivide the tests into the cognitive domains memory 
and executive functioning (19). Since psychopathology can have an effect on cognitive func-
tioning, independent variables related to psychopathology affecting cognitive functioning 
in patients were explored. The scores on various psychopathology questionnaires (Apathy 
Scale, Irritability Scale, Mood and Anxiety Symptoms Questionnaire short-form (MASQ), and 
Hospital Anxiety and Depression Scale (HADS)) were derived from an early study by our 
research group (15).
Memory 
Wechsler Memory Scale (WMS) provides a memory quotient (MQ) based on various subscales 
(i.e. Information, Orientation, Concentration, Logical Memory, Digit Span, and Visual Mem-
ory). A higher MQ indicates a better performance. A MQ between 95 and 104 is considered 
average (20). 
Verbal Learning Test of Rey consists of a list of 15 words, which are visually presented and 
have to be remembered by the patient. There is a three-trial presentation of this list. After 
142
Chapter 7
each trial, the patient is asked to recall the remembered words. Furthermore, there is a fourth 
delayed reproduction. The amount of recalled words after each trial is counted. The more 
produced words each trial, the better the learning capability (21). In the present study, only 
trial 1 (imprinting), trial 2 (immediate reproduction), and trial 4 (delayed reproduction) were 
used, while trial 3 (second round of immediate reproduction) was omitted from the analyses.
Rey Complex Figure Test measures visual memory. The participant is asked to draw a copy of 
a complex figure. After three minutes, the patient is asked to draw the complex figure from 
memory (immediate recall). After 30 minutes, the patient is asked to draw the complex figure 
again (delayed recall).  A higher score indicates better visual memory (22). 
Executive functioning
Verbal Fluency Test (FAS) measures verbal fluency and mental flexibility. The participant is 
asked to produce as many words starting with F, A, or S as possible in one minute. The total 
amount of produced words is counted, as well as the number of errors and repeats. The more 
correct words produced, the better the verbal mental flexibility and fluency (23).
Letter-Digit Substitution Test measures mental flexibility, psychomotor speed and speed of 
information processing. Number of correctly substituted letters and errors within 60 seconds 
are counted (24). 
Stroop color-word test (Stroop-cwt) measures interference sensibility. Patients are asked to 
name the color of the ink and inhibit reading the word (25).The number of correct and false 
responses, in 45 seconds, are counted. 
Trail Making Test (TMT) requires complex visual scanning and measures motor speed and 
attention. In part A, the patient is asked to connect the numbers 1 to 15 (TMT-A). In part B, the 
patient is asked to connect alternately a number and a letter in the right sequence (TMT-B). 
The time used and the number of errors made are counted. The more time used and the more 
errors made, the lower the performance on this test (26). 
Sustained Attention to Response Task (SART) assesses sustained attention via a go-no-go 
signal detection task. The participant is subjected to a white digit (1 to 9) 225 times on a 
black computer screen. Each number is shown 25 times in a predetermined and quasi-
random order. Each number is presented for 250 ms, followed by a black screen for 900 ms. 
Participants are asked to respond to the appearance of each number by pressing a button, 
except for the number 3. The SART was performed two times, the time in between was spent 
on other neuropsychological tests (i.e. RCFT, FAS, LDST, Stroop). The average score of the two 
sessions was calculated and consists of the number of times the button was pressed when a 
‘3’ was shown (errors of commission), plus the number of omissions (errors of omission). The 
reaction time is the average time in milliseconds between the appearance of any number and 
the subject’s presses (27). 




The Groninger Intelligence Test 2 (GIT-2) consists of 9 subscales and provides an IQ score. In the 
present study, only the synonyms subtest was used in order to estimate verbal intelligence. 
This subtest consists of 20 words. The patient is asked to choose the synonym of each word 
out of a list of four words. Based on the number of correct answers, an index score can be 
determined. A higher index score demonstrates a better performance (28). 
cortisol levels
Saliva samples were collected to assess cortisol levels before and after the cognitive tests. 
Samples were collected using a Salivette® (Sarstedt) containing a sterile polyester swab. The 
salivettes were used in accordance with the instructions from the manufacturer. All salivettes 
were centrifuged at 2000g for 10 minutes, and filtrates were stored at -20oC until analysis. 
All samples were analyzed on the same day, using Roche cortisol assays (i.e. competitive 
electrochemiluminescence immunoassays). The protocol for analyzing salivary cortisol using 
Roche cortisol assays is described in detail elsewhere (29).
statistical analyses
All data were analysed using PASW Statistics for Windows version 20.0 (SPSS Inc., Chicago, IL). 
The primary analysis comprised the comparison of the neuropsychological tests scores of the 
patients with PAI with regular morning HC intake and the scores of matched healthy controls, 
by using a linear mixed model with the matched patient-control couples as a random factor. 
The secondary analysis comprised the comparison of the neuropsychological test scores of 
patients with regular morning HC intake and patients with postponed intake. In order to 
compare these scores, an independent-samples t-test was used. When data was not normally 
distributed, the non-parametric Mann-Whitney Test was used. Since psychopathology can 
have an effect on cognitive functioning, independent variables related to psychopathology 
affecting cognitive functioning in patients were explored by linear regression analysis. The 
standardized β-coefficients of this analysis were reported. To check the appropriateness of 
assumptions for each statistical analysis Levene’s test, Durbin-Watson test, histograms and 
scatter plots were used. Due to the exploratory nature, the level of significance was set at P 
≤ .05. 
resulTs
clinical characteristics (Table 2)
A total of sixty patients with PAI were included in the present study, of whom 31 patients 
with regular morning HC intake at the time of awaking (11 males, 36%), and 29 patients with 
postponed HC intake until after the tests, which started at 09.00 a.m. (12 males, 41%). In 
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addition, thirty-one healthy controls were included matched for age, gender, and education 
to the patients with regular HC intake. Since they were perfectly matched, the 31 patients 
with regular HC intake did not differ from the 31 matched controls regarding age, gender 
and education. The clinical characteristics of the patients with regular morning HC intake 
(n=31) also did not differ from the patients with postponed intake (n=29). The mean weight 
adjusted dose of HC was 0.31 mg/kg for the entire sample of patients. The mean HC dose per 














Test statistic and 
P-value
Hc intake versus 
postponed intake
cohen’s d effect 
size  Hc intake 
vs postponed 
intake
Gender (m/f ) 11/20 11/20 12/17 χ2=0.220, p =0.639 0.121
Age (yrs) 49 (11) 45 (12) 50 (14) t(58)=0.320, p=0.750 0.083
Educational level
  Low 4 (13%) 4 (13%) 7 (24%) χ2=3.998, p=0.135 0.534
  Medium 15 (48%) 15 (48%) 7 (24%)
  High 12 (39%) 12 (39%) 15 (52%)
BMI 27.6 (6.2) 25.3 (3.1) 24.8 (3.8) U=346.0, p=0.126 0.540
Glucose level 6 (1) 6 (1) 5 (1) U=371.5, p=0.248 0.402
Blood pressure (systolic, 
mmHg)












Heart rate (bpm) 67 (10) 70 (10) 67 (11) U=427.5, p=0.742 0.084
Cortisol level before 
assessment (nmol/L)
20 (14) NA 4 (2) U=36.0, p<0.001
1.634
Cortisol level after 
assessment (nmol/L)
9 (5) NA 4 (2) U=79.0, p<0.001
1.554
PAI diagnose (n)
  Autoimmune 19 (61%) NA 19 (66%) χ2=0.178, p=0.915 0.109
  Non-autoimmune 2 (7%) NA 3 (10%)
  BA 1 (3%) NA 1 (3%)
Duration of follow-up (yrs) 10 (8) NA 10 (8) U=146.5, p=0.855 0.035
Hydrocortisone dose (mg)# 23 (7) NA 26 (8) U=492.5, p=0.369 0.285
Fludrocortisone, n (%) 27 (87%) NA 23 (79%) χ2=1.366, p=0.505 0.305
DHEA, n (%) 5 (16%) NA 9 (31%) χ2=1.861, p=0.173 0.358
L-thyroxine,  n (%) 13 (42%) 1 (3%) 13 (45%) χ2=0.051, p=0.821 0.058
Anti-hypertensive drugs, 





Insulin, n (%) 0 (0%) 0 (0%) 0 (%) Constant, p=1.000 NA
Data are mean (SD) or number and %; BA: Bilateral adrenalectomy; # total dose per day. 
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body surface was 12.20 mg/m2. For the HC intake group, the mean weight adjusted dose of 
HC was 0.28 mg/kg, while the postponed intake group had a mean weight adjusted dose of 
HC of 0.34 mg/kg. In addition, the mean HC dose per body surface was 11.4 mg/m2 for the HC 
intake group, and 13.3 mg/m2 for the postponed intake group. Before testing started at 9 am, 
the mean salivary cortisol level of the regular HC intake group was 20.4±14.1 nmol/L, while 
the group that postponed HC intake showed a mean salivary cortisol level of 3.9±2.3 nmol/L. 
There was a significant difference in cortisol levels between both groups (U=36, P<0.001). 
After the neuropsychological assessment (at approximately 10.30 am), the mean salivary 
cortisol level of the HC group was 9.5±5.0 nmol/L, while the group that postponed HC intake 
showed a mean salivary cortisol level of 3.5±2.1 nmol/L. Again, there was a significant differ-
ence in post-test cortisol levels between the groups (U=79, P<0.001).
We asked all participants whether they experienced cognitive limitations. Fifty-seven 
percent of the patients reported difficulties with attention, compared to 19% of the controls. 
Seventy percent of the patients reported difficulties with memory compared to 26% of the 
controls. Problems with executive functioning were reported in 25% of the patients com-
pared to 3% of the controls.
cognitive functioning of patients with PaI vs. matched healthy controls (Table 3)
Patients with PAI (with regular HC intake, n=31) performed worse on Logical memory (WMS) 
(P = .006), and recalled fewer words on the Rey Auditory Verbal Learning Test on imprinting (P 
= .024), immediate recall (P = .001) and delayed recall (P = .016) than their matched controls. 
On the Rey Complex Figure Test, patients performed worse on the immediate (P = .009), as 
well as the delayed recall (P = .007). Furthermore, patients had more repeats on the FAS (P = 
.003) and they needed more time to complete the TMT-B (P = .012) compared with controls. 
Nevertheless, patients seemed to perform better on the Concentration subscale of the WMS 
(P = .015) and made fewer errors during TMT-A (P = .041) than controls. 













Wechsler Memory Scale Memory Quotient 110.9 (13.7) 113.7 (13.9) F=0.748, p=0.394 0.223
Information 5.9 (0.4) 6.0 (0.2) F=0.682, p=0.412 0.213
Orientation 5.0 (0.2) 5.0 (0.0) F=1.000, p=0.325 0.258
Concentration 7.9 (1.2) 7.1 (1.4) f=6.255, p=0.015 0.646
Logical memory 6.4 (2.3) 8.1 (2.4) f=8.749, p=0.006 0.764
Digit span 10.0 (1.8) 9.9 (1.2) F=0.007, p=0.934 0.022
Visual memory 10.2 (2.7) 11.1 (3.6) F=1.542, p=0.224 0.321
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cognitive functioning of patients with postponed Hc intake vs. patients with 
Hc intake immediately after awakening
Patients who postponed their HC intake made fewer repeats (FAS) compared to patients with 
normal HC intake (P = .025). There were no significant differences on other cognitive tests. 












Associative learning 16.1 (2.8) 17.0 (3.1) F=2.566, p=0.120 0.414
Verbal Learning Test of Rey Imprinting, total 5.3 (1.7) 6.5 (2.5) f=5.645, p=0.024 0.613
Immediate, total 7.9 (1.8) 9.7 (2.5) f=12.921, p=0.001 0.928
Delayed, total 7.5 (2.6) 9.2 (3.4) f=6.466, p=0.016 0.657
Rey Complex Figure test Immediate 18.7 (6.5) 22.2 (7.7) f=7.816, p=0.009 0.722
Delayed 18.6 (6.9) 22.8 (7.8) f=8.581, p=0.007 0.756
executive function
Verbal Fluency Test (FAS) # correct 33.6 (12.8) 33.3 (12.9) F=0.008, p=0.931 0.023
% repeats 1.1 (1.2) 0.4 (0.6) f=10.680, p=0.003 0.844
% errors 0.9 (1.4) 0.4 (0.7) F=3.163, p=0.080 0.459
Trail Making Test Trail A, time 0.3  (0.1) 0.3 (0.2) F=1.456, p=0.237 0.312
Trail A, errors 0.1 (0.3) 0.2 (0.4) f=4.564, p=0.041 0.552
Trail B , time 0.9 (0.4) 0.7 (0.4) f=7.081, p=0.012 0.687
Trail B, errors 0.3 (0.7) 0.2 (0.5) F=1.198, p=0.282 0.283
Letter-Digit Substitution Test # correct 35.8 (5.1) 37.8 (9.1) F=1.335, p=0.257 0.298
# errors 0.2 (0.8) 0.03 (0.2) F=1.895, p=0.174 0.355
Stroop Color-Word Test Interference, total 43.5 (7.7) 42.0 (8.2) F=0.672, p=0.419 0.212
Interference, mistakes 0.5 (1.9) 0.03 (0.2) F=1.811, p=0.183 0.347
SART session 1 Errors of ommission 2.52 (6.1) 2.35 (4.9) F=0.025, p=0.877 0.041
Errors of commission 9.23 (3.9) 8.9 (4.7) F=0.104, p=0.749 0.083
Total error score 11.74 (8.8) 11.26 (8.9) F=0.079, p=0.781 0.073
Mean reaction time 309.86 (48.5) 307.03 (51.6) F=0.055, p=0.817 0.061
SART session 2 Errors of ommission 2.55 (5.5) 1.74 (3.3) F=1.524, p=0.227 0.319
Errors of commission 8.74 (4.8) 9.32 (4.9) F=0.296, p=0.590 0.140
Total error score 11.29 (8.7) 11.06 (7.1) F=0.027, p=0.871 0.042
Mean reaction time 322.73 (73.1) 304.54 (62.6) F=1.220, p=0.278 0.285
Synonyms subtest of the 
Groninger Intelligence test
Synonyms score 4.9 (1.5) 4.9 (2.0) F=0.006, p=0.941 0.020
Data are mean (SD), significant test results are printed bold, intermediate (d=0.5-0.7) and large (d≥0.8) effect sizes 
are printed bold.
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cognitive limitations and current psychological state in patients with PaI
When combining both patients groups, patients who reported memory impairments scored 
significantly lower on associative learning (U=248, P=0.046), and were able to recall less 
words on the immediate recall trial of the Verbal Learning Test of Rey (U=237.5, P=0.028). 
Furthermore, patients who reported impairments in executive functioning needed more 
time to finish Trail A of the Trail Making Test (t(57)=-2.211, P=0.031) compared with patients 
who did not report impairments in executive functioning. There were no differences on tests 
assessing concentration or attention between patients who reported impairments in those 
domains and patients who did not.
The possible influence of psychopathology on cognitive functioning was explored by tak-
ing both patient groups together. In the memory domain, visual memory was negatively 
associated with the lack of positive affect subscale of the MASQ (β=-0.578, P=0.006). In the 
executive functioning domain, the total score on the Stroop Color-Word Test was negatively 
associated with the lack of positive affect subscale of the MASQ (β=-0.439, P=0.034). The 
number of errors on trail A of the Trail Making Test was negatively associated with the anxiety 
subscale of the HADS (β=-0.616, P=0.012) and positively associated with the Irritability scale 
(β=0.576, P=0.004). On the second session of the SART, the errors of omission was negatively 
associated with the lack of positive affect subscale of the MASQ (β=-0.578, P=0.006). The 
mean reaction time on the second session of the SART was positively associated with the 
depression subscale of the HADS (β=0.767, P=0.004), and negatively associated with the 
negative affect subscale of the MASQ (β=-0.548, P=0.035). The total error score on the second 
session of the SART was negatively associated with the lack of positive affect subscale of the 
MASQ (β=-0.488, P=0.022).
dIscussIon 
The present study demonstrates that patients on HC replacement for PAI performed worse 
on memory and to a lesser degree on executive functioning tasks when compared with 
healthy matched controls. It is important to note that patients with PAI in the current study 
were treated with HC replacement. Nevertheless, they showed subtle cognitive impairments 
in comparison with healthy matched controls. When patients with regular morning HC intake 
and patients with postponed HC intake were compared, no immediate deterioration in cog-
nitive functioning was observed (except for one executive functioning task). Furthermore, 
there were some associations between cognition and patients’ current psychological state. 
Visual memory and various executive functions were related to psychopathology, where a 
worse score on the cognitive tests was associated with a higher (i.e. worse) score on psycho-
pathology measures. 
Although visual memory and executive functioning have been studied in patients with 
PAI, the observed alterations in visual memory and executive functioning in patients on 
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long-term HC replacement for PAI have not previously been reported. The other observations 
in the present study were in accordance with recent other studies, documenting deficits in 
episodic and verbal memory in patients with PAI (30;31), as well as reduced speed of process-
ing and subtle impairments in attention (31;32).  The subtle cognitive impairments observed 
in patients with PAI might be explained by the HPA-axis dysregulation associated with HC 
therapy in the presence of primary hypocortisolism. As a result, MR and GR activation may 
not be optimally adjusted to the situation and the mediating function on memory may 
not be appropriate (3). This is also in accordance with the study of Tytherleigh et al. (2004), 
which suggested that a balanced activation of both receptors is needed for optimal memory 
function in humans (16).  It should be noted that the neuropsychological assessment in the 
present study was performed at 9 am, since longer withdrawal of HC is not indicated for 
safety reasons. However, cortisol levels are naturally higher in the morning (33) in the healthy 
population. These higher cortisol level could have negatively influenced cognitive function-
ing in the healthy controls (34), leading to smaller differences between patients and controls. 
In the present study, we did not observe major differences in cognitive functioning be-
tween patients with postponed HC intake and patients with regular HC intake. This might 
be explained by the inverted u-shaped dose response curve with very low cortisol levels 
(predominantly activating the MRs), as well as very high cortisol levels (activating MRs and 
GRs both to a large amount) negatively influencing the mediating function of MRs/GRs on 
information processing (3). It might be that patients were on either end of the inverted u-
shape (postponed: only MR activation vs. normal intake: both MR and GR highly activated) 
and therefore did not differ on cognitive functioning. In addition to dysregulation of HPA-axis 
within the CNS, another explanation for the results in the present study might be previous 
long-term hypocortisolism. The effect of prolonged hypocortisolism has been studied in ani-
mal models. After adrenalectomy, rats demonstrated neurodegeneration and loss of synaptic 
function in the hippocampus (2). However, it might also be possible that patients with PAI 
are exposed to prolonged exposure to elevated cortisol levels, as a result of the imperfect 
replacement with HC. The suggestion of over-replacement of HC in patients with adrenal 
insufficiency is supported by a recent study examining hair cortisol levels in patients with 
adrenal insufficiency on long-term HC replacement. That study showed significantly higher 
hair cortisol levels in patients with adrenal insufficiency on HC replacement, compared to 
patients with pituitary deficiencies without adrenal insufficiency and healthy controls (35). 
The negative effect of exposure to elevated cortisol levels on cognitive functioning and brain 
characteristics has been reported in patients with CD (5-8). In line with these observations, 
a direct comparison of the cognitive performance of patients with PAI in the present study, 
with cognitive functioning of patients in long-term remission of CD (data derived from a 
previous study by our research group (10)) revealed that patients with PAI and patients in 
long-term remission of CD perform generally similar (data not shown). 
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In the review process of the manuscript, there was concern with respect to the presenta-
tion of the data without adjustments for multiple comparisons. Simply defined, these adjust-
ments test for no effects in all the primary end points undertaken vs. an effect in one or 
more of those end points.  This is a difficult methodological issue because there are divergent 
views on the need for statistical adjustment for multiplicity. This is also reflected in the Lancet 
papers by Schulz and Grimes (36;37), who advocate a restrictive approach toward adjust-
ments for multiple comparisons. If we consider our own data and if we would assume that the 
differences would mostly reflect false-positive results, it is to be expected that the positive 
significant results would have been randomly distributed among the different variables. 
However, this is not the case, as shown in Table 3. We designed this study in our patients with 
PAI with the primary aim to evaluate cognitive function in detail, in view of the documented 
abnormalities in previous studies and those observed in experimental animal studies. In-
deed, the main results of our study point toward similar adverse effects of PAI documented 
in previous studies, although these had a different study design. According to Schulz and 
Grimes, statistical adjustments somewhat rescue the positive results of scattershot analyses. 
However, we performed a targeted evaluation and analysis focused on cognitive function 
related to PAI rather than a scattershot analysis of cognitive functions in general. Therefore, in 
our opinion, our data should not be neglected merely because of the absence of adjustments 
for multiple comparisons. Moreover, this would carry the serious risk of missing an important 
association between PAI and cognitive impairments. 
Cognitive functioning can be affected by many factors. In order to minimize the effect 
of external variables, participants and healthy controls were matched for age, gender, and 
education. However, the present study still has some limitations. Certain prescribed drugs, 
such as DHEA or levothyroxin, might have an effect on cognitive functioning. Due to power 
limitations, subgroup analyses to explore possible confounding effects could not be car-
ried out. Future studies might take this into account and explore the effect of DHEA and 
levothyroxin intake on cognitive functioning in patients with PAI. Another limitation of the 
present study concerns the different types of PAI. We have no information about the different 
types of autoimmune causes of PAI, which could be accompanied by comorbidities. These 
comorbidities in turn could have an effect on cognitive functioning. In addition, regularity 
of HC intake was not asked nor controlled for. Furthermore, the study was not blinded, and 
therefore patients were aware of  postponed HC intake. This awareness might have resulted 
in a higher motivation and, therefore, better performance in a subset of the cognitive tests 
in patients who postponed HC intake compared with patients who took the morning dose 
of HC at the habitual time. Likewise, patients might have been more motivated than healthy 
controls, which could explain why patients with HC intake performed better on the concen-
tration subscale of the WMS and made fewer errors during the first trail of the trail making 
test. Lastly, due to the cross-sectional design of the present study, no causal conclusions 
could be drawn. Future studies might want to implement a randomized controlled trial with 
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cross-over design with different substitution dosing regimens. Such a design would provide 
more relevant data to control our hypothesis that patients’ substitution therapy is not equal 
to physiologic cortisol secretion which in turn might affect cognitive functioning. To provide 
more insight into the underlying neuronal mechanisms of the observed cognitive deficits in 
patients with PAI, future (functional) magnetic resonance imaging studies using a longitudi-
nal design are needed.
In conclusion, the present study shows that patients with PAI show mild cognitive deficits 
compared to controls. Furthermore, the present study is the first to examine the effect of 
postponing HC intake in patients with PAI and demonstrates that there was no immediate 
effect of postponement of hydrocortisone intake on cognition.  Future studies in animal 
models and (functional) MRI research in patients with PAI could provide more insight into 
underlying mechanisms of cognitive impairment due to cortisol imbalances. 
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Chapter 8
Psychological morbidity and impaired quality of 
life in patients with stable treatment for primary 
adrenal insufficiency: Cross-sectional study and 
review of the literature
Jitske Tiemensma*, Cornelie D. Andela*,  Ad A. Kaptein, Johannes A. Romijn, Roos C. van der 
Mast, Nienke R. Biermasz, and Alberto M. Pereira
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context: A high prevalence of psychological morbidity and maladaptive personality as well 
as impaired quality of life (QoL) is observed in patients with and without hydrocortisone 
dependency following (cured) Cushing’s syndrome. However, it is currently unclear whether 
a similar pattern is present in patients with chronic glucocorticoid replacement for primary 
adrenal insufficiency (PAI).
objective: To evaluate psychological functioning, personality traits, and QoL in patients with 
PAI.
design and subjects:  A cross-sectional study including 54 patients with stable treatment for 
PAI and 54 healthy matched controls. Both patients and controls completed questionnaires 
on psychological functioning (Apathy Scale, Irritability Scale, Mood and Anxiety Symptoms 
Questionnaire short-form, and Hospital Anxiety and Depression Scale), personality traits 
(Dimensional Assessment of Personality Pathology short-form), and QoL (Multidimensional 
Fatigue Inventory, Short-Form 36, EuroQoL-5D, Nottingham Health Profile, and Physical 
Symptom Checklist).
results: Patients with PAI suffered from more psychological morbidity (i.e. irritability and 
somatic arousal) and QoL impairments compared with controls (all P<0.01). There were no 
differences regarding maladaptive personality traits between patients and controls. However, 
there was a strong and consistent positive association between the daily hydrocortisone 
dose and prevalence of maladaptive personality traits (i.e. identity problems, cognitive dis-
tortion, compulsivity, restricted expression, callousness, oppositionality, rejection, conduct 
problems, social avoidance, narcissism, and insecure attachment, all P<0.05). There was also 
a strong relation between the mean daily hydrocortisone dose and both psychological mor-
bidity (i.e. depression, P<0.05) and QoL impairments (i.e. general health perception, several 
measures of physical functioning, and vitality, all P<0.05). 
conclusion: Patients with stable glucocorticoid replacement therapy for PAI report psycho-
logical morbidity and impaired QoL. Psychological morbidity, impaired QoL, and maladaptive 
personality traits were all associated with higher hydrocortisone dosages. 




Primary adrenal insufficiency (PAI) is characterized by insufficient secretion of glucocorticoids 
and mineralocorticoids, most frequently caused by autoimmunity or following bilateral 
adrenalectomy. Replacement therapy consists of hydrocortisone, fludrocortisone, and some-
times, additional DHEA replacement. 
Cortisol has a crucial function in the central nervous system via stimulation of both the 
mineralocorticoid- (MRs) and glucocorticoid receptors (GRs). An appropriate balance 
between the activation of these two receptors is necessary for adequate stress responses, 
including behavioral adaptations. Imbalance between MR and GR activations might enhance 
vulnerability to disease in predisposed individuals. The current notion is that the effects of 
glucocorticoids binding to MR and GR include an inverted u-shape dose-response curve, in-
dicating that both pathologically low and high cortisol levels negatively affect the mediating 
functions of these receptors as is the absence of physiological circadian pulsatile secretion 
(1). The negative influence of glucocorticoid excess on psychological functioning in humans 
is clearly evident during active Cushing’s disease since serious co-morbid psychopathology, 
such as major depression and anxiety is prevalent (2). Although these symptoms improve 
substantially after correction of cortisol excess, consistent residual impairments persist, 
even after prolonged cure of cortisol excess. This is reflected by an increased prevalence of 
psychopathology and maladaptive personality traits as well as  impairments in quality of life 
(QoL) (3–7) in many patients, either hydrocortisone dependent or independent. 
Conversely, it is possible that previous exposure to insufficient glucocorticoid levels and 
current imperfections in replacement therapy in mimicking the pulsatile secretion of cortisol, 
such as in PAI, may also be associated with persistent psychosocial effects, considering the 
inverted u-shape of optimal corticosteroid receptor function. However, in contrast to the 
large number of reports in patients with Cushing’s syndrome, less is known about the ef-
fects of previous insufficient cortisol exposure on psychological functioning and QoL in PAI 
(see Table 1 for an overview). Heijmans and de Ridder (1998) reported a significant relation 
between personality-related variables (i.e. optimism/pessimism, locus of control) and illness 
perceptions (8). However, there are no studies on personality traits in patients with PAI. To 
date, studies in patients with PAI have demonstrated impaired QoL (9–15), and a higher risk 
for the development of affective disorders such as depression or bipolar disorder (16). The 
QoL impairments in patients with PAI have been attributed, at least in part, to intrinsic imper-
fections of hormone replacement therapy (12). In accordance, some studies demonstrated a 
positive effect of DHEA replacement on QoL (13,17–19). On the other hand, strategies aiming 
at adjusting cortisol replacement therapy mimicking a more diurnal profile by adjusting the 
time and frequency of hydrocortisone intake did not positively affect QoL (9,11,20). Further-
more, dosages above 30 mg hydrocortisone per day were associated with worse subjective 



















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Considering the limited amount of studies on psychological functioning in patients with 
PAI and the fact that studies on personality traits are lacking, the aim of the present study was 
to evaluate psychological functioning and personality traits, as well as QoL in patients with 
stable treatment for PAI. In accordance to previous studies, we hypothesized that patients 
with PAI not only would report impaired QoL, but also psychological morbidity, despite long-
term stable replacement with hydrocortisone. Furthermore, we hypothesized that patients 
with PAI demonstrate maladaptive personality traits. The second aim was to explore a poten-
tial association between hydrocortisone intake and psychological functioning, personality 
traits and QoL in patients with PAI. 
PaTIenTs and MeTHods
Participants
Patients with PAI were recruited via the outpatient clinic of the department Endocrinology 
of the Leiden University Medical Center (LUMC) and by advertisement via the Dutch Adrenal 
Patient Society for Addison and Cushing Patients (NVACP; www.nvacp.nl). Thirty-nine pa-
tients were derived from the patient network en fifteen patients were derived from the LUMC 
outpatient clinic. There were no differences regarding gender and age between patients 
derived from the patient network and patients derived from the outpatient clinic. 
Patients with current or previous drug or alcohol abuse or with neurological problems 
were excluded. A total of 54 participants were included in this study (21 men and 33 women). 
The mean age of the patients was 50±12 years. Each patient was asked to provide a control 
person of comparable gender, age (+/- 10 years), and educational level in order to create 
a control group. The self selection of controls enabled a perfect match for an additional 
parameter, i.e. social-economic status. Exclusion criteria for controls were present or previous 
drugs/alcohol abuse or neurological problems.
PAI had been diagnosed based on the classical clinical symptoms and biochemical confir-
mation of adrenal insufficiency in the presence of increased ACTH concentrations. Adrenal 
insufficiency was diagnosed when basal cortisol concentrations were below the reference 
range of normal (<0.12umol/l) or below 500 nmol/l after stimulation with ACTH. Forty-four 
patients (82%) had been diagnosed with PAI due to autoimmune disease with positive 
autoantibodies against adrenal cortex, five patients (9%) had been diagnosed with PAI due 
to non-autoimmune causes (e.g. congenital adrenal aplasia, adrenal calcification), and two 
patients (4%) were treated with bilateral adrenalectomy for pheochromocytomas. The origin 
of PAI was unknown for three patients (5%). 
The Medical Ethics Committee of the LUMC approved the protocol and written informed 
consent was obtained from all subjects. 




Both patients and controls were asked to complete the following questionnaires on psycho-
logical functioning, personality traits and QoL at home and to return the questionnaires in a 
prepaid envelope.
The Apathy Scale consists of 14 questions on a 4-point scale measuring different features 
of apathy in the two previous weeks. The score for each item ranges from 0 (no apathy) to 3 
(maximum intensity of apathy). The total score ranges from 0-42 points, with higher scores 
indicating greater apathy. A total score ≥14 points is being used to characterize subjects as 
apathetic (21,22). 
The Irritability Scale consists of 14 items measuring different features of irritability in the 
two previous weeks. The total score ranges from 0-42 points, with higher scores indicating 
greater irritability. A total score ≥14 points is being used to characterize subjects as irritable 
(22).  
The Mood and Anxiety Symptoms Questionnaire short-form (MASQ-30) assesses symptoms 
that occur in mood and anxiety disorders subdivided into the three subscales negative af-
fect, lack of positive affect and somatic arousal. The scores for each subscale ranges from 
10-50, with higher scores indicating more severe negative affect, more positive affect or more 
somatic arousal. There are no formal cut-off scores (23).
The Hospital Anxiety and Depression Scale (HADS) consists of 14 items, and both the anxiety 
and the depression subscale scores range from 0-21 points. Higher scores indicate more 
severe anxiety and/or depression. A score >8 points on one of the subscales is being used to 
characterize subjects as being anxious or depressed, respectively (24,25). 
The Multidimensional Fatigue Inventory (MFI-20) assesses fatigue. Five different dimensions 
of fatigue are calculated: 1) General fatigue, 2) Physical fatigue, 3) Reduced activity, 4) Re-
duced motivation, and 5) Mental fatigue. Scores vary from 0-20; with higher scores indicating 
greater fatigue (26).
The Short-Form 36 (SF-36) assesses functional status and general well-being during the pre-
vious month (23;24). The items cover nine health concepts: 1) physical functioning, 2) social 
functioning, 3) role limitation (physical), 4) role limitation (emotional), 5) mental health, 6) 
vitality, 7) pain, 8) general health perception, and 9) general perception of change in health. 
Scores are expressed on a 0–100 scale, and higher scores indicate a better QoL (27,28). 
The EuroQoL-5D (EQ-5D) assesses current health status reflected in five dimensions; mobil-
ity, self-care, usual activities, pain/discomfort, and anxiety/depression. Scores are expressed 
on a 1-3 scale per dimension, with higher scores indicating worse QoL. The questionnaire 
also includes a visual analogue scale (VAS) which comprises a standard vertical 20 cm scale 
(similar to a thermometer) for recording an individual’s rating for their current health-related 




The Nottingham Health Profile (NHP) assesses general well-being and consists of 38 yes/
no questions, which are subdivided into six scales assessing impairments, i.e. pain (8 items), 
energy level (3 items), sleep (5 items), emotional reactions (9 items), social isolation (5 items), 
and disability/functioning (8 items). Subscale scores are calculated as a weighted mean of the 
associated items and are expressed as a value between 0-1 (30,31). 
The Physical Symptom Checklist (PSC) assesess 55 physical symptoms that are mentioned 
in the DSM-III classification (32). The presence of symptoms is rated on a severity scale from 
0 to 3. We excluded the gender specific items (n=4) from the analyses to rule out bias by 
gender. The total symptom score ranges from 0 to 153. A higher score indicates more (severe) 
physical symptoms in the preceding week (33). 
The Dimensional Assessment of Personality Pathology short-form (DAPPs) consists of 136 
items to assess personality traits, which are subdivided into 18 subscales: submissiveness, 
cognitive distortion, identity problems, affective lability, stimulus seeking, compulsivity, 
restricted expression, callousness, oppositionality, intimacy problems, rejection, anxious-
ness, conduct problems, suspiciousness, social avoidance, narcissism, insecure attachment, 
and self-harm. The score for each subscale differs with maxima of 30-40, with higher scores 
indicating more pronounced maladaptive personality traits (34). 
statistical analysis
Data were analyzed using IBM SPSS Statistics version 20.0.0 (SPSS Inc., Chicago, IL). All data 
were presented as mean±standard deviations, unless mentioned otherwise. The primary 
analysis comprised the comparison of scores on the questionnaires between patients with 
stable treatment for PAI and healthy matched controls. To check the normality of data, the 
Kolmogorov-Smirnov test was used in addition to histograms and boxplots. Groups were 
compared using independent samples t-test. A Mann-Whitney U test was used in case of non-
parametric data. χ2 was used in case of categorical data. Because of multiple comparisons, the 
level of significance for this analysis was set at P≤0.01. The secondary analysis comprised the 
relationship between the scores on the various questionnaires and the mean daily dose of 
hydrocortisone, using a stepwise linear regression model. We included age and gender as ad-
ditional independent variables. Because of the exploratory nature of this secondary analysis, 
adjustment of the level of significance for multiple testing was not performed, and the level 
of significance was set at P≤0.05. 
resulTs
sociodemographic and clinical characteristics (Tables 2 and 3)
A total of 54 patients with PAI and 54 healthy controls matched for gender, age, and educa-
tion, were included. All patients were on stable hydrocortisone and fludrocortisone replace-
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ment therapy for a mean duration of 10.1±8.5years (range 2-38 years), as prescribed by their 
individual physicians (mean daily hydrocortisone intake of 25±7 mg (range 10-50 mg), di-
vided in two to three dosages). Eighty-three percent of the patients also used fludrocortisone 
in addition to hydrocortisone. Additional medical therapy included DHEA (26% of patients), 
levothyroxine (46%), anti-hypertensive drugs (13%), and oral contraceptives (9%). Forty-five 
percent of female patients were postmenopausal. 
Psychological functioning and quality of life (Table 4)
Patients with PAI had a higher total score on the Irritability Scale (P=0.004) compared with 
matched controls. Patients also showed higher scores on the somatic arousal subscale of the 
MASQ-30 (P=0.003). Clinically significant apathy and irritability (a score of ≥ 14 on the Apathy 
Scale and on the Irritability Scale) was present in 35% and 33% of patients, respectively, and 
significantly more irritability was observed in patients than in controls (P=0.01). On the HADS, 
11% of patients had a score of ≥ 8 on the anxiety subscale and 6% on the depression subscale. 
This is indicative for the presence of clinically relevant anxiety or depression, respectively. 
There were no significant differences between patients and controls on the depression sub-
scale, anxiety subscale or total HADS score.
Table 2. Clinical characteristics 
PaI (n=54) Matched controls (n=54)
Gender (m/f ) 21/33 21/33
Age (yrs) 49.67 (11.8) 49.26 (12.5)








BMI 26.42 (5.3) NA
PAI diagnose Autoimmune: 44 (82%)
Non-autoimmune: 5 (9%)
Bilateral adrenalectomy:  2 (4%)
Unknown: 3 (5%)
NA
Hydrocortisone dose# 24.90 (7.2) NA
Florinef, n (%) 45 (83%) NA
DHEA, n (%) 14 (26%) NA
Levothyroxine, n (%)* 25 (46%) NA
Oral contraceptive, n (%) 2 (11%) NA
Anti-hypertensives, n (%)  7 (13%) NA
Menopause, n (%) 15 (45%) NA
Data are noted in mean (SD) or number and %; PAI, primary adrenal insufficiency, NA, not applicable; #total dose 




Patients scored worse on all subscales of the MFI-20 compared with matched controls, i.e. 
general fatigue (P<0.001), physical fatigue (P<0.001), reduced activity (P=0.003), reduced 
motivation (P=0.006), and mental fatigue (P<0.001). Patients with PAI also scored worse on 
the physical functioning subscale (P<0.001), social functioning subscale (P=0.001), role limita-
tion (physical) subscale (P<0.001), vitality subscale (P=0.009), and general health perception 
subscale (P<0.001) of the SF-36. On the EQ-5D, patients scored worse than matched controls 
on activity (P<0.001) and the VAS (P<0.001). Furthermore, patients scored worse on energy 
(P<0.001) and physical ability (P<0.001) compared with matched controls as measured with 
the NHP. Lastly, patients reported more general/neurological symptoms (P<0.001), auto-
nomic symptoms (P<0.001), genital symptoms (P=0.002), and feeling hot/cold (P<0.001) on 
the PSC compared with matched controls. 
Personality traits
The scores of the patients on the DAPPs personality traits were not different from those of 
the matched controls. 
The association with daily hydrocortisone intake (Table 5)
Higher hydrocortisone intake was associated with lower psychological well-being, more 
maladaptive personality traits, and more impaired QoL. More specifically, a higher hydro-
cortisone dose was associated with more depressive symptoms (HADS Depression subscale, 
β=0.282, P=0.038), as well as decreased physical functioning (β=-0.365, P=0.008), more 
Table 3. clinical characteristics 
Males with PaI (n=21) females with PaI (n=33)
Age (yrs) 48.48 (13.1) 50.52 (11.0)






BMI 26.12 (3.6) 26.62 (6.3)
PAI diagnose Autoimmune: 17 (81%)
Non-autoimmune: 2 (10%)




Bilateral adrenalectomy: 0 
Unknown: 3 (9%)
Hydrocortisone dose# 26.90 (6.8) 23.62 (7.3)
Florinef, n (%) 16 (76%) 29 (88%)
DHEA, n (%) 2 (10%) 12 (36%)
Levothyroxine, n (%)* 6 (29%) 19 (58%)
Oral contraceptive, n (%) NA 2 (11%)
Anti-hypertensives, n (%)  3 (14%) 4 (12%)
Menopause, n (%) NA 15 (45%)
Data are noted in mean (SD) or number and %; PAI, primary adrenal insufficiency, NA, not applicable; # total dose 
per day; * Hypothyroidism due to M. Hashimoto. 
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Table 4. Psychological functioning, QoL, and personality in patients with PAI
PaI (n=54) Matched controls 
(n=54)
P-value
Irritability scale Total score







MasQ-30 Somatic arousal 15.49 (7.0) 12.00 (2.6) 0.003
MfI-20 General fatigue 12.15 (5.5) 7.21 (3.5) <0.001
Physical fatigue 11.04 (5.1) 6.83 (2.6) <0.001
Reduced activity 9.72 (4.1) 7.40 (3.3) 0.003
Reduced motivation 8.67 (3.5) 6.87 (3.0) 0.006
Mental fatigue 11.08 (4.4) 7.38 (2.9) <0.001
sf-36 Physical functioning 80.29 (19.6) 94.15 (7.7) <0.001
Social functioning 77.12 (24.5) 91.27 (14.6) 0.001
Role limitation (physical) 65.28 (43.8) 93.75 (17.8) <0.001
Vitality 48.21 (9.8) 52.92 (8.5) 0.009
General health perception 54.06 (26.1) 77.31 (15.5) <0.001
eQ-5d Activity 1.35 (0.5) 1.06 (0.2) <0.001
VAS 72.66 (15.9) 84.12 (10.2) <0.001
nHP Energy 0.29 (0.4) 0.03 (0.1) <0.001
Physical ability 0.09 (0.1) 0.01 (0.0) <0.001
Psc General/neurological 0.73 (0.5) 0.35 (0.2) <0.001
Autonomic symptoms 0.53 (0.4) 0.16 (0.2) <0.001
Genital symptoms 0.29 (0.4) 0.11 (0.2) 0.002
Feeling hot/cold 0.79 (0.7) 0.27 (0.3) <0.001
Data are noted in mean (SD), only significant results are listed. Level of significance was set at P≤0.01, adjusting 
for multiple testing. 
figure 1. Associations between hydrocortisone dosage and identity problems.
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physical role limitations (β=-0.329, P=0.015) and more pain (β=-0.272, P=0.047) (all SF-36 
subscales). Moreover, the SF-36 subscale Vitality was negatively associated with gender 
(β=-0.284, P=0.039), indicating that females reported less vitality. Furthermore, a higher hy-
drocortisone intake was associated with worse scores on mobility (β=0.345, P=0.011) and the 
VAS (β=-0.335, P=0.013) of the EQ-5D. Lastly, a higher hydrocortisone intake was associated 
with several maladaptive personality traits, including more cognitive distortion (β=0.288, 
P=0.037), identity problems (β=0.474, P=0.000) (Figure 1), compulsivity (β=0.302, P=0.029), 
restricted expression (β=0.277, P=0.042), callousness (β=0.376, P=0.005), oppositionality 
(β=0.291, P=0.035), rejection (β=0.282, P=0.043), social avoidance (β=0.316, P=0.021), and 
narcissism (β=0.273, P=0.036). Moreover, narcissism  was negatively associated with age (β=-
0.337, P=0.010) and self-harm was positively associated with age (β=0.324, P=0.017). Female 
patients reported less conduct problems (β=-0.358, P=0.008).






sf-36 Physical functioning β=-0.365**
















Only associations that reached statistical significance (P<0.05) are depicted.
There were no significant associations between daily hydrocortisone dosage, age and gender, and scores on the 
Apathy scale, Irritability scale, MAQ-30, MVI-20, NHP and PSC. 




This study demonstrates that patients with stable treatment for PAI suffer from more psy-
chological morbidity with irritability and somatic arousal, in addition to impairments of QoL 
compared with matched healthy controls. However, personality traits were not different 
between patients and controls, which indicates that personality traits in patients with PAI, 
in contrast to psychological functioning, are not sensitive to the effects of a chronic disease, 
such as PAI and its pharmacological treatment in contrast to psychological morbidity. To our 
knowledge, this is the first study on personality traits in patients with PAI. Interestingly, there 
was a strong and consistent association between the mean daily hydrocortisone dose and 
the prevalence of maladaptive personality traits, like cognitive distortion, identity problems, 
and compulsivity, and also with restricted expression, callousness, oppositionality, rejection, 
social avoidance and narcissism. Furthermore, there was a strong positive relation between 
the mean daily hydrocortisone intake and reported psychological morbidity (i.e. depression) 
and QoL impairments (i.e. several measures of physical functioning, and pain). 
Previous studies by our group have shown similar results with regard to psychological 
functioning and QoL in patients in long-term remission of Cushing’s disease, though patients 
in remission of Cushing’s disease also showed more maladaptive personality traits than their 
matched controls (3–5,35). These observations suggest that psychological functioning and 
QoL indeed follow the inverted u-shape dose response curve of cortisol exposure related to 
MR and GR activation, whereas this is not the case for personality traits and lower cortisol 
levels. Intriguingly, higher daily hydrocortisone intake seemed to be strongly associated with 
maladaptive personality traits, indicating that hydrocortisone intake does have a consider-
able effect on personality traits in patients with adrenal insufficiency. 
Our findings regarding QoL are in line with the results of previous studies on decreased QoL 
in patients with adrenal insufficiency (9,14,36,37) and the self-reported impact of the disease 
or treatment on subjective health status (38). In addition, several QoL studies demonstrated 
that inadequate hydrocortisone replacement dosages and, especially, a high hydrocortisone 
dosages negatively affected QoL (11,37,39,40). Accordingly, we found negative effects of 
high hydrocortisone intake on QoL in patients with PAI. Intriguingly, we also found a nega-
tive effect of high hydrocortisone intake on psychological morbidity and the prevalence of 
maladaptive personality traits. 
In healthy individuals cortisol is secreted in a pulsatile fashion with a superimposed circa-
dian rhythm. It is actually impossible to mimic this normal pattern of hormonal secretion by 
hydrocortisone replacement. These imperfections in pharmacotherapy are, at least in part, 
associated with persisted vague complaints and a decreased QoL (9). The importance of 
mimicking the circadian rhythm of cortisol secretion in patients with adrenal insufficiency, 
is supported by a study of Johannsson et al., which demonstrated that patients treated with 
once-daily dual release hydrocortisone tablets, had a more circadian-based cortisol profile, 
and had more favorable scores on questionnaires assessing psychological well-being and 
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fatigue, compared to patients treated with conventional hydrocortisone treatment (41). 
Furthermore, both Lovas et al. (42) and Oksnes et al. (43) reported that continuous hydro-
cortisone infusion in patients with PAI resulted in cortisol and ACTH levels towards normal 
circadian levels and positively affected QoL. These two studies suggest that the physiological 
profile might be related to QoL outcomes. 
A previous study by Thomsen et al., (16) reported an increased risk for developing affec-
tive disorders (e.g. depression, bipolar disorder) in hospitalized patients with adrenal insuf-
ficiency. In our cohort of patients with stable PAI, we did not find differences in depressive 
symptoms between patients and healthy controls. However, considering the fact that we did 
find other psychological morbidity (i.e. irritability and somatic arousal), we postulate that 
even after correction of hypocortisolism, patients with PAI remain vulnerable for developing 
psychological and, in particular, mood symptoms. 
Recently, female gender, manifestation at older age, more autoimmune comorbidities, and 
latency between first symptoms and diagnosis were found to negatively affect QoL in patients 
with adrenal insufficiency (44). Our data indicate that the amount of daily hydrocortisone 
intake should also be included as a potential influencing factor of QoL. Nevertheless, because 
of the exploratory nature of our study, future research is needed to provide more insight in 
predictors of reduced QoL in patients with adrenal insufficiency and to further distinguish 
whether the QoL impairments are caused by the disease itself or its treatment. In addition to 
the focus on research about somatic predictor variables, researchers should pay attention to 
potential psychological contributing factors, such as negative illness perceptions and ineffec-
tive coping strategies, because recent data have indicated that negative illness perceptions 
were related to a decreased QoL inpatients in long-term remission of Cushing’s diseases (45).
A possible limitation of the present study is the cross-sectional design, which does not 
preclude that maladaptive personality traits and QoL impairments were already present be-
fore onset of the disease. Furthermore, we cannot simply conclude that high hydrocortisone 
intake causes a decreased QoL, since it might be that high hydrocortisone dosages were 
prescribed because patients suffered from psychological symptoms or a decreased QoL. 
Therefore, future studies should use a longitudinal design to enable the evaluation of the 
course of psychological functioning, QoL, and personality, and of the influence of adaptations 
in hydrocortisone intake on these three domains over time. A longitudinal design might also 
elucidate the interesting discrepancy between our finding that personality traits of patients 
with PAI do not differ from healthy controls, whereas higher daily hydrocortisone intake is 
significantly associated with maladaptive personality traits in patients with PAI. 
In summary, patients with stable treatment for PAI report psychological morbidity and im-
paired QoL. There is a positive association between the daily hydrocortisone intake and the 
presence of psychological morbidity, maladaptive personality traits and QoL impairments. 
These results point toward the possibility to intertwine psychosocial parameters in care for 
patients with endocrine replacement in general, and for patients with adrenal insufficiency 
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specifically. This approach would open the area of self-management research in this patient 
category, which has already been shown to have positive effects on QoL in patients with 
other chronic somatic diseases (46–48). 
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Chapter 9
Quality of life (QoL) impairments in patients with 
a pituitary adenoma: a systematic review of QoL 
studies






Purpose: Pituitary adenomas give rise to physical and psychological symptoms, which may 
persist after biochemical cure. Growing attention has been paid to Quality of Life (QoL) in 
these patients. We aimed to systematically analyze QoL assessment methods and QoL out-
come in these patients. 
Methods: We conducted a systematic literature search up to January 2014 in PubMed, Web 
of Knowledge, PsycInfo and EMBASE.
results: 102 papers assessing QoL in patients with a pituitary adenoma were included. In 
clinical (original) studies in which QoL was the primary outcome parameter (n=54), 19 studies 
combined a generic questionnaire with a disease-specific questionnaire. QoL was found to 
be impaired in patients with active disease relative to controls, and generally improved dur-
ing biochemical cure. However, no normalization occurred, with patients with remitted Cush-
ing’s disease demonstrating the smallest improvement. Somatic factors (e.g. hypopituitarism, 
sleep characteristics), psychological factors (illness perceptions) and health care environment 
(rural vs. urban) were identified as influencing factors. Intervention studies (predominantly 
evaluating medical interventions) have been found to improve QoL. 
conclusions: The growing number of studies assessing QoL generally described the negative 
impact of pituitary adenomas. QoL research in this patient group could be further elaborated 
by the development of disease-specific questionnaires for prolactinoma and non-functioning 
adenoma, consequent use of generic and disease-specific questionnaires and using a long-
term (longitudinal) follow-up.  Surgical and pharmacological interventions improve but not 
normalize QoL. We postulate that there might be margin for further improvement of QoL, 
for instance by using psychosocial interventions, in addition to optimal medical treatment. 




Pituitary adenomas can result in classical medical conditions, such as Cushing’s disease (CD), 
acromegaly, non-functioning adenoma (NFA) or prolactinoma. Pituitary adenomas can be 
treated by transsphenoidal surgery, and some patients undergo additional medical treat-
ment or radiotherapy when needed (1). After successful biochemical treatment many physi-
cal, cognitive and psychological symptoms resolve, but may (partly) persist during long-term 
remission (2). 
The research interest for Quality of Life (QoL) in patients with a pituitary adenoma has 
been emerging in recent years and disease-specific QoL questionnaires have been devel-
oped. These disease-specific QoL questionnaires assess QoL aspects relevant to a specific 
pituitary disease, e.g. ACROQoL for acromegaly (3-5), QoL-AGHDA or the Questions on Life 
Satisfaction-Hypopituitarism (QLS-H) (6) for growth hormone deficiency (GHD) (7), and the 
Tuebingen CD-25 and the CushingQoL for CD (8-10). Numerous other QoL questionnaires 
can assess general QoL domains (generic questionnaires) or a particular domain of QoL, 
which usually is relevant for more than one illness (e.g. dyspnea, nausea, pain, fatigue) 
(domain-specific) (11). It is usually recommended that a generic questionnaire is combined 
with a disease-specific questionnaire, in order to assess both specific characteristics and the 
general perspective of QoL. This also prevents that unexpected impairments in QoL remain 
undetected (12). The assessment of QoL is commonly used to evaluate QoL in general or 
patient populations, to compare treatment in clinical trials, or to support treatment choices 
in individual patient care (11). The lack of an unambiguous definition of QoL poses major 
challenge for the evaluation and interpretation of QoL. QoL can be interpreted differently 
and authors may mean different topics, from different perspectives (13). A commonly used 
definition is that QoL is “the functional effect of an illness and its consequent therapy upon a 
patient, as perceived by the patient” (13).
Considering the potential short-term, but also long-term negative impact of pituitary ad-
enomas on QoL, the growing attention for QoL in patients with a pituitary adenoma, and the 
variety of QoL questionnaires available, we aimed to systematically analyze QoL assessment 
methods and QoL outcome in patients with a pituitary adenoma. Furthermore, we aim to 




search strategy, eligibility criteria and data extraction
In order to identify papers that examined QoL in patients with pituitary adenomas, we 
searched Pubmed, Web of Knowledge, PsycInfo and EMBASE up to 16 January 2014. We com-
posed a search strategy focusing on QoL in patients with, or treated for, pituitary adenomas. 
We used all relevant keyword variations, including free text words. Duplicates were excluded. 
For the complete search strategy, see Appendix 1. Only original articles were included. 
Studies were eligible when all of the following criteria were met: 1) addressing patients 
with pituitary adenomas (CD, prolactinoma, acromegaly, NFA), 2) pituitary disease was not 
caused by an hereditary component by an hereditary gene mutation (e.g. MEN-I), 3) QoL was 
assessed and used as a parameter, 4) a clear description of QoL assessment, 5) clear descrip-
tion/presentation of QoL results, 6) groups of pituitary patients > n=10, 7) written in English, 
and 8) pertaining to adult patients. Reviews, case-reports and letters were excluded. Papers 
which included patients with pituitary adenomas, but which analyzed data in one group of 
patients with patients with pituitary adenomas in general (i.e. group consisted of a mixture 
of patients treated for prolactinoma, craniopharyngioma, non-functioning adenoma, etc.), or 
combined with patients with other diseases (e.g. other skull based tumors, GHD not related 
to pituitary adenoma), were not included.
Eligibility and data extraction were assessed by two independent investigators (C.D.A. and 
A.G.). Inconsistencies were resolved by consensus. The following data were extracted: sample 
size, gender distribution, disease status (active vs. non-active), design, used QoL scales and 
outcome.
resulTs
Identifi cation and selection of literature
The initial search identifi ed 1364 studies, 1237 were excluded based on title and abstract. 
We retrieved 127 studies for detailed assessment. Twenty-fi ve studies were excluded for the 
following reasons: no clear description of QoL research (n=6), meeting abstracts (n=5), too 
small number of included patients (n=8), not original article (n=3), article was not available in 
English (n=1) or article not available (n=2). Consequently, 102 studies were eligible for inclu-
sion (Figure 1). Based on publication dates of the included articles, it can be seen that over 
the last decade the number of studies studying QoL assessment in patients with pituitary 
adenomas has been increasing considerably (Figure 2).  
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1364 potentially relevant 
publications identified from 
electronic search 
1237 studies excluded based on title 
and abstract 
127 publications retrieved for 
more detailed assessment 
25 articles did not fulfill the inclusion criteria 
because of the following reasons: 
• 5 Meeting abstracts 
• 6 No (clear description of) QoL research 
• 8 No or not enough pituitary patients 
• 3 Not original article 
• 1 Not available in English 
• 2 Not available 
102 studies eligible for inclusion 

























































In the 102 studies a total of 49 different questionnaires have been used (10 generic, 9 disease-
specific, 30 domain-specific). Sixteen studies assessed QoL with the aim to develop or vali-
date a (disease-specific) questionnaire i.e. the AcroQoL (3-5;14;15), the CushingQoL (8;16-19), 
the Tuebingen CD-25 (9;10;20) and the QoL-AGHDA (21). Lenderkring et al. developed the 
Impact on lifestyle Questionnaire and validated it in a group of patients with acromegaly 
(22). Tiemensma et al. evaluated whether QoL could be assessed with patient’s drawing and 
demonstrated that drawing reflect another dimension (23). 
In the other 86 clinical studies, QoL was the primary outcome in 54 studies (63%).  Nineteen 
studies combined a generic with a disease-specific questionnaire. Thirty-four studies (40%) 
used a domain-specific questionnaire assessing a particular domain, e.g. anxiety and depres-
sive symptoms, pain, fatigue, cognitive failure, sexual function, or social situation.  In three 
studies (5%) QoL was assessed by a simple question or a visual analogue scale (24;25), and in 
one study the name of the questionnaire was not mentioned (26).
Qol outcome in patients with a pituitary adenoma 
Sixty-two studies reported the outcome of QoL in patients with pituitary adenomas i.e. 
prolactinoma (n=8), NFA (n=16), acromegaly (n=31), and CD (n=24) (Table 1). The majority 
(n=58, 94%) used a cross-sectional design to compare QoL of patients with pituitary disease 
to QoL of healthy controls (n=17) reference values (n=13). A minority used patients with other 
pituitary adenomas (n=6), other patient groups (n=8), or compared patients with the same 
pituitary disease but with different clinical characters (e.g. male vs. female gender, controlled 
vs. uncontrolled disease, with or without GHD) (n=16) (findings are described in the next 
paragraph). Most studies included patients with exclusively controlled disease (n=38, 61%). 
Eighteen studies (29%) included patients with different diseases stages, i.e. active disease 
and remission, and five studies (8%) included only patients with active disease. Eight of these 
studies (13%) were intervention studies which evaluated QoL at baseline. 
In eight studies with a total number of 387 patients with prolactinoma, it was demonstrated 
that patients treated for a prolactinoma reported impairments in QoL, when compared to 
healthy controls (27-30) and reference values, with most pronounced impairments in mental 
measures during active disease (31). 
Summarizing fourteen studies on 2708 patients with NFA (the number of unique patients 
might be lower, since two studies reported from the KIMS-database) it can be observed that 
QoL outcome in patients with NFA demonstrated more diversity. Some studies reported a de-
creased QoL, relative to healthy controls and reference values  (32;33), with most pronounced 
impairments in physical and mental measures during active disease (31), while others did not 
find differences in QoL between patients treated for NFA and reference values (30;34;35), or 
other patient groups  (i.e. mastoid surgery vs. NFA surgery, NFA with GHD vs. traumatic brain 
injury with GHD) (36-38). Compared to patients with GHD due to a craniopharyngioma, male 




























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































patients with GHD due to a NFA reported a better QoL, whereas female patients with GHD 
due to a NFA reported worse QoL (39).
Evaluating fifteen studies on acromegaly with a total number of 820 patients, it was 
demonstrated that patients with active, as well as controlled acromegaly reported more 
impairments in QoL, relative to healthy controls and reference values (29-31;40-43) which 
encompassed depressive symptoms and sexual dysfunction (44;45). Furthermore, patients 
with prior acromegaly with current untreated GHD reported worse QoL compared to patients 
with GHD due to other aetiologies (46;47).
Summarizing twenty-two studies on CD with a total number of 1713 patients, it can be ob-
served that in patients with active, as well as controlled disease, QoL was impaired compared 
with healthy controls and reference values (29;31;42;48-58). Abraham et al. compared QoL of 
patients with active CD, with that of obese individuals, and demonstrated a reduced QoL in 
CD (59). Furthermore, patients with CD with current untreated GHD reported worse QoL than 
counterparts with GHD due to other aetiologies (46;60). Other studies reported a less nega-
tive effect on QoL, among which the study of Negasser et al. reporting that after treatment 
of CD, QoL scores were close to optimal, except for mental health and health perception (26). 
Furthermore, Thompson et al. reported that the majority of the patients treated with bilateral 
adrenalectomy fell within the top two thirds of the national average for physical and mental 
composite domains (SF-12) (61).
Studies comparing groups of patients with different pituitary adenomas demonstrated 
that either patients with CD (31;60;62;63) or patients with acromegaly have worse QoL 
relative to NFA and prolactinoma patients (64;65). A single study did not find differences 
between patients treated for NFA (n=16) and small groups of patients treated for CD (n=5) or 
acromegaly (n=4) (66).
Spider plots of studies reporting results of the Short-Form 36 health survey (SF-36) 
The SF-36 was the most frequently used generic questionnaire (n=44, 43%), and therefore, we 
created spider plots to represent the average QoL outcome as assessed with the SF-36 (Figure 
3a-d). Twenty-eight studies (28%) reported the mean and standard deviation of the SF-36 
subscales and we calculated the average score on each subscale, categorized per disease 
(acromegaly, CD, NFA, prolactinoma) and disease status (non-treated/treated) (Appendix 1). 
Scores of a Dutch sample of healthy controls (67) were also represented in the spider-plots 
(Dutch data were comparable to normative data of other countries (68-72)).
Examining the four spider plots it can be observed that during active disease patients with 
CD report most impaired QoL. During remission, patients with CD still report the worst QoL 
when compared to the other three groups, followed by patients with acromegaly. When 
comparing QoL in groups of active/non-treated patients, with QoL in groups of controlled/
treated patients, it can be seen that QoL generally improves after treatment in patients with 
a pituitary adenoma. Apparently, the smallest improvement can be seen in patients with CD. 
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figure 3d. SF-36-scores in patients with Prolac-
tinoma
Acromegaly-before treatment: Johnson et al. (31), Psaras et al. (42), Milian et al. (62); Acromegaly-after treatment: 
Biermasz et al. (41), Biermasz et al. (86), Miller et al. (113), Van der der Klaauw et al. (91), Wexler et al. (79), Wassenaar 
et al. (85), Psaras et al. (42), Valassi et al. (47), Postma et al. (92), Milian et al. (62), Miller et al. (87); Cushing’s disease-
before treatment: Johnson et al. (31), Lindsay et al. (53), Psaras et al. (42), Van der Pas et al.  (48), Milian et al. (62); 
Cushing’s disease-after treatment*: Van Aken et al. (54), Lindsay et al. (53), Smith et al. (56), Psaras et al. (42), Hawn 
et al. (51), Tiemensma et al. (23); NFA-before treatment: Johnson et al. (31); NFA-after treatment: Page et al. (36), 
Dekkers et al. (32), Van Beek et al. (75), Nielsen et al. (35), Miller et al. (87), Biermasz et al. (33), Capatina et al. (34); 
Prolactinoma-before treatment: Johnson et al. (31); Prolactinoma-after treatment: Kars et al. (27), Cesar de Oliveira 
Natiato et al. (28); mean scores a-select sample: mean scores of an a-select group of individuals in The Netherlands. 
*The study of Alcalar et al. (52) was not included for the spider plots, because SF-36 scores were that low (range), 
that it can be questioned whether SF-36 was scored adequately.
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When comparing the average QoL of patients after treatment, with QoL of an a-select healthy 
Dutch sample, it can be seen that QoL does not normalize after treatment. Nevertheless, in 
patients after treatment for NFA or prolactinoma some subscales were equal to the mean 
scores of this a-select sample (i.e. NFA: Mental health, Pain; prolactinoma: Physical function-
ing, Physical role). 
Influencing factors 
Fifty-six studies (55%) described influencing factors on QoL in patients with a pituitary 
adenoma. A great variety of influencing factors has been reported, with same factors being 
relevant for two or more types of pituitary adenomas, such as current age and gender, while 











Craniotomy vs transsphenoidal surgery 
















Delay of diagnos�c process
Healthcare environment (urban vs. rural)
Disease status







figure 4. Influencing factors.
Factors which have been found to significantly influence QoL. Normal: consistent between studies. Italian: incon-
sistent between studies. ACRO: acromegaly, NFA: non-functioning pituitary adenoma, CD: Cushing’s disease; PRL: 
prolactinoma. 
Quality of life impairments in pituitary disease
191
9
In patients treated for prolactinoma, prolactin levels and free androgen levels were nega-
tively associated with reported QoL (28), whereas others found no correlation with hyperpro-
lactemia (27;30). Furthermore, a negative influence was found for problems in reproductive 
status and higher anxiety and depression levels (27), and present use of dopamine agonists 
(DA) (30), whereas others found no significant effect of DA use (27;64), nor a significant effect 
of tumor size (micro/macro) (64).
Factors that negatively influenced QoL in patients with NFA were impairments in visual 
function, pain (34;73), sleep disturbances (33), daytime sleepiness (74), older age, female sex, 
tumor recurrence, hypopituitarism (32;34;36;73;75), and radiotherapy therapy (36;73), where-
as in other studies no  significant influence of pituitary deficiency (30;36) or radiotherapy was 
observed (30;32;75). Interestingly, Capatina et al. reported a positive effect of non-replaced 
GHD on QoL (34). Patients treated with craniotomy reported more QoL impairments relative 
to patients who had undergone transsphenoidal surgery (35). 
In patients with acromegaly, an uncontrolled disease status or biochemical activity (e.g. 
high IGF-I levels) were found to negatively influence QoL (43;45;76-79), whereas other studies 
did not find this association (30;42;44;78;80-83). Other negatively influencing factors were 
radiotherapy (30;42;44;78;80-83), restless leg syndrome (84), clinical osteoarthritis (85), joint 
complaints (86) musculoskeletal pain (42;86;87), numbness of fingers, hypertension (88), 
sexual dysfunction (44), depressive symptoms (45;47;81), GHD (79;89;90), and persistent co-
morbidities (42). Most studies reported the negative effect of female gender (62;64;83;91;92), 
whereas one study reported the negative effect of male gender (30). As expected, current 
older age was found to negatively influence QoL (41;43;47;62;64;85;86;91). Medical treat-
ment for acromegaly was negatively associated with QoL (30;78;82;92). Patients only treated 
with surgery reported a better QoL relative to patients treated with surgery and medical 
treatment (93), whereas others found no effect of medical treatment versus treatment with 
surgery and/or radiotherapy (64). In addition, delay of the diagnostic process (>1 year) and 
living in an urban health care environment (instead of rural health care environment) were 
also found to be disadvantageous (94).  In 2011, researchers of our group demonstrated that 
in patients with long-term remission of acromegaly also psychological factors (i.e. negative 
illness perceptions) negatively influenced QoL (95). 
In patients with remission of CD, shorter duration of remission (53;57), female gender 
(54;54;57) older age and older age at diagnosis, and hypopituitarism (54) were found to 
negatively influence QoL, while Psaras et al. found that younger age and not undergoing 
reoperation were found to be negatively associated with QoL (42). Others reported no 
association with hormonal deficiencies, etiology of CS (pituitary- or adrenal-dependent), 
treatment strategies (53;57;96), and current disease status (42). On the other hand, Alcalar et 
al. did demonstrate that the scores for physical functioning, bodily pain, and general health 
were all lower in patients without remission, when compared to those in remission (52). The 
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differences in laparoscopic adrenalectomy versus open adrenalectomy (50). In addition, 
psychological factors (i.e. negative illness perceptions) were also reported to be negatively 
related to QoL in patients in remission of CD (97). 
Interventions (Table 2)
Twenty-eight intervention studies used QoL as an outcome parameter, including six random-
ized studies, three placebo controlled studies, and six follow-up studies using more than 
two measurement time points. In 11 studies QoL was the primary outcome parameter. Ap-
parently, there were no intervention studies in patients with prolactinoma using QoL as an 
outcome parameter. 
Surgery (n=4)
Four studies including 221 patients evaluated the effect of surgery. In patients with NFA, QoL 
increased after surgery (6 months) (73). Milian et al. reported that QoL improved within 3 
months after surgery in patients with a pituitary adenoma and a trend was found for further 
amelioration at 12 months after surgery (62). In patients with CD, surgical treatment (trans-
sphenoidal, as well as adrenalectomy) was found to improve QoL (25;53).
Pharmaceutical interventions (n=23)
Twenty-three studies evaluated the effect of pharmaceutical interventions (other than 
growth hormone replacement therapy), including a total of 464 patients. The majority of the 
intervention studies evaluated the effect of medical treatment in patients with acromegaly. 
Treatment with long-acting Lanreotide improved QoL in patients with active acromegaly 
(98-100). However, Karaca et al. did not find differences in improvements in QoL after treat-
ment with Octreotide LAR compared to surgery (101). Furthermore, no differences were 
found between naïve patients treated with octreotide LAR and naïve patients treated with 
Pegvisomant (102). In addition, QoL improvements have been reported after treatment 
with Pegvisomant, or combination therapy (Pegvisomant/LAR) in patients with controlled 
acromegaly (103). Moreover, a placebo controlled study demonstrated the positive effect of 
combination therapy (somatostatine analog+Pegvismant) vs. monotherapy (somatostatine 
analog+placebo) (104), whereas others did not find significant improvement of QoL after co-
treatment with Pegvisomant in addition to the usual treatment with somatostatine analog 
(105). There were no differences found in QoL in patients who previously used Octreotide 
LAR, who switched to Lanreotide autogel (106). Biermasz et al. examined whether the interval 
between sandostatin LAR injections could be increased and demonstrated that there were 
no differences in QoL during withdrawal after an injection up to 8 weeks (107). 
In patients with CD the relatively new treatment with glucocorticoid receptor antagonist 
(Mifepristone) was found to positively affect QoL (108;109). Recently, Van der Pas et al. evalu-
ated the effect of a stepwise medical treatment (i.e. pasireotide, cabergoline, ketoconazole) 
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on QoL in patients with de novo, residual or recurrent CD and reported no improvement in 
QoL (except for emotional reaction) (48).
Ten studies investigated the effect of GH replacement therapy, covering a total sample size 
of 2852 patients. The number of unique patients might be lower, since two studies reported 
from the KIMS-database. It was reported that GH replacement therapy positively affects QoL 




Generic sf-20/36/sf-6d: Short-Form health survey
(P)GWbs: (Psychological) General Well-Being Schedule
nHP: Nottingham Health Profile
eQ-5d: European Quality of Life Scale
GHQ-12/28/30: General Health Questionnaire-28/30
WHo-Qol-bref: World Health Organization Quality of Life Scale-abbreviated version
sIP: Sickness Impact Profile
15d: producing a 15-dimensional profile and a single index score
scl-90 (-r): Symptom Checklist 90 (revised)
srT: symptom rating test 
disease-
specific
acroQol: Acromegaly Quality of Life Questionnaire
sss: Signs and Symptoms Scale-acromegaly
PasQ: Patient-assessed-Acromegaly Symptom Questionnaire
Qls-H: Questionnaire of Life Satisfaction-Hypopituitarism
cushingQol: Cushing Quality of Life questionnaire
Tuebingen cd-25: Tuebingen Cushing’s disease quality of life inventory
Qol-aGHda: Quality of Life Assessment of Growth Hormone Deficiency in Adults 
domain-
specific
Hads: Hospital Anxiety Depression Scale
MfI-20: Multidimensional Fatigue Inventory
MdI: Major Depression Inventory
nrs-pain: Numerical Rating Scale-pain
cfQ: Cognitive Failure Questionnaire
facT: Functional Assessment of Cancer Therapy
sas 1-2: Social Adjustment Scale-modified
fsfI: Female Sexual Function Index
ssQ: Social Support Questionnaire
sQ: Symptom Questionnaire (anxiety, depression, somatic symptoms, anger/hostility)
bdI: Beck Depression Inventory
MbsrQ: Multidimensional Body-Self Relations Questionnaire
Psles: Presumptive Stressful Life Events Scale
HIT-6: Headache Impact Test scale
cscl: Coping Strategies Check List
aIMs2: Arthritis Impact Measurement Scale 2
csKslPP: Cognitive Scale of Kellner’s Screening List for Psychosocial Problems
cPrs: Comprehensive Psychopathological Rating Scale
MssQ: Marks’ Social Situation Questionnaire
KsQ: Kellner’s Symptom Questionnaire (psychological distress, well-being)
dcPr: Diagnostic Criteria for Psychosomatic Research (irritable mood, demoralization, persistent 
somatization)
PsI: Psychosocial Index (chronic stress, psychological distress, abnormal illness behavior, psychological 
well-being)
daQ: Dysfunction Analysis Questionnaire (social, vocational, personal, family, cognitive)
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in patients with GHD due to a prior NFA (37-39;60;110;111). In patients with GHD due to prior 
acromegaly, some studies reported no effect of GH replacement therapy (46;112), whereas 
others did find a positive effect of GH replacement therapy in these patients (47;110;113). 
Some studies reported that QoL improves after GH replacement therapy in patients with 
GHD due to prior CD (60), whereas other studies did not report this improvement (46).
Other interventions (n=1)
Interestingly, a recent study of Hatipoglu et al. evaluated the potential beneficial effects of 
physical exercise on perceived body-image and QoL in acromegalic patients (n=20). They 
demonstrated that an exercise program positively affected self-assessed body-image, but 
that it did not affect QoL or depressive symptoms (114). 
dIscussIon
This first systemic review on QoL research in patients with a pituitary adenoma showed 
that there is considerable variation in used questionnaires and combinations of question-
naires. It demonstrated the negative impact of pituitary adenomas on QoL, with patients 
with acromegaly or Cushing’s disease generally demonstrating the most impaired QoL. The 
cause of this (persistent) impairment in QoL seems to be multi-factorial, since a variety of 
somatic, psychological and environmental factors are found to influence QoL. A relatively 
small number of studies evaluated interventions aiming to improve QoL. Intervention stud-
ies, predominantly evaluating medical interventions, have been demonstrated to improve 
QoL, but no normalization occurs, with patients biochemically cured for CD demonstrating 
the smallest improvement in QoL relative to patients with active disease. 
Patients with acromegaly or Cushing’s disease generally reported the most impairment in 
QoL relative to patients with prolactinoma or NFA. This observation is in accordance with the 
findings of Van der Klaauw et al. which demonstrated that patients in remission of acromegaly 
had the most impaired overall QoL, followed by Cushing’s disease, prolactinoma and NFA 
(64). We speculate that these differences could be explained by the fact that these patients 
have not been exposed to elevated hormone secretion and therefore, probably experience 
less severe consequences. Nevertheless, a disease-specific QoL questionnaire for NFA is lack-
ing, which for instance should assess visual dysfunction, a common symptom which has been 
found to contribute to QoL in patients with NFA (73). Therefore, it could be that the impact 
of NFA is underestimated by the currently available QoL studies. Until a disease-specific 
questionnaire is available, QoL studies in patients with NFA should take into consideration 
the assessment of domain-specific questionnaires, such as the National Eye Institute Visual 
Functioning Questionnaire (NEI VFQ-25) (115;116). 
The majority of the predictors identified in the available literature consist of somatic fac-
tors, and surgical and pharmacological interventions targeting these somatic factors have 
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been found to improve QoL. However, the effects of some medical interventions for pituitary 
disease, such as replacement therapy for hypopituitarism, have not yet been evaluated. As 
illustrated by the spider-plots (figure 3a-d), there might be room for further improvement 
in QoL for patients with pituitary diseases. Tiemensma et al. demonstrated negative illness 
perceptions and ineffective coping strategies in patients with pituitary disease (95;97). They 
postulated that these psychological aspects could be a potential target for improving QoL 
and the authors point toward the potential beneficial effect of psychosocial interventions, 
adapting illness perceptions and coping strategies, next to medical treatment. Until now, 
there is only one pilot-study which described the efficacy of a 26-week patient education 
intervention for patients with neuroendocrine tumors. This program mainly focused on 
enhancing self-efficacy (117). The results of this study demonstrated that perceived stress 
decreased and self-efficacy and physical functioning (SF-36) improved after the intervention 
(118). Although the efficacy of psychosocial interventions should be further investigated in 
a randomized controlled trial in a homogenous group of patients with a pituitary adenoma, 
this study provided promising data for the efficacy of psychosocial interventions for the 
improvement of QoL in patients treated for pituitary adenomas. 
When examining the selected QoL studies, some interesting facts can be observed. For 
instance, the number of studies assessing QoL differs considerably between the four patient 
populations, with the largest number of studies in patients with acromegaly, followed by 
Cushing’s disease and NFA, and the smallest number in patients with prolactinoma. This is in 
particular interesting, considering the fact, that prolactine hypersecretion is most common 
in pituitary adenomas (119). Future research should focus on QoL in this under-evaluated 
group. It should be noted that some papers were not selected for the present review, be-
cause they did not met inclusion criteria for this review, although they did measure QoL 
related aspects (e.g. general well-being (120), psychological symptoms (121)). Furthermore, 
studies with patients with other pituitary tumors were also not selected for the present 
review, although they did measure important QoL-related factors, such as personality traits, 
psychopathology (122-125) and perceived health (126). A relatively small number of studies 
evaluated interventions aiming to improve QoL in patients with pituitary disease, in contrast 
to the large number of observational studies reporting the impairments in QoL. Furthermore, 
the number of studies examining QoL in naïve patients is quite small. In addition, only a 
few studies evaluated QoL in patients during long-term follow-up. More longitudinal studies 
including naïve patients are needed to provide more information about the time course of 
QoL in patients with pituitary diseases. 
The definition of QoL in the book of Spilker stresses the importance of the patient perspec-
tive of QoL (13). During a recent focus group study of our research group we elucidated the 
patient perspective of QoL. This study identified QoL aspects which are not (yet) covered by 
available disease-specific QoL questionnaires (127), such as visual problems, issues with a 
changed personality, feelings of frustration, and a reduced social network. Therefore, it might 
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be suggested that the available QoL questionnaires can be further elaborated by including 
the patient perspective. Furthermore, disease-specific QoL questionnaires for NFA, prolacti-
noma or pituitary diseases in general should be developed, in order to further improve the 
quality of QoL research is patients with a pituitary adenoma. 
In conclusion, the growing number of studies using QoL assessment in patients with a 
pituitary adenoma generally described the negative impact of these medical conditions on 
QoL of the patients afflicted. QoL research in this patient group could be further elaborated 
by the development of disease-specific questionnaires, consistent use of generic, as well 
as disease-specific questionnaires, evaluating naïve patients and using a long-term follow-
up. Surgical and pharmacological interventions have been demonstrated to improve QoL. 
Nevertheless, considering the multi-factorial determination of QoL, we postulate that there 
is substantial room for further improvement of QoL, by for instance using psychosocial inter-
ventions, besides optimal medical treatment.
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aPPendIx 1. searcH sTraTeGy 
PubMed:
(“Pituitary neoplasms”[mesh] OR “Pituitary Neoplasms”[all fields] OR “Pituitary Neoplasm”[all fields] 
OR “Pituitary Tumors”[all fields] OR “Pituitary Tumor”[all fields] OR “Pituitary Adenomas”[all fields] OR 
“Pituitary Adenomas”[all fields] OR “ACTH-Secreting Pituitary Adenoma”[all fields] OR “ACTH-Secreting 
Pituitary Adenomas”[all fields] OR “Corticotroph Adenoma”[all fields] OR “Corticotroph Adenomas”[all 
fields] OR “Cushing syndrome”[mesh] OR “Cushing syndrome”[all fields] OR “Cushing’s Syndrome”[all 
fields] OR “Hypercortisolism”[all fields] OR “Cushing disease”[all fields] OR “Cushing’s disease”[all fields] 
OR “Growth Hormone-Secreting Pituitary Adenoma”[all fields] OR “Growth Hormone-Secreting Pituitary 
Adenomas”[all fields] OR “Acromegaly”[all fields] OR “Prolactinoma”[all fields] OR “Prolactinomas”[all 
fields] OR “Microprolactinoma”[all fields] OR “Microprolactinomas”[all fields] OR “Macroprolactinoma”[all 
fields] OR “Macroprolactinomas”[all fields] OR “non-functioning adenoma”[all fields] OR “non-func-
tioning adenomas”[all fields] OR “non-functioning pituitary adenoma”[all fields] OR “non-functioning 
pituitary adenomas”[all fields] OR “non-functioning macroadenoma”[all fields] OR “non-functioning 
macroadenomas”[all fields] OR “nonfunctioning adenoma”[all fields] OR “nonfunctioning adenomas”[all 
fields] OR “nonfunctioning pituitary adenoma”[all fields] OR “nonfunctioning pituitary adenomas”[all fields] 
OR “nonfunctioning pituitary macroadenoma”[all fields] OR “nonfunctioning pituitary macroadenomas”[all 
fields] OR “nonfunctioning macroadenoma”[all fields] OR “nonfunctioning macroadenomas”[all fields]) 
AND (“quality of life”[mesh] OR “quality of life”[all fields] OR “life quality”[all fields] OR “qol”[all fields] OR 
“daily functioning”[all fields] OR “daily routine”[all fields] OR “health related quality of life”[all fields] OR 
“well-being”[all fields] OR “wellbeing”[all fields]) 
PsycInfo:
(“Pituitary neoplasms” OR “Pituitary Neoplasms” OR “Pituitary Neoplasm” OR “Pituitary Tumors” OR “Pi-
tuitary Tumor” OR “Pituitary Adenomas” OR “Pituitary Adenomas” OR “ACTH-Secreting Pituitary Adenoma” 
OR “ACTH-Secreting Pituitary Adenomas” OR “Pituitary Corticotropin-Secreting Adenoma” OR “Pituitary 
Corticotropin-Secreting Adenomas” OR “Corticotroph Adenoma” OR “Corticotroph Adenomas” OR “Growth 
Hormone-Secreting Pituitary Adenoma” OR “Growth Hormone-Secreting Pituitary Adenomas” OR “Pituitary 
Growth Hormone Secreting Adenoma” OR “Pituitary Growth Hormone Secreting Adenomas” OR “Prolacti-
noma” OR “Prolactinomas” OR “Microprolactinoma” OR “Microprolactinomas” OR “Macroprolactinoma” OR 
“Macroprolactinomas” OR “Acromegaly” OR “non-functioning adenoma” OR “non-functioning adenomas” 
OR “non-functioning macroadenoma” OR “non-functioning macroadenomas” OR “nonfunctioning adeno-
ma” OR “nonfunctioning adenomas” OR “nonfunctioning pituitary adenoma” OR “nonfunctioning pituitary 
adenomas” OR “nonfunctioning pituitary macroadenoma” OR “nonfunctioning pituitary macroadenomas” 
OR “nonfunctioning macroadenoma” OR “nonfunctioning macroadenomas” OR “Cushing syndrome” OR 
“Cushing syndrome” OR “Cushing’s Syndrome” OR “Hypercortisolism” OR “Cushing disease” OR “Cushing’s 
disease” OR “Cushings Syndrome” OR “Hypothalamic Pituitary Adrenal Axis” OR “Hypopituitarism” OR “Pitu-
itary Disorders” OR “Hypopituitarism”) AND (“Quality of Life” OR “Quality of Work Life” OR “Relationship Qual-
ity” OR “Family Relations” OR “Life Changes” OR “Life Experiences” OR “Lifestyle” OR “Spirituality” OR “quality 
of life” OR “quality of life” OR “life quality” OR “qol” OR “daily functioning” OR “daily routine” OR “limitations of 
functioning” OR “health related quality of life” OR “quality of life” OR “quality of life” OR “life quality” OR “qol” 
OR “daily functioning” OR “daily routine” OR “limitations of functioning” OR “health related quality of life” OR 
“well-being” OR “wellbeing” )
Web of Science:
Ts=(Pituitary neoplasms OR Pituitary Neoplasm OR Pituitary Tumors OR Pituitary Tumor OR Pituitary 
Adenomas OR Pituitary Adenomas OR ACTH-Secreting Pituitary Adenoma OR ACTH-Secreting Pituitary 
Adenomas OR Corticotroph Adenoma OR Corticotroph Adenomas OR Cushing syndrome OR Cushing 
syndrome OR Cushing’s Syndrome OR Hypercortisolism OR Cushing disease OR Cushing’s disease OR 
Growth Hormone-Secreting Pituitary Adenoma OR Growth Hormone-Secreting Pituitary Adenomas OR 
Prolactinoma OR Prolactinomas OR Microprolactinoma OR Microprolactinomas OR Macroprolactinoma 
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OR Macroprolactinomas OR Acromegaly OR non-functioning adenoma OR non-functioning adenomas OR 
non-functioning macroadenoma OR non-functioning macroadenomas OR nonfunctioning adenoma OR 
nonfunctioning adenomas OR nonfunctioning pituitary adenoma OR nonfunctioning pituitary adenomas 
OR nonfunctioning pituitary macroadenoma OR nonfunctioning pituitary macroadenomas OR nonfunc-
tioning macroadenoma OR nonfunctioning macroadenomas OR Cushing syndrome OR Cushing syndrome 
OR Cushing’s Syndrome OR Hypercortisolism OR Cushing disease OR Cushing’s disease) AND TS=(quality of 
life OR quality of life OR life quality OR qol OR daily functioning OR daily routine OR health related quality 
of life OR well-being OR wellbeing)
embase:
(exp hypophysis tumor/ OR “Pituitary Neoplasms”.mp OR “Pituitary Neoplasm”.mp OR “Pituitary Tumors”.
mp OR “Pituitary Tumor”.mp OR “Pituitary Adenomas”.mp OR “Pituitary Adenomas”.mp OR “ACTH-Secreting 
Pituitary Adenoma”.mp OR “ACTH-Secreting Pituitary Adenomas”.mp OR “Corticotroph Adenoma”.mp OR 
“Corticotroph Adenomas”.mp OR Cushing syndrome/ OR “Cushing syndrome”.mp OR “Cushing’s Syndrome”.
mp OR “Hypercortisolism”.mp OR “Cushing disease”.mp OR “Cushing’s disease”.mp OR “Growth Hormone-Se-
creting Pituitary Adenoma”.mp OR “Growth Hormone-Secreting Pituitary Adenomas”.mp OR “Acromegaly”.
mp OR “Prolactinoma”.mp OR “Prolactinomas”.mp OR “Microprolactinoma”.mp OR “Microprolactinomas”.mp 
OR “Macroprolactinoma”.mp OR “Macroprolactinomas”.mp OR “non-functioning adenoma”.mp OR “non-
functioning adenomas”.mp OR “non-functioning pituitary adenoma”.mp OR “non-functioning pituitary 
adenomas”.mp OR “non-functioning macroadenoma”.mp OR “non-functioning macroadenomas”.mp OR 
“nonfunctioning adenoma”.mp OR “nonfunctioning adenomas”.mp OR “nonfunctioning pituitary adeno-
ma”.mp OR “nonfunctioning pituitary adenomas”.mp OR “nonfunctioning pituitary macroadenoma”.mp OR 
“nonfunctioning pituitary macroadenomas”.mp OR “nonfunctioning macroadenoma”.mp OR “nonfunction-
ing macroadenomas”.mp) AND (exp “quality of life”/ OR “quality of life”.mp OR “life quality”.mp OR “qol”.mp 




aPPendIx 2. sPIder PloT daTa
PF: Physical functioning, PR: Physical role, GH: General health, Vit: Vitality, SF: Social function-
ing, ER: Emotional role, MH: Mental health
dutch a-select sample (67)
PF PR Pain GH Vit SF ER MH
average score 81.9 79.4 79.5 72.7 67.4 86.9 84.1 76.8
Prolactinoma
Active/naïve patient groups:
PF PR Pain GH Vit SF ER MH
Johnson, 2003 49.3 46.2 47.9 47 43.8 41.3 40.3 43.8
average score 49.3 46.2 47.9 47 43.8 41.3 40.3 43.8
Controlled/treated patient groups:
PF PR Pain GH Vit SF ER MH
Cesar de Oliveira Naliato, 2008 78.6 86 70.1 69 61.1 69.5 67.3 66.6
Kars, 2007 85.5 70.9 81.2 67.6 73.4 75.8
average score 82.1 78.5 75.7 68.3 61.1 71.5 71.6 66.6
nfa
Active/naïve patient groups:
PF PR Pain GH Vit SF ER MH
Johnson, 2003 45.9 43 46.2 46.4 40.9 41.7 41.2 44.8
average score 45.9 43 46.2 46.4 40.9 41.7 41.2 44.8
Controlled/treated patient groups:
PF PR Pain GH Vit SF ER MH
Biermasz, 2011 (remission) 85.6 76.5 87.8 68.4 89.0 90.2
Dekkers, 2006 (remission) 79.0 65 81.3 57.3 79.0 69.1
Page, 1997 (treated) 79 73 80 66 57 86 78 75
Nielsen. 2007 (treated) 84 72.4 82.8 70.1 66.3 90.6 77.5 82.3
Van Beek, 2007 (RT+) 84 76 84 60 66 85 88 79
Van Beek, 2007 (RT-) 74 69 81 59 56 77 78 72
Capatina, 2013 (treated) 71.5 64.5 75.3 62.1 55.0 79.1 75.9 76.6
Miller, 2008 (after GH therapy) 85.4 98.1 78.1 76.8 61.5 96.2 92.3 85.2
Miller, 2008 (after placebo) 63.9 62.5 61.1 48.6 46.1 67 57.1 66.3
average score 78.5 73.0 79.0 63.1 58.3 83.2 78.5 76.6





PF PR Pain GH Vit SF ER MH
Milian, 2013 (preoperative) 37 45.4 29.7 31.5 25.8 30.8 48.1 34.2
Johnson, 2003 (active) 46 45 46.5 43.6 43.5 46.7 47.1 47.2
Psaras, 2011 
(no remission)
51 43.2 35.7 39.9 33.8 43.4 39.7 38.2
average score 44.7 44.5 37.3 38.3 34.4 40.3 45.0 39.9
Controlled/treated patient groups:
PF PR Pain GH Vit SF ER MH
Miller, 2010 
(after GH therapy)
85.4 98.1 78.1 76.8 61.5 96.2 92.3 85.2
Miller, 2010 (after placebo) 63.9 62.5 61.1 48.6 46.1 67 57.1 66.3
Wassenaar, 2010 (spine OA) 72.6 58.9 67.1 54.4 77.2 62
Wassenaar, 2010 
(no spine OA)
84.7 90 86.9 72.7 93.3 95.5
Van der Klaauw, 2008 (follow-up) 72.1 67.4 72.6 59.9 79 75.1
Wexler, 2009 (GHD) 72 68 64.9 55.2 38.4 74.5 72 66.7
Wexler, 2009 (GH sufficient) 94.4 100 84.6 78.3 66.8 95.8 100 78.2
Biermasz, 2004 (remission) 68.6 57.4 72.2 55.6 79.6 70.3
Biermasz, 2005 
(no joint problems)
83.9 76.9 92 70.6 88 84
Biermasz, 2005
(joint problems)
64 51.7 66.3 51.2 77.1 66.3
Postma, 2012 (SSTA+) 65 46 65 49 48 66 78 72
Postma, 2012 (SSTA-) 79 65 78 63 58 75 75 75
Milian, 2013 
(12 months after surgery)
51.1 54.3 36.5 46.7 52.2 55.8 56.7 60.5
Miller, 2008 (controlled) 65 65.7 60.7 55.4 51 76.9 76.6 73
Psaras, 2011 (remission) 34.3 35.9 32.3 33.5 32.5 37.6 38.7 45.2
Valassi, 2012 (placebo) 63.8 68.8 63.1 38.8 26.9 65.6 62.5 55
Valassi, 2012 (GH) 80.6 58.3 76.4 61.7 28.9 70.8 77.8 65.3
average score 70.6 66.2 68.1 57.1 46.4 75.0 72.9 67.5
cushing’s disease
Active/naïve patient groups:
PF PR Pain GH Vit SF ER MH
Milian, 2013 (preoperative) 9.6 21.6 24.9 12.1 9.8 12.4 22.1 13
Johnson, 2003 (active) 36.6 36.1 40.8 36.4 35.4 35 38.8 38.4
Psaras, 2011 (no remission) 37.6 25 44.6 39.7 47.2 31.6 26 43.8
Lindsay, 2006 (pre-surgery) 28.3 31.8 41.9 34.4 36.4 29.8 36.6 39.7
Van der Pas, 2012, 2013 
(untreated)
54.4 33.6 75.3 45.6 59.4 60.4




PF PR Pain GH Vit SF ER MH
Lindsay, 2006 (remission) 45.5 45.7 47.4 44.2 46.5 47.2 45.6 47.3
Lindsay, 2006 (after surgery) 45.9 45.9 48.6 48.1 48.3 46.7 49 51.4
Van Aken, 2005 (remission) 68 65 73 54 73 67
Tiemensma, 2012 (remission) 63.5 51.3 69.6 50.1 48.6 72.1 62.7 61.4
Milian, 2013 
(12 months after surgery)
41.9 39.5 43 37.5 32 40.5 42.9 52.1
Psaras, 2011 (remission) 43.3 40.1 38.3 31.6 36.9 32.9 58.3 40.7
Hawn, 2012 
(after adrenalectomy)
65 39 52 44 30 53 43 58
Smith, 2009 
(after adrenalectomy)
48.5 45.4 50.1 42.5 41.8 45.1 48.9 46.6
average score 52.7 46.5 52.8 44.0 40.6 51.3 52.2 51.1
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More concerns and stronger beliefs about 
the necessity of medication in patients with 
acromegaly are associated with negative illness 
perceptions and impairment in Quality of Life 
Cornelie D. Andela, Nienke R. Biermasz, Adrian A. Kaptein, Alberto M. Pereira, and Jitske 
Tiemensma




objective: Patients with acromegaly can be treated with surgery, radiotherapy and/or 
medical treatment. In general, patients’ beliefs about medication are associated with illness 
perceptions, a contributory factor of Quality of Life (QoL). At present, there are no quantita-
tive studies on medication beliefs in patients with acromegaly. Here, we aimed to examine 
possible associations between medication beliefs, illness perceptions, and QoL. Furthermore 
we aimed to explore whether illness perceptions of patients with remission of acromegaly 
receiving medical treatment differ from patients without medical treatment.  
design:  Cross-sectional evaluation of 73 patients with remission of acromegaly (n=28 
patients with medication, n=45 without medication). The Beliefs about Medicines Question-
naire (BMQ), Illness Perception Questionnaire-Revised (IPQ-R), EuroQoL-5D, and AcroQoL 
were used for the assessment. 
results: Stronger beliefs about the necessity of medical treatment and stronger concerns 
about the adverse effects were associated with attributing more symptoms to acromegaly, 
perceiving more negative consequences, and having a stronger belief in a cyclical timeline 
(BMQ, all P<0.05). Stronger beliefs about the necessity of medical treatment were associated 
with a worse disease-specific QoL (BMQ, P<0.01). Patients with medical treatment perceived 
a more chronic timeline of their disease, compared to patients without medical treatment 
(IPQ-R, P=0.002).
conclusion: Negative medication beliefs were related to more negative illness perceptions 
and worse disease-specific QoL. Patients receiving medical treatment for acromegaly tend 
to perceive a more chronic timeline of their disease, compared to patients with remission 
without medical treatment. These psychological factors need to be taken into account when 
treating patients and developing a psychosocial education program aiming to improve QoL.




Acromegaly is characterized by exposure to elevated growth hormone (GH) levels, most 
frequently due to a GH-producing pituitary adenoma. Patients are usually treated with trans-
sphenoidal surgery and sometimes by additional radiotherapy. When this treatment is not 
(completely) successful, or when surgery and/or radiotherapy is not preferred, patients can 
be medically treated with somatostatin analogs (SA) (e.g. Octreotide, Lanreotide) and/or a 
GH receptor antagonist (e.g. Pegvisomant). Patients with acromegaly report impairments 
in Quality of Life (QoL) (1;2), which may persist even after long-term remission (3;4). These 
persistent impairments have been (partly) attributed to comorbidities, such as osteoarthritis 
(5), musculoskeletal pain (6-8), and psychopathology (9). Besides physical factors, Tiemensma 
et al. elucidated psychological factors (i.e. negative illness perceptions) which were related to 
QoL impairments in patients after long-term remission of acromegaly (10). 
Recently Gurel et al. carried out structured interviews that explored patients’ perceived 
impact of acromegaly. These interviews revealed that patients did not feel “cured” after treat-
ment, particularly when patients realized they had to take medication for the rest of their life. 
The use of medication resulted in confusion between being a patient and being a person. Fur-
thermore, patients had to make specific injection schedules to plan their medication around 
work, travel, and big events, in order to minimize the negative influence of side-effects on 
everyday life (11). A previous focus group study carried out by our group elucidated medicine 
beliefs and illness perceptions in patients with acromegaly. Specifically, during these focus 
group conversations patients reported that they experienced the use of injections as awful 
(12) (for illustrative, unpublished quotes, see Table 1). These two qualitative studies point 
toward the potential existence of negative beliefs about medicines in patients medically 
treated for acromegaly. Furthermore, it illustrated the need for self-management skills in 
patients with acromegaly in order to minimize the negative influence on their daily life. 
Beliefs about medicines can be quantitatively assessed by using the Beliefs about Medi-
cines Questionnaire (BMQ) (13), which assesses beliefs about necessity and concerns of tak-
ing a specific medicine. Until now, there are no quantitative studies available about beliefs 
about medication for acromegaly (i.e. SA) and beliefs about medication in general in patients 
with acromegaly. 
The important influence of beliefs about medicines on illness perceptions, coping strate-
gies, and therefore QoL, is demonstrated in the Common-Sense Model of self-regulation 
(CSM) (14). This model describes how individuals come to understand their illness and how 
they develop coping strategies. The model comprises three stages. During stage one, illness 
perceptions are identified and organized around five categories: identity, cause, timeline, 
consequences, and cure/control. These illness perceptions determine coping strategies 
(stage two). The third stage comprises the appraisal of these coping strategies. Recently, 
the extended CSM was formulated by including beliefs about medicines. Specifically, it was 
demonstrated that beliefs about medicines were associated with illness perceptions in pa-
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tients with chronic diseases (e.g. asthma (15)), adrenal insufficiency (16)). In addition, beliefs 
about medicines have also been found to be predictive of self-management behavior, such 
as adherence to medication (15;17). 
In the present study, we aimed to assess the contribution of beliefs about medicines to 
illness perceptions and QoL in acromegaly. We examined possible associations between 
beliefs about medication, illness perceptions, and QoL in patients with remission of acro-
megaly. Considering the extended CSM we hypothesized that beliefs about medication are 
associated with illness perceptions and QoL. Furthermore, we evaluated whether there are 
differences in illness perceptions and QoL between patients with remission of acromegaly 
Table 1. Illustrative quotes on medication beliefs and illness perceptions in acromegaly
Medicine beliefs: concerns I take very intense medications, which is difficult.
I noticed, towards the end of my injections, that my sleep 
problems increased. My body would start functioning 
differently when my injection would wear off.
I find information about side effects very important. I thought 
those side effects were very severe.
Illness perception: Identity I believe I am just tired earlier and experience stress faster.
You are more sensitive to stress, which has an impact on your 
physical well-being, I think.
Your central nervous system must be damaged here and there 
because of the illness, it is almost inevitable.
Illness perception: consequences It had a huge impact. You are working, you have a house, you 
have a good job, and all of a sudden you are ill.
In the meantime, you basically lost your entire life.
It is very two-sided of course. On the one hand, you are happy 
to know where your symptoms came from after getting the 
diagnosis. Subsequently, you undergo surgery, which goes 
well, and afterwards you are happy you are still alive, you can 
finally do all the fun things you haven’t done in years, because 
I was always working and very busy. Afterwards, you still have 
a body that doesn’t want to even though you want it to. That 
is difficult sometimes.
Illness perception: Timeline You feel like you may have been cured because the values 
normalized so the surgery was successful, but the damage 
that preceded this is permanent so you obviously have 
damage somewhere.
Permanent damage, that troubles me the most.
You may not actually be sick, but you do have a disease as a 
result.
And you keep that with you for the rest of your life, so to what 
extent are you cured?
Unpublished quotes from a recent focus group study of our department. The main results are described in (12). Dur-
ing the focus groups patients with acromegaly reported concerns about their medication, and perceptions about 
the identity of their disease, the consequences and the timeline.
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receiving medical treatment and patients without medical treatment. Considering the po-
tential negative effect patients may perceive when taking medication for acromegaly (11;12), 
we hypothesized that patients medically treated for acromegaly have more negative illness 




Patients with acromegaly were invited to fill out questionnaires on medication beliefs, ill-
ness perceptions, and QoL. Patients were asked to complete the questionnaires at home 
and return them in a prepaid envelope. Inclusion criteria were adult patients (age >18yr) 
and remission defined by strict biochemical criteria (see below for details) for at least 1 year. 
Institutional Medical Ethics Committee approved the protocol.  
Patients
A clinical chart review of 156 patients with acromegaly was performed. All patients were in 
biochemical remission for at least 1 year at the time of the present study. We invited these 
patients to fill out the questionnaires. Seventy-three patients (47%) refused to participate 
for several reasons (e.g. too busy, old age, debilitating disease). Eighty-three (53%) patients 
returned the questionnaires and filled out at least one questionnaire. Seventy-seven of these 
patients (49%) completed both the Beliefs about Medicines Questionnaire, as well as the Illness 
Perception Questionnaire. Patients with acromegaly who used medication other than soma-
tostatin analogs (SA), i.e. dopamine agonists (n=2), or Pegvisomant (n=2) were excluded from 
the analysis because of the low power for separate analyses. Therefore, a final number of 73 
patients (47%) were included in the present study. Sixty-five of these patients (42%) also filled 
out QoL questionnaires. For an overview of this process, see Figure 1.
The diagnosis of acromegaly had been established by clinical signs and symptoms, and 
by biochemical tests, including insufficient suppression of GH during the glucose tolerance 
test and increased IGH-I levels for age. Normal serum IGF-I levels for age and serum GH 
levels below 1.9 μg/liter defined biochemical control of acromegaly for all patients and, in 
patients without SA treatment, also by suppression of GH levels (<0.38 mcg/l) during glucose 
tolerance test (18). Remission was reconfirmed at yearly intervals. Pituitary function was 
monitored and pituitary hormone replacement was prescribed dependent on the results of 
the yearly evaluation of pituitary functions. In case of corticotrope insufficiency, documented 
by insulin tolerance test (ITT) or CRH test, hydrocortisone was prescribed (20 mg/d divided 
into 2-3 dosages). Evaluation of GH deficiency was performed by ITT or GHRH-arginine test, 
only in patients under the age of 70 years and only after at least 2 years of remission. Somato-
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trope insufficiency was treated with rhGH replacement, aiming at IGF-I concentrations in the 
normal range for age. In addition, free T4 and testosterone levels (in male patients) were 
assessed. If results were below the lower limit of the respective ranges, substitution with L-T4 
and/or testosterone was prescribed. In the case of amenorrhea and low estradiol levels in 
premenopausal women, estrogen replacement was provided.
Questionnaires
Beliefs about Medicines Questionnaire (BMQ)
The BMQ aims to assess cognitive and emotional representations of medication and compris-
es of two sections (i.e. BMQ-Specific and BMQ-General), each divided into two subscales. The 
BMQ-Specific comprises two subscales assessing representations of medication prescribed 
for personal use (i.e. SA): the Specific-Necessity subscale, which is focusing on the perceived 
necessity of taking medications to remain healthy, and the Specific-Concerns subscale, 
focusing on concerns about the adverse effects of taking medications. The BMQ-General 
comprises two four item subscales assessing beliefs about medicines in general: the General-
Overuse subscale assesses beliefs that medicines are over-prescribed, and the General-Harm 
subscale assesses beliefs about medicines as harmful, addictive or poisonous. All items were 
156 patients were invited to fill-out 
questionnaires
73 patients refused to participate for several 
reasons (e.g. too busy, old age, debilitating disease)
83 patients retuned questionnaires with 
filling-out at least 1 questionnaire
10 patients were excluded:
• 6 patients did not complete both the IPQ and BMQ
• 2 used no SA, but used dopamine agonists
• 2 used no SA, but used Pegvisomant
73 patients completed the IPQ-R and BMQ 
• 28 patients medically treated
• 45 patients in remission
65 patients completed both the IPQ-R and 
BMQ
• 25 patients medically treated
• 40 in remission
8 patients did not complete QoL questionnaires in 
addition to IPQ and BMQ
65 patient  c l t  IPQ-R, BMQ, and 
QoL
• 25 patients medically treated
• 40 patients in remission
figure 1. Flow-chart of included patients.
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rated on a five-point Likert-scale ranging from 1 strongly agree to 5 strongly disagree. The 
Specific-Necessity subscale ranged from 5 to 25 (midpoint = 15), the Specific-Concerns 
subscale ranged from 6-30 (midpoint = 18), and both General subscales ranged from 4 to 
20. Higher scores indicate stronger beliefs. Among general medical patients, the Cronbach’s 
alpha ranged from 0.51 to 0.86 (13). 
Illness Perception Questionnaire - Revised (IPQ-R)
The Illness Perception Questionnaire-Revised (IPQ-R) was used to assess cognitive and emo-
tional representations of illness. The questionnaire was developed to assess the components 
of the illness representation of Leventhal’s Common Sense Model and is frequently used to 
study illness perceptions in chronic conditions (19-23). The IPQ-R is divided into three sec-
tions. The first part consists of the illness identity dimension, with a list of fourteen general 
commonly occurring symptoms. Patients are asked to rate whether or not they experienced 
the symptoms, and if they believe the symptom to be related to their illness (yes/no). The 
summed yes-rated items of the disease related symptoms are used in the analysis. 
The second part of the questionnaire, assessing illness perception dimensions, consists 
of 38 statements concerning views on the illness, scored on a 5-point Likert scale (from 
strongly disagree to strongly agree). The questions are transformed to seven dimensions: 
timeline acute/chronic (beliefs about the chronic nature of the condition), timeline cyclical 
(beliefs regarding the cyclical nature of the condition i.e. perceived variability in symptoms), 
consequences (negative consequences of the disease), personal control (perceived personal 
controllability of the disease), treatment control (perceived treatment controllability of the 
disease), emotional representations (the emotional responses generated by the illness), and 
illness coherence (personal understanding of the disease). A higher score indicates a stronger 
belief in that particular dimension. The third and final part of the questionnaire is about the 
causal attributions. This section consists of 18 statements concerning possible causes that 
patients consider that contributed to their disease, scored on a 5-point Likert scale (strongly 
disagree to strongly agree). 
As recommended by the developers of the questionnaire, a principal component analysis 
with varimax rotation was performed on the causal items to cluster variables with shared 
variance (24). This analysis produced two factors: 1) psychological attributions (i.e. stress/
worries, family problems/worries, emotional state, mental attitude, own behavior, overwork, 
aging, personality, altered immunity, poor medical care), and 2) risk factors (smoking, alcohol 
use, accident/injury, bacteria/virus, diet/eating habits, pollution in environment). The princi-
pal component analysis is described in detail by Tiemensma et al. 2010 (10). 
EuroQoL-5D (EQ-5D)
The EQ-5D assesses the current health status reflected in five health dimensions; mobility, 
self-care, usual activities, pain/discomfort, and anxiety/depression. Scores are expressed 
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on a 1-3 scale per dimension, with higher scores indicating worse QoL. The questionnaire 
also includes a visual analogue scale (VAS) which comprises a standard vertical 20 cm scale 
(similar to a thermometer) for recording an individual’s rating for their current health-related 
well-being (25). The VAS score ranges from 0 to 100, with higher scores indicating a better 
health status.
AcroQoL
The AcroQoL is a disease-specific QoL questionnaire assessing acromegaly related QoL. The 
AcroQOL consists of 22 items on a five-point Likert scale, measuring frequency of occurrence 
(ranging from always to never) and agreement (ranging from completely agree to completely 
disagree). The 22 items are subdivided into three subscales: physical scale (8 items), psycho-
logical-appearance scale (7 items), and psychological-personal relations scale (7 items). The 
total score ranges from 0-100, with lower scores indicating a more impaired QoL (26;27).
statistical analysis
Data were analyzed using PASW Statistics version 20 (SPSS Inc., Chicago, IL). All data are pre-
sented as means ± standard deviations, unless mentioned otherwise. To check the normality 
of data, the Kolmogorov-Smirnov test was used in addition to histograms and boxplots. 
The primary analysis comprised the relationship between medication beliefs, illness per-
ceptions and QoL. Pearson correlation coefficients were calculated when data were normally 
distributed and Spearman’s rho were calculated when data were not normally distributed. 
The secondary analysis comprised the evaluation of potential differences in illness percep-
tions between patients with medical treatment for acromegaly and patients without medical 
treatment. Independent sample t-tests were used when data were normally distributed and 
Mann-Whitney U tests were used when data were not normally distributed. Because of the 
exploratory nature of the primary and secondary analysis, adjustment of the level of signifi-
cance for multiple testing was not performed, and the level of significance was set at P≤0.05.
resulTs
Patient characteristics (Table 2)
Seventy-three patients participated in the present study (40 males, 55%). The mean duration 
of follow-up was 16.1±10 years. Eighty-five percent of the patients were treated with trans-
sphenoidal surgery, and 23% of the patients were additionally treated with radiotherapy. 
Forty-five patients were not using medication for acromegaly. Of these patients, 44 patients 
(98%) were treated with transsphenoidal surgery and one patient was biochemically cured 
after pituitary apoplexy. Twenty-eight patients were receiving medical treatment for acro-
megaly. Of these medically treated patients, 18 patients (25%) used only SA, six patients 
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(8%) used SA and Pegvisomant, three patients (4%) used SA and dopamine agonists, and 
one patient used SA, Pegvisomant, and dopamine agonists. Patients only using Pegvisomant 
(n=2) or dopamine agonist (n=2) had been excluded from the analysis. All medically treated 
patients were well-controlled as measured by GH (in SA patients only) and IGF-1 concentra-
tions (in all 28 patients) that were below 2.5 mcg/L and within the normal reference range, 
respectively (biochemical remission). 
Of the SA treated, 79 percent reported the need for using SA (scores above the midpoint 
of the specific necessity subscale), whereas 50 percent of these patients reported concerns 
about the use of SA (scores above the midpoint of the specific concerns subscale). 













Gender (male/female) 40/33 13/15 27/18 .257c
Age (yrs) 60.10 (11.6) 59.96 (11.0) 60.18 (12.1) .860b
Education (n)
    Low 29 (40%) 9 (32%) 20 (44%)
.403c
    Medium 17 (23%) 6 (22%) 11 (25%)
    High 27 (37%) 13 (46%) 14 (31%)
Transsphenoidal surgery, n (%) 62 (85%) 18 (64%) 44 (98%) .000c
Additional radiotherapy, n (%) 17 (23%) 5 (18%) 12 (27%) .387c
Somatostatin analogs only 18 (25%) 18 (64%) NA NA
Somatostatin analogs & Pegvisomant 6 (8%) 6 (21%) NA NA
Somatostatin analogs & Dopamine 
agonists
3 (4%) 3 (11%) NA NA
Somatostatin analogs & Pegvisomant & 
Dopamine agonists
1 (1%) 1 (4%) NA NA
Duration follow-up (yrs) 16.07 (10.0) 13.96 (10.8) 17.38 (9.4) .067b
Hypopituitarism, n (%)
    GH 12 (16%) 0 (0%) 12 (27%) .003c
    LH/FSH 13 (18%) 5 (18%) 8 (18%) .993c
    TSH 19 (26%) 6 (21%) 13 (29%) .480c
    ACTH 19 (26%) 5 (18%) 14 (31%) .210c
    ADH 2 (3%) 0 (0%) 2 (4%) .258c
a patients medically treated for acromegaly (n=28) vs. patients without medical treatment for acromegaly (n=45), 
b Mann-Whitney U test, c Chi-Square test.
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relationship between medicines beliefs and illness perceptions (Table 3, figure 
2)
In the subgroup of patients using SA, Specific-Necessity SA (i.e. the necessity of taking SA to 
remain healthy) was positively associated with illness identity (r=.406, P=.032) and conse-
quences (r=.398, P=.040). This indicates that stronger beliefs about the necessity of SA to stay 
healthy are related to attributing more symptoms to acromegaly and perceiving more nega-
Table 3. Correlations between illness perception dimensions, EQ-5D dimensions, BMQ dimensions, and 












    Identity .406* .367 .053 -.040
    Timeline (chronic/acute) .173 -.278 -.186 -.202
    Timeline (cyclical) .266 .396* -.020 .066
    Consequences .398* .348 .009 -.040
    Emotional representations .290 .294 .280* .269*
    Personal control† .012 -.076 .141 .139
    Treatment control -.331 -.298 -.108 -.109
    Illness coherence -.069 -.277 .007 -.002
    Psychological attributions -.059 .144 .237* .176











    EQ-5D
    Mobility .265 .034 -.031 .025
    Self-care .206 .155 .117 .132
    Activity .275 .099 .017 .060
    Pain .140 .262 -.011 -.018
    Anxiety -.144 .203 -.073 -.022
    VAS† -.361 -.281 -.164 -.112
AcroQoL
    Physical scale -.383 -.184 .010 -.002
    Psychological-appearance† -.423* .034 .163 .054
    Psychological-personal    
    relations†
-.567** -.311 .029 -.007
    Total score† -.594** -.006 .078 .025
Spearman’s correlations; † Pearson’s correlations. *P<0.05, **P<0.01; a= patients medically treated for acromegaly 
who filled out IPQ-R and BMQ. b= total sample of patients with and without medication for acromegaly who filled 
out IPQ-R and BMQ. c= patients medically treated for acromegaly who filled out AcroQoL and EQ-5D, as well as IPQ-
R and BMQ. d= total sample of patients with and without medication for acromegaly who filled out AcroQoL and 
EQ-5D, as well as IPQ-R and BMQ. SA: somatostatin analogs.
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tive consequences. Specific-Concerns SA (i.e. concerns about the adverse effects of taking SA) 
were positively associated with perceptions of a cyclic timeline (r=.396, P=.037), indicating 
that stronger concerns about the adverse effects of SA are related to perceiving a more cyclic 
timeline of the disease i.e. more perceived variability in symptoms. 
In the entire sample, the subscale General-Harm (i.e. beliefs about medicines in general 
being harmful, addictive or poisonous) was positively associated with emotional representa-
tions (r=.280, P=.017), psychological attributions (r=.237, P=.048), and risk factors (r =.240, 
P =.045). This indicates that stronger beliefs about harm of medication use in general are 
related to stronger emotional responses generated by the disease, having stronger beliefs 
about psychological causes of the disease, and perceiving risk factors to be the cause of 
the disease. The subscale General-Overuse (i.e. beliefs that medicines in general are over-
prescribed) was also positively associated with emotional representations (r=.269, P=.022) 
indicating that stronger beliefs about the overuse of medication in general are related to 
















figure 2. Observed correlations between illness perceptions and medication beliefs.
SA: somatostatin analogs. Absence of line indicates non-significant correlation.
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relationship between medicines beliefs and Qol (Table 3)
Specific-Necessity SA (i.e. the necessity of taking SA to remain healthy) was negatively associ-
ated with AcroQoL subscales Psychological-appearance (r=-.423, P=.035) and Psychological-
personal relations (r=-.567, P=.009), and the total score on the AcroQoL (r=-.594, P=.007). This 
indicates that stronger beliefs about the necessity of SA to stay healthy are related to a worse 
disease-specific QoL. 
The other specific, as well as general subscales of the BMQ were not significantly associated 
with QoL.
Illness perceptions and Qol in patients undergoing medical treatment vs. 
patients in remission (Table 4)
Patients treated with SA reported to perceive the timeline of their disease more chronically 
compared to patients in remission (25.69±4.07 versus 20.95±6.47, P=.002).
There were no significant differences on the other illness perception subscales or QoL 
scores between patients with medical treatment and patients without medical treatment. 
dIscussIon
The present study demonstrates that medication beliefs in patients with acromegaly are 
related to illness perceptions and QoL. Stronger beliefs about the necessity of SA were 
associated with attributing more symptoms to acromegaly, perceiving more negative con-
sequences, and lower disease-specific QoL. More concerns about the perceived side effects 
of SA were associated with perceiving more variability in symptoms. Furthermore, patients 
who are medically treated for acromegaly with adequate biochemical control of disease have 
stronger beliefs about the chronicity of the disease than patients in remission without medi-
cal treatment for acromegaly. 
The found correlations, together with the previously described correlations between 
illness perceptions and QoL in patients with acromegaly by Tiemensma et al. (10), support 
the theory of the extended CSM. This extended model shows how medication beliefs are 
associated both with illness perceptions and QoL in patients with chronic diseases (15;16).
Concerns about medication and negative illness perceptions in patients with acromegaly 
have been previously elucidated in a recent qualitative focus group study by our research 
group (12) (see Table 1). The present study provided quantitative data about these medica-
tion beliefs and illness perceptions. The important role of medication, and therefore of medi-
cation beliefs, is also properly illustrated by a recent interview study of Gurel et al. in which 
patients reported they felt not “cured” after treatment, particularly when they realized the 
medication had to be taken lifelong. The use of medication resulted in confusion between 
being a patient and being a person (11). The results of our study are in accordance with the 
latter study, since we demonstrate that patients using medication reported stronger beliefs 
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about the chronicity of the disease than patients not using medication. This negative illness 
perception about a more chronic time line of the disease may lead to more impairments in 
QoL, as demonstrated by Tiemensma et al. (10). This would be in accordance with previous 
literature demonstrating that patients with controlled acromegaly treated with Lanreotide 
reported worse QoL, compared with controlled patients who did not have to take medication 
(28), and patients cured by a single surgical intervention reporting better QoL than patients 
cured with SA, radiotherapy, or treated for hypopituitarism (3). However, in the present study 







    Identity 2.86 (2.22) 2.31 (2.56) .202
    Timeline (chronic/acute) 25.69 (4.07) 20.95 (6.47) .002*
    Timeline (cyclical) 10.11 (4.14) 10.23 (3.80) .788
    Consequences 16.89 (5.44) 16.67 (5.11) .898
    Emotional representations 12.18 (3.20) 12.71 (3.73) .361
    Personal control† 17.06 (4.14) 17.44 (4.94) .734
    Treatment control 18.68 (3.03) 17.69 (3.51) .299
    Illness coherence 17.86 (2.81) 17.07 (2.69) .137
    Psychological attributions 16.18 (5.61) 19.26 (7.19) .076
    Risk factors 9.22 (3.33) 10.60 (3.74) .161
BMQ
    Specific Necessity SA 17.04 (3.54) NA NA
    Specific Concerns SA 17.75 (2.61) NA NA
    General harm 9.69 (2.67) 9.71 (2.64) .914
    General overuse 10.13 (2.69) 10.77 (2.09) .215
EQ-5Da
    Mobility 1.44 (0.51) 1.33 (0.47) .354
    Self-care 1.08 (0.28) 1.05 (0.22) .627
    Activity 1.56 (0.65) 1.52 (0.60) .885
    Pain 1.80 (0.65) 1.75 (0.59) .787
    Anxiety 1.28 (0.54) 1.42 (0.64) .342
    VAS† 69.58 (14.68) 69.77 (16.31) .963
AcroQoLa
    Physical 64.32 (21.33) 61.14 (20.56) .551
    Psychological-appearance† 62.14 (22.14) 52.56 (18.84) .069
    Psychological-personal   
    relations†
81.43 (11.45) 77.38 (14.56) .289
    Total score† 71.83 (15.50) 63.57 (14.09) .052
Mann-Whitney U test; † Independent sample t-test. Data presented as mean (standard deviation). *P<0.01. a Pa-




we did not find differences in QoL between patients medically treated and patients without 
medical treatment, which is in accordance with others (29;30), but which could also be due 
to limited power due to the relatively small sample size. 
It might be that the association between medication beliefs and disease-specific QoL is 
mediated by the previously demonstrated relation between medication beliefs and self-
management behavior (e.g. adherence to medication) (15), since adequate self-management 
skills are needed to optimize coping with the disease and it consequences, in order to 
minimize the negative influence on daily life (i.e. QoL). Future research in a larger group of 
medically treated patients with acromegaly is needed to further elucidate the role of medica-
tion beliefs in self-management behavior and QoL. Furthermore, it would be interesting to 
examine whether medication beliefs (and illness perceptions) can be modified by offering a 
psychosocial intervention, and whether changes towards more adaptive beliefs affect QoL. In 
addition, it should be acknowledged that illness perceptions and beliefs about treatment are 
related to cultural background (31-33). In the present study, ethnicity or cultural background 
was not assessed, and therefore analyses could not be adjusted for culture.
In a previous study by our research group in patients with adrenal insufficiency treated 
with hydrocortisone, we demonstrated strong and consistent correlations between beliefs 
about hydrocortisone and illness perceptions (16). The correlations found in the present 
study are similar to those in patients with adrenal insufficiency and demonstrated the same 
direction of correlations (i.e. stronger necessity beliefs and more concerns are related with 
more negative illness perceptions). However, in the present sample of patients medically 
treated for acromegaly, fewer correlations were found and correlations were less strong. This 
could possibly be explained by limited power due to a relatively small sample size. On the 
other hand, it could also be that the impact of medication in acromegaly is less strong com-
pared to hydrocortisone treatment. Comparing the mean medicine beliefs about SA in the 
present sample with medicine beliefs in patients treated with hydrocortisone (i.e. necessity 
beliefs ranging from 18.4 to 20.9, and concerns ranging from 18.1 to 18.9 respectively) (16), 
it can be noted that medicine beliefs about SA are less strong. As suggested by the authors 
of the BMQ, differences between groups could be explained by differences in diagnosis, type 
of treatment, and perceived side effects (34). Therefore, we postulate that these distinctions 
could indeed be related to the different diagnoses, but also to the differences in type of treat-
ment (i.e. suppressant medication vs. replacement therapy, injections vs. pills). Furthermore, 
there could be differences in perceived side effects (e.g. forgetting hydrocortisone intake 
could be life threatening, while forgetting SA is not). 
The results of this study can be used by the treating physician during their consultations, 
but also by medical psychologists during psychological treatment. Awareness of clinicians 
about the potential existence of negative medication beliefs and/or illness perceptions 
would be helpful in order to assess those beliefs. Furthermore, an adequate assessment of 
these beliefs is needed to determine the potential strategy to adapt these beliefs in order 
Medicine beliefs in acromegaly
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to improve self-management behavior, and therefore QoL. When needed, physicians could 
cooperate with medical psychologists and refer patients for psychological treatment, since a 
medical psychologist can assist patients to adapt inadequate cognitions in order to develop 
effective self-management strategies. This strategy is in accordance with the multi-phase 
approach described in a previous paper by our research group (16). This multi-phase ap-
proach consists of three phases: 1) provide patients with a clear rational for their medication, 
2) assess and address patients’ concerns regarding their medication use (when necessary in 
cooperation with a medical psychologist), and 3) support patients in the optimal and persis-
tent use of their medication by assessing the potential barriers regarding their medication 
use. We believe that such a multi-phase approach that includes collaboration with a medical 
psychologist, enables improving medication beliefs, more positive illness perceptions, better 
self-management strategies, and thereby improving QoL.
In conclusion, specific beliefs about the necessity of somatostatin analogs and concerns 
about its adverse effects are strongly associated with more negative illness perceptions and 
worse disease-specific QoL. Furthermore, patients with remission of acromegaly who are 
medically treated perceive a more chronic timeline of their disease than patients in remis-
sion without medical treatment. The findings of the present study could be incorporated in 
routine clinical care of patients with acromegaly, enabling optimized clinical care, and are 
instrumental in the development of a self-management intervention aiming to improve QoL. 
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Chapter 11
Towards a better quality of life (QoL) for patients 
with pituitary diseases: Results from a focus 
group study exploring QoL
Cornelie D. Andela, Nicolasine D. Niemeijer, Margreet Scharloo, Jitske Tiemensma, Shaaji 






Purpose: Patients treated for pituitary adenomas generally report a reduced quality of life 
(QoL). At present, the patient’s perspective of QoL has not been fully addressed and this, and 
further insight in potential determinants of QoL in pituitary diseases is required to design 
strategies to improve QoL. We aimed to define patients’ perceived QoL and to identify  poten-
tial factors  they perceive to contribute to QoL.
Methods: We conducted four independent focus groups of 6 patients each, per specific 
pituitary disease (Cushing’s disease, Non-functioning pituitary macroadenoma, acromegaly, 
prolactinoma). In two sessions these focus groups discussed aspects of QoL. Verbatim tran-
scripts were analyzed using a grounded theory approach.
results: The issues raised by the patient groups were compatible with statements and items 
of available QoL questionnaires. In addition, other QoL aspects emerged, such as visual limi-
tations (physical problems); issues with a desire to have children/family planning, fear of col-
lapsing, fear of recurrence, panic, persisting thoughts, problems with an altered personality, 
anger, jealousy, sadness, frustration (psychological problems); and difficulties communicating 
about the disease, lack of sympathy and understanding by others, and a reduced social 
network (social problems). Next, this study uncovered factors which might contribute to a 
decreased QoL (e.g. less effective coping strategies, negative illness perceptions, negative 
beliefs about medicines, unmet needs regarding care). 
conclusions:  This focus group study demonstrated that important disease-specific aspects 
of QoL are neglected in current pituitary disease-specific questionnaires and elucidated 
potential factors that contribute to a decreased QoL. Information provided in this study can 
(and will) be used for developing additional items for disease-specific QoL questionnaires 
and for the development of a self-management intervention aiming to improve QoL in 
patients treated for pituitary diseases. 




Patients with pituitary diseases experience considerable physical and psychosocial conse-
quences in the chronic state of their disease (1). Persistently impaired quality of life (QoL) was 
observed in patients in biochemical remission of Cushing’s disease (2-4), non-functioning 
macroadenoma (NFA) (4;5), acromegaly (4;6), and prolactinoma (4;7). QoL has been reported 
to improve after successful biochemical treatment, but does not normalize. QoL has been 
usually assessed by either generic questionnaires (e.g. Medical Outcome Study 36-item 
Short Form health survey, Nottingham Health Profile), dimension specific questionnaires 
(e.g. Multidimensional Fatigue Inventory 20, Hospital Anxiety and Depression Scale) (2;5;7-
12) or disease-specific questionnaires (available for acromegaly (13-15), Cushing’s disease 
(16-18) and growth hormone deficiency (GHD)(19)). Disease-specific questionnaires have 
been developed based on semi-structured interviews of individual patients using topics 
preselected by physicians. Afterwards the emerging topics were checked and modulated by 
the same physicians. Although patients’ experience was included, the development has been 
controlled by the QoL perception of the physician from the beginning, instead of starting 
with QoL as formulated by patients. 
In contrast, a valuable example of a research method which starts with the patient’s 
perception, is focus groups research. Focus group research incorporates a small number of 
people (4-8 persons) discussing a particular subject in an informal group discussion. Unlike 
individual interviews, focus group interviews explicitly use group interaction as part of the 
method. This method is particularly useful in exploring people’s knowledge and experience 
and can be used to examine not only what people think, but also how they think and why 
they think that way (20). Focus group methodology is frequently used to assess health and 
illness related topics, such as QoL, health care needs and experiences of everyday life in 
patients with chronic diseases (21-24). Furthermore, it has been used for the development 
of disease-specific QoL questionnaires (25;26) and to identify disease-specific QoL aspects 
(27-29).
Factors explaining persistently impaired QoL in patients with pituitary diseases are not well 
established, but are likely to be multi-factorial. Several studies revealed predictors (of aspects) 
of QoL, such as age, gender, tumor recurrence, non-replaced hypogonadism, non-replaced 
GHD, visual field deficits, sleepiness, joint complaints, clinical osteoarthritis, radiotherapy and 
delay of diagnostic process (8;30-35). Besides these biomedical predictors, we recently dem-
onstrated that negative illness perceptions correlate with QoL in patients with acromegaly 
or Cushing’s disease (10,47). We speculate that also other psychological or social factors can 
contribute to the persistently reduced QoL, i.e. unmet needs regarding care, which appear to 
be associated with QoL in other chronic diseases (36). 
The primary aim of the present focus group study was to explore QoL as reported by 
patients treated for pituitary diseases. In addition, we aimed to identify potential factors that 
contribute to a decreased QoL. We hypothesized that focus group research would provide 
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ideas complementary to currently available diseases-specific QoL questionnaires, and would 
elucidate potential factors that contribute to QoL in pituitary diseases. This would give the 
opportunity to optimize biopsychosocial care for patients treated for pituitary adenomas, 
aiming to ultimately improve QoL. 
MeTHods
subjects
Patients were recruited from the outpatient clinic of the department of Endocrinology and 
they were selected by their consultant endocrinologists. Patient selection was based on pre-
specified criteria aiming at a focus group composition that would be representative for the 
chronic situation of the specific pituitary disease (and its sequelae) with respect to: 1) age, 
2) gender (almost equal distribution of men and women, except for the CD group consider-
ing the high prevalence of CD in females), 3) time since diagnosis and 4) degree of medical 
complaints as estimated by the consultant endocrinologist, including a mix of cured and 
medically treated patients, if applicable, and a mix of patients dealing with hypopituitarism 
and  those having normal pituitary function. Four groups were formed each consisting of 6 
patients (Cushing’s disease (CD), Non-functioning macroadenoma (NFA), acromegaly (ACRO), 
prolactinoma (PRL)), see Table 1. Group size and composition were chosen according to the 
published guidelines for focus group research (37). 
The diagnosis and state of biochemical remission were confirmed in all patients, following 
previously described criteria (7;38-40). All patients gave written informed consent. The Medi-
cal Ethical Committee of the LUMC approved the research protocol. 
study design
The focus group meetings were chaired by a health psychologist (moderator), experienced 
in group discussions who took the role of an independent moderator (NGAK) (41-43). The 
investigator (CDA, psychologist) and a research intern (EK) observed both meetings, but did 
not participate in the discussions. All 4 groups met twice for a focus group discussion of ~2 
hours each. The first meeting had the primary aim to get acquainted and to ensure a safe and 
confidential group setting in which everybody felt comfortable to speak and act freely. Pa-
tients were asked to introduce themselves, then the discussion continued with open-ended 
questions raised by the moderator about spontaneously reported issues. For example, when 
one participant spontaneously reported to be depressed sometimes, the moderator asked 
the other group members: “Are there moments when you feel depressed?” Based on the 
discussion of this first meeting, a topic list was formulated which was used during the second 
meeting (Appendix 1). During both meetings the moderator used open-ended questions. 




Transcripts were analyzed following the steps of a grounded theory approach (44). First, two 
researchers (NDN  endocrinologist, CDA psychologist) listened to the recorded discussions 
and carefully read and reread the transcripts. These two researchers independently per-
formed open coding of the transcripts for each disease separately, using Atlas.ti 6.2 software. 
Discrepancies between coding were discussed and coding of transcripts of all groups as 
a whole was checked. As a result, categories were inductively identified from the data. In 
the second phase an axial coding method was performed, which is used to reflect on the 
properties of the categories (i.e. are categories applicable?) and to consider the relation-
ships between the different categories (i.e. how are categories linked to each other?). The 
biopsychosocial model (45) was deductively used to reformulate categories. In the last phase 
data was integrated around the established categories and it was conceptualized how these 
categories may be integrated into a theory. 









Age (years) 48.6 (36-65) 42.4 (25-58) 44.5 (34-54) 49.2 (27-64)






















Duration of follow-up (yrs) 6.5 (2-19) 10.3 (1-23) 9.6 (2-20) 5.2 (1-12)


























































Data are presented as median (IQR) or number. 
Education classification: low elementary school, preparatory low-level applied education – 
medium preparatory middle-level applied education, higher general continued education, preparatory scientific 
education, middle-level applied education – high higher professional education, scientific education. TSS: Trans-
sphenoidal surgery.




resulTs (figure 1, Table 2) 
All patients were present during both focus group meetings, except one patient of the PRL-
group who was absent during the second meeting, due to personal circumstances. 
From the transcripts thirteen main categories of issues were identified. Nine categories 
corresponded to the biopsychosocial domains of QoL (46) (physical complaints, cognitive 
complaints, sexual problems, personality issues, psychological problems, negative feelings, 
social problems, work related problems and limitations in leisure activities). Four alternative 
categories were identified that might contribute to QoL (less effective coping strategies, 
negative illness perceptions, negative beliefs about medicines, unmet needs regarding care). 
Figure 1 presents the overlap and connections between the biological, psychological and 
figure 1.Qol in patients with pituitary diseases, as perceived by patients.
Italic: additional aspects which are not included in available disease-specific questionnaires.
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social categories and the possible influence of the alternative categories. Table 2 summarizes 
the identified categories and the similarities and differences between the respective pituitary 
diseases, together with some representative quotes. Newly raised aspects are further elabo-
rated below. Topics which are not included in available disease-specific QoL questionnaires 
(13-19) are highlighted in bold.
Physical complaints were fatigue, physical pain, sleeping problems, changes in physical ap-
pearance and visual problems. Fatigue was the most profound physical complaint in all 
groups. The cause of fatigue was not easily explained and it was attributed to their pituitary 
disease, their job or impaired sleep. The fatigue was both physical and mental. In addition, 
lowered muscle strength and impaired physical condition were reported. Sleeping problems 
were reported in all groups (except PRL). For example, difficulty with falling asleep due to 
persisting thoughts (CD)Q1, or difficulty staying asleep due to sleeping in blocks of 2 to 3 
hours (NFA). A long lag time after awakening was also reported (ACRO)Q3. Visual problems, 
such as tunnel vision, were reported (NFA), and the severity was related to fatigue. Some 
patients had problems sleeping in total darkness because of disorientation due to the visual 
impairment. 
Cognitive problems were characterized by concentration and attention problems, short-term 
memory problems, executive functioning problems and a feeling of over-stimulation. 
Sexual problems were physical sexual dysfunction, such as erectile dysfunction, decreased 
libido and issues with a desire to have children. Some patients reported inability to get an 
orgasm. Female patients reported menstruation problems (i.e. chronic menstruation), which 
interfered with sexual activity. (New) relationships were perceived to be affected by physical 
sexual dysfunction. Decreased libido (all groups) was discussedQ12, although the cause was 
not unanimously attributed to the disease, but also to aging, a negative self-image, shame, 
physical pain and as a side effect of medication. The awareness of a decreased libido resulted 
in the fact that sexual intimacy was not initiated by the patient and therefore gave tension 
between partnersQ13. A desire to have children and family planning were serious issues for 
some young women as they felt uncertain whether it would be possible to conceive at all, or 
alternatively whether they would be capable of caring for a child. 
Psychological complaints were depressive symptoms, mood swings, melancholy, anxiety, 
stress, fear of collapsing, fear of recurrence, panic and persisting thoughts. Fear of 
collapsing was related to situations with higher temperatures and physical strain. Fear of 
recurrence was reported in all groups and it was provoked by physical complaints (flu-like 
symptoms or pangs in the head). Fear of recurrence was aggravated by discontinuation of 
medical treatment and by uncertainty about the cause of the adenoma. Patients reported 
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caTeGory subcaTeGory reported by Quotes nr
Illustration of complaint CD ACRO PRL NFA
Physical 
complaints
Fatigue* Fatigue was the profound physical complaint. Lowered muscle strength and 
impaired physical condition were also reported. The nature of fatigue differed 
between the four pituitary diseases: either strange intense fatigue which took 
them by surprise and could disappear in just half an hour (PRL), severe fatigue 
requiring a two hour nap in the afternoon (CD) or extreme chronic tiredness  
with a “shaking” body (ACRO).
x x x x
Physical pain Physical pain was especially reported by the ACRO-group, which included 
headaches, a tickling and inflamed sensation of the whole body, arthralgias 
with red thick joints. CD and NFA patients also reported joint complaints.
x x x
Sleeping problems Sleeping problems were reported, for example, difficulty with falling asleep 
due to persisting thoughts (CD)Q1, or difficulty staying asleep due to sleeping 
in blocks of 2 to 3 hours (NFA). The perception of interrupted sleep was not 
always negative, since some patients liked easy waking in the morningQ2. A 
long lag time after awakening was also reported (ACRO)Q3.
x x x It takes time before I can get to sleep because I have to organize my thoughts 
first; thoughts about what is yet to happen and what I have to do.
Q1
On the one hand I think it is quite nice. I used to be able to sleep and wake up 
only when the alarm rang. Now I don’t have the feeling that I’m lying down.
Q2
If I am awakened in the morning because something has to happen, then my 
whole system becomes disrupted; I might as well forget the rest of the day.
Q3
Changes in Physical 
appearances
Changes in physical appearance were reported, with main feature weight gain. 
The ACRO-group experienced coarsening of appearance, with features as a 
bigger mouth, nose and cheeks, large spaces between teeth, big hands and 
feet being perceived as very negativeQ4.
x x x My appearance has changed, and it has not had a positive effect on me. I 
don’t like the fact that my face has changed.
Q4








Concentration and attention problems and problems with mental focusing 
were reported by all groups. Concentrating was reported to be energy 
consuming.
x x x x
Short-term memory 
problems
Short-term memory problems were reported with word-finding problems and 





Executive dysfunction was reported, such as decreased ability to formulate 
sentences, problems with multitasking, lowered processing speed and 
decreased ability to orientateQ5. Problems in keeping up with the speed of 
conversations were mentioned (ACRO)Q6.
x x x When I was in an unfamiliar city, I walked through a shopping mall and I 
went in and out of shops, I couldn’t really remember from which part I came 
or how I should walk back. After the operation, things go better, but it is still 
different to the situation before the operation.
Q5
When I am in a conversation, I want to keep up with the conversation, but I 
notice I just cannot.
Q6
Over-stimulation A feeling of overstimulation was experienced and they mentioned difficulty to 
deal with large crowds.
x
Sexuality Physical sexual 
dysfunction
Physical sexual dysfunction such as erectile dysfunction was reported (PRL). 
Some male and female patients of the ACRO-group reported inability to get an 
orgasm. Patients reported menstruation problems (i.e. chronic menstruation), 
which interfered with sexual activity (NFA). (New) relationships were perceived 
to be affected by physical sexual dysfunction.
x x x
Bold: QoL which has not earlier been studied and which is not included in a disease-specific QoL questionnaire. 
Grey: category which is earlier used in other disease-specific questionnaires for pituitary diseases.
* Category was mentioned biologically, as well as psychologically.
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caTeGory subcaTeGory reported by Quotes nr
Illustration of complaint CD ACRO PRL NFA
Physical 
complaints
Fatigue* Fatigue was the profound physical complaint. Lowered muscle strength and 
impaired physical condition were also reported. The nature of fatigue differed 
between the four pituitary diseases: either strange intense fatigue which took 
them by surprise and could disappear in just half an hour (PRL), severe fatigue 
requiring a two hour nap in the afternoon (CD) or extreme chronic tiredness  
with a “shaking” body (ACRO).
x x x x
Physical pain Physical pain was especially reported by the ACRO-group, which included 
headaches, a tickling and inflamed sensation of the whole body, arthralgias 
with red thick joints. CD and NFA patients also reported joint complaints.
x x x
Sleeping problems Sleeping problems were reported, for example, difficulty with falling asleep 
due to persisting thoughts (CD)Q1, or difficulty staying asleep due to sleeping 
in blocks of 2 to 3 hours (NFA). The perception of interrupted sleep was not 
always negative, since some patients liked easy waking in the morningQ2. A 
long lag time after awakening was also reported (ACRO)Q3.
x x x It takes time before I can get to sleep because I have to organize my thoughts 
first; thoughts about what is yet to happen and what I have to do.
Q1
On the one hand I think it is quite nice. I used to be able to sleep and wake up 
only when the alarm rang. Now I don’t have the feeling that I’m lying down.
Q2
If I am awakened in the morning because something has to happen, then my 
whole system becomes disrupted; I might as well forget the rest of the day.
Q3
Changes in Physical 
appearances
Changes in physical appearance were reported, with main feature weight gain. 
The ACRO-group experienced coarsening of appearance, with features as a 
bigger mouth, nose and cheeks, large spaces between teeth, big hands and 
feet being perceived as very negativeQ4.
x x x My appearance has changed, and it has not had a positive effect on me. I 
don’t like the fact that my face has changed.
Q4








Concentration and attention problems and problems with mental focusing 
were reported by all groups. Concentrating was reported to be energy 
consuming.
x x x x
Short-term memory 
problems
Short-term memory problems were reported with word-finding problems and 





Executive dysfunction was reported, such as decreased ability to formulate 
sentences, problems with multitasking, lowered processing speed and 
decreased ability to orientateQ5. Problems in keeping up with the speed of 
conversations were mentioned (ACRO)Q6.
x x x When I was in an unfamiliar city, I walked through a shopping mall and I 
went in and out of shops, I couldn’t really remember from which part I came 
or how I should walk back. After the operation, things go better, but it is still 
different to the situation before the operation.
Q5
When I am in a conversation, I want to keep up with the conversation, but I 
notice I just cannot.
Q6
Over-stimulation A feeling of overstimulation was experienced and they mentioned difficulty to 
deal with large crowds.
x
Sexuality Physical sexual 
dysfunction
Physical sexual dysfunction such as erectile dysfunction was reported (PRL). 
Some male and female patients of the ACRO-group reported inability to get an 
orgasm. Patients reported menstruation problems (i.e. chronic menstruation), 
which interfered with sexual activity (NFA). (New) relationships were perceived 
to be affected by physical sexual dysfunction.
x x x
Bold: QoL which has not earlier been studied and which is not included in a disease-specific QoL questionnaire. 
Grey: category which is earlier used in other disease-specific questionnaires for pituitary diseases.
* Category was mentioned biologically, as well as psychologically.
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caTeGory subcaTeGory reported by Quotes nr





Current depressive symptoms were discussed. x x
Melancholy Melancholy was reported, which was perceived to be caused by 
physical complaints.
x x x
Mood swings Mood swings were discussedQ7. x x Within a short period of time your feelings fluctuate. Q7
Worries Some groups reported worries in relation to physical complaints and 
the possible progression of these complaints in the futureQ8.
x x I sometimes feel like an elderly-person, how will it be in ten years time? I 
worry about that.
Q8
Stress Patients perceived more stressful events than before the diagnosis, 
but also a higher sensitivity to stress, most pronounced in the CD- and 
ACRO-group.
x x x x
Fatigue* Both physical and mental fatigue are reported. x x
Anxiety Patients reported (some) anxiety and panic attacks, associated with 
unexpected situations (CD)Q9, or in relation to orientation problems 
(ACRO)Q10.
x x
fear of collapsing x x x
fear of recurrence x x x x
Panic x x When friends invite me to go to the city, I already panic and I think “O no” 
then I have to do this and that the next day.
Q9
I panic terribly, when I am in the city or wherever I am. When I come out of 
a store I don’t know whether I left the shop on my right or on my left. For 
instance when I am in a big shopping mall, I will stay at the same point when 
my friend goes to look at something.
Q10
Persisting thoughts x If I forgot to buy butter, then I have to immediately return to the stores to buy 
it, even though there’s no need for it, because otherwise I would not be able 
to sleep a wink.  
Q11
Sexuality Decreased libido Decreased libido was discussedQ12, although the cause was not 
unanimously attributed to the disease, but also to aging, a negative 
self-image, shame, physical pain and as a side effect of medication. 
The awareness of a decreased libido resulted in the fact that sexual 
intimacy was not initiated by the patient and therefore gave tension 
between partnersQ13.
x x x x I don’t have the need to have sex. Q12
My libido is decreased; at a certain moment you come to a point that you 
doubt your relationship.
Q13
Issues with a desire to have children and family planning x x




Furthermore, changes in emotional functioning were reported, for 
instance being more sensitive to emotions (CD )Q15, having extreme 
emotions (PRL)Q16,  or a flattened affect with less fantasy (e.g. 
daydreaming, fantasizing) (ACRO )Q17.
x x x I get very emotional very quickly. Someone saying “boo” to me is sufficient to 
make me cry. It can also be of happiness.
Q15
When I was angry, I became furious. When I had to laugh, I laughed 
hysterically. 
In a way the emotional part is also beautiful.
Q16
Fantasizing about future plans or about nice things is decreased. Q17





A lowered self-esteem was reported, either initiated by the disease 
or already present before the diagnosis. The current experienced 
insecurity was mainly caused by functional limitationsQ18.
x x x It is your awareness of your limitations that thwart you and makes you act 
insecure.
Q18
Problems with a changed personality x x x x I am having difficulty with the fact that I have changed mentally and 
psychologically.
Q14
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x x x It is your awareness of your limitations that thwart you and makes you act 
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Negative feelings Tension* Both physical and psychological tensionQ19, Q20 x The whole day I am tensed. Q20
Loneliness Loneliness was reported in connection with fatigue or depressive 
symptoms.
x x
Guilt Guilt was reported and this was especially felt in their partner 
relationship, since patients sometimes felt they were less able  to pay 
attention to their partner or because of the decreased sexual libido.
x x
Shame Patients reported shame because of physical sexual dysfunction, but 
also because of being ashamed of their body during sexual activity.
x x
anger x x At first, I was really angry at my body. A failure in my body has let me down. Q21
jealousy x I envy friends who look feminine and I envy friends when they get children. Q22
sadness x x I have gone through a lot of sorrow in the last couple of years. All this 
because I discovered that I wasn’t myself anymore and I couldn’t do things 
that I could do.
Q23
frustration x x x
Bold: QoL which has not earlier been studied and which is not included in a disease-specific QoL questionnaire. 
Grey: category which is earlier used in other disease-specific questionnaires for pituitary diseases.
* Category was mentioned biologically, as well as psychologically.
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caTeGory subcaTeGory reported by Quotes nr
Illustration of complaint cd acro Prl nfa
Work related 
problems




Social problems Issues in social 
functioning
Patients reported issues in social functioning. They felt insecure and 
nervous in social situationsQ24. Moreover, they experienced some 
difficulties with social contactsQ25.
x x I get tensed when I have to go to a birthday party. If I go then I have to 
socialise and do fun things – that is something that I find difficult. It is 
actually too much for me to cope.
If I see 6 people waiting to pay near the cashier, I will not even enter the shop. 
I would rather go another time than wait impatiently in the line.
Q24
I have difficulty with social contacts.  If the friendship does not work out, I 





The whole process of diagnosis frequently had a negative influence 
on the partner relationship and some marriages had fallen apart 
during the time of diagnosisQ28. Also after treatment, relationships 
were negatively influenced by changed personalities and decreased 
sexual activity and libido. In addition, patients also reported negative 
influences on their family.
x x x He made the best of a bad bargain, Perhaps none of this would have 
happened if part of the care plan included teaching the partners of patients 
the effects the disease can have on someone’s psychology. As a result, my 




x x I had a large network of friends and relatives, but in the meantime I lost 98% 
of those people.
Q29
I have lost no one with whom I have discussed my disease as they have 





x x x x Sometimes I walk a bit strange because of problems in my cartilage. Then 
I tell people that it will disappear sooner or later and that it was a result of 
doing too much sport. 
Q26
lack of sympathy 
of environment
x x x My employer has all the brochures, but he puts them on a pile. He would 
prefer it if I quit the job and that I be replaced by someone who is healthier 
and who is able to earn money for him.
Q27
Bold: QoL which has not earlier been studied and which is not included in a disease-specific QoL questionnaire. 
Grey: category which is earlier used in other disease-specific questionnaires for pituitary diseases. * Category was 
mentioned biologically, as well as psychologically.
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caTeGory subcaTeGory reported by Quotes nr
Illustration of complaint CD ACRO PRL NFA
Negative illness 
perceptions
Consequences Patients  reported a severe  impact of the disease on their lives and 
told that they had underestimated the consequencesQ31. They pointed 
out that  factors such as age at diagnosis or duration of active disease 
prior to diagnosis may have influence the  experienced impact. 
Some considered the influence of the disease on their life, personal 
development and life choicesQ32.
x x x It has had quite an impact, you have a house, a good job, and all of a sudden 
you are ill. Meanwhile you have lost your complete life. It controls your life 
completely, your whole day.
Q31
I was thinking, suppose if I didn’t suffer from the disease – would my life 
have been different? Would it have been better or would I have made other 
choices? How has my personality developed as a result of my disease and 
medication?
Q32
Timeline Perceptions of a chronic timeline were noticeable in the awareness of 
the irreversible damage to their body (ACRO)Q33. Furthermore, patients 
reported the experience of physical complaints, such as physical 
weakness (PRL), physical pain, and joint complaints arriving by fits and 
starts (ACRO) (cyclical timeline).
x x The damage is long lasting. The symptoms in your joint, your mental 
limitations and other signs which are part of the disease remain with you 
lifelong.
Q33
Cause Sometimes there was confusion about the cause of the pituitary 
adenoma, for example explanations were a fall, medication or 
congenitalQ34. Furthermore, patients were wondering when the 
disease actually startedQ35.
x x I find it difficult to decide for myself what the cause is. Has the disease 
progressed slowly or was it always present? 
Q34
Did I have it already during my puberty? Then I can understand why I was 
depressive then. 
Q35
Cure/control It was thought that stress played a major role in the origination of the 
adenoma and/or in the recurrence of the adenomaQ36.
x I always have this feeling that stress plays a role in my life. I fear that 
something might grow.
Q36
Identity Some patients wondered whether certain complaints, such as 
complaints of fatigue or influenza were caused by their pituitary 
disease, or that they experienced common complaints. Some refused 
to attribute certain complaints to their pituitary diseaseQ37. Others said 
that in a way, the complaints suited themQ38.
x x x x I think it is a kind of excuse, I have to handle it myself. The diagnosis of 
‘Cushing’s Disease’ is insignificant.
Q37
All complaints have a cause, actually it suits me the way it is. Q38
Negative beliefs 
about medicines
concerns x x x The lower the mess, the better Q39
Less efficient coping 
strategies
Withdraw Some patients preferred to withdraw and to be alone sometimesQ40. x I retreat every now and then to recover; I think it is a painful situation. Q40


















x x x x I can discuss about my medication and basically everything with my doctor, 




aspects of medical 
care
x x x The ideal training should teach one how you can keep stress under control. Q44
What are the do’s and don’ts to keep the disease under control? Q45
A psychologist can support those with acromegaly. He/she could prepare us 
in advance for what to expect 
Q46
My husband could not go through it alone. He really needed help. Q47
Bold: category which has not been studied before in patients with pituitary diseases. Grey: category which has 
been examined earlier (by the studies of Tiemensma et al. (10;47)).
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panic attacks, associated with unexpected situations (CD)Q9, or in relation to orientation 
problems (ACRO)Q10. Less established complaints were for instance that patients reported to 
be unable to let go persisting thoughts about pointless issues (CD)Q11 and the perception of 
mental absence, foremost during the ‘active’ disease period (ACRO).
Personality issues were problems with changes in emotional functioning, lowered self-
esteem, irritation and problems with a changed personality. Patients (all groups) reported 
a personality change to some degreeQ14, for example they experienced to be less approach-
able, more tolerant and more peaceful to other people, or more conscious of their feelings. 
Negative feelings were tension, loneliness, guilt, shame, anger, jealousy, sadness and frustra-
tion. Patients reported to be more sensitive to anger (CD, NFA). Furthermore, they felt anger 
towards their own bodyQ21. Jealousy was noticed, i.e. due to the inability to do what  healthy 
friends can do (ACRO)Q22. Sadness was associated with fatigue or emerged because someone 
was not feeling his usual self (CD)Q23 and they reported to cry more easily. All groups (except 
NFA) felt frustration facing the persisting physical and cognitive complaints, especially when 
their medical doctors or the social environment turned a deaf ear to their complaints. 
Social problems were issues in social functioning, negative influence on the partner relation-
ship, difficulties communication about their disease, a lack of sympathy of environment 
and a reduced social network. All groups reported difficulty communicating about their 
disease, for instance because they did not want to frighten somebody or being looked at 
with pity. Patients used little tricks to avoid talking about their diseaseQ26. Frequently, patients 
only told the direct environment about their disease. Patients informed their present em-
ployer about their disease, but patients hesitated to tell a new employer, because they were 
afraid to be rejected for a new job. Unfortunately, patients in all groups (except PRL) often 
encountered a lack of sympathy, for instance by acquaintances, colleagues and employersQ27.
However, this lack of sympathy was most of the time resulting from ignorance about the 
disease. Patients experienced that their social network declined (CD, ACRO)Q29. However, in 
some cases discussing the disease within their social network prevented the loss of friendsQ30. 
Work related problems were experienced in all groups. Patients experienced changes in their 
work situation due to their disease. Some lost their jobs or were (partly) rejected as medically 
unfit. Reasons for these changes were diminished ability to function, to concentrate and to 
cooperate. Most patients currently work part-time.
Limitations in leisure activities were perceived in their ability to perform sports, due to their 
physical limitations (all except PRL). In addition, they experienced limitations in social activi-
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ties, such as going to parties and on trips. They reported that these activities were energy 
consuming and that they had to take into account the extended resting time afterwards.  
Negative illness perceptions were reported. Illness perceptions are defined as: “the beliefs 
that a patient holds about his/her health problems”, influence how patients respond to their 
illness. They are conceptualized in the Common Sense Model of self-regulation (CSM) of 
Leventhal et al. (1980). Illness perceptions in patients with pituitary diseases are previously 
evaluated by Tiemensma et al. (10;47). In general, patients cluster beliefs about their illness 
around five cognitive components: consequences, timeline, cause, control/cure and identity 
(48). All components were spontaneously mentioned during the focus group discussions. 
Negative beliefs about medicines were reported. Beliefs about medicines can be grouped 
into two major categories, beliefs about the necessity of prescribed medication and concerns 
about the potential aversive/side effects (49). In these discussions, concerns about medica-
tions were most dominant. Patients reported negative experiences with medication (e.g. 
negative effect on mood) and they reported beliefs about the use of medication changing 
their personality (PRL). Patients in the ACRO-group experienced the use of injections as awful. 
Some patients reported that they disliked the use of hydrocortisone, and therefore preferred 
to take a low doseQ39.
Less effective coping strategies used by patients were withdraw, overdoing activities and 
problems with acceptance. Some patients felt it was difficult to let go feelings of frustration 
and reported the need for alcohol intake to relax (ACRO, NFA). All groups reported that they 
overdo their activitiesQ41. Some patients reported problems with acceptance of the disease 
and its consequences (ACRO, CD)Q42. 
Unmet needs regarding care were insufficient information, better cooperation and com-
munication between medical specialties, absence of recognition for certain complaints 
and dissatisfaction with other aspects of medical care. The most prominent unmet need 
regarding care was insufficient information about the disease at diagnosis and during ac-
tive disease (all groups). For instance, information about the adverse effects of medication 
(effect on personality), physical complaints, psychological complaints, cognitive complaints, 
sexuality and the ability to have children. They would have liked to be better prepared with 
regard to the impact of the disease and the overall short- and long-term consequences of be-
ing a patient with a pituitary disease. Furthermore, patients agreed that medical specialties 
should better cooperate and communicate together and that other medical specialists than 




All groups experienced absence of recognition for certain complaints by medical profes-
sionals, i.e. lack of response to complaints of sexuality, fatigue, and other physical complaints. 
Psychological, social and personal issues were hard to discussQ43.
To some degree patients were also dissatisfied with other aspects of medical care (CD, 
ACRO, PRL), since they reported a need for stress-managementQ44 and lifestyle recommenda-
tionsQ45. In addition, there was a need for special care of physiotherapists, dietitans, medical 
sports experts and psychologistsQ46. Support was not only needed for patients, but also for 
their partners according to patientsQ47.
dIscussIon
In this focus group study in patients treated for pituitary diseases, we explored QoL as 
perceived and discussed in representative patient groups. This study puts forward new QoL 
aspects from the patient’s perspective, which are not included in the currently available 
disease-specific questionnaires, and identified factors which may contribute to decreased 
QoL. The primary aim was to explore disease-specific QoL as reported by patients treated 
for pituitary diseases. Earlier qualitative studies used semi-structured interviews about pre-
selected topics to develop disease-specific QoL questionnaires (i.e. CushingQoL, Tuebingen 
CD-25, AcroQoL, QoL-AGHDA) (13-19). These topics can be categorized according to the 
biopsychosocial approach of QoL: (1) physical problems, (2) psychological problems, (3) social 
problems. Although the majority of these dimensions also emerged during the focus group 
discussions, new QoL aspects were also identified. 
Newly raised physical issues were the presence of visual limitations, which is indeed a 
common symptom in patients treated for pituitary adenomas (1), but which is not included 
in available disease-specific QoL questionnaires. Uncovered psychological problems were 
issues with a desire to have children and family planning. At present, this issue is not in-
corporated in existing disease-specific QoL questionnaires, although many patients are of 
reproductive age. Furthermore, patients reported that they were unable to let go persisting 
thoughts, and had feelings of panic and fear. The reported fear of recurrence of the adenoma, 
is also frequently seen in cancer survivors (50) and is usually associated with increased use 
of health care services (e.g. a greater number of outpatient visits and emergency room visits) 
(51). Interestingly, this fear may be neglected by the physician, since they consider adenomas 
to be benign. Other uncovered psychological problems were the feeling that their personality 
was changed and feelings of anger, jealousy, sadness and frustration. Additionally revealed 
social problems were issues with communicating about the disease, facing a lack of empathy 
of others and a reduced social network. These physical, psychological and social issues were 
not included in earlier disease-specific QoL questionnaires. In conclusion, disease-specific 
QoL as formulated in available disease-specific QoL questionnaires for pituitary diseases 
could be further elaborated by incorporating the patient’s perspective. 
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The second aim of our study was to identify factors that may contribute to a decreased 
QoL. Recent papers discussed the presence of negative illness perceptions and ineffective 
coping strategies (10;47;52). The present study revealed examples of negative illness per-
ceptions and less effective coping strategies, but also negative beliefs about medicines and 
unmet needs regarding care. We believe that further exploration of the significance of these 
uncovered factors is relevant for the care of patients with pituitary adenomas, since these 
factors may affect QoL (10;36;47). 
Concerns about medication and unmet needs regarding care were not previously 
described in patients treated for pituitary adenomas. In a study by Horne and Weinman it 
was found that concerns about adverse effects of medication were significantly associated 
with non-adherence to medication in patients with asthma (53). Considering the large part 
of patients with pituitary diseases that is treated with substitution therapy and medication, 
our findings suggest that physicians should be aware of, and adequately cope with these 
concerns. Furthermore, medical experts and other healthcare providers could play a role in 
meeting patient needs by being aware of the reported unmet needs. This awareness could 
improve the communication and care for patients treated for pituitary diseases. In addition, 
the patient’s perspective of QoL explored in this study can be helpful for medical experts 
in their communication with patients, since it describes experiences, rather than numbers 
provided by QoL questionnaires. Patients reported an explicit need regarding care, such 
as stress-management, psychological care, and physiotherapy and nutrition and sports 
recommendations. Experts in these fields could play a major role in meeting this need, 
for instance by offering self-management interventions (SMI) including these aspects. It is 
found that SMI’s positively affect well-being of patients suffering from chronic conditions 
(e.g. asthma, diabetes, arthritis, Parkinson’s disease) (43;54;55). Obviously, objectives of SMI’s 
differ between various diseases. For instance, SMI’s for asthma aim to monitor symptoms and 
to improve adherence to medication, and SMI’s for diabetes tend to focus on lifestyle issues. 
These differences in focus result in a range of different contents and methodologies in SMI’s 
(56). The information provided in this study could be used for the adjustment of a SMI for 
patients treated for pituitary diseases. 
There are some limitations to this study, all largely due to general limitations of focus 
group methodology. For instance, a dominant participant with his/her own agenda could 
have influenced the groups discussions. Nevertheless, the moderator aimed to prevent 
this by giving each patient equal space to speak. Although we aimed at a representative 
group composition able to reflect a broad range of experiences, a selection bias is inevitable. 
Moreover, with four different focus groups we considered the number of included patients 
adequate for conclusions for pituitary diseases in general. There was a considerable overlap 
in reported issues between the groups, but we also identified differences between the vari-
ous pituitary adenomas. However, since there was only a single group per specific disease, 
we were unable to draw firm conclusions about Cushing’s disease, Non-functioning pituitary 
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macroadenoma, acromegaly, and prolactinoma specific issues. Future quantitative research 
in a larger group of patients is needed to further evaluate the differences between groups 
and to determine the importance of each aspect to QoL. This could also give more insight in 
the potential influence of clinical characteristics, such as the influence of pituitary deficiency, 
disease severity and duration of follow-up.
In conclusion, this focus group study showed disease-specific QoL as formulated and 
perceived by patients treated for pituitary diseases. Furthermore, it uncovered potential 
contributing factors. The information provided in this study can be used for developing 
additional items for disease-specific QoL questionnaires and for the development of a SMI 
aiming to improve QoL in patients treated for pituitary diseases. 
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Final questions (specifying unmet needs):
1. Given all of this, what would you prefer to have known / to have had after receiving the 
diagnosis?
2. What is your advice for someone who just received the diagnosis?
Chapter 12
The partner perspective of the impact of 
pituitary disease: looking beyond the patient
Cornelie D. Andela, Jitske Tiemensma, Margreet Scharloo, Adrian A. Kaptein, Alberto M. 
Pereira, Noëlle GA Kamminga, and Nienke R. Biermasz




People with pituitary disease report impairments in quality of life. The aim of this study was 
to elucidate the impact of the pituitary condition on the lives of partners. Four focus groups 
of partners of people with pituitary disease (Cushing’s disease, non-functioning adenoma, 
acromegaly, prolactinoma) were conducted. Partners mentioned worries related to the pitu-
itary disease and negative beliefs about medication, coping challenges, relationship issues, 
social issues, and unmet needs regarding care. This study emphasizes the importance of not 
only paying attention to psychosocial well-being of people with pituitary disease, but also to 
their partners. 




Pituitary adenomas can be considered a rare disease with an estimated prevalence of 78 to 
94 cases per 100,000 individuals, and an incidence of four cases per 100,000 individuals (1). 
These benign tumours on the pituitary gland can result in classical medical conditions, such as 
Cushing’s disease (CD), acromegaly (ACRO), prolactinoma (PRL) or clinically non-functioning 
pituitary adenoma (NFA). These conditions can be categorized by etiology. For instance, CD is 
referred to an overproduction of cortisol and is related to hypertension, changes in physical 
appearance and proximal muscle weakness. ACRO is characterized by an overproduction of 
growth hormone, and is related to physical disfigurement, mainly involving the face, hands 
and feet. PRL is featured by an overproduction of prolactin resulting in milk production by 
the breast and reduced libido in both men and women, and menstrual problems in women. 
Although people with NFA are not exposed to hormone excess, they may suffer from the mass 
effects of the adenoma resulting in symptoms such as visual field defects and headaches. 
Pituitary adenomas can be treated by surgery, and sometimes additional medical treatment 
or radiotherapy when needed. As a consequence of the mass effect of the adenoma and/or 
the treatment, the pituitary can be damaged resulting in hormone insufficiency. When this is 
the case, people receive life-long replacement therapy (2). People with a pituitary adenoma 
report impairments in physical functioning, as well as in psychosocial functioning, which usu-
ally improve after biomedical treatment, but which do not appear to normalize (3). During 
the chronic state of their disease people still report impairments in quality of life (QoL) (4-7). 
Considering these persistent impairments and the life-long medical (replacement) therapy, 
pituitary disease can be considered a chronic condition. In a recent qualitative focus group 
study these QoL impairments have been further elucidated in people with CD, ACRO, NFA, 
and PRL (8). They reported psychological complaints, problems with personality changes, 
issues regarding sexuality, and a negative impact on the relationship with their partner.
Weitzner and Knutzen (1998) reviewed literature on caregiving in dementia and cancer, 
and although the characteristics of these diseases are considerably different compared to 
pituitary disease, they suggested that there might be some issues that are also applicable 
to caregiving and family issues in pituitary disease. For instance, the authors reported that 
a major primary stressor in caregiving for people with dementia is the patients’ disruptive 
behavioural problems (e.g. personality changes, agitation), and suggested that this stressor 
has general applicability to caregiving for people with pituitary disease. Furthermore, the 
authors describe that when caregiving continues over a longer time period, changes in social 
support become more persistent and are less likely to return to the premorbid situation 
(9). To the best of our knowledge, there is one qualitative study in partners of people with 
pituitary disease, which partially confirmed the postulations of Weitzner and Knutzen. This 
qualitative study by Dunning and Alford (2009) explored experiences of partners of people 
with pituitary disease using a focus group and interviews (n=12 partners). It was reported 
that the partner sometimes became annoyed by the tiredness and mood swings of the ill 
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partner, because there was no obvious cause. Some partners felt they had to take on extra 
responsibilities at home and managing the children. They were aware of the burden on their 
family, but they felt unable to cope emotionally or physically. However, in some cases the 
quality of the relationship was enhanced (10).
From quantitative QoL studies in partners of people with other chronic diseases it is known 
that partner QoL is negatively affected (11-14). From previous research it is also known that 
the role of the partner also strongly influences QoL of people with chronic disease. For in-
stance, unsupportive behaviour of partners was associated with more distress in women with 
early stage breast cancer (15). On the other hand, solicitous behaviour of partners of people 
with chronic fatigue syndrome negatively affected improvement in fatigue and disability 
during cognitive behavioural therapy (16).
People with a chronic disease, as well as their partners, develop representations of the 
disease i.e. illness perceptions. These illness perceptions can be categorized around five com-
mon themes: identity, cause, timeline, consequences, and cure/control (17). Illness percep-
tions have been shown to exert a substantial influence on coping and QoL (18). In addition, 
addressing maladaptive illness perceptions has been shown to result in improvements in 
outcome measures (19;20). It is possible that illness perceptions of persons with a chronic 
disease differ from the ideas of their partners. For instance, partners of people with primary 
adrenal insufficiency, i.e. Addison’s disease (AD), were more pessimistic about the timeline 
of the disease than the ill persons themselves. Partners were also more negative about the 
curability/controllability and the consequences of the disease. Moreover, dissimilarity in ill-
ness perceptions between persons with AD and their partners was associated with adaptive 
outcomes of the ill person (21). Illness perceptions were also different between people with 
Huntington’s disease and their partners, with partners’ beliefs about a longer duration of the 
disease and less belief in cure being associated with higher vitality rating of the ill persons 
(22), suggesting that partners who are realistic (even if negative) about the possibilities for 
cure and the long-lasting timeline of the disease might be beneficial.
In view of the persistent QoL impairments in people with pituitary disease (e.g. psycho-
logical complaints, personality changes, issues regarding sexuality), and the small number 
of studies in partners of people with pituitary disease, the aim of the present study was to 
explore the impact of the pituitary condition on the lives of partners. In the present study 
we used focus group interviews, which incorporate group interaction as part of the method. 
Focus groups are particularly useful in exploring people’s experiences and knowledge, since 
it does not only assess what people think, but also the reasons why they think that way, 
and how they think (23). Focus groups are commonly used in illness related topics, such as 
QoL and healthcare needs in people with chronic disease (24;25), and disease and treatment 
experiences in caregivers of ill people (26;27). We hypothesized that in accordance with 
previous literature, partners of people with pituitary disease would also report a negative 
impact of the medical condition on their lives, including issues that are similar to partners of 
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people with chronic disease in general, but potentially also disease-specific issues that are 
more relevant for partners of people with pituitary disease.  
MeTHods
Participants
Partners who were willing to discuss the influence of the pituitary condition on their lives 
were recruited via their ill partners from the outpatient clinic of the department of Endocri-
nology, Leiden University Medical Center, the Netherlands. Seven (35%) of the participants 
were partners of people with pituitary disease included in a previous focus group study (8). 
Participant selection was aimed to result in a sample that would be representative of the 
partner population (e.g. regarding age, gender, education, and duration since diagnosis). 
Four focus groups were formed per disease (CD, ACRO, NFA, PRL). Recommendations for 
focus group sizes vary considerable, but it has been stated that groups with three to eight 
participants work best for generating rich discussions (28). Therefore the present focus 
groups consisted of four to six partners (i.e. CD:P1-P5, ACRO: P1-P5, NFA:P1-P6, PRL:P1-P4).
All participants gave written informed consent. The Medical Ethical Committee of the 
LUMC approved the research protocol. 
study design
The focus group conversations were chaired by a health psychologist (moderator), experi-
enced in group discussion (NGAK). The investigator (CDA, psychologist/researcher) observed 
the focus group meetings, but did not participate in the discussions. Each of the four groups 
met twice for a discussion of ±2 hours. The focus group conversations took place in Septem-
ber 2012 and were held in a meeting room at the LUMC. The first meeting had the primary 
aim to get acquainted and to ensure a safe and confidential setting. Participants introduced 
themselves and then the discussion continued with open-ended questions suggested by the 
moderator. Based on the issues raised during the first meeting, a topic list was formulated for 
the second meeting (Supplement 1). 
data analysis
Data was analysed using an experiential thematic analysis following the six steps proposed 
by Braun and Clarke (2013). First, the audio-typed focus group conversations were typed out 
verbatim.  Second, the transcripts were read and reread by the first and second author (JT 
psychologist/senior researcher, CDA psychologist/researcher) in order to get familiar with 
the data, and potential items of interest were noted. Third, initial codes were produced from 
the data and the entire dataset was coded. Discrepancies between coding were discussed, 
and resolved by consensus (i.e. JT, CDA). Atlas.ti 6.2 software was used for managing and ana-
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lysing the data. Fourth, codes were sorted into potential themes. Fifth, preliminary themes 
were reviewed and a thematic map was created considering the formation of themes and 
subthemes. Extensive revision of themes was performed by splitting, merging and renaming 
themes. Finally, (sub)themes were further defined and named. 
resulTs
Twenty partners participated in the focus group discussions (11 females) and were present 
during both focus group meetings. Age ranged from 29 to 69 years (mean 48 years). Duration 
of follow-up ranged from a few months to 27 years (mean 9 years). After a total of eight focus 
groups (4 groups x 2 meeting) in our view, no new issues were discussed and data satura-
tion was reached. From the focus group conversations, five themes were derived: worries 
related to the pituitary disease and negative beliefs about medication, coping challenges, 
relationship issues, social issues, and unmet needs regarding care (Figure 1). The current 
study envisioned to evaluate the present impact of pituitary disease. Interestingly, during the 
focus group conversations partners frequently referred to the stressful and intense moments 
experienced during the period of diagnosis, suggesting that this event still is an important 
issue. However, retrospectively evaluating this period of diagnosis did not match the scope 
of the research and data about this topic were therefore not incorporated.
Worries related to the pituitary disease and treatment
Worries related to the pituitary disease: Partners reported concerns about the current health 
status of the ill partner. For example, worries about something happening to the ill partner 
(e.g. too low cortisol levels resulting in a life threatening situation, which is named an Ad-
Table 1. Demographic variables of participants
Patients’ pituitary disease:
Total (n=20) cd (n=5) acro (n=5) nfa (n=6) Prl (n=4)
Gender (M/F) 9/11 3/2 3/2 2/4 1/3
Age (years) 48 (39-57) 52 (36-56) 46 (43-66) 50 (38-61) 40 (35-48)
Duration of follow-up (years) 8 (3-13) 8 (7-18) 4 (3-22) 5 (2-9) 12 (3-18)
Education
    Low 2 0 1 1 0
    Medium 6 1 3 0 2
    High 12 4 1 5 2
Marital status
    Living together 3 1 0 1 1
    Married 17 4 5 5 3
Data are presented as median (IQR) or number. CD=Cushing’s disease, ACRO=Acromegaly, NFA=Non-Functioning 
pituitary adenoma, PRL= Prolactinoma.
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disonian crisis) when the partner is not around, but also concerns about how the ill partner 
is feeling that day. Partners also brought up concerns about the future, such as whether 
new problems will arise or whether existing problems will worsen. Another aspect was fear 
of recurrence. For example, when new symptoms are being experienced, partners wonder 
whether the new symptoms indicate tumor growth, recurrence of the tumor, or possibly 
something else. Partners also mentioned concerns about the possible heritability of the 
disease “The fear that you pass it on to your children is very scary. We have done some research 
but there is almost no chance, at least in our case. But my son had lots of headaches last year, then 
I’m like okay, well, now what?” (PRL-P2).  
Negative beliefs about medication: Partners reported worries related to medication e.g. 
about the effectiveness of suppressive medication in the future and uncertainty about pos-
sible side-effects: “I am anxious about the medicine use in the future, what if the medication 
doesn’t work anymore at a certain moment, then you have to search for another treatment” 
(ACRO-P4). They reported a strong negative attitude towards the medication, with the most 
negative thoughts mentioned in the PRL group. The partners commented on the negative 
effect of medication on the character of the ill partner (e.g. flattened affect, no highs and lows 
anymore):  “The moment he stops his medication I see my old husband. But that disappears as 
soon as he starts again” (PRL-P2) and “I think to myself: there goes another heap of poison” (PRL-
P1). Medication use was perceived as having a negative effect on sexuality “There is certainly a 
big difference in sexuality between before and after the medication for the illness. That was quite 
difficult, but I knew there was that connection and that medication was the cause. I did not suffer 
from relationship problems or uncertainty, because I had that knowledge” (PRL-P4).
Coping challenges
Uncertainty about accommodating or encouraging the ill partner: Many partners indicated 
difficulty in deciding when to accommodate the complaints experienced by their partner 
(e.g. fatigue) and when to encourage their partner to manage certain complaints by encour-
aging engagement in specific activities. Partners indicated that this difficulty improved over 
the years. “It is difficult to determine when you need to be that shoulder to cry on, when you need 
to pull somebody up, or when to say ‘don’t be silly, get up, and do it’” (CD-P5). 
Making adaptations: Many partners reported adapting their own behaviour to accom-
modate the complaints of their ill partners. For example, taking on specific tasks and provid-
ing extra protection for their partner. “I try to protect her every now and then” (NFA-P2) and 
(another partner) “We now have a young family, so that is very busy, it’s half a pace faster than 
he can handle” (CD-P2). Partners tried to protect the ill partner by not talking about difficul-
ties experienced at work, since this potentially could be distressing for the non-working ill 
partner. Limiting potential topics of discussion led to feelings of inequality in the relation-
ship. Furthermore, partners adjusted certain activities to the situation at hand “My partner 
no longer drives, I always have to. Sometimes I feel like a taxi driver” (ACRO-P1) and “I cannot 
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take her for a walk on the beach, because that won’t work. But I can take her for a walk in the city 
with a pair of crutches” (ACRO-P4). Partners often felt that making such adjustments provided 
necessary support for the ill partner. They felt their ill partner was the weaker one. This is why 
partners were inclined to protect their ill partner: “You are the one taking the blows” (ACRO-P1). 
Partners reported feeling inhibited by the consequences of the disease, and feeling pressured 
to make certain decisions in specific situations. Interestingly, many partners were putting it 
all in perspective “If my partner would be manic depressive, I would not recognize her. With her 
current medical condition, however, I can still recognize my wife, so it is still the same woman. This 
is incredibly helpful for me, because I can see whom I fell in love with” (ACRO-P1).
High sense of responsibility: Partners reported they felt more responsibility in multiple 
contexts, which may result in adaptation of their own behaviour (see previous section). For 
example, partners felt responsible when it came to being well-informed “because if something 
happens, you are the one who needs to act” (NFA-P5). In addition, a (partial) loss of income of 
the ill partner may have resulted in a larger financial responsibility for the healthy partner. 
Furthermore, partners had difficulty determining their own limits. Many felt that they should 
show understanding and empathy, but also that they should maintain their own well-being 
(i.e. being clear about their limits). 
Differences in coping styles: Partners found it difficult when their own coping techniques 
did not match those of the ill partner. For example, the ill partner would rather not talk about 
the disease and deny certain consequences, while the partner may feel the need to talk about 
it (see also next section).
Relationship issues
Changes in the relationship: Relationship difficulties sometimes arose during active disease 
and treatment periods. Partners reported feelings of inequality and the emergence of per-
ceptions of a counselor-patient relationship. The skewed relationship usually returned to a 
balanced one over time. Some partners mentioned that their relationship became stronger 
because they fought together to get through the disease process: “Our relationship has 
become very strong, because we fought the disease together and we came through together” 
(CD-P5). Other partners reported a lasting negative impact on their relationship, for instance 
inequality on some fronts (i.e. there is still somewhat a counselor-patient relationship), or a 
general change in the relationship “I find that it changes your relationships anyway, yeah, the 
positivity is gone” (PRL-P4). 
Communication with partner: Partners reported needing to express sensitivity in com-
municating when the ill partner was suffering from mood swings. Uncertainty about the ill 
partner’s response during mood swings often led to tensions.  Partners reported being able 
to talk about most topics, although issues related to sexuality were harder to discuss. 
Viewing the partner differently: Some partners reported viewing their partner differently. 
For example, partners found their ill partner less attractive due to the changes in their rela-
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tionship (i.e. shifting towards a counselor-patient relationship). However, partners also found 
their ill partner more beautiful, because they were proud of the way their ill partner coped 
with the consequences of the disease. Partners reported having great difficulty with the 
character changes of the ill partner (PRL) “She/he is still my best friend, but she/he changed from 
a very positive person to somebody who is very black-and-white” (PRL-P2), while other partners 
reported a positive character change: “I tell my partner that he/she has changed considerably, 
became sweeter, and even more attractive to me” (NFA-P3).
Issues regarding sexuality: Some partners reported that sex/intimacy with their ill partner 
improved compared to the past, and that it became more valuable. Other partners reported 
that sex/intimacy decreased during active disease, and that it recuperated but did not nor-
malize “Our sex life took quite a hit” (NFA-P3). 
Issues with the desire to have children: Partners reported concerns about the inability to 
conceive, either currently or in the past “You have a certain expectation about your life, and you 
need to adjust that expectation” (PRL-P2). 
Social issues
Difficulties in communicating about the disease: Difficulties in talking about the disease, 
as well as talking about potential consequences were reported. Partners had a hard time 
determining whom to tell about the disease. When partners decided to tell somebody about 
the disease, they found it difficult to explain what was going on “It is like you lost your arm, 
which will never grow back. Other people then understand it cannot be reversed, because that 
is often the question” (ACRO-P1). Some partners reported giving shorter answers over time 
when questions about the disease came up because they faced misunderstanding from 
people around them.
Lack of sympathy from the social network: Partners reported that people in their social 
network asked questions about the disease with the assumption that it would get better. 
Similarly, they felt that symptoms were downplayed by their social network “When a friend 
says: sure, I experience the same symptoms every now and then, I think I am suffering from the 
same disease” (NFA-P2) or “People in your social environment say: it’s not malignant, so it is noth-
ing” (PRL-P4). The social network does not understand why people with pituitary disease and 
their partners cannot participate in certain activities. Some partners reported loneliness due 
to the misunderstanding in their social network. Partners mentioned that the ill partner does 
not look sick, which could be the source of the misunderstanding in their social environment. 
Some partners also indicated that they are tired of being asked about the well-being of their 
ill partner, and that they themselves are rarely asked about their own well-being.
Changes in social network: Partners reported that their social network had shrunk or at 
least had changed in a negative way.
Negative impact on family: Partners were concerned about the impact on their family. For 
example, expression of increased irritability around their children “We currently experience 
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that she/he is very tired and her/his patience runs out quickly. This is also towards the children” 
(NFA-P4). Partners also mentioned that their children were concerned about the ill partner. 
Negative impact on work: Partners reported they sometimes take time off work to accom-
pany the ill partner to the doctor. Some partners even quit their job to keep everything afloat 
at home and to create stability (a somewhat forced choice). 
Unmet needs regarding care
Insufficient information: Partners felt inadequately informed about the disease and its treat-
ment, and felt they did not get clear answers to some questions. Partners would have liked to 
be more involved in the information process “If it is explained to me how it works psychologi-
cally, than I would have a lot less difficulty, less burden, and it would cost less energy. That would 
benefit the relationship when it comes to what you have to offer a partner” (PRL-P4). Further-
more, partners mentioned that doctors should use less jargon when providing information 
to facilitate understanding.  
No recognition for certain complaints: Partners experienced insufficient recognition for 
certain complaints, such as questions pertaining to the psychosocial aspects of the disease, 
questions about practical issues such as contraceptives, and questions about medication 
use abroad. Partners also felt that certain aspects of the treatment were easily dismissed, 
for example life-long medication use “Your pituitary is damaged and it is possible that partial 
removal of the pituitary is necessary. However, this was easily dismissed with statements about 
‘eliminating the effects of partial pituitary removal with medication’, and ‘everything will be 
alright’” (NFA-P3).
Dissatisfaction about aspects of medical care: Partners would like additional guidance 
with psychosocial issues (e.g. medical psychologist, social worker, coach) or for example a 
help line to talk and get things off their chest. Partners in the PRL group mentioned they 
would like to learn the best way to deal with potential psychological symptoms of their ill 
partners. Partners would have liked more guidance during active disease and treatment. For 
example, guidance for children of parents with a pituitary adenoma, but also advice on how 
they can best guide their children. There was also a need for peer support. Partners would like 
to receive help and guidance in how to best support the ill partner. Other partners indicated 
they do not want to be a ‘life coach’ for the ill partner, since this could disrupt the balance in 
their relationship. 
dIscussIon
This explorative focus group study in partners of people with pituitary disease provided an 
overview of the impact of the pituitary disease on their lives. The main issues reported by 
partners were that they were worried about the pituitary disease, had negative beliefs about 
the medication, and that they encountered challenges in coping with the consequences. Fur-
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thermore, partners experienced issues in their relationship and in their social environment. 
Considering aspects of medical care, they felt inadequately informed about the disease and 
its treatment, they experienced insuffi  cient recognition for certain complaints, and they 
would like to have additional guidance (e.g. psychological support). 
Weitzner and Knutzen (1998) speculated about issues for caregivers of people with 
pituitary disease based on observations in caregivers for people with dementia or cancer 
(i.e. stress due to disruptive behavioural problems e.g. personality changes, and changes in 
social support). Both aspects were reported by partners in the present study; however some 
partners considered the personality changes of their ill partner bothersome, while others 
perceived these changes rather positive. Similar to the results of the qualitative study of 
Dunning and Alford (2009) in partners of people with pituitary disease (10), the partners in 
the present study reported the negative eff ects of the mood swings and fatigue of their ill 
partners. They also reported the higher sense of responsibility and negative impact on their 
family life. On the other hand, enhanced relationships were also reported. Furthermore, the 
partners in the study of Dunning and Alford felt excluded from much of the decision-making 
process and reported that they had to rely on the information given by their ill partner. This 
issue somewhat resemble what the partners in the present study reported i.e. they would 
have liked to be more involved in the information process. Furthermore, in a qualitative 
figure 1. The partner perspective of the impact of pituitary disease.
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study in people needing testosterone replacement and their partners it was observed that 
partners reported changes in their relationship i.e. they reported loneliness, less affection, 
and they felt unwanted sexually (29). These observations are in accordance with our finding 
that partners reported that sex/intimacy decreased during active disease.
Partners reported unmet needs regarding care including insufficient information, no 
recognition for certain complaints, and dissatisfaction about aspects of medical care. Health 
care professionals could play a role in fulfilling these unmet needs by first and foremost be-
ing aware of these unmet needs. This awareness could facilitate the communication with 
patients and partners, and encouraging the provision of patient (and partner)-centered 
care. Furthermore, partners explicitly reported a need for additional guidance regarding 
psychosocial issues, such as support from a health psychologist, social worker, or coach. 
Therefore, experts working in this field should be incorporated in the multidisciplinary team 
of healthcare professionals taking care of patients with pituitary disease. In addition, a self-
management programme for patients and their partners could support them to cope with 
the disease and its consequences together.  
It should be noted that some of the issues reported by partners of people with pituitary 
disease are also observed in partners of people with other chronic diseases. For instance, 
in a recent focus group study in partners of people with prostate cancer, partners reported 
a need to be involved in the treatment process, reported issues in how to support one’s 
husband (who is experiencing a loss of masculinity), problems regarding incongruent coping 
responses between partners, and constrained communication between partners (30). Fur-
thermore, mainly of the enlisted issues for partners of people with chronic disease in general 
in the review of Rees et al. (2001) were also reported by the partners of the present study 
e.g. fear of the future, deterioration in the partner relationship and sex life, concern about 
suffering of the ill partner, and social disruption (31). 
Although the majority of the reported aspects may also be observed in partners of people 
with chronic disease in general, it is tempting to speculate that some of these issues are 
more pronounced in partners of people with pituitary disease. For instance: the negative 
beliefs about medication, since the majority of the patients need life-long (daily) replace-
ment therapy and/or suppressant medication. Issues regarding sexuality and the desire to 
have children can also be more pronounced considering the important role of the endocrine 
system in fertility and sexuality. Finally, we postulate that the reported lack of sympathy of 
the environment is more pronounced in partners of people with pituitary disease than in 
other chronic diseases, considering the fact that a pituitary adenoma is a rare disease and 
relatively unknown in society.
The limitation of research reflexivity could potentially be found in the previous research 
by our research group into the psychosocial impact of pituitary disease (3;8;32-35). Although 
we strongly attempted to approach the partners’ stories unprejudiced, it might be that our 
preconceived views of psychosocial issues in patients with pituitary disease have influenced 
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the research process. Furthermore, we aimed to have a representative group composition 
able to reflect a broad range of experiences, however selection bias may be inevitable. Future 
quantitative research is needed to examine well-being of partners of people with pituitary 
disease. This would provide the opportunity to examine how well-being of partners of people 
with pituitary disease relates to well-being of partners of people with other chronic diseases 
(11;13;14), as well as whether illness perceptions of people with pituitary disease are similar 
to the perceptions of their partners.
In summary, this explorative focus group study in partners of people with pituitary disease 
illustrates the negative impact of pituitary diseases on the lives of partners. This study em-
phasizes the importance of not only paying attention to the psychosocial impact of people 
with pituitary disease during medical consultation, but also to their partners. Furthermore, 
information obtained in this study can be used for the development of a disease-specific 
questionnaire for partners of people with pituitary disease, in order to quantitatively assess 
their well-being, as well as for optimizing psychosocial care not only for people with pituitary 
disease, but also for their partners.
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·  Aim of the focus group conversation is to explore  experiences of living with a person with a pituitary disease and 
the impact on their lives
·  All conversations are confidential
·  Conversations will be audiotaped and typed-out verbatim
·  Please avoid talking over each other
·  Avoid non-verbal communication (i.e., nodding), since this cannot be audiotaped
·  Ask everyone to introduce themselves and say briefly something about work, family composition, hobbies, when 
was  your partner diagnosed with the pituitary condition
Starting question:
·  What do you encounter in daily life related to the pituitary condition of your partner?
The discussion will be continued by using open-questions sometimes followed by closed questions that act as prompts 
for discussion
Finishing conversation:
·  Ask whether participants want to add a final remark to the conversation.




·  Aim of the present focus group meeting is to have a more in-depth conversation based on issues raised during the 
previous meeting 
·  All conversations are confidential
·  Conversations will be audiotaped and typed-out verbatim
·  Please avoid talking over  each other
·  Avoid non-verbal communication (i.e., nodding), since this cannot be audiotaped
The discussion during the second focus group meeting was held by using a topic list (below) based on the first focus 
group meeting. The discussion was continued by using open-questions sometimes followed by closed questions that 
act as prompts for discussion.
Topic list
Mood











How do you cope with emotions/tension?
stress
How do you experience stress?
How do you cope with stress?




Which adaptation do you need to make in your daily life, as a result of the pituitary condition of your partner?
• Problems accepting?
• Crossing own limits 
relationship
When the physical appearance of your partner has changed, how does this affect you?
When your partner has physical complaints, hoe does this affect you?
When the personality of your partner has changed, how does this affect you?
When your partner suffers from mood changes, how does this affect you?
When your partner suffers from cognitive complaints, how does this affect you?
When your partner suffers from sleep problems, how does this affect you?
Is the balance in your relationship influenced by the pituitary condition?
When this is the case, how is it affected?
• Skewed relationship?
Do you have the feeling that you need to protect your partner? When this is the case, how does this affect you?
Do you feel supported by your partner?
Is the communication between you and your partner influenced as a result of the pituitary condition? When this is the 
case, how is it affected?
Do you encounter problems with a desire to have children?
Has sexuality/intimacy changed in your relationship, when yes how does this affect you?
family
Does the pituitary condition of your partner influence your family? When this is the case how does it affect your family?
Do you feel supported by your family?
social functioning
Do you feel supported by your social network?
Is the communication between you and your social network influenced as a result of the pituitary condition? When this 
is the case, how is it affected?
How does the pituitary condition of your partner affect your social life?
How does the pituitary condition of your partner affect your social network?
employment
How does the pituitary condition of your partners affect your financial situation?
How does the pituitary condition of your partner affect your work?
unmet needs (final questions):
·  Given all of this, what would you prefer to have known / to have had after receiving the diagnosis of your ill 
partner?
·  What is your advice for someone who just received the diagnosis?
Finishing conversation:
Thank participants for their contribution
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The development and validation of the Leiden 
Bother and Needs Questionnaire for patients 
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background: Patients report persisting impairment in Quality of Life (QoL) after treatment 
for pituitary disease. At present, there is no questionnaire to assess (a) whether patients with 
pituitary disease are bothered by these consequences, and (b) their needs for support. 
objective: To develop and validate a disease-specific questionnaire for patients with pitu-
itary disease which incorporates patient perceived bother related to the consequences of the 
disease, and their needs for support.
Methods: Items for the Leiden Bother and Needs Questionnaire for patients with pituitary 
disease (LBNQ-Pituitary) were formulated based on results of a recent focus group study 
(n=49 items). 337 patients completed the LBNQ-Pituitary and six validated QoL question-
naires (EuroQoL-5D, SF-36, MFI-20, HADS, AcroQol, CushingQoL). Construct validity was 
examined by exploratory factor analysis. Reliabilities of the subscales were calculated with 
Cronbach’s alphas, and concurrent validity was assessed by calculating Spearman’s correla-
tions between the LBNQ-Pituitary and the other measures. 
results: Factor analyses produced five subscales (i.e. Mood problems, Negative illness 
perceptions, Issues in sexual functioning, Physical and cognitive complaints, Issues in social 
functioning) containing a total of 26 items. All factors were found to be reliable (Cronbach’s 
alphas all ≥.765), and the correlations between the dimensions of the LBNQ-Pituitary and 
other questionnaires (all P≤.0001) demonstrated convergent validity.
conclusions: The LBNQ-Pituitary can be used to assess the degree to which patients are 
bothered by the consequences of the pituitary disease, as well as their needs for support. It 
could also facilitate an efficient assessment of patients’ needs for support in clinical practice. 
We postulate that paying attention to needs for support will lead to optimal patient care (e.g. 
improvement in psychosocial care), and positively affect QoL.




Pituitary adenomas can cause several symptoms in the physical, psychological, and social do-
main, and can be treated by surgery, drug treatment or additional radiotherapy. Symptoms 
can (partly) resolve upon treatment, but many patients will have permanent hypopituitarism 
and will require life-long multiple hormone replacement therapy and/or will experience 
remaining symptoms (1). In line with these findings, research in patients with pituitary 
diseases demonstrated that patients report Quality of Life (QoL) impairments (2), also after 
long-term remission (3-6). The increasing number of QoL studies in patients with pituitary 
disease suggests a growing interest in the patient’s perspective (7). QoL in patients with 
pituitary disease has been mainly evaluated by generic QoL questionnaires assessing sev-
eral domains, disease-specific QoL questionnaires assessing disease related QoL aspects, or 
domain-specific questionnaires assessing particular domain(s) of QoL. Disease-specific QoL 
questionnaires for pituitary diseases are available for Cushing’s syndrome (i.e. CushingQoL, 
Tuebing CD-25 (8-10)), acromegaly (AcroQoL (11-13)) and growth-hormone deficiency (QoL-
AGHDA (14)), whereas no questionnaires are available for patients with non-functioning 
pituitary adenoma or prolactinoma.
Recently, we  performed a qualitative study utilizing focus group interviews in patients 
with pituitary diseases in order to further explore the patient’s perspective on QoL (15). Issues 
raised in these conversations were compatible with items of available questionnaires, but 
other topics also emerged. New issues raised that are not covered in existing questionnaires 
were visual problems, fear of recurrence of the pituitary adenoma, problems with an altered 
personality, and lack of sympathy and understanding by others. Furthermore, patients re-
ported unmet needs regarding care, such as dissatisfaction with other aspects of medical 
care i.e. psychological support (15). In contrast to the large number of studies measuring 
QoL in patients with pituitary disease, only few studies suggest strategies to improve QoL (7). 
Exploration of the patient’s perspective is crucial in identifying potential unmet needs and 
aspects for improvement in QoL. 
Therefore, the aim of the present study was to develop and validate a new questionnaire 
aiming to assess the degree to which patients are bothered by the consequences of their 
pituitary disease, as well as their needs for support. The patient’s perspective elucidated 






Patients between 18 and 80 years old with a pituitary disease (i.e. Cushing’s disease (CD), 
acromegaly (ACRO), prolactinoma (PRL), and non-functioning adenoma (NFA)) monitored at 
our institute were invited by letter for this study (N=554). Those who did not respond were 
contacted by phone and encouraged to participate. A response was received from 408 pa-
tients (74%), but sixty-one of them (15%) denoted that they did not want to participate. Main 
reported reasons for not participating were language barrier or perceiving the questionnaire 
as being too time consuming. Eventually, 347 (63%) patients completed the questionnaires. 
Of these, 10 patients filled out less than 75% of the LBNQ-pituitary and were excluded from 
the analyses, resulting in a total number of 337 (61%) patients for inclusion. Clinical charac-
teristics of patients were derived from medical records. 
diagnosis, treatment and follow-up
Details on diagnostic criteria and criteria for remission and follow-up have been previously 
described: CD (16), ACRO (3), PRL (5), NFA (17). Essentially, international guidelines for di-
agnosis, management were followed. At the time of the current study, all patients were in 
remission or well controlled with medical treatment regimens. 
Procedure
All patients were asked to complete our newly developed questionnaire (see next para-
graph), two generic QoL questionnaires and two domain-specific questionnaires. In addition, 
patients with CD or ACRO were also asked to fill out a disease-specific QoL questionnaire 
(CushingQoL or AcroQoL, respectively). Based on the preference of the patient, question-
naires were sent by email (online survey) or by regular mail, in order to increase response 
rate.  255 patients completed the questionnaire online, 82 patients by postal survey.  Previous 
research demonstrated that paper-and-pencil and online surveys did not lead to different 
results (18).  The Medical Ethical Committee of the LUMC approved this study. 
development of lbnQ-Pituitary
The items of the Leiden Bother and Needs Questionnaire for patients with Pituitary disease 
(LBNQ-Pituitary) were derived from recent focus group conversations (15). The format of the 
LBNQ-Pituitary was based on the “Belastungsfragebogen Parkinson kurzversion (BELA-P-k)” 
(Questionnaire on psychosocial Burden and Needs for help in Parkinson’s disease) (19), which 
has been found to be valid and reliable for Dutch patients with Parkinson’s disease (20). 
Consequently, each item consists of three parts. Part A) a screening question to ask 
whether a certain complaint is present (Yes/To a certain extent/No). For some questions 
regarding fertility, their family or their partner, patients could also indicate “Not applicable”. 
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Part B) a question on the extent by which the patients is bothered by the complaint (Bothered 
by (Bb)). Part C) a question to assess how much importance patients place on the attention 
form their healthcare provider for their complaint (Needs for Support (NfS)). Part B and C were 
scored on a 5-point Likert scale (0=“not at all” to 4=“extremely”)  and (0=“not important” to 
4=“extremely important”). 
The initial LBNQ-Pituitary consisted of 49 items and one open-ended question (Supplement 
1). To establish face validity, items were reviewed by experts from the field i.e., psychologists 
(MS, NGAK, AAK) and endocrinologists (NRB, AMP). In order to confirm the content and face 
validity (i.e. relevance, comprehensibility and acceptability of the items), cognitive debriefing 
interviews with 4 patients were conducted by the investigator (CDA).
Validated questionnaires to test concurrent validity 
Generic QOL questionnaires:
EuroQoL-5D (EQ-5D) assesses the current health status reflected in five health dimensions: 
mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Scores are 
expressed on a 1-3 scale per dimension, with higher scores indicating worse QoL. The ques-
tionnaire also includes a visual analogue scale (VAS) ranging from 0 to 100 for recording an 
individual’s rating of their current health-related well-being, with higher scores indicating a 
better health status. The EQ-5D was found to be reliable and valid (21).
MOS Short Form 36 (SF-36) assesses functional status and general well-being during the 
previous month. The items cover nine health concepts: 1) physical functioning, 2) social 
functioning, 3) role limitation (physical), 4) role limitation (emotional), 5) mental health, 6) 
vitality, 7) pain, 8) general health perception, and 9) general perception of change in health. 
Scores are expressed on a 0–100 scale, and higher scores indicate a better QoL. The SF-36 has 
been found to be reliable and valid (22;23).
Domain-specific QoL questionnaires:
Multidimensional Fatigue Inventory (MFI-20) assesses fatigue, using a five-point scale. Five 
different dimensions can be calculated: 1) General fatigue, 2) Physical fatigue, 3) Reduced 
activity, 4) Reduced motivation, and 5) Mental fatigue. Scores vary from 0-20; with higher 
scores indicating greater fatigue. The MFI-20 yields adequate levels of reliability and validity 
(24).
Hospital Anxiety and Depression Scale (HADS) assesses anxiety and depressive symptoms 
and consists of 14 items on a 4-point scale, and both anxiety (7 items) and depression (7 
items) scores range from 0-21 points. Higher scores indicate more severe anxiety and/or 
depressive symptoms. A score >8 points on one of the subscales is being used to indicate 
patients as being anxious or depressed respectively (25). The HADS yields adequate levels of 




AcroQoL assesses acromegaly-related QoL and consists of 22 questions on a five-point scale. 
Three different dimensions can be calculated: 1) Physical score, 2) Psychological-appearance, 
3) Psychological-personal relations, and a total score. Lower scores indicate worse QoL. The 
AcroQoL was found to be reliable and valid (11-13). 
CushingQoL assesses Cushing-related QoL and consists of 12 questions on a five-point 
scale. The total score ranges from 12 to 60, with a lower score indicating worse QoL. The 
CushingQoL yields adequate levels of reliability and validity (10;28). 
statistics
In order to assess the construct validity of the LBNQ-Pituitary, an exploratory factor analysis 
was performed on all items using the Bothered by (Bb) scores (n = 49). We conducted ex-
ploratory factor analysis using oblique rotation. To check for multicollinearity the correlation 
matrix was studied. The Kaiser-Meyer-Olkin (KMO) measure was used to test for sampling 
adequacy. KMO can range from 0 to 1, with values near 0 indicating diffusion in the pattern 
of correlations, and values near 1 indicating compact patterns of correlation. Internal consis-
tency of the LBNQ-Pituitary dimensions was measured using Cronbach’s alpha coefficients. 
To establish concurrent validity correlations between Bb scores and scores on the other 
questionnaires were calculated. Pearson’s correlations were calculated when data were nor-
mally distributed and Spearman’s correlations were calculated when data were not normally 
distributed. Correlation coefficients ranging from .10 to .30 indicate a small effect, .30 to .50 
a medium effect, and >.50 a large effect. It was expected that scales that are conceptually 
related correlate moderately to highly with one another (convergent validity). Conversely, 
scales with a less clear or absent conceptual relation are expected to show weak correlations 
(divergent validity). In order to correct for multiple testing the Bonferroni correction was ap-
plied and the level of significance was set at P≤.0001. 
Discriminant validity was examined by LBNQ-Pituitary scores between the different pitu-
itary diseases and by using the HADS cut-off points (score>8 points). For the comparison 
between pituitary diseases an ANOVA was used when data were normally distributed and 
a Kruskal Wallis Test was used when data were not normally distributed. For the comparison 
between patients being clinically anxious or depressed, independent sample t-tests were 
used when data were normally distributed, and Mann-Whitney U tests when data were not 
normally distributed. The level of significance was set at P<.05. 




cognitive debriefing interviews 
The LBNQ-Pituitary was completed by four patients in the presence of the investigator (CDA) 
(3 men and 1 woman; mean age: 57.5±18.7 years). Patients were asked to fill-out the question-
naire and were asked about their thoughts about the questions and whether they thought 
items were missing. Patients agreed with the items and found it relevant that attention was 
being paid to the psychosocial consequences of their disease. The LBNQ-Pituitary proved to 
be feasible and there were no cues for missing items. Only question 49 ('As a consequence 
of my pituitary condition, I experience difficulties in performing my work') was adapted by 
adding the answer option 'Not applicable'.  
Patient characteristics (Table 1) 
The full survey was completed by 337 patients (61% females). The mean age of patients was 
56.8±13.7 years with a mean duration since diagnosis of 15.3±11.4 years. 











Gender (M/F) 131/206 16/56 38/38 23/69 54/43
Age (yrs) 56.8 (13.7) 54.5 (12.6) 60.6 (13.1) 50.7 (13.3) 61.3 (13.0)
Education, n (%)
    Low 108 (32%) 25 (35%) 33 (43%) 22 (24%) 28 (29%)
    Medium 97 (29%) 20 (28%) 21 (28%) 27 (29%) 29 (30%)
    High 132 (39%) 27 (37%) 22 (29%) 43 (47%) 40 (41%)
Marital status, n (%)
    Single 43 (13%) 11 (15%) 7 (9%) 15 (16%) 10 (10%)
    Relationship/marriage 262 (78%) 52 (72%) 62 (82%) 68 (75%) 80 (83%)
    Divorced 17 (5%) 7 (10%) 3 (4%) 5 (5%) 2 (2%)
    Widow 15 (4%) 2 (3%) 4 (5%) 4 4%) 5 (5%)
Pituitary surgery, n (%) 228 (68%) 53 (74%) 68 (90%) 26 (28%) 81 (84%)
Radiotherapy, n (%) 76 (23%) 22 (31%) 19 (25%) 10 (11%) 25 (26%)
Duration of follow-up (yrs) 15.3 (11.4) 16.2 (13.6) 18.7 (10.6) 16.1 (10.5) 11.3 (10.1)
Medical treatment for the pituitary disease# 231 (69%) 49 (68%) 52 (68%) 61 (66%) 69 (71%)
*21 patients were diagnosed with adrenal Cushing’s syndrome, of whom 12 were treated with bilateral adrenal-
ectomy and 10 were treated with unilateral adrenalectomy. # hormonal replacement therapy and/or suppres-




frequency of reported bother and needs for support (Table 2)
The number of patients who reported to be bothered by a certain complaint (i.e. “This prob-
lem and its consequences bother me:” 3. Considerably or 4. Extremely) were counted, as well 
as the number of patients who reported a need for support for a certain complaint (i.e. “I 
find attention from my healthcare providers to be:” 3. Considerably important or 4. Extremely 
important).  Among the most bothersome complaints, fatigue was mentioned by 63 patients 
(17%), while a larger group reported need for support regarding fatigue from their healthcare 
providers (25%). 
construct validity and reliability analysis (Table 3)
Of the initial 49 items, after factor analyses 26 items remained (see Supplement 2 for a de-
tailed description). A factor structure with five factors with eigenvalues over Kaiser’s criterion 
1 and a total explained variance of 58.5% fitted the data best. The KMO measure of sampling 
adequacy was 0.94 indicating adequate fit for factor analysis (i.e. the data are likely to factor 
well) (29). Cronbach alpha’s were calculated for each factor, and all factors were found to be 
reliable (Cronbach’s alpha .765, or higher). 
All items that fell out during factor analyses were inspected (n=23). Some items appeared 
to be of interest only for a subset of subjects, for instance, ‘Deteriorated partner relation-
ship’, ‘Worries not being able to have children’ and ‘Feeling to fail in care for family’ and were 
kept as optional items for these subjects. Furthermore, some items appeared rather disease 
specific, and of significant interest for the respective diseases; ‘Difficulties letting go of certain 
thoughts’, ‘Jealousy’, ‘Trouble accepting’, ‘Sleeping problems’, ‘Sadness’ and ‘Shame’ were more 
relevant to patients with CD, whereas ‘Negative thoughts about medication’ turned out to 
be more relevant to patients with PRL, and ‘Impaired eyesight’ more relevant to patients 
with NFA. Therefore, these items (n=8) were retained in the questionnaire and added as 
optional questions for patients with CD, PRL or NFA. The sum scores of the subscales were 
Table 2. Top-10 highest Bothers and Needs for Support
Highest bothered by (bb) n (%)  Highest needs for support (nfs) n (%)
Fatigue 63 (17%) Fatigue 84 (25%)
Difficulties in performing work 42 (12%) Afraid that pituitary tumour will recur 68 (20%)
Problems concentrating 37 (11%) Worried about physical symptoms 65 (19%)
More sensitive to stressful situations 35 (10%) Problems concentrating 62 (18%)
Pain 35 (10%) Less interested in sex 55 (16%)
Going beyond own limits 34 (10%) Mood swings 55 (16%)
Less interested in sex 34 (10%) Memory problems 54 (16%)
Physical problems during sex 34 (10%) Difficulties in performing work 52 (15%)
Sleeping problems 34 (10%) More sensitive to stressful situations 51 (15%)
Difficulties letting go of certain thoughts 33 (10%) Sleeping problems 50 (15%)
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Table 3. Results final factor analysis: factor loadings in bold














More easily irritated (20) .780 .058 .097 -.074 .034
Changes in personality (18) .595 -.137 .098 -.091 .120
Emotional reactions have changed (19) .585 -.011 .027 -.219 .049
Mood swings (12) .584 -.128 .091 -.125 .022
Anger (23) .491 -.220 -.033 .056 .227
Panic (13) .319 -.078 -.079 -.204 .224
Negative thoughts about how condition 
will progress (37)
-.028 -.809 -.018 -.040 .081
Negative thoughts about the extent to 
which the condition can be kept under 
control (38)
-.109 -.756 .043 -.029 .163
Negative thoughts about the 
consequences of the condition (36)
.135 -.678 -.050 -.027 .054
Worried about physical symptoms (16) .218 -.537 .070 -.168 -.021
Afraid that pituitary tumour will recur (17) .240 -.438 .159 .089 -.004
Less interested in sex (41) .010 .040 .822 -.063 -.056
Physical problems during sex (40) -.017 .017 .783 .018 .114
Guilt towards partner/close family (26) .200 -.170 .305 -.051 .193
Problems concentrating (6) .079 .066 .010 -.766 .097
Memory problems (8) .114 .152 -.010 -.704 .127
Fatigue (1) -.023 -.108 .185 -.694 -.096
Difficulties in doing several things at the 
same time (7)
.076 .015 .048 -.644 .137
Pain (2) -.134 -.365 .028 -.501 .022
Going beyond own limits (33) .167 -.135 .052 -.461 -.003
Changes in physical appearance (3) .093 -.174 .052 -.358 .036
Circle of friends has become smaller (45) -.127 -.017 .085 .027 .847
Loneliness (25) .195 -.051 -.087 -.110 .682
Feeling uncomfortable in social situations 
(46)
.058 -.073 .046 .001 .620
Lack of understanding of the 
consequences of the condition from 
people in social circle (47)
.074 -.028 .025 -.130 .548
Feeling the need to be alone (30) .260 -.038 .089 -.092 .421
 cronbach alfa .889 .861 .765 .876 .862
α: Cronbach’s alpha coefficient.
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all transformed to a 0-100 scale. The final LBNQ-Pituitary consisted of 26 items, which can be 
extended by three optional items being relevant for a subset of patients and eight optional 
items being relevant for a specific pituitary condition. For an overview of retained items see 
Supplement 3. 
concurrent validity (Table 4)
As expected, a higher Bb score on Mood problems was strongly associated with worse mood 
on the EQ-5D, as well as with more anxiety and more depressive symptoms (HADS) (conver-
gent validity). On the other hand, a higher Bb score on Mood problems was also strongly 
associated with more impairment in social functioning (SF-36) (less divergent validity). 
Furthermore, in patients with CD a higher Bb on Mood problems was strongly associated 
with worse disease-specific QoL.
A higher Bb score on Negative illness perceptions was strongly associated with more 
impairment in social functioning (SF-36), more anxiety and a higher total score on the HADS. 
In patients with CD a higher Bb score on Negative illness perceptions was strongly associated 
with worse disease-specific QoL.
A higher Bb score on Issues in sexual functioning was associated with more impairment 
in disease-specific QoL in patients with CD and in patients with ACRO (i.e. AcroQoL, except 
subscale Psychological appearance). 
As expected, a higher Bb score on Physical and Cognitive complaints was strongly cor-
related with more impairments in the performance of daily activities (EQ-5D), worse general 
well-being (VAS EQ-5D), more impairments in physical functioning, more physical role limita-
tions, and more pain (SF-36) (convergent validity). On the other hand, a higher Bb score on 
Physical and Cognitive complaints was also strongly associated with more impairment in 
social functioning, more emotional role limitations (SF-36), more anxiety and more depres-
sive symptoms (HADS) (less divergent validity). In addition, it was associated with worse 
disease-specific QoL in patients with CD and in patients with ACRO (i.e. AcroQoL Physical 
score and Total score) (convergent validity), whereas no significant correlations were found 
with the AcroQoL subscales Psychological-appearance and Psychological-personal relations 
(divergent validity). 
As expected, a higher Bb score on Issues in social functioning was strongly associated with 
more impairment in social functioning (SF-36) (convergent validity), whereas also high as-
sociations were found with physical and emotional role limitations (SF-36). Furthermore, a 
higher Bb score on Issues in social functioning was highly associated with more depressive 
symptoms and a higher total score on the HADS (less divergent validity). In addition, it was 
associated with worse disease-specific QoL in patients with CD and patients with ACRO (i.e. 
AcroQoL all subscales).
Finally, a higher total Bb score was strongly associated with more impairment in daily activi-
ties, worse mood (EQ-5D), worse general well-being (VAS EQ-5D), more impairment in social 
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Mobility .261 .297 .236 .275
Selfcare .232 .214 .221
Daily activity .387 .459 .304 .547 .449 .534
Pain .302 .369 .480 .337 .421
Mood .499 .440 .340 .422 .427 .501
VAS (well-being) -.496 -.482 -.335 -.596 -.413 -.599
sf-36
Physical  functioing -.358 -.433 -.244 -.518 -.418 -.483
Social functioing -.599 -.534 -.414 -.629 -.662 -.690
Role limitations   Physical -.457 -.489 -.329 -.639 -.530 -.611
Role limitations       Emotional -.492 -.406 -.328 -.569 -.531 -.561
Mental Health -.247 -.209 -.220
Vitality -.252 -.289 -.264
Pain -.372 -.432 -.240 -.559 -.436 -.505






Reduced  motivation -.220 -.245 -.220 -.265
Mental fatigue
Hads
Anxiety .598 .552 .389 .530 .471 .612
Depression .576 .493 .458 .632 .565 .670
Total score .659 .572 .469 .649 .573 .716
cushingQol -.696 -.661 -.675 -.873 -.802 -.884
acroQol
Physical score -.513 -.705 -.586 -.661
Psychological-appearance -.509
Psychological-personal relations -.593 -.525 -.563
Total score -.533 -.575 -.644 -.613
All Spearman’s correlations, P ≤ .0001. Empty cells: correlation was not significant. Bold: correlations (r ≥ .500).
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functioning, more physical and emotional role limitations, and more pain (SF-36). Likewise, 
a higher total Bb score was associated with more anxiety and more depressive symptoms 
(HADS). In addition, a higher Bb total score was associated with worse disease-specific QoL 
in patients with CD and patients with ACRO (i.e. AcroQoL, except subscale Psychological ap-
pearance). 
discriminant validity 
Between different pituitary diseases
Patients with CD reported a higher Bb and NfS score on Physical and Cognitive complaints 
compared to the other groups (ACRO, PRL, NFA) (P=.004 and P=.043, respectively). Further-
more, patients with CD reported a higher Bb score on Issues in Social functioning, as well as 
a higher Bb Total score compared to patients with PRL (P=.004 and P=.023, respectively). In 
addition, patients with CD reported a higher NfS score on Issues in Social functioning, as well 
as Total NfS compared to patients with ACRO (P=.012 and P=.034, respectively) (Supplement 
4). On all other subscales of the LNBQ-Pituitary no significant differences were found, point-
ing to a considerable overlap in perceived consequences between pituitary diseases.
Cut-off scores HADS (Figure 1a-b)
Based on the clinically used cut-off score of the HADS it was observed that 47 patients (14%) 
were clinically anxious and 45 (13%) were clinically depressed. Based on this observation, 
groups were formed (anxious vs. not anxious; depressed vs. not depressed) and the scores 
on the Bb subscales of the LBNQ-Pituitary were compared between groups. It was found that 
patients who could be classified as anxious and/or depressed (>8 points on HADS subscales 
respectively) showed higher scores on all Bb subscales, as well as the Bb Total score (P≤.0001).
dIscussIon
The present study demonstrated that the resultant factors derived from the exploratory 
factor analysis of the Bothered by (Bb) items of the LBNQ-Pituitary were in accordance with 
the themes discussed in the focus group conversations i.e. mood problems, negative illness 
perceptions, issues in sexual functioning, physical and cognitive complaints, and issues in so-
cial functioning (15). Internal consistency of these underlying dimensions was supported by 
high Cronbach’s alphas. Convergent validity was observed for the subscales Mood problems, 
Physical and Cognitive complaints and Issues in social functioning. Although divergent valid-
ity was also observed by no or weaker correlations with incongruous subscales, some strong 
correlations were observed between these LBNQ-Pituitary subscales and non-corresponding 
subscales, such as the strong correlation between Bb subscale Mood problems and Social 
functioning (SF-36). Furthermore, the LBNQ-Pituitary showed good discriminant validity 
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between patients with various pituitary disease (e.g. patients with CD reported a higher 
score on all Bb and NfS subscales compared to the other groups) and between patients being 
anxious or depressed as determined by the scores on the HADS.
Based on the results of our recent focus group study (15) it was assumed that physical and 
cognitive complaints would be identified as two separate dimensions. Surprisingly, in the 
present study physical complaints and cognitive complaints both loaded on one factor. A 
possible explanation might be that the question assessing fatigue was not explicitly divided 
into physical fatigue and mental fatigue. We speculate that specifying this item in future 
research, might result in fatigue being represented in two factors. 
The subscale Negative illness perceptions showed strong correlations with social function-
ing (SF-36) and anxiety (HADS). These correlations could be explained by previous literature 


















figure 1a. Bothered by scores of patients with vs. without anxiety
figure 1b. Bothered by scores of patients with vs. without depression.
Median and inter quartile range (IQR). HADS-A: Anxiety subscale of the Hospital Anxiety and Depression Scale. 
HADS-D: Depression subscale of the Hospital Anxiety and Depression Scale. MP: Mood Problems, NIP: Negative 
Illness Perceptions, ISeF: Issues in Sexual Functioning, PC: Physical and Cognitive complaints, ISoF: Issues in Social 
Functioning, Tot: Total score.
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showing that illness perceptions contribute to QoL in patients with pituitary disease (30;31), 
and in other patient populations (32;33). Furthermore, the subscale Issues in sexual func-
tioning showed strong correlations with disease-specific QoL (i.e. CushingQoL, AcroQoL), 
whereas only small to moderate associations were found with generic QoL measures. This is 
probably explained by the fact that both disease-specific QoL measures include items about 
sexuality, whereas the generic measures do not assess sexuality. This observation points to 
convergent validity of this subscale. Furthermore, it could be observed that scores on the 
LBNQ-Pituitary correlate highly with outcomes on the disease-specific questionnaires, which 
supports the convergent validity in terms of disease specificity.
The observation that strong correlations were observed between incongruous subscales, 
could possibly be explained by the tight connections between the domains of the biopsy-
chosocial model (34), such as that mood problems might also result in less social functioning. 
Surprisingly, the LBNQ-Pituitary showed only weak correlations with the Multidimensional 
Fatigue Inventory-20. This might also be explained by the fact that fatigue was assessed with 
just one item in the present version of the LBNQ-Pituitary. 
Furthermore, the disease-specific burden of pituitary adenomas observed in this study is 
in accordance with previous literature, with patients with CD reporting the largest negative 
impact on QoL (7;35;36). The LBNQ-Pituitary offers the possibility to assess bother and needs 
for support in people with pituitary disease in general with potential comorbid hypopituita-
rism, while it can also be used to assess aspects related to specific pituitary disease, such as 
CD or PRL. Moreover, since there are no questionnaires available for patients with NFA or PRL, 
the LBNQ-Pituitary can be used in these patient groups. 
To the best of our knowledge, no work has been published reporting a similar ques-
tionnaire to the LBNQ-Pituitary which can assess to which extent patients are bothered 
by consequences of the disease, as well as their needs for support. We postulate that this 
questionnaire will provide valuable information, in addition to already available QoL data, 
which is needed for the improvement of psychosocial care in patients with pituitary disease. 
Furthermore, the LBNQ-Pituitary can be used by clinicians to distinguish between specific 
bothers and/or specific needs for support. Awareness of patients’ needs for support could 
facilitate the translation from patients’ needs to optimal patient care. For an overview of the 
distribution of reported needs for support in our cohort, see Figure 2. Considering the fact 
that unmet needs are found to influence QoL (37), and that patients with pituitary disease 
previously reported unmet needs (e.g. “better cooperation and communication between 
medical specialties”, “absence of recognition for certain complaints”) (15), we postulate that 
paying attention to patients’ needs for support will positively affect QoL. 
In conclusion, the LBNQ-Pituitary can be used to assess whether patients are bothered 
by the consequences of the disease, as well as their needs for support. Nevertheless, future 
research is needed to further establish the psychometric properties, for instance by the use 
of a confirmatory factory analysis in another cohort in the Netherlands, but also in patients 
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from a different country and with a different language. The LBNQ-Pituitary can be used in 
clinical research (e.g. to compare bother and needs for support between groups, to evaluate 
the effect of interventions regarding bother and needs). It can also be used to facilitate the 
efficient assessment of bother and needs for support in patients with pituitary disease in 
clinical practice, and further research into this area is warranted. 
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suPPleMenT 1a. forMaT of THe lbnQ-PITuITary
suPPleMenT 1b. oVerVIeW of InITIal ITeMs*
1. As a consequence of my pituitary condition, I experience fatigue.
2. As a consequence of my pituitary condition, I experience physical pain.
3. As a consequence of my pituitary condition, I experience changes in my physical ap-
pearance.
4. As a consequence of my pituitary condition, I experience impaired eyesight.
5. As a consequence of my pituitary condition, I experience sleeping problems. 
6. As a consequence of my pituitary condition, I experience problems concentrating. 
7. As a consequence of my pituitary condition, I experience difficulties in doing several 
things at the   same time.  
8. As a consequence of my pituitary condition, I experience memory problems. 
9. As a consequence of my pituitary condition, I experience difficulties letting go of cer-
tain thoughts. 
10. As a consequence of my pituitary condition, I feel down.
11. As a consequence of my pituitary condition, I experience anxiety. 
12. As a consequence of my pituitary condition, I experience mood swings. 
13. As a consequence of my pituitary condition, I have a tendency to panic in certain situa-
tions. 
14. As a consequence of my pituitary condition, I am more sensitive to stressful situations 
than before. 
15. As a consequence of my pituitary condition, I am afraid to faint in certain situations. 
16. As a consequence of my pituitary condition, I am worried about physical symptoms. 
17. I am afraid that the pituitary tumour will recur. 
18. As a consequence of my pituitary condition, I experience changes in my personality. 
19. As a consequence of my pituitary condition, my emotional reactions have changed. 
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20. As a consequence of my pituitary condition, I am more easily irritated than before. 
21. As a consequence of my pituitary condition, my confidence has decreased.
22. As a consequence of my pituitary condition, I experience shame. 
23. As a consequence of my pituitary condition, I experience anger.
24. As a consequence of my pituitary condition, I experience sadness.
25. As a consequence of my pituitary condition, I experience loneliness.
26. As a consequence of my pituitary condition, I experience guilt towards my partner/
close family.
27. As a consequence of my pituitary condition, I experience frustration.
28. As a consequence of my pituitary condition, I experience tension. 
29. As a consequence of my pituitary condition, I experience jealousy towards other 
(healthy) people.
30. As a consequence of my pituitary condition, I sometimes feel the need to be alone for 
a while.
31. As a result of my pituitary condition, I drink more alcohol than previously.
32. I have trouble accepting my pituitary condition and its consequences.
33. I do more than is actually good for me (I go beyond my own limits).
34. I think that every (new) symptom is related to my pituitary condition. 
35. I often brood on the causes of my pituitary condition.
36. I have negative thoughts about the consequences of my pituitary condition.
37. I have negative thoughts about how my pituitary condition will progress. 
38. I have negative thoughts about the extent to which my pituitary condition can be kept 
under control. 
39. I have negative thoughts about the medication I take for my pituitary condition.
40. As a consequence of my pituitary condition, I experience physical problems during sex.
41. As a consequence of my pituitary condition, I am less interested in sex.
42. As a consequence of my pituitary condition, I worry that I will not be able to have 
children.
43. As a consequence of my pituitary condition, I feel that I am failing to adequately care 
for my family.
44. As a consequence of my pituitary condition, the relationship with my partner has 
deteriorated.
45. As a consequence of my pituitary condition, my circle of friends has become smaller.
46. As a consequence of my pituitary condition, I feel uncomfortable in social situations.
47. I experience a lack of understanding of the consequences of my pituitary condition 
from the people in my social circle. 




49. As a consequence of my pituitary condition, I experience difficulties in performing my 
work.
50. Other problems that I experience: ... (Please also indicate whether you need attention for 
or coaching in dealing with these problems)
*The Dutch items of the LBNQ-Pituitary were translated by using a forward-backward method 
i.e., items were first translated into English, and then the English items were translated back 
into Dutch. Discrepancies were discussed. Then the English items of the LBNQ-Pituitary were 
presented to seven native English patients being monitored at the department of diabetes 
and Endocrinology of the University College London Hospital (UK). 
suPPleMenT 2. descrIPTIon of facTor analyses
The first factor analysis was conducted on the initial 49 items. Ten factors had eigenvalues 
over Kaiser’s criterion of 1 and in combination explained 59.8% of the variance. Items with 
initial statistics (communalities) <0.30 were excluded (n=8: Difficulties letting go of certain 
thoughts (9), Negative thoughts about medication (39), Jealousy (29), Limitations in engag-
ing hobbies (48), Deteriorated partner relationship (44), Every (new) symptom being related 
to condition (34), Sadness (24), Trouble accepting (32)). After excluding these variables, we 
re-ran the factory analysis.
This second factor analysis was conducted on 41 items. Nine factors had eigenvalues over 
Kaiser’s criterion of 1 and in combination explained 59.9% of the variance. Items with initial 
statistics (communalities) <0.30 were excluded (n=4: Feeling down (10), difficulties perform-
ing work (49), afraid to faint in certain situations (15), drinking more alcohol than previously 
(31)). After excluding these variables, we re-ran the factory analysis.
This third factor analysis conducted on the 37 items, indicated eight factors with eigen-
values over Kaiser’s criterion of 1 and in combination explained 60.7% of the variance. Items 
with initial statistics (communalities) <0.30 were excluded (n=1: Worries not being able to 
have children (42)). After excluding this variable, we re-ran the factory analysis.
The fourth factor analysis on 36 items indicated seven factors with eigenvalues over Kaiser’s 
criterion of 1 and in combination explained 60.8% of the variance. Items with initial statistics 
(communalities) <0.30 were excluded (n=2: Feeling to fail in care for family (43), Impaired 
eyesight (4)). After excluding these variables, we re-ran the factory analysis.
This fifth factor analysis on 34 items indicated seven factors with eigenvalues over Kaiser’s 
criterion of 1 and in combination explained 62.7% of the variance. Items which loaded on 
more than one factor and with differences in factor loadings <.05 were excluded from the 
analysis (n=2: Frustration (27), Sleeping problems (5)). After excluding these variables, we 
re-ran the factory analysis.
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This sixth factor analysis on 32 items indicated six factors with eigenvalues over Kaiser’s 
criterion of 1 and in combination explained 61.0% of the variance. Items which loaded on 
more than one factor and with differences in factor loadings <.05 were excluded from the 
analysis (n=1: Brood on causes of condition (35)). After excluding this variable, we re-ran the 
factory analysis.
This seventh factor analysis on 31 items indicated six factors with eigenvalues over Kaiser’s 
criterion of 1 and in combination explained 61.6% of the variance. Items which loaded on 
more than one factor and with differences in factor loadings <.05 were excluded from the 
analysis (n=1: More sensitive to stressful situations than before (14)). After excluding this 
variable, we re-ran the factory analysis.
This eighth factor analysis on 30 items indicated six factors with eigenvalues over Kaiser’s 
criterion of 1 and in combination explained 61.6% of the variance. Items which loaded on 
more than one factor and with differences in factor loadings <.05 were excluded from the 
analysis (n=1: Shame (22)). After excluding this variable, we re-ran the factory analysis.
This ninth factor analysis on 29 items indicated six factors with eigenvalues over Kaiser’s 
criterion of 1 and in combination explained 61.1% of the variance. Items which loaded on 
more than one factor and with differences in factor loadings <.05 were excluded from the 
analysis (n=1: Tension (28)). After excluding this variable, we re-ran the factory analysis.
This tenth factor analysis on 28 items indicated five factors with eigenvalues over Kaiser’s 
criterion of 1 and in combination explained 58.3% of the variance. Items which loaded on 
more than one factor and with differences in factor loadings <.05 were excluded from the 
analysis (n=1: Confidence has decreased (21)). After excluding this variable, we re-ran the 
factory analysis.
This eleventh factor analysis on 27 items indicated five factors with eigenvalues over Kai-
ser’s criterion of 1 and in combination explained 58.2% of the variance. Items which loaded 
on more than one factor and with differences in factor loadings <.05 were excluded from the 
analysis (n=1: Anxiety (11)). After excluding this variable, we re-ran the factory analysis.
The twelfth and final factor analysis on 26 items indicated five factors with eigenvalues 
over Kaiser’s criterion of 1 and in combination explained 58.5% of the variance. Kaiser-Meyer-
Olkin (KMO) measure was 0.94 (‘superb’), indicating adequate sample size (29). These five 
factors were retained in the final analysis. Cronbach’s α were calculated for each factor, and 
all factors were found to be reliable (> .765).
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suPPleMenT 3. ITeMs reTaIned In THe lbnQ-PITuITary
subscale Item (item nr.)
1. Mood problems More easily irritated (20)
Changes in personality (18)




2. negative illness perceptions Negative thoughts about how condition will progress (37)
Negative thoughts about the extent to which the condition can be kept 
under control (38)
Negative thoughts about the consequences of the condition (36)
Worried about physical symptoms (16)
Afraid that pituitary tumour will recur (17)
3. Issues in sexual functioning Less interested in sex (41)
Physical problems during sex (40)
Guilt towards partner/close family (26)
4. Physical & cognitive complaints Problems concentrating (6)
Memory problems (8)
Fatigue (1)
Difficulties in doing several things at the same time (7)
Pain (2)
Going beyond own limits (33)
Changes in physical appearance (3)
5. Issues in social functioning Circle of friends has become smaller (45)
Loneliness (25)
Feeling uncomfortable in social situations (46)
Lack of understanding of the consequences of the condition from people 
in social circle (47)
Feeling the need to be alone (30)
relevant for a subset of patients Worries not being able to have children (42)
Feeling to fail in care for family (43)
Deteriorated partner relationship (44)
additional items cd Difficulties letting go of certain thoughts (9)
Jealousy (29)




additional items Prl Negative thoughts about medication (39)
additional items nfa Impaired eyesight (4)
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Mood problems 12.5 (0.0-29.2) 4.2 (0.0-12.5) 6.3 (0.0-29.2) 4.2 (0.0-25.0) .169
Negative illness perceptions 10.0 (5.0-20.0) 5.0 (0.0-15.0) 5.0 (0.0-18.8) 5.0 (0.0-20.0) .118
Issues in sexual functioning 8.3 (0.0-25.0) 0.0 (0.0-25.0) 8.3 (0.0-25.0) 0.0 (0.0-25.0) .313
Physical and Cognitive 
complaints
25.0 (8.0-46.4)b, c, d 16.1 (4.5-34.8)a 14.3 (3.6-25.0)a 10.7 (3.6-30.4)a .004
Issues in Social functioning 5.0 (0.0-20.0)b 0.0 (0.0-5.0) 0.0 (0.0-10.0)a 0.0 (0.0-5.0) .004
Total bothered by 15.4 (7.7-29.8)b 7.7 (2.9-17.3) 10.6 (1.2-19.7)a 7.7 (2.3-22.1) .023
needs for support
Mood problems 12.5 (0.0-41.7) 4.2 (0.0-16.7) 8.3 (0.0-36.5) 8.3 (0.0-29.2) .163
Negative illness perceptions 15.0 (5.0-25.0) 10.0 (0.0-20.0) 10.0 (0.0-23.8) 10.0 (0.0-30.0) .072
Issues in sexual functioning 8.3 (0.0-25.0) 0.0 (0.0-25.0) 0.0 (0.0-33.3) 0.0 (0.0-25.0) .364
Physical and Cognitive 
complaints
25.0 (4.5-56.3)b, c, d 14.3 (3.6-31.3)a 14.3 (0.0-32.1)a 14.3 (0.0-32.1)a .043
Issues in Social functioning 5.0 (0.0-23.8)d 0.0 (0.0-5.0)a 0.0 (0.0-10.0) 0.0 (0.0-10.0) .012
Total Needs for Support 20.2 (6.0-32.5)d 8.7 (1.9-19.2)a 11.1 (1.0-27.9) 8.7 (3.4-24.5) .034
Data is presented as median and inter quartile range (IQR). Non-parametric Kruskal Wallis Test, P<.05. 
*21 patients were diagnosed with adrenal Cushing’s syndrome, of whom 12 were treated with bilateral adrenalec-
tomy and 10 were treated with unilateral adrenalectomy. CD: Cushing’s disease; ACRO: acromegaly; PRL: prolac-
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context: Patients with pituitary disease report impairments in Quality of Life (QoL) despite 
optimal biomedical care. Until now, the effects of a self-management intervention (SMI) ad-
dressing psychological and social issues for these patients and their partners have not been 
studied.
objective: To examine the effects of a SMI i.e. the Patient and Partner Education Programme 
for Pituitary disease (PPEP-Pituitary).
design and subjects: A multicentre randomized controlled trial included 174 patients with 
pituitary disease and 63 partners allocated to either PPEP-Pituitary or a control group. PPEP-
Pituitary included eight weekly sessions (90 minutes). Self-efficacy, bother and needs for sup-
port, illness perceptions, coping, and QoL were assessed before the intervention (T0), directly 
after (T1), and after six months (T2). Mood was assessed before and after each session. 
results: Patients in PPEP-Pituitary reported improved mood after each session (except for 
session 1). In partners, mood only improved after the last three sessions. Patients reported 
higher self-efficacy at T1 (P=.016) which persisted up to T2 (P=.033), and less bother by mood 
problems directly after PPEP-Pituitary (P=.01), but more bother after six months (P=.001), 
although this increase was not different from baseline (P=.346). Partners in PPEP-Pituitary re-
ported more vitality (P=.008) which persisted up to T2 (P=.034). At T2, partners also reported 
less anxiety and depressive symptoms (P≤.014). 
conclusion: This first study evaluating the effects of a SMI targeting psychosocial issues in 
patients with pituitary disease and their partners demonstrated promising positive results. 
Future research should focus on the refinement and implementation of this SMI into clinical 
practice.




Patients with long-term biochemical remission of pituitary disease report impairments in 
Quality of Life (QoL) (1). Until now, little attention has been  paid to interventions aiming 
at improving psychosocial aspects of QoL (2). The need for a psychosocial intervention in 
patients with pituitary disease was supported by results of recent focus group conversations 
reporting unmet needs regarding psychosocial care. Other reported issues in these focus 
groups were fatigue, increased sensitivity to stress, anxiety, depressive symptoms, difficul-
ties communicating about the disease, and a reduced social network (3). In addition, a focus 
group study in partners of patients with pituitary disease reported that partners sometimes 
became annoyed by the tiredness and mood swings of their ill partner. Some partners felt 
they had to take on extra responsibilities at home (e.g. taking care of the children). They were 
aware of the negative consequences of the disease on their family, but they felt unable to 
cope emotionally or physically (4).
For patients with other chronic somatic diseases, psychosocial interventions, i.e. self-
management interventions (SMIs), have been developed aiming to improve well-being of 
patients (5). Self-management is defined by Barlow et al. as “the individual’s ability to manage 
the symptoms, treatment, physical and psychosocial consequences and life style changes 
inherent to living with a chronic condition. Efficacious self-management encompasses the 
ability to monitor one’s condition and to affect the cognitive, behavioural and emotional 
responses necessary to maintain a satisfactory QoL” (6). SMIs in several chronic conditions 
(e.g. asthma, diabetes and arthritis) have demonstrated a positive effect on well-being of 
patients (6). Martire et al. (2010) demonstrated that couple-oriented interventions were more 
efficacious than psychosocial interventions that only included the patient or usual care (7). 
Although self-management interventions for any chronic disease may be based on general 
theoretical constructs, the composition and focus of the SMI also depends on the type of 
disease and self-management aims, e.g. focus on the prevention of exacerbations in asthma, 
or focus  on lifestyle habits in diabetes (8).
There are only a few studies evaluating the effect of a SMI in patients with neuroendocrine 
disease. Martinez-Momblan et al. evaluated the effects of a 9-month educational nursing 
programme (5 visits) for patients with Cushing’s syndrome in a randomized controlled trial 
(n=61). This educational programme included knowledge on Cushing’s syndrome, comor-
bidities, treatment, general management, and autonomy in healthy lifestyles. Patients who 
followed this educational programme reported better disease-specific QoL, reduced pain, 
improved physical activity and a healthier lifestyle, compared to controls (9). Furthermore, 
Haugland et al. evaluated a 26-week educational programme in patients undergoing medical 
treatment for a neuroendocrine tumor in the gastrointestinal tract (n=37), and demonstrated 
improvement in physical components of QoL, reduced stress, and increased self-efficacy (10). 
These available SMI’s focus primarily on education about Cushing’s disease and its treatment 
and management (9) or education in patients with a neuroendocrine tumor in the gastro-
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intestinal tract (10).  Currently, a SMI for patients with pituitary disease and their partners 
addressing the psychosocial consequences and management of these consequences, of the 
disease  is lacking. 
Considering the patient and partner reported need for psychosocial care in pituitary 
disease, and the current lack of a SMI addressing psychological and social issues in these 
patients and their partners, the aim of the present study was to evaluate the effects of such 




This multicentre two-arm randomized controlled trial was initiated by researchers at the 
department of Medicine of the Leiden University Medical Centre (LUMC). Patients were 
randomized for the SMI or the control group; 1:1 randomization was performed by the first 
author (CDA). Partners of patients who agreed to participate (n=63) were allocated to the 
same condition as their ill partner. 
For ethical reasons, patients and partners who were randomized to the control group were 
also offered the SMI after the last measurement. The medical ethical committee of the LUMC 
approved the study, and written informed consent was obtained from all participants.
Participants (figure 1)
The recruitment was coordinated by the out-patient departments of Medicine of the LUMC 
and the Radboud University Medical Centre (Radboudumc). Exclusion criteria were: <18 or 
>75 years of age; since older patients might have more comorbidity, current psychological 
treatment, current intensive medical treatment (e.g. radiotherapy, recovery from surgery) 
and psychiatric illness. A total number of 931 patients (and their partner when applicable) 
were informed about the study and were invited to participate (i.e. 462 from the LUMC; 
469 from the Radboudumc). Reasons for not participating in the study were not speaking 
Dutch, not feeling comfortable talking in a group, too time consuming, burden too large 
(physically and/or mentally), not able to come due to other obligations (e.g. work, staying 
abroad, pregnancy, surgery), long travel distance, not perceiving problems, and no need 
for support (anymore), because patients already receive psychological counseling or previ-
ously received it, or learned to cope with their illness by themselves. One-hundred-and-eight 
patients (LUMC) and 80 patients (Radboudumc) agreed to participate. From the initial 188 
incorporated patients, fourteen patients (7%) did not fill out the questionnaires. Therefore, a 
total number of 174 patients were included. 
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development of the sMI
The SMI was based on the standardized Patient (and Partner) Education Programme ini-
tially developed for Parkinson’s disease (PEPP), and evaluated in seven European countries 
(11;12) including the Netherlands (13-15), and is currently operational in patient care. The 
programme was then adapted for Huntington’s disease (PEP-HD) (16) and was further devel-
oped and clinically tested in patients with chronic disease with psychiatric co-morbidity (17). 
Since the self-management techniques seemed to be generally applicable, the programme 
has recently been developed for patients with chronic disease in general (PPEP4ALL) (18). 
PPEP4ALL addresses psychological and social issues related to all chronic disease and uses 
techniques from cognitive behavioural therapy such as cognitive restructuring, systematic 
relaxation training, situational behavioural analyses, and training in social skills. 
In order to assess whether PEPP was also suitable for patients with pituitary disease, focus 
group conversations in patients with pituitary disease were performed (3). The focus group 
guided us in laying the priorities and preferred options (e.g. fatigue, cognitive complaints, and 
problems with sexuality) within the PPEP4ALL. Based on these results we hypothesized PEPP/
PPEP4ALL (Figure 2) would also be of relevance for patients with pituitary disease and their 
partners (when applicable). Then, we pilot tested it in 28 patients and 6 partners. Patients and 
partners reacted positively to the programme. Therefore, we decided to evaluate PPEP4ALL 
with the preferred options fatigue, cognitive complaints, and problems with sexuality. It was 
not necessary to drop any of the other components of PPEP4ALL and considering the patient 
group we named it the ‘Patient and Partner Education Programme for Pituitary disease (PPEP-
Pituitary)’.




PPEP-Pituitary includes self-management components of potential relevance for pituitary 
disease, i.e. fatigue management, stress management, dealing with anxiety and depression, 
and communication training (Supplement 1). The programme consisted of eight weekly ses-
sions of 90 minutes moderated by psychologists and medical social workers. Patients and 
partners participated separately and from their own perspective, in groups of 5-7 participants 
at the LUMC or at the Radboudumc. The same one or two trainers guided each group for 8 
weeks (CDA, SM, RM, NF, MP-D, RG, JL, MS, MV). All trainers were trained in/experienced with 
the PPEP/PPEP4ALL, and followed a one-day training to get familiar with the disease-specific 
focus on pituitary disease. 
Procedure 
All included participants were asked to fill-out questionnaires prior to the programme (T0). 
Next, participants in PPEP-Pituitary followed the 8-week SMI, while the participants in the 
control group were invited for a single (optional) information meeting in week 4 or 5. For the 
formation of the patient groups, groups were stratified by disease in 3 groups i.e. 1) Cushing’s 
disease (CD), 2) acromegaly or 3) prolactinoma/non-functioning pituitary adenoma (NFA)/
FSH-adenoma/craniopharyngeoma/hypopituitarism due to other causes. Partners in PPEP-
figure 2. The themes and aims of the PPEP-Pituitary.
Figure derived from from A’Campo et al. (2010) (13).
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Pituitary were not stratified by pituitary disease of their partner. Participants were asked to 
fill-out the questionnaires again after the 8-week intervention (T1) and 6 months later (T2). 
Demographic characteristics (i.e. age, gender, marital status, education) and medication 
use were assessed by a self-report. Clinical characteristics of patients (e.g. type of pituitary 
disease, duration of follow-up) were derived from medical records.
Measures
For an overview of the used measures see Table 1. 
Based on the preference of participants, questionnaires were sent by email (online survey) 
or by regular mail, to increase the response rate. Hundred-nine patients and 53 partners 
completed the questionnaires online, and 65 patients and 10 partners by postal survey. 
Previous research demonstrated that paper-and-pencil and online surveys do not lead to 
different results (19). Partners completed the same questionnaires except the LBNQ-Pituitary, 
the EQ-5D, the IPA, and the disease-specific QoL questionnaires (i.e. AcroQoL, CushingQoL). 
In addition, patients and partners in the PPEP-Pituitary group were asked to fill-out an evalu-
ation form about PPEP-Pituitary (Supplement 2).
statistical analyses
Data were analyzed using PASW Statistics version 20.0.0 (SPSS Inc., Chicago, IL). To check the 
normality of data, the Kolmogorov-Smirnov test was used. Demographic characteristics and 
the baseline scores (Supplement 3) were compared using independent sample t-test and 
Chi-square test when data were normally distributed and by using Mann-Whitney U test and 
Fisher’s exact when data were not normally distributed. To compare pre- and post-session 
mood ratings paired sample t-tests were used. A linear mixed model with random participant 
effect, and fixed time and group effects, as well as group by time interactions measured the 
effects of the programme. The linear mixed model enables accommodating missing data 
points (20), and corrects for potential baseline differences. The effects of the programme were 
evaluated following intention to treat (ITT) principles, including all participants. Although 
ITT analysis is the golden standard for analyzing an RCT, it is also considered conservative 
(21) since not all participants in PPEP-Pituitary attended all sessions. Therefore, the post-hoc 
analyses comprised the clinical sample analyses including only the patients that attended 
at least six sessions, since this is the minimum amount of sessions to consider that someone 
completed PPEP-Pituitary, and since this situation will be more similar to the clinical situ-
ation. This analysis was performed using the same linear mixed model. The data from the 
evaluation were analyzed descriptively. Due to the explorative nature of this study, the level 
of significance was set at P<0.05. However, to take into account the effect of multiple testing, 





























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































baseline characteristics (Table 2)
Of the 188 patients incorporated, 94 patients were allocated to PPEP-Pituitary and 94 patients 
to the control group.  Fourteen patients (8 in PPEP-Pituitary and 6 in the control group) did 
not complete any of the questionnaires and were not included in the ITT analysis. Therefore, 
a final number of 174 patients were included in the ITT analysis (PPEP-Pituitary: n=86 and 
control group: n= 88). Seventy percent of the patients (n=60) in PPEP-Pituitary attended at 
least 6 sessions i.e. the clinical sample. 
From this clinical sample, 12 patients (20%) attended 6 sessions, 24 patients (40%) attended 
7 sessions, and another 24 patients (40%) attended all 8 sessions. 
From the patients in the control group, 42 patients (48%) attended the optional informa-
tion meeting. Furthermore, 70% of the patients were married or in a relationship (n=122), and 
63 partners (52%) were willing to participate. Twenty-five partners were in the PPEP-Pituitary 
group and 38 partners in the control group. From the partners in PPEP-Pituitary, 52% (n=13) 
attended at least 6 sessions (i.e. the clinical sample). From the partners in the control group, 
16 (42%) attended the optional information meeting.
Mood changes after each PPeP-Pituitary session (Table 3)
Patient reported mood improved significantly after each session (all P<.001), except for ses-
sion 1. Partners’ mood improved only after sessions 6, 7, and 8 (all P≤.030).
effects of intervention: Intention to treat analysis (Table 4)
Self-efficacy
For patients a significant interaction was found for self-efficacy (GSE) (P=.020), with PPEP-
Pituitary reporting more self-efficacy compared to controls (difference 1.35, P=.016) (T1 vs. 
T0), which persisted up to the 6 month follow-up (difference 1.74, P=.033) (T2 vs T0). No 
significant difference in self-efficacy was observed in partners.
Bother and Needs for support 
An interaction was found for being bothered by mood problems (LBNQ-Pituitary) (P=.002), 
with PPEP-Pituitary, reporting to be less bothered by mood problems compared to controls 
(difference -6.27, P=.010) (T1 vs. T0). At T2 relative to T1, PPEP-Pituitary reported more bother 
by mood problems compared to controls (difference 8.71, P=.001), but this increase at T2 was 
not significantly different from baseline (difference 2.44, P=.346). Furthermore, an interaction 
was observed on the Total score of the Bothered by items of the LBNQ-Pituitary (P=.028), 
with PPEP-Pituitary reporting more overall bother (total score) at T2 relative to T1 compared 
to controls (difference 4.58, P=.008), but this increase at T2 was also not significantly different 
from baseline (difference 2.20, P=.219). 
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Table 2. Demographic variables of patients and partners














Gender (M/F) 33/53 31/57 .667 17/8 18/20 .107
Age (years) 52.7 (11.9) 53.4 (12.7) .600 55.7 (10.6) 58.9 (9.9) .298
Condition-condition of ill partner .866 .835
    Cushing’s disease 21 (24%) 19 (22%) 7 (28%) 6 (16%)
    Acromegaly 12 (14%) 10 (11%) 5 (20%) 7 (18%)
    Prolactinoma 18 (21%) 20 (23%) 3 (12%) 9 (24%)
    NFA 27 (31%) 30 (34%) 8 (32%) 13 (34%)
    FSH-adenoma 0 (0%) 1 (1%) 0 (0%) 0 (0%)
   Craniopharyngeoma 5 (6%) 3 (3%) 2 (8%) 0 (0%)
    Hypopituitarism due to other    
    causes*
3 (4%) 5 (6%) 0 (0%) 1 (3%)
Education, n (%) .219 .238
    Low 20 (23%) 27 (31%) 4 (16%) 13 (34%)
    Medium 23 (27%) 29 (33%) 11 (44%) 11 (29%)
    High 42 (49%) 32 (36%) 10 (40%) 14 (37%)
    Unknown 1 (1%) 0 (0%) 0 (0%) 0 (0%)
Marital status, n (%) .027 NA
    Single 16 (19%) 11 (13%) 0 (0%) 0 (0%)
    Relationship/marriage 55 (64%) 67 (76%) 25 (100%) 38 (100%)
    Divorced 8 (9%) 9 (10%) 0 (0%) 0 (0%)
    Widow 7 (8%) 0 (0%) 0 (0%) 0 (0%)
    Unkown 0 (0%) 1 (1%) 0 (0%) 0 (0%)
Pituitary surgery, n (%) 60 (70%) 63 (72%) .792 NA NA NA
Radiotherapy, n (%) 19 (22%) 21 (24%) .781 NA NA NA
Duration since diagnosis (yrs) 11.7 (10.8) 13.0 (13.5) .884 NA NA NA
Hypopituitarism, n (%)
    ACTH 40 (47%) 50 (57%) .174 NA NA NA
    TSH 42 (49%) 46 (52%) .650 NA NA NA
    LH/FSH 40 (47%) 41 (47%) .992 NA NA NA
    GH 36 (42%) 40 (46%) .633 NA NA NA
   ADH 6 (7%) 8 (9%) .608 NA NA NA




No significant differences in illness perceptions (B-IPQ) were observed for patients over time. 
For partners an interaction was found for perceived treatment control (P=.025), with PPEP-
Pituitary perceiving more treatment control compared to controls (difference 3.12, P=.008) 
(T2 vs. T1), but this increase at T2 was not significant from baseline (difference 1.43, P=.230)
Coping
No significant differences in coping styles (UCL) were found for patients and partners over 
time. 
Participation and autonomy
No significant differences in participation and autonomy (IPA) were found for patients over 
time.
Quality of life
For patients no significant differences were found for QoL (i.e. EQ-5D, SF-36, MFI-20, HADS, 
CushingQoL, AcroQoL).
For partners an interaction was found for vitality (SF-36) (P=.026), with PPEP-Pituitary 
reporting more vitality compared to controls (difference 14.03, P=.008) (T1 vs. T0), which 
persisted up to the 6 month follow-up (difference 15.45, P=.034) (T2 vs. T0). Furthermore, an 
interaction was found for anxiety (HADS) (P=.035), with PPEP-Pituitary reporting less anxiety 
at T2 relative to T0 (difference -2.65, P=.014). In addition, an interaction was found for depres-
sive symptoms (HADS) (P=.012), with PPEP-Pituitary reported less depressive symptoms at T2 
relative to T0 (difference -3.47, P=.003), as well as at T2 relative to T1 (difference -2.60, P=.012). 
Finally, an interaction was found for the HADS total score (P=.005), with PPEP-Pituitary re-





session before session after session P value before session after session P value
1 69.91 (13.14) 70.94 (12.09) .384 71.15 (10.24) 71.92 (12.17) .776
2 68.03 (14.83) 74.32 (12.27) <.001* 72.00 (9.02) 73.13 (10.46) .687
3 65.27 (14.48) 73.11 (12.41) <.001* 68.75 (14.32) 74.83 (9.11) .090
4 68.96 (12.93) 75.39 (10.32) <.001* 70.58 (8.37) 73.42 (7.83) .055
5 68.77 (10.55) 73.55 (11.94) <.001* 73.60 (8.51) 73.40 (7.90) .920
6 67.96 (12.81) 73.18 (11.22) <.001* 73.00 (6.95) 77.17 (6.46) .005*
7 70.76 (10.02) 75.25 (9.43) <.001* 75.08 (7.32) 78.15 (7.03) .025*
8 70.65 (10.48) 77.93 (9.33) <.001* 73.08 (6.09) 77.54 (7.66) .030*
All data are mean (sd) * P<0.05.
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porting a lower total HADS score at T2 relative to T0 (difference -6.51, P=.002), as well as at T2 
relative to T1 (difference -4.54, P=.034) compared to controls.
Table 4. Changes in the outcome measures in patients and partners (ITT sample) 



















































































Mood problems -6.27* 8.71# 2.44 .002# NA NA NA NA
Negative illness perceptions -2.14 4.03 1.89 .176 NA NA NA NA
Issues in sexual functioning 2.92 2.02 4.94 .272 NA NA NA NA
Physical & cognitive complaints -0.77 4.66 3.89 .127 NA NA NA NA
Issues in social functioning -3.06 1.54 -1.52 .347 NA NA NA NA
Total score -2.37 4.58* 2.20 .028* NA NA NA NA
Need for support
Mood problems -4.69 8.26 3.57 .073 NA NA NA NA
Negative illness perceptions -1.92 6.33 4.41 .131 NA NA NA NA
Issues in sexual functioning 4.09 2.03 6.12 .309 NA NA NA NA
Physical & cognitive complaints 0.79 5.85 6.63 .077 NA NA NA NA
Issues in social functioning -4.38 2.75 -1.64 .199 NA NA NA NA
Total score -1.65 5.17 3.53 .078 NA NA NA NA
eQ-5d 
Mobility -0.07 0.04 -0.03 .509 NA NA NA NA
Selfcare 0.01 0.01 0.02 .904 NA NA NA NA
Daily activity -0.15 0.05 -0.10 .167 NA NA NA NA
Pain -0.03 -0.04 -0.06 .781 NA NA NA NA
Mood -0.06 -0.05 -0.10 .408 NA NA NA NA
VAS -3.63 0.84 -2.79 .352 NA NA NA NA
sf-36
Physical functioning 3.45 -4.82 -1.37 .211 1.95 7.66 9.62 .302
Social functioning 2.08 -1.92 0.17 .722 3.04 14.71 17.75 .084
Role limitations-Physical 2.39 -12.03 -9.64 .203 -6.87 29.52 22.65 .111
Role limitations-Emotional -3.31 3.19 -0.12 .831 -15.99 30.92 14.93 .156
Mental Health 1.63 -2.18 -0.55 .480 -6.26 11.61 5.35 .330
Vitality 3.14 -3.43 -0.29 .284 14.03* 1.42 15.45* .026*
Pain -2.62 -0.79 -3.40 .505 -4.42 9.57 5.15 .281
General Health -0.62 3.77 3.14 .179 2.82 -2.66 0.17 .729
Health change .03 -7.79 -7.50 .234 12.72 8.74 21.46 .083
MfI-20
General fatigue -0.37 0.40 0.03 .441 1.18 -0.58 0.61 .215
Physical fatigue 0.20 -0.42 -0.22 .389 -0.13 -0.10 -0.23 .932
Reduced activity -0.20 0.27 0.07 .731 0.44 -0.70 -0.26 .700
Reduced motivation 0.07 0.02 0.10 .961 -0.40 -0.48 -0.88 .373
Mental fatigue 0.37 1.44 1.82 .107 -0.16 -0.88 -1.04 .152
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Table 4. Changes in the outcome measures in patients and partners (ITT sample)  (continued)


















































































Anxiety -0.09 0.07 -0.02 .976 -0.91 -1.74 -2.65* .035*
Depression -0.36 0.99 0.63 .056 -0.87 -2.60* -3.47# .012*
Total score -0.50 1.20 0.71 .221 -1.97 -4.54* -6.51# .005#
b-IPQ
Consequences 0.03 0.50 0.54 .221 0.64 -0.23 0.41 .770
Timeline -0.28 0.27 -0.01 .662 -0.42 0.38 -0.04 .712
Personal control -0.46 -0.22 -0.68 .430 1.07 0.45 1.53 .504
Treatment control -0.11 0.43 0.32 .547 -1.69 3.12* 1.43 .025*
Identity -0.25 0.07 -0.18 .773 -0.24 0.79 0.55 .589
Coherence -1.12 0.47 -0.65 .491 -1.13 0.29 -0.83 .142
Emotional representations 0.68 0.05 0.73 .133 0.29 0.57 0.86 .737
Concerns -0.51 0.77 0.26 .108 -0.63 1.30 0.67 .359
ucl
Active coping -0.26 -0.27 -0.53 .808 1.25 0.84 2.09 .628
Seeking distraction 0.99 -0.16 0.83 .348 -0.88 2.48 1.60 .191
Avoiding 0.31 0.27 0.58 .711 0.35 0.36 0.71 .834
Seeking social support -0.48 0.21 -0.26 .544 0.71 -1.63 -0.92 .501
Passive coping 0.41 0.64 1.05 .281 -0.96 0.20 -0.76 .503
Expression of emotions 0.07 -0.07 0.00 .944 -0.35 0.38 0.03 .771
Fostering reassuring thoughts -0.16 -0.04 -0.20 .907 -1.31 1.63 0.33 .111
Gse
Total score 1.35* 0.39 1.74* .020* 0.45 -0.77 -0.32 .830
IPa
Autonomy indoors -0.01 .12 0.11 .247 NA NA NA NA
Familiy role -0.00 -0.03 -0.03 .956 NA NA NA NA
Autonomy outdoors -0.08 0.01 -0.07 .657 NA NA NA NA
Social life and relationships 0.06 -0.34 0.02 .694 NA NA NA NA
Work and education -0.07 0.26 0.19 .869 NA NA NA NA
cushingQol†
Psychosocial issues 4.16 -4.36 -0.20 .337 NA NA NA NA
Physical problems 3.68 -1.06 2.63 .666 NA NA NA NA
Total score 3.83 -4.07 -0.24 .304 NA NA NA NA
acroQol‡
Physical score 3.32 -15.64 -12.31 .101 NA NA NA NA
Psychological-appearance -6.72 -2.05 -8.77 .504 NA NA NA NA
Psychological-personal relations 5.65 -18.17 -12.52 .124 NA NA NA NA
Total score 1.25 -12.16 -10.91 .149 NA NA NA NA
* P<.05, # P<.005. †Only patients with Cushing’s disease; ‡Only patients with acromegaly. LBNQ-Pituitary, Leiden 
Bother and Needs Questionnaire for pituitary diseases; EQ-5D, EuroQoL-5D; SF-36, Short Form 36; MFI-20, Multidi-
mensional Fatigue Inventory; HADS, Hospital Anxiety and Depression Scale; B-IPQ, Brief Illness Perception Ques-
tionnaire; UCL, Utrecht Coping List; GSE, General Self-Efficacy Scale; IPA, Impact on Participation and Autonomy 
questionnaire. P value group x time: significance of the interaction i.e. PPEP-Pituitary vs. control group x time point 
(i.e. baseline (T0), directly after PPEP-Pituitary (T1), 6 months follow-up (T2)).
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Post-hoc analysis: clinical sample 
All findings from the ITT analyses were also observed in the clinical sample analysis (Supple-
ment 4). However, some new findings were observed. Patients in PPEP-Pituitary reported a 
higher need for support for coping with negative illness perceptions (LBNQ-Pituitary) than 
controls (difference 7.88, P=.018) at T2 relative to T1, but this increase at T2 was not signifi-
cantly different from baseline (difference 3.14, P=.422). Furthermore, PPEP-Pituitary reported 
a higher need for support for physical and cognitive problems (LBNQ-Pituitary) at T2 relative 
to T1 (difference 7.01, P=.023) which was also significantly different from baseline (difference 
7.43, P=.036). PPEP-Pituitary reported more depressive symptoms (HADS) (difference 1.17, 
P=.008) at T2 relative to T1, but this increase at T2 was not significantly different from baseline 
(difference 0.67, P=.191). Partners in PPEP-Pituitary reported better social functioning (SF-36) 
at T2 relative to T1 (difference 19.70, P=.023) compared to controls, which was also signifi-
cantly different from baseline (difference 22.30, P=.012).
Patient and partner evaluation
Of the patients who followed at least 6 sessions i.e. the clinical sample (n=60), 55 patients 
filled-out the evaluation form (92%). Ninety-five percent of the patients agreed that the 
exchange of experiences within the group was helpful, and over half of the patients (53%) 
reported a better understanding of the psychological effects of their disease. Two thirds of 
the patients (67%) reported their expectations were fulfilled, and 84% would recommend the 
programme to other patients. All partners who followed at least 6 sessions (n=13), filled-out 
the evaluation form. All partners agreed that the exchange of experiences was helpful; two 
thirds of the partners (62%) reported a better understanding of the psychological effects of 
the disease. In 54% of the partners their expectations were fulfilled and 77% would recom-
mend the programme to other partners.
dIscussIon
PPEP-Pituitary resulted in enhanced self-efficacy in patients which persisted after the 6 month 
follow-up. Perceived bother by mood problems decreased directly after PPEP-Pituitary, but 
returned to baseline level after 6 month follow-up. Partners reported more vitality immedi-
ately after PPEP-Pituitary, which was still present after 6 months. Partners also reported less 
anxiety and depressive symptoms after 6 months. Furthermore, mood improved after each 
session (except for session 1) in patients and after the last three sessions in partners. 
Similar to the results of the SMI described by Haugland et al. (10), PPEP-Pituitary enhanced 
self-efficacy in patients. The term self-efficacy is described in the ‘Social Cognitive Theory’ of 
Bandura (22) and defined as the person’s beliefs in his or her own capabilities to perform a 
certain action, in a certain environment. Following this model, behaviour is directly influenced 
by goals and self-efficacy expectations. In line with this model, several studies demonstrated 
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that self-efficacy influences self-management behaviour (23;24), as well as SMIs improving 
self-efficacy in patients with chronic disease (25;26).  For instance, Steed et al. evaluated a 
SMI which was based on the Social Cognitive Theory and demonstrated a positive effect on 
diabetes self-management behaviour, i.e. diabetes-specific-diet, exercise and blood glucose 
monitoring (27). Following Bandura, self-efficacy can be increased and behaviour change 
enhanced by four components: 1) mastery, which refers to the direct experience of success 
in performing a certain behaviour; 2) vicarious experience which refers to modelling gained 
by successful behaviour of a person with whom one identifies (e.g. person with the same 
illness); 3) social persuasion e.g. encouragement from health professionals or members of the 
self-management group; and 4) reducing feelings of stress and altering negative emotional 
tendencies, since this may lead to reducing misinterpretations of physical symptoms or one’s 
physical state (28).  All four components were used in PPEP-Pituitary. 
The results of the ITT analysis were further confirmed by the analyses including only partici-
pants that followed at least six sessions (i.e. the clinical sample). In the clinical sample analysis 
as well as in the ITT analysis we observed that depressive symptoms and bother by mood 
problems increased during 6 month follow-up after PPEP-Pituitary, although not different 
from baseline levels. Furthermore, the clinical sample analysis complemented the ITT results 
by observations that patients reported a higher need for support for coping with negative 
illness perceptions and physical and cognitive problems. This finding might be explained by 
the fact that patients in PPEP-Pituitary learned skills to concretize/verbalize their healthcare 
needs, but also suggests that it might be useful to implement one or two additional refresh-
ing/booster sessions during follow-up e.g. after 6 months or even over 12 months. On the 
other hand, partners reported an increase in social functioning 6 months after PPEP-Pituitary. 
This seems to indicate that partners needed time to implement the newly learned skills in 
their daily lives. It could also be that aspects of QoL improved in partners as a result of the 
improvement in self-efficacy in their ill partners. 
In the present study we did not observe any effects in patients on QoL, illness perceptions, 
coping, and autonomy and participation in different life domains. It should, however, be 
noted there was a relatively long duration since diagnosis (i.e. PPEP-Pituitary: 12 years, con-
trol group: 13 years). It is conceivable that during this long period of living with the disease, 
patients and partners adapted to the consequences of the disease and/or already had re-
ceived appropriate support, which may have limited the beneficial effects of our programme 
in improving psychosocial aspects. It should also be realized that although some aspects did 
not change during the time of the study, it could be that due to the learned psychosocial 
skills, patients and partners became more resilient to develop psychosocial morbidity, and 
future research into this area is warranted. 
Due to the explorative nature of the present study, a large number of outcome parameters 
was used which could have led to a higher chance of type I error. After the post-hoc Bon-
ferroni correction, the effect on mood problems in patients and the effect on anxiety and 
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depressive symptoms could still be observed. Furthermore, the large number of outcome 
parameters could also have influenced the response rate of the participants, considering 
the duration of filling-out the questionnaires. In addition, it should be acknowledged that 
self-management is by definition largely implemented by the participants themselves with 
limited external supervision. For instance, it is not known how often participants practised 
the learned skills at home. This information could have provided additional insight into the 
effects of the program, and should therefore be taken into account in future research by for 
instance asking participants to keep up a diary. Another limitation related to research in SMIs 
is that they largely rely on self-report measures. The measures used in this study were all 
validated, but probably not equal to direct observation. 
A strength of the present study is the inclusion of both patients and partners, and the 
relatively large sample size. In addition, the variability in included centres, as well as in 
trainers (n=9) (i.e. psychologist, medical social workers) increases the validity of the effect 
of PPEP-Pituitary. For future implementation of the programme in (other) medical centres, 
PPEP-Pituitary can be provided by psychologist and social workers, but also by other health 
care professionals such as endocrine nurses as long as they are trained in the principles of 
PPEP-Pituitary and have an appropriate level of knowledge about pituitary disease. Sixty-
seven percent of the patient reported that their expectation about PPEP-Pituitary were met. 
From the notes written on the evaluation forms it became apparent that patients would have 
liked more (practical, medical) information about their disease (i.e. bodily changes due to 
disease, medication, side-effects). Therefore, we are considering the invitation of an endo-
crine nurse to the first session to provide (practical) information about the disease.  For future 
implementation of PPEP-Pituitary, it is very difficult to form separate groups per disease (i.e. 
CD, acromegaly, NFA/PRL), considering the low incidence of pituitary adenomas. Therefore, 
we postulate that groups can be formed with patients with different pituitary diseases. This 
seems to be suitable considering the overlapping symptoms (i.e. hypopituitarism, fatigue), 
but on the other hand it can be imagined that for a patient it can be helpful to have at least 
one other person in the group with the same disease. Future implementation of PPEP-
Pituitary groups of patients with different pituitary diseases can be formed, but with taking 
into account the distribution of diseases per group. Furthermore, a question that needs to 
be further clarified in future research is determining the best moment to offer PPEP-Pituitary 
during the disease process. We believe that directly after biomedical treatment is not the 
right moment, because patients need their time and energy to recover from treatment, but 
also because patients will not have a clear idea about the psychosocial consequences of the 
disease making it difficult to work on during PPEP-Pituitary. On the other hand, when the pro-
gramme is offered years after biomedical treatment, patient may have learned to cope with 
the consequences and/or they had to search for psychological care by themselves. Therefore, 
we postulated that the ideal moment to offer the programme will be between 6-12 months 
after biochemical remission. It is speculated that offering the programme at that time might 
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lead to less healthcare consumption. Therefore, for future research it would be interesting to 
assess the effects of PPEP-Pituitary in a clinical setting that also includes patients that have 
recently obtained a stable medical situation. 
In conclusion, this first study about the effects of PPEP-Pituitary in a large cohort of patients 
with on average a relatively long duration since diagnosis, demonstrated that PPEP-Pituitary 
enhances self-efficacy in patients, and their partners report better QoL in the long-term. We 
postulate that implementing PPEP-Pituitary in clinical care will (at least partly) meet the cur-
rent unmet needs regarding psychosocial care in patients with pituitary disease and their 
partners. For the implementation of PPEP-Pituitary we are currently evaluating the approach 
to schedule one or two additional refreshing/booster sessions after 6 months or 12 months. 
Future research will need to focus on the implementation of this programme into clinical care 
trajectories.
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Introduction ·	 Acquaintance with each other
·	 Overview of the program is provided
·	 Participant expectations and needs are elucidated
Active information ·	 	The importance of taking an active and central role in the 
health care system
Exercise ·	 How to ask questions to healthcare professionals
Homework ·	 To draft questions for a visit to health care professionals
Appetizer Past experiences with keeping a diary/journal
2. Self-monitoring Homework discussion Homework discussion of session 1
Active information ·	 To learn about self-monitoring techniques, such as a diary
·	 	Fatigue management by self-monitoring and behavioral 
adaptations
Exercise An exercise ‘body-awareness’ focused on breathing and muscular 
tension
Homework ·	 Using a diary to record e.g. fluctuations in fatigue or mood
·	 Performing the exercise ‘body awareness’
Appetizer Bringing something pleasant to the next session (e.g. an object or 
experience)




Homework discussion Homework discussion of session 2
Active information To improve well-being through pleasant activities
Exercise Exploring pleasant activities
Homework To plan and perform one or more pleasant activities in the 
upcoming week
Appetizer Observing your own behavior in stressful situations
4. Stress-
management
Homework discussion Homework discussion of session 3
Active information The role of unrealistic and unhelpful thoughts in stressful situations
Exercise Learning to use alternative ways of thinking; Performing relaxation 
exercises to deal with stress
Homework ·	 Trying out alternative ways of thinking
·	 Relaxation training
Appetizer Observing changes of mood and causes of worry
5.  Management 






Homework discussion Homework discussion of session 4
Active information ·	 	To learn about the difference between normal feelings of 
anxiety and sadness and when they turn into anxiety disorders 
or depression -partner/caregiver overload
·	 	To learn about the role of unrealistic, unhelpful cognitions
Potential issues with a decreased libido and problems in sexual 
functioning are discussed
Exercise Positive thoughts and rewards; Maintaining health activities 
(patients/partners)
Homework ·	 Positive thoughts and rewards (patients)
·	 Thinking of a positive event (partners)
·	 Maintaining health activities (patients/partners)
Appetizer Noticing situations in which you want to express your thoughts and 
feelings but do not have the confidence to do so 
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6.  Social 
competence
Homework discussion Homework discussion of session 5
Active information Social skills to communicate are discussed
Exercise To learn about unhelpful and helpful thoughts in communication 
and ways of communication
Homework •	 	Noticing situations in which helpful thoughts contributed to a 
lack of socially competent behavior
•	 Telling someone that you have a pituitary disease
Appetizer To focus on the informal and formal support they currently have 
and what they would like to receive
7. Social support Homework discussion Homework discussion of session 6
Active information To discuss the importance of social support and how to obtain 
social support
Exercise Role play/discussion
Homework Finding sources of support and asking for support
Appetizer Reflecting about the entire program
8. Evaluation Homework discussion Homework discussion of session 7
Active information •	 	The group goes through the previous sessions and the 
program is evaluated
•	 Expectations and achievements are compared
Exercise Writing a postal card for each other and filling out the evaluation 
questionnaire
Adapted from A’Campo et al. (2010) (13). Topics are the same for patients and partner al-
though they participate in separate groups. Only session 5  has a different topic for patients 
and partners, i.e., patients learn about the management of anxiety and depression, while 
partners learn about challenges for being a partner of a patient with pituitary disease. 
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suPPleMenT 2. eValuaTIon QuesTIonnaIre
Below are statements relevant to the education programme you have just completed. For 




1.  I have received helpful information about the pituitary disease and the 
possible psychosocial problems related to the pituitary disease. 
2. The exchange of experiences and ideas within the group was helpful.
3. The information presented in the programme often confused me. 
4. I would have liked even more information to be presented.
5. Too much theoretical information was given during the programme.
6. Much of the information was new to me.
7.  My understanding of the pituitary disease and the problems associated 
with the pituitary disease has improved.
8.  I believe that I can now deal better with the problems related to the 
pituitary disease.
9. Too little practical information was given during the programme.
10. I found some of the exercises too difficult.
11.  My understanding of the psychological effects of the pituitary disease 
has improved.
12. In general, the programme fulfilled my expectations.
13.  The programme was appropriate for me.
14. I would participate in another programme of a similar nature if available.
15. I would recommend this programme to other people.
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suPPleMenT 3. baselIne scores










Bb-Mood problems 24.3 (22.5) 24.1 (21.8) NA NA
Bb-Negative illness  perceptions 18.5 (21.8) 19.1 (17.8) NA NA
Bb-Issues in sexual functioning 18.4 (24.1) 22.5 (24.4) NA NA
Bb-Physical and Cognitive  
    complaints
31.0 (25.9) 34.5 (21.9) NA NA
Bb-Issues in Social functioning 17.6 (22.8) 15.2 (18.4) NA NA
Bb-Total score 23.0 (19.7) 24.2 (17.3) NA NA
NfS-Mood problems 31.5 (27.8) 31.1 (27.1) NA NA
NfS-Negative illness perceptions 27.0 (27.5) 29.9 (26.1) NA NA
NfS-Issues in sexual functioning 21.5 (26.7) 26.4 (30.0) NA NA
NfS-Physical and Cognitive 
    complaints
36.9 (29.5) 40.8 (28.8) NA NA
NfS-Issues in Social functioning 21.9 (26.6) 19.3 (22.3) NA NA
NfS-Total score 29.1 (23.3) 30.7 (23.3) NA NA
eQ-5d 
Mobility 1.4 (0.5) 1.4 (0.5) 1.1 (0.3) 1.2 (0.4)
Selfcare 1.1 (0.3) 1.1 (0.3) 1.0 (0.0) 1.0 (0.2)
Daily activity 1.5 (0.6) 1.5 (0.5) 1.1 (0.2) 1.3 (0.4)
Pain 1.6 (0.6) 1.7 (0.6) 1.5 (0.5) 1.6 (0.6)
Mood 1.4 (0.6) 1.4 (0.5) 1.1 (0.2) 1.5 (0.5)
VAS 68.4 (15.7) 64.4 (19.9) 77.4 (13.1) 77.0 (16.4)
sf-36
Physical functioning 74.0 (26.3) 67.9 (25.1) 90.0 (16.3) 85.2 (19.9)
Social functioning 69.8 (26.3) 71.2 (23.2) 90.3 (20.4) 78.1 (25.4)
Role limitations-Physical 54.3 (43.9) 49.7 (43.9) 91.7 (25.7) 79.5 (36.0)
Role limitations-Emotional 71.5 (39.6) 71.8 (40.0) 90.7 (25.1) 75.0 (42.2)
Mental Health 65.6 (17.2) 68.8 (16.7) 80.9 (10.4) 72.1 (16.7)
Vitality 50.2 (22.0) 49.2 (21.2) 68.9 (19.0) 64.6 (19.9)
Pain 73.4 (26.7) 69.3(24.4) 90.6 (11.1) 78.9 (23.6)
General Health 50.0 (15.8) 51.4 (16.1) 31.9 (13.3) 50.4 (19.4)
Health change 54.0 (25.3) 49.7 (23.6) 50.0 (17.1) 55.2 (21.5)
MfI-20
General fatigue 11.6 (2.3) 11.6 (1.6) 12.2 (1.5) 12.0 (1.2)
Physical fatigue 13.4 (1.5) 13.5 (2.1) 12.9 (1.5) 13.0 (1.3)
Reduced activity 12.3 (2.0) 12.2 (1.9) 13.1 (2.0) 13.9 (6.2)
Reduced motivation 11.5 (2.2) 12.0 (2.0) 12.2 (1.2) 12.4 (1.9)
Mental fatigue 11.1 (1.9) 11.3 (1.8) 11.6 (0.7) 11.4 (1.7)
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Anxiety 5.8 (4.1) 5.9 (4.0) 4.0 (2.9) 6.3 (4.3)
Depression 4.6 (3.8) 5.3 (3.7) 3.3 (4.1) 4.9 (4.7)
Total score 10.4 (7.0) 11.3 (6.9) 7.3 (6.2) 11.2 (8.7)
IPQ-brief
Consequences 5.6 (2.9) 6.0 (2.6) 4.2 (3.2) 5.2 (3.3)
Timeline 8.7 (2.7) 9.2 (2.1) 9.8 (.07) 9.3 (2.5)
Personal control 5.3 (3.0) 4.8 (3.0) 5.3 (3.8) 5.1 (3.4)
Treatment control 7.3 (2.7) 7.5 (2.4) 6.9 (2.9) 7.0 (2.9)
Identity 5.8 (2.8) 5.6 (2.6) 6.2 (2.9) 6.3 (2.9)
Coherence 6.8 (2.7) 6.5 (2.2) 8.3 (1.6) 7.5 (2.1)
Emotional representations 4.2 (3.0) 5.4 (2.8) 2.5 (2.3) 4.7 (3.1)
Concerns 4.4 (2.8) 4.7 (2.7) 5.1 (3.0) 5.9 (3.2)
ucl
Active coping 18.6 (6.4) 17.5 (5.7) 20.0 (3.9) 19.0 (7.3)
Seeking distraction 17.2 (3.9) 17.5 (5.6) 15.5 (3.8) 15.8 (3.8)
Avoiding 16.1 (3.0) 17.6 (6.0) 15.3 (2.9) 15.0 (3.6)
Seeking social support 12.7 (4.0) 12.4 (3.8) 11.9 (2.1) 11.8 (3.8)
Passive coping 12.3 (3.2) 12.6 (6.6) 10.1 (2.7) 10.6 (3.0)
Expression of emotions 5.5 (1.5) 5.5 (1.7) 4.8 (1.4) 4.8 (1.1)
Fostering reassuring thoughts 12.4 (3.6) 12.5 (3.1) 11.6 (2.6) 10.8 (2.4)
Gse
Total score 29.6 (4.8) 29.8 (5.1) 33.2 (3.2) 30.4 (5.0)
IPa
Autonomy indoors 0.5 (0.6) 0.6 (0.6) NA NA
Familiy role 1.1 (1.0) 1.2 (0.9) NA NA
Autonomy outdoors 1.4 (1.1) 1.3 (0.8) NA NA
Social life and relationships 1.0 (0.7) 1.0 (0.7) NA NA
Work and education 2.3 (4.2) 3.0 (5.4) NA NA
cushingQol# 37.6 (10.6) 36.4 (8.2) NA NA
Psychosocial issues 54.1 (25.7) 49.2 (19.9) NA NA
Physical problems 51.2 (22.6) 55.1 (19.0) NA NA
Total score 53.4 (22.0) 50.7 (17.5) NA NA
acroQol^
Physical score 58.8 (16.5) 51.6 (15.6) NA NA
Psychological-appearance 52.9 (22.2) 42.0 (20.0) NA NA
Psychological-personal relations 73.1 (15.2) 76.0 (13.9) NA NA
Total score 61.5 (16.0) 58.4 (12.8) NA NA
bold P< .05. Mann-Whitney U tests. #only assessed in patients with Cushing’s disease; ^only assessed in patients 
with acromegaly. NA: not applicable.
324
Chapter 14
suPPleMenT 4. PosT-Hoc analysIs: clInIcal saMPle 
Self-efficacy
Similar to the results of the ITT analyses, a significant interaction was found for self-efficacy 
(GSE) (P=.013), with PPEP-Pituitary reporting more self-efficacy (difference 1.66, P=.007) 
compared to controls (T1 vs. T0), which persisted up to the 6 month follow-up (difference 
1.77, P=.044) (T2 vs T0). No significant difference in self-efficacy was observed in partners.
Bother and Needs for Support
Similar to the results of the ITT analyses, an interaction was revealed on being bothered 
by mood problems (P=.006), with PPEP-Pituitary reporting to be less bothered by mood 
problems compared to controls (LBNQ-Pituitary) (difference -6.67, P=.011) at T1 relative to 
T0. At T2 relative to T1 PPEP-Pituitary reported more bother by mood problems compared 
to controls (difference 8.54, P=.003), but this increase was not significantly different from 
baseline (difference 1.87, P=.483). In addition, an interaction was found for the Total bother 
score (LBNQ-Pituitary) (P=.023), with PPEP-Pituitary reporting a higher Total bother score 
compared to controls (difference 5.11, P=.006) at T2 relative to T1, but this increase was also 
not significantly different from baseline (difference 2.44, P=.193). New findings raised in the 
clinical sample analyses were that there was a significant interaction for need for support for 
negative illness perceptions (LBNQ-Pituitary) (P=.048), with PPEP-Pituitary reporting a higher 
need for support than controls (difference 7.88, P=.018) at T2 relative to T1, but this increase 
was not significantly different from baseline (difference 3.14, P=.422). Furthermore, an inter-
action was found for need for support for physical and cognitive problems (LBNQ-Pituitary) 
(P=.046), with PPEP-Pituitary reporting a higher need for support compared to controls at T2 
relative to T0 (difference 7.43, P=.036) and at T2 relative to T1 (difference 7.01, P=.023).  
Illness perceptions
Similar to the results of the ITT analyses in patients, no significant differences in illness per-
ceptions were observed (B-IPQ). 
Similar to the observations of the ITT analyses in partners, an interaction was found for 
perceived treatment control (B-IPQ) (P=.045), with PPEP-Pituitary reporting more treatment 
control compared to controls at T2 relative to T1 ( difference 3.24, P=.016), but this increase at 
T2 was not significantly different from baseline (difference 1.26, P=.360).
Coping
Similar to the observations of the ITT analyses, no significant differences in coping styles 
(UCL) were found for patients and partners. 




Similar to the observations of the ITT analyses, no significant differences in participation and 
autonomy (IPA) were found for patients.
Quality of life
In contrast to the ITT analyses in patients, a significant interaction was found for depres-
sive symptoms (HADS) (P=.027), with PPEP-Pituitary reporting more depressive symptoms 
compared to controls at T2 relative to T1 (difference 1.17, P=.008), but this increase was not 
significantly different from baseline (difference 0.67, P=.191).
Similar to the results of the ITT analyses in partners, an interaction was found for vitality 
(SF-36) (P=.029), with PPEP-Pituitary reporting more vitality compared to controls (difference 
15.70, P=.009) (T1 vs. T0), which persisted up to 6 month follow-up (difference 17.75, P=.033) 
(T2 vs. T0). Furthermore, an interaction was found for anxiety (HADS) (P=.023), with PPEP-
Pituitary reporting less anxiety at T2 relative to baseline (difference -3.10, P=.007). In addition, 
an interaction was found for depressive symptoms (HADS) (P=.025), with PPEP-Pituitary 
reporting less depressive symptoms at T2 relative to T1 (difference -2.86, P=.011), as well as at 
T2 relative to T0 (difference -3.38, P=.009). Furthermore, an interaction was found for the Total 
HADS score (P=.009), with PPEP-Pituitary reporting a lower total HADS score at T2 relative to 
T1 (difference -5.33, P=.021), as well as lower at T2 relative to T0 (difference -6.85, P=.002). A 
new finding raised in this clinical sample analysis in partners was that a significant interaction 
was found for social functioning (SF-36) (P=.036), with PPEP-Pituitary reporting better social 
functioning at T2 relative to T1 (difference 19.70, P=.023), which was also significantly differ-
ent from baseline (difference 22.30, P=.012).
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Patients with pituitary disease in a stable medical condition demonstrate persistent mor-
bidity. This thesis describes their health outcomes by using a biopsychosocial approach 
covering a continuum ranging from biological and physiological measures, to measures of 
general health perceptions, as described by the Wilson-Cleary model (1). In this chapter the 
Wilson-Cleary model will be elaborated for pituitary disease based on the health outcomes 
described in this thesis (Figure 1). 
biological and physiological variables
In clinical practice, endocrine diseases are diagnosed and followed by evaluating clinical 
signs and hormone measurements. Serum, plasma or urinary hormone concentrations are 
commonly used tools by clinicians to classify disease status in chronic care. It is well acknowl-
edged that the currently available physiological measures do not always reliable represent 
the clinical situation. A main problem is that serum hormones do not refl ect hormone action 
at the tissue level. Therefore, there is an unmet need for better biochemical measures refl ect-
ing organ specifi c physiological hormone action. In the present thesis, new/less commonly 
used biological factors – as examples of measuring hormone (action) at the tissue level - were 
assessed in patients with (previous) dysfunction of the HPA-axis, namely brain characteristics 
in patients with remission of Cushing’s disease, and scalp hair samples refl ecting long-term 
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figure 1. The Wilson and Cleary model elaborated for pituitary disease.
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Reviewing existing literature on brain characteristics in patients with Cushing’s disease 
revealed that patients with active disease demonstrated smaller hippocampal volumes, more 
cerebral atrophy, smaller volumes of the bilateral cerebellum, and decreased neurochemical 
activity in frontal and thalamic areas. Functional MRI in adults with active Cushing’s disease 
using an emotional faces task demonstrated less activation in the left anterior superior tem-
poral gyrus and higher activation in the frontal, medial, and subcortical regions during the 
identification of emotional faces. Longitudinal studies demonstrated that after correction of 
hypercortisolism, hippocampal volumes and neuronal activity increased, and brain atrophy 
regressed. Cross-sectional studies in patients with long-term remission of Cushing’s disease, 
showed no differences in hippocampal volumes between patients and healthy matched 
controls, however cortical grey matter volumes were smaller, and the cortical thickness was 
found to be decreased. Neurochemical alterations were also found in patients with long-term 
remission. Furthermore, associations were found between alterations in the brain and clinical 
and laboratory characteristics (e.g. duration of hypercortisolism, plasma cortisol, urinary free 
cortisol), as well as associations between structural and functional brain abnormalities and 
behavioural outcomes, especially in memory and mood domains (Functional status) (chapter 
2). In a study of our department it was demonstrated that patients with long-term remission 
of Cushing’s disease, when compared to matched healthy controls, demonstrated smaller 
grey matter volumes in areas in the anterior cingulate cortex, and larger grey matter volumes 
in the left posterior lobe of the cerebellum in the presence of more depressive symptoms, 
anxiety, social phobia, apathy and cognitive failure. However, no associations were found 
between brain alterations and psychological morbidity (chapter 3). A functional MRI analysis 
in the same cohort of patients revealed that these patients demonstrated hypoactivation 
of the ventromedial prefrontal cortex during processing of facial expressions (vs. scrambled 
faces), without alterations in amygdala activation. Post-hoc analyses revealed decreased 
functional coupling between the ventromedial prefrontal cortex and the posterior cingulate 
cortex. Similar to what was observed in chapter 3, no associations were found between brain 
activation and psychological morbidity (chapter 4). For an explanation of the potential 
mechanisms that underlie these alterations in specific brain areas, we presently examine 
if, and to what extent MR and GR co-localize with other receptors which enable to identify 
signalling pathways and functionally coordinated regions (2). 
Currently, the literature about brain characteristics in patients with long-term remission 
of Cushing’s disease has been extended. In the same cohort of patients described in chapter 
3 and 4, we found widespread reductions in white matter integrity though the whole brain. 
Interestingly, severity of depressive symptoms correlated with reductions in white matter 
integrity in the left uncinate fasiculus i.e. a white matter bundle connecting the limbic system 
with the frontal regions and also known to be an important connection in networks for emo-
tional regulation and stress (3).  In addition, patients with long-term remission of Cushing’s 
disease showed increased resting-state functional connectivity between the limbic network 
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and the subgenual subregion of the anterior cingulate cortex which is an important target 
side for negative feedback effects of glucocorticoids and stress-induced HPA-axis activity 
(4). These findings together with the results reported in chapter 2-4 suggest that previous 
exposure to hypercortisolism results in long-standing or even irreversible changes in the 
brain. It should be acknowledged that Cushing’s disease is associated with pituitary deficien-
cies and multisystem morbidity, which all can affect the brain. For instance, a recent study 
demonstrated that patients with remission of Cushing’s disease had a higher degree of white 
matter lesions than controls and patients with active Cushing’s disease, and that the severity 
of white matter lesions correlated with diastolic blood pressure and duration of hypertension 
(5), suggesting that the persisting comorbid increased cardiovascular risk also contributes 
to brain abnormalities. It is tempting to speculate that the observed brain alterations found 
in patients in remission of Cushing’s disease could, at least in part, explain the psychological 
morbidity (Symptom status) and subtle cognitive impairments (Functional status). Finally, it 
is plausible to assume that this specific vulnerability of specific brain regions also applies for 
patients treated with exogenous glucocorticoids (6). 
In chapter 5 a new tool to measure long-term cortisol was used and evaluated in patients 
treated for adrenal insufficiency, i.e. measuring cortisol levels in scalp hair. It was observed that 
patients with hydrocortisone replacement therapy for adrenal insufficiency showed higher 
hair cortisol levels than both patients with pituitary disease without adrenal insufficiency 
and healthy controls. Furthermore, male patients with adrenal insufficiency demonstrated 
higher hair cortisol levels compared to female patients with adrenal insufficiency while using 
the same hydrocortisone dose. In male patients higher hair cortisol levels were associated 
with higher BMI (Symptom status). Next, in the same cohort of patients we explored whether 
systemic cortisol exposure as measured in hair cortisol is reflected by QoL (chapter 6). It was 
revealed that patients reported more impairments in QoL compared to healthy controls. A 
higher daily hydrocortisone intake was associated with more impairment in QoL, but only 
a few correlations were found for hair cortisol levels, suggesting that QoL impairments in 
patients with adrenal insufficiency are not per se due to higher cortisol exposure related to 
replacement therapy.
symptom status
When changes in biological and physiological variables occur, an individual might perceive 
symptoms. Symptom status is defined by Wilson and Cleary as a patient’s perception of an 
abnormal physical, emotional, or cognitive state (1). As described in the introduction (chap-
ter 1) patients with pituitary disease can suffer from profound symptoms, which may persist 
even after long-term remission. General examples of symptoms reported by patients with 
pituitary disease are mood swings, pain, visual symptoms, fatigue, joint complaints, weight 
gain, menstrual problems in females, and erectile dysfunction in men. In the present thesis 
the examination of symptom status focussed on psychological symptoms in patients with 
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adrenal insufficiency. Moreover, during the focus group conversations somatic and psycho-
logical symptoms were explored. 
In chapter 8, psychological morbidity was examined in patients with adrenal insufficiency 
treated with hydrocortisone replacement therapy. It could be observed that patients with 
adrenal insufficiency in a stable medical condition reported more irritability and somatic 
arousal compared to healthy controls. Similar to the results of chapter 6, hydrocortisone 
intake was associated with the prevalence of psychological morbidity. In chapter 11 focus 
group conversations were described in patients with pituitary disease (i.e. Cushing’s disease, 
acromegaly, prolactinoma, NFA). The most profound symptom perceived by patients was 
fatigue. Other examples were pain, visual problems, sleeping problems, changes in physical 
appearance, physical sexual dysfunction, depressive symptoms, melancholy, mood swings, 
and anxiety. 
functional status
The symptoms patients perceive largely determine whether patients perceive issues in their 
functioning. Functional status refers to the ability of the patient to perform particular defined 
tasks. 
In the present thesis functional status was examined by the assessment of cognitive func-
tioning in patients with adrenal insufficiency. During the focus group conversations patients 
also mentioned perceived issues in several functional domains. 
Regarding cognitive functioning, it was observed that patients with adrenal insufficiency 
on long-term hydrocortisone replacement therapy performed worse on memory and execu-
tive functioning tasks compared to healthy matched controls. When patients with regular 
morning hydrocortisone intake were compared with patients that postponed their hydrocor-
tisone morning intake leading to lower cortisol levels (Biological and Physiological variables), 
we did not observe any immediate deterioration in cognitive functioning. Furthermore, psy-
chological morbidity was associated with more problems with visual memory and executive 
functioning (chapter 5). Problems in cognitive functioning were also reported in patients 
with pituitary disease during the focus group conversations (chapter 11). Furthermore, 
impairments were mentioned in physical-, sexual-, psychological- and social functioning. For 
example, patients reported to feel insecure in social situations and to experience difficulties 
is social contacts. 
General health perceptions
General health perceptions integrate all of the preceding concepts, as well as others such as 
mental health. It refers to a patient’s general perception of his/her current health. Although 
detailed perceptions of patients of overall well-being were assessed during the focus group 
conversations, their general health perceptions were less extensively examined. A frequently 
used manner to assess a patient’s general health perception is by using a visual analogue scale 
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(VAS)  ranging from 0 to 100 (or 0 to 10) and ask the patient to rate his/her general health. 
The EQ-5D questionnaire includes such a VAS (7) and was assessed in patients with adrenal 
insufficiency during the study described in chapter 8. Patients with adrenal insufficiency 
on long-term hydrocortisone replacement therapy reported a worse perceived health status 
compared to matched healthy controls. Worse perceived health status was also observed in 
patients with pituitary disease (i.e. NFA) (8).
overall quality of life
Following the Wilson-Cleary model overall QoL integrates all of the preceding concepts, with 
the influence of characteristics of the patient and the environment. As previously mentioned, 
QoL should be formulated from the patient perspective. In patients with pituitary disease 
QoL is commonly evaluated by the use of validated questionnaires, but qualitative methods 
(e.g. focus group conversations, interviews, drawings) can be used to further elaborate the 
patient perspective.
A review of the available QoL literature in patients with pituitary disease revealed the 
negative impact of pituitary disease on QoL, with patients with acromegaly or Cushing’s 
disease generally demonstrating the greatest impairment in QoL. A relatively small number 
of studies evaluated interventions aiming to improve QoL, predominantly examining phar-
macological and surgical interventions. The number of studies examining QoL in treatment 
naïve patients was limited, and only a few studies evaluated QoL in patients during long-term 
follow-up. The cause of the persistent impairment in QoL seems to be multifactorial, since a 
variety of somatic, psychological and environmental factors has been identified to influence 
QoL (chapter 9). Furthermore, the case-control study described in chapter 6 demonstrated 
that patients with adrenal insufficiency treated with hydrocortisone replacement therapy 
reported worse QoL compared to matched healthy controls. 
Although the majority of the studies on QoL and QoL-related factors used quantitative 
methods (i.e. questionnaires), only a very few used qualitative methods (i.e. interviews, focus 
group conversations), despite that qualitative methods allow to extensively explore the 
patient perspective. Therefore, in chapter 11 focus group conversations were used to define 
patient perceived QoL, and also to identify factors they perceive to contribute to QoL. Issues 
emerged that are not currently included in available disease-specific questionnaires i.e. visual 
limitations, issues with a desire to have children/family planning, fear of collapsing, fear of 
recurrence, panic, persisting thoughts, problems with an altered personality, anger, jealousy, 
sadness, frustration, difficulties in communicating about the disease, lack of sympathy and 
understanding by others, and a reduced social network. Factors that may contribute to a 
decreased QoL were less effective coping strategies, negative illness perceptions, negative 
beliefs about medicines (Characteristics of the patient), and unmet needs regarding care 
(Characteristics of the patient and the environment).
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Individual and environmental characteristics
Individual characteristics (or patient characteristics) as formulated in the Wilson-Cleary model 
cover factors such as personality, motivation, values, and preferences. Patients’ preferences or 
values refer to the value patients attach to a particular consequence of a disease. For instance, 
a particular symptom can be more burdensome to a patient, while the same symptom is not 
for another patient. Illness perceptions and beliefs about medication as formulated by the 
extended Common-Sense Model of Self-Regulation (CSM) can be categorised into values and 
preference in the Wilson-Cleary model. These preferences and values play an important role 
at several points of the Wilson-Cleary model and are particular important in understanding 
general health perceptions and overall QoL, which is in accordance with the extended CSM, 
since this model also states that illness perceptions and beliefs about medication correlate 
with QoL (Chapter 1, Figure 3).
Because the majority of the patients with pituitary disease may need lifelong medical treat-
ment and in keeping with the theory of the extended CSM (see chapter 1), we assessed illness 
perceptions and beliefs about medicines in patients with acromegaly in chapter 10. This 
study demonstrated that stronger beliefs about the necessity of somatostatin analogs were 
associated with attributing more symptoms to acromegaly, perceiving more negative conse-
quences, and lower disease-specific QoL. More concerns about the perceived side-effects of 
somatostatin analogs were associated with perceiving more variability in symptoms. During 
the focus group conversations (Chapter 11) patients also reported negative illness percep-
tions, such as the chronic time course of their disease, and they reported concerns about po-
tential side effects of their medication. In accordance, negative illness perceptions in patients 
with Cushing’s disease or acromegaly were previously reported in a quantitative study (9;10). 
Furthermore, less efficient coping strategies were reported in the focus group conversations, 
such as withdrawal and overdoing activities. These less efficient coping strategies were also 
previously observed in a quantitative study (11). A recent study in patients with Cushing’s 
disease demonstrated that these less efficient coping strategies were associated with more 
impairment in QoL (12). 
Another characteristic of the patient is the personality. Personality traits were assessed 
in chapter 6 in patients with adrenal insufficiency on long-term stable hormone replace-
ment. In this study, we did not find any differences in personality traits between patients 
and healthy matched controls. Although these results suggest that personality traits are less 
sensitive to pituitary/adrenal dysfunctions (in contrast to psychological functioning), it is 
intriguing that maladaptive personality traits have been observed in patients with long-term 
remission of Cushing’s, disease (13;14), acromegaly (15;16), prolactinoma (17), and to some 
extent in NFA(16). Therefore, one might speculate that it is more likely that the observed mal-
adaptive personality traits seen in patients with a functional pituitary adenoma are related to 
the (previous) exposure to excessive hormone levels, since the maladaptive personality traits 
were not observed in patients with primary adrenal insufficiency. 
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Environmental characteristics may underlie factors such as economical-, psychological-, 
and social support, with the last two playing an important role at General Health perception 
sand Overall Quality of Life.
During the focus group conversations patients reported unmet needs regarding care, such 
as insufficient information and no recognition for certain complaints. These unmet needs can 
be categorised under patient characteristics, since they can be influenced by personal factors. 
On the other hand, unmet needs can also be influenced by environmental characteristics 
(e.g. availability of healthcare facilities). For example, patients reported dissatisfaction with 
other aspects of medical care i.e. stress-management training, lifestyle recommendations, 
physiotherapists, dietitians, medical sports experts and psychologists. These unmet needs 
can be caused by limitations in economical supports or inadequate referral of a patient to 
healthcare professionals in other medical disciplines. It should also be acknowledged that 
some types of support (e.g. psychological-, social support) are less well developed for a spe-
cific disease as pituitary disease. Besides professional environmental factors (i.e. healthcare 
facilities), there are also personal environmental factors. The most important person in a 
patient’s social network is most of the time the spouse or partner. Therefore, the perspective 
of the partner was also elucidated by the use of focus group conversations (chapter 12). 
Partners reported worries related to the pituitary disease and negative beliefs about medica-
tion, coping challenges, relationship issues, social issues, and unmet needs regarding care. 
These observations clearly demonstrate that chronic care for patients with pituitary disease 
in not limited to the patient alone. 
Based on the focus group conversations with patients (chapter 11), a disease-specific 
patient reported outcome measure (PROM) was developed. This measure assesses to which 
extent patients are bothered by certain complaints, as well as their needs for support from 
healthcare professionals, and was named the Leiden Bother and Needs Questionnaire for 
Pituitary disease (LBNQ-Pituitary). The final LBNQ-Pituitary consists of 26 items covering 
5 subscales i.e. mood problems, negative illness perceptions, issues in sexual functioning, 
physical and cognitive complaints, issues in social functioning. These subscales were found 
to be reliable, and their validity was established by significant correlations between the 
LBNQ-Pituitary and other validated measures (chapter 13). This questionnaire can be helpful 
in addressing the unmet needs experienced by patients. 
Finally, a SMI was developed for patients with pituitary disease and their potential partners 
i.e. Patient and Partner Education Programme for pituitary disease (PPEP-Pituitary). This SMI 
was aimed to (at least partly) fulfil the unmet needs regarding support for psychological and 
social issues. PPEP-Pituitary was based on the standardized Patient and Partner Education 
Programme initially developed for patients (and partners) with Parkinson’s disease (18). A 
multicenter randomized-controlled trial revealed that patients reported more self-efficacy 
after PPEP-Pituitary which persisted after 6 months. Furthermore, patients reported less 
bother by mood problems directly after PPEP-Pituitary, however this returned to baseline 
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levels after 6 months follow-up. Partners reported more vitality, less depressive symptoms 
and more treatment control after PPEP-Pituitary which persisted to after 6 months (chapter 
14).  
future research perspectives 
With the studies described in this thesis we aimed to provide an overview of health outcomes 
in persons with pituitary disease following the concepts of the Wilson-Cleary model. Al-
though this shows health outcomes in each concept of the model, the performed studies are 
only a start of the full picture. For instance, there might be differences between the different 
pituitary/adrenal diseases, and the health outcomes are not elaborated for each disease. For 
example, (f )MRI studies were performed in patients with long-term remission of Cushing’s 
disease, but considering the present observations in patients with adrenal insufficiency, it 
would also be interesting to investigate whether, possibly similar underlying biological 
variables might also explain the impairments seen in patients with adrenal insufficiency. 
This would be very intriguing to investigate, because the actions of glucocorticoids in the 
brain appear to follow an u-shaped dose response curve (19). Furthermore, more prospec-
tive QoL studies with long-term follow-up including treatment naïve patients are needed 
to provide better insight into the time course of QoL and potential modifiers. An increased 
awareness of patients' needs for support would facilitate the translation from patients' needs 
to optimal patients' care. The reported unmet needs described in chapter 11 exemplify that 
it is plausible to assume that paying more attention to patients' needs for support will most 
likely positively affect QoL, but of course, this should be investigated in future studies (Figure 
1). Finally, the randomized, controlled trial (PPEP-Pituitary) aiming at intervening at the level 
of patient- and environmental characteristics, demonstrated both an increased self-efficacy 
in patients and better QoL in their partners. For the next steps the aim is to evaluate PPEP-
pituitary in a clinical setting with one or two additional refreshing/booster sessions after 6 
months-12 months.
clinical implications of the Wilson-cleary model
The studies described in this thesis emphasize that although patients may be in a stable 
medical condition, health issues are present at each level of the Wilson-Cleary model. By 
applying the Wilson-Cleary model to patients with pituitary disease, it can be observed that 
persistent impairments in QoL in these patients might be explained by issues at each stage 
of this model. This also provides some insight into the variety in clinical outcome with some 
patients facing severe problems, while others are not or only slightly affected. It emphasises 
that improvement in overall QoL in patients with pituitary disease needs optimal biomedical 
treatment initiating a cascade of improvement in health outcomes starting with a better 
symptom status. Further improvement of QoL should be supported by a pituitary specific 
care trajectory, including PPEP-Pituitary, in order to beneficially affect characteristics of the 
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patient and the (healthcare) environment, with the ultimate goal to optimize QoL in patients 
with long-term remission of pituitary disease.
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Patiënten met een hypofyse ziekte in een stabiele medische conditie laten aanhoudende 
morbiditeit zien. Dit proefschrift beschrijft de gezondheidsuitkomsten van deze patiënten 
vanuit een biopsychosociaal model, met biologische en fysiologische uitkomstmaten aan de 
ene kant en maten voor de gezondheidspercepties aan de andere kant, volgens het Wilson-
Cleary model (1) (Figuur 1). 
deel I: lange termijn eff ecten van de ziekte van cushing op het menselijke 
brein 
Bestaande literatuur over het brein van patiënten met actieve ziekte van Cushing laat zien 
dat er bij deze groep patiënten sprake is van een kleiner volume van de hippocampus, meer 
cerebrale atrofi e, een kleiner volume van het cerebellum (bilateraal) en verminderde neuro-
chemische activiteit in de frontaal kwab en de thalamus. Functionele MRI in volwassenen 
met actieve ziekte van Cushing waarbij gebruik werd gemaakt van een emotionele gezichten 
taak toonde verminderde activiteit in de linker anterieure superieure temporale gyrus en 
verhoogde activiteit in frontale, mediale, en subcorticale gebieden. Longitudinaal onderzoek 
laat zien dat na behandeling voor hypercortisolisme, het volume van de hypocampus en de 
neurale activiteit toeneemt en dat atrofi e van het brein afneemt. Cross-sectioneel onderzoek 
bij patiënten na langdurige remissie van de ziekte van Cushing, laat geen verschil zien in het 
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figuur 1. Wilson en Cleary model uitgewerkt voor hypofyse ziekten.
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patiënten groep was er wel sprake van een verminderde totale hoeveelheid grijze stof (cor-
ticaal en subcorticaal), een dunnere cortex en neuro-chemische afwijkingen.  De gevonden 
veranderingen in het brein bleken geassocieerd te zijn met klinische karakteristieken (bijv. 
duur van blootstelling aan hypercortisolisme, plasma cortisol, cortisol in urine) en gedrags-
matige uitkomsten, zoals geheugen en stemming (Functionele status) (Hoofdstuk 2).
In een onderzoek uitgevoerd op onze afdeling werden patiënten na langdurige remissie 
van de ziekte van Cushing vergeleken met controlepersonen die gelijk waren voor leeftijd, 
geslacht en opleidingsniveau. Dit onderzoek laat zien dat patiënten kleinere grijze stof 
volumes hadden in de anterieure cingulate cortex en grotere grijze stof volumes in de linker 
posterieure kwab van het cerebellum in vergelijking met de controlepersonen. De patiënten 
rapporteerden eveneens meer depressieve klachten, angst, sociale fobie, apathie en cogni-
tieve klachten. De gevonden veranderingen in het brein waren echter niet gerelateerd aan 
de gerapporteerd psychologische morbiditeit (Hoofdstuk 3). Een functionele MRI analyse in 
dezelfde groep patiënten en controlepersonen laat zien dat patiënten een verminderde acti-
viteit hadden in de ventromediale prefrontale cortex tijdens het verwerken van emotionele 
gezichten (i.v.m. vervormde gezichten), waarbij er geen verschil was in amygdala activiteit. 
Tevens laat een post-hoc analyse zien dat er een verminderde functionele koppeling was 
tussen de ventromedicale cortex en de posterieure cingulate cortex. Net zoals bij de obser-
vaties van hoofdstuk 3, werden er geen associaties gevonden tussen activiteit in het brein 
en gerapporteerd psychologische morbiditeit (Hoofdstuk 4). De observaties beschreven 
in hoofdstuk 2-4 suggereren dat de eerdere bootstelling aan hypercortisolisme mogelijk 
heeft geleid to veranderingen in het brein. Echter, de beschreven studies waren allen cross-
sectioneel, waardoor er geen definitieve conclusie kan worden getrokken over het bestaan 
van een causaal verband.
deel II: Klinische implicaties van bijnier insufficiëntie
In Hoofdstuk 5 hebben we een nieuwe methode om cortisol te meten over een lange 
periode geëvalueerd. Hiervoor hebben we cortisol gemeten in hoofdhaar bij patiënten die 
behandeld werden voor bijnier insufficiëntie. We vonden dat patiënten met hydrocortison 
suppletie therapie voor bijnier insufficiëntie hogere haar cortisol niveaus hadden dan 
patiënten met een hypofyse ziekte zonder bijnier insufficiëntie en gezonde controleperso-
nen. Zoals verwacht bleek dat een hogere hydrocortison dosis geassocieerd was met hogere 
haar cortisol niveaus. Uit aanvullende analyses bleek dat mannen met bijnier insufficiëntie 
hogere haar cortisol niveaus hadden in vergelijking met vrouwen, terwijl zij dezelfde dosis 
gebruikten. Dit verschil tussen mannen en vrouwen werd niet gezien bij patiënten met een 
hypofyse aandoening zonder bijnier insufficiëntie en gezonde controlepersonen. Bij de 
mannelijke patiënten waren hogere haar cortisol niveaus geassocieerd met een hogere Body 
Mass Index (BMI).  Deze observaties zouden een milde overbehandeling met hydrocortison 




In hetzelfde cohort als beschreven in hoofdstuk 5 werd vervolgens onderzocht of systemi-
sche cortisol blootstelling gemeten in hoofdhaar geassocieerd was met de door patiënten 
gerapporteerde kwaliteit van leven (Hoofdstuk 6). In dit hoofdstuk staat beschreven dat 
patiënten met bijnier insufficiëntie meer beperkingen in kwaliteit van leven rapporteren in 
vergelijking met gezonde controlepersonen. Het bleek dat een hogere hydrocortison inname 
was geassocieerd met meer beperkingen in kwaliteit van leven. Slechts enkele correlaties 
werden gevonden tussen haar cortisol niveaus en kwaliteit van leven. Deze bevindingen 
suggereren dat beperkingen in kwaliteit van leven bij patiënten met bijnier insufficiëntie 
niet per se gerelateerd zijn aan een hogere cortisol blootstelling als gevolg van hydrocortison 
suppletie therapie.
In Hoofdstuk 7 is het cognitief functioneren onderzocht van patiënten met bijnier insuf-
ficiëntie die behandeld werden met hydrocortison suppletie therapie. De resultaten laten 
zien dat patiënten slechter presteerden op geheugen taken en executieve functie taken in 
vergelijking met gezonde controlepersonen die gelijk waren voor leeftijd, geslacht en oplei-
ding. Bij de vergelijking tussen patiënten die hun gebruikelijke dosis hydrocortison hadden 
ingenomen en patiënten die hun hydrocortison inname hadden uitgesteld werd geen direct 
verschil in het cognitief functioneren gezien. Daarnaast was gerapporteerde psychologische 
morbiditeit geassocieerd met een verslechtering in het visuele geheugen en executief 
functioneren. In Hoofdstuk 8 staat beschreven dat patiënten met bijnier insufficiëntie die 
behandeld worden met hydrocortison suppletie therapie meer psychologische morbiditeit 
rapporteren en meer beperkingen in kwaliteit van leven in vergelijking met gezonde con-
trolepersonen. Er werden geen verschillen gevonden op persoonlijkheidstrekken. In over-
eenstemming met de resultaten beschreven in hoofdstuk 6, was een hogere hydrocortison 
inname geassocieerd met een hogere prevalentie van maladaptieve persoonlijkheidstrek-
ken, meer psychologische morbiditeit en meer beperkingen in kwaliteit van leven. 
deel III: de volgende stap in het verbeteren van kwaliteit van leven bij 
hypofyse ziekten
Bestaande literatuur over kwaliteit van leven van patiënten met een hypofyse ziekte laat 
zien dat kwaliteit van leven sterk negatief beïnvloed wordt door de hypofyse ziekte, waarbij 
patiënten met acromegalie of de ziekte van Cushing het meest aangedaan lijken. In de litera-
tuur wordt er gebruik gemaakt van veel verschillende vragenlijsten om kwaliteit van leven te 
meten. Een relatief klein aantal studies heeft interventies geëvalueerd om kwaliteit van leven 
te verbeteren, waaronder farmaceutische en chirurgische interventies. Het aantal studies 
dat kwaliteit van leven heeft onderzoek bij (nog) niet behandelde patiënten is vrij klein en 
slechts enkele studies hebben kwaliteit van leven onderzocht bij patiënten na langdurige 
follow-up. De oorzaak voor de blijvende klachten na behandeling lijkt multifactorieel te zijn, 
gezien de variatie aan somatische, psychologische en omgevingsfactoren die van invloed 
zijn op kwaliteit van leven. Een van de psychologische factoren die van invloed is op kwaliteit 
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van leven, is negatieve ziekte percepties (Hoofdstuk 9). Daarnaast is het zo dat een groot 
gedeelte van de patiënten met een hypofyse aandoening levenslang medicatie nodig heeft. 
Volgens de theorie van het ‘Extended Common-Sense Model’ (zie hoofdstuk 1), hebben zo-
wel ziekte percepties, als de opvattingen over de behandeling invloed op kwaliteit van leven. 
In Hoofdstuk 10 zijn daarom de opvattingen over de medicatie onderzocht bij patiënten 
met acromegalie. De resultaten laten zien dat sterkere opvattingen over de noodzaak van 
het gebruiken van somatostatine analogen geassocieerd is met het toeschrijven van meer 
klachten aan de ziekte, het ervaren van meer negatieve consequenties en een slechtere 
ziekte-specifieke kwaliteit van leven. Het hebben van meer zorgen over de mogelijke bijwer-
kingen van somatostatine analogen is geassocieerd met het ervaren van meer fluctuaties in 
de klachten. 
In Hoofdstuk 11 werd gebruik gemaakt van focus groep gesprekken om kwaliteit van 
leven van patiënten met een hypofyse ziekte verder in kaart te brengen. Onderwerpen die 
tijdens de gesprekken naar voren kwamen, die tot op heden niet in ziekte-specifieke kwali-
teit van leven lijsten zijn opgenomen, waren problemen met het gezichtsveld, problemen 
rondom een kinderwens, angst om flauw te vallen, angst dat de hypofyse tumor weer terug 
komt, paniek, aanhoudende gedachten, problemen met een veranderde persoonlijkheid, 
boosheid, jaloezie, verdriet, frustratie, moeilijkheden bij de communicatie over de aandoe-
ning, onbegrip vanuit de omgeving en een kleiner sociaal netwerk. Factoren die mogelijk 
van invloed zijn op kwaliteit van leven waren minder efficiënte coping strategieën, negatieve 
ziekte percepties, negatieve opvattingen over de medicatie en 'unmet needs' met betrek-
king tot de zorg. Naast focus groep gesprekken met patiënten hebben we ook focus groep 
gesprekken gevoerd met partners van patiënten, omdat dit vaak de belangrijkste persoon 
in iemands omgeving is (Hoofdstuk 12). In de gesprekken met partners kwam naar voren 
dat zij zich zorgen maken over de hypofyse ziekte en negatieve opvattingen hebben over de 
medicatie. Zij ervaren uitdagingen in het omgaan met de gevolgen van de ziekte, problemen 
in de relatie, sociale problemen en ‘unmet needs’ met betrekking tot de zorg.
Op basis van de focus groep gesprekken met patiënten (Hoofdstuk 11) hebben we ver-
volgens een ziekte-specifieke vragenlijst ontwikkeld en geëvalueerd (Hoofdstuk 13). Deze 
vragenlijst meet in hoeverre patiënten belast worden door hun ziekte en in hoeverre zij be-
hoefte hebben aan ondersteuning/hulp van gezondheidszorgprofessionals. Deze vragenlijst 
heet de Leiden Bother and Needs questionnaire for pituitary disease (LBNQ-Pituitary). Deze lijst 
bevat 26 items en 5 subschalen; stemmingsproblemen, negatieve ziekte percepties, proble-
men in het seksueel functioneren, fysieke en cognitieve problemen, problemen in het sociaal 
functioneren. De resultaten laten zien dat de subschalen betrouwbaar zijn. De validiteit van 
de vragenlijst werd vastgesteld door de verkregen correlaties tussen de LBNQ-Pituitary en 
andere gevalideerde vragenlijsten. 
Tot slot werd in hoofdstuk 14 een zelfmanagement programma voor hypofyse patiënten 




hypofyse ziekten (PPEP-Hypofyse) is gebaseerd op een gestandaardiseerd zelfmanagement 
programma voor patiënten en partners met verschillende chronische ziekten (PPEP4ALL) 
(2). De resultaten laten zien dat de stemming van patiënten die het PPEP-Hypofyse volgde 
na elke sessie verbeterde, behalve tijdens sessie 1. Bij de partners verbeterde de stemming 
alleen tijdens de laatste drie sessies. Na het volgen van PPEP-Hypofyse rapporteerden 
patiënten meer zelfeffectiviteit en dit was ook na 6 maanden nog steeds zichtbaar. Daarnaast 
rapporteerden patiënten minder belast te worden door stemmingsproblemen direct na 
PPEP-Hypofyse, maar na 6 maanden keerde dit weer terug naar het begin niveau. Na PPEP-
Hypofyse rapporteerden partners meer vitaliteit en dit effect was na 6 maanden nog steeds 
zichtbaar. Daarnaast geven partners 6 maanden na PPEP-Hypofyse aan minder depressieve 
klachten te hebben en meer controle over de behandeling te ervaren.
slotopmerkingen
Dit proefschrift beschrijft de gezondheidsuitkomsten van hypofyse ziekten vanuit een 
biopsychosociaal benadering. Uit de studies beschreven in dit proefschrift kunnen we con-
cluderen dat:
•	 Patiënten na langdurige remissie van die ziekte van Cushing structurele en functionele 
veranderingen hebben in het brein die gepaard gaan met psychologische morbiditeit.
•	 Patiënten die behandeld worden met hydrocortison voor bijnier insufficiëntie worden 
blootgesteld aan verhoogde systemische cortisol niveaus zoals cortisol niveaus gemeten 
in hoofdhaar.
•	 Mannelijke patiënten die behandeld worden met hydrocortison voor bijnier insufficiëntie 
hebben hogere haar cortisol niveaus dan vrouwelijke patiënten terwijl zij dezelfde dosis 
gebruiken.
•	 Patiënten die behandeld worden met hydrocortison voor bijnier insufficiëntie psycholo-
gische morbiditeit rapporteren en beperkingen in kwaliteit van leven.
•	 In patiënten met bijnier insufficiëntie zijn beperkingen in kwaliteit van leven geas-
socieerd met een hogere hydrocortison inname en worden minder gereflecteerd door 
cortisol niveaus gemeten in hoofdhaar.
•	 Patiënten die behandeld worden met hydrocortison voor bijnier insufficiëntie laten milde 
cognitieve beperkingen zien in het geheugen en executief functioneren.
•	 Bij patiënten met bijnier insufficiëntie een hogere hydrocortison inname geassocieerd 
is met meer psychologische morbiditeit, meer maladaptieve persoonlijkheidstrekken en 
meer beperkingen in kwaliteit van leven. 
•	 Patiënten met een hypofyse ziekte rapporteren beperkingen in kwaliteit van leven, die 
verbeteren na behandeling, maar niet lijken te normaliseren.
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•	 Meer zorgen en sterke opvattingen over de noodzaak van medicatie in patiënten met 
acromegalie zijn geassocieerd met negatieve ziekte percepties en slechtere ziekte-
specifieke kwaliteit van leven.
•	 Partners van patiënten met een hypofyse ziekte rapporteren een negatieve impact op 
hun dagelijks leven.
•	 Patiënten rapporten meer zelfeffectiviteit na het volgen van PPEP-Hypofyse.
•	 Partners van patiënten rapporteren een positief effect op aspecten van hun kwaliteit van 
leven na het volgen van PPEP-Hypofyse.
De studies beschreven in dit proefschrift laten zien dat ondanks dat patiënten in een stabiele 
medische conditie zijn, er gezondheidskwesties kunnen zijn op elk niveau van het Wilson-
Cleary model (1). Door gebruik te maken van dit model wordt inzichtelijk dat de aanhoudende 
klachten verklaard en/of veroorzaakt kunnen worden door problemen in elke stadium van dit 
model. Hiermee geeft het ook inzicht in de grote variatie aan klinische uitkomsten tussen 
patiënten, waarbij sommige patiënten bijna dagelijks te kampen hebben met ernstige be-
perkingen, terwijl anderen dit niet ervaren of slechts licht zijn aangedaan. Het benadrukt dat 
een verbetering in kwaliteit van leven bij patiënten met een hypofyse ziekte optimale biome-
dische behandeling vraagt om zo de cascade aan verbeteringen in gezondheidsuitkomsten 
in gang te zetten. Verdere verbetering in kwaliteit van leven kan worden bevorderd door een 
hypofyse-specifiek zorgpad, waar PPEP-Hypofyse deel van uitmaakt. Op deze manier kunnen 
zowel karakteristieken van patiënt, als van de (gezondheidszorg) omgeving positief worden 
beïnvloed, met het uiteindelijke doel kwaliteit van leven van patiënten met een hypofyse 
ziekte te optimaliseren. 
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ACTH   Adrenocorticotropic hormone
ACRO   Acromegaly
ADH   Anti-diuretic hormone
BMI   Body Mass Index
CD   Cushing’s disease
CS   Cushing’s syndrome
CORThair    Hair cortisol levels
CSM   Common-Sense Model
CRH   Corticotropin-releasing hormone
DTI   Diffusion tensor imaging
fMRI   Functional magnetic resonance imaging
FSH   Follicle-stimulating hormone
GH   Growth hormone
GHD   Growth hormone deficiency
GHRH   Growth hormone releasing hormone
GnRH   Gonadotropin-releasing hormone
HPA-axis   Hypothalamic-pituitary-adrenal-axis
IGF-1   Insulin-like growth factor-1
LBNQ-Pituitary  Leiden Bother and Needs Questionnaire for Pituitary disease
LH   Luteinising hormone
MRI   Magnetic resonance imaging
NFA   Non-functioning pituitary adenoma
PAI   Primary adrenal insufficiency
PPEP-Pituitary  Patient and Partner Education Program for Pituitary disease
PRL   Prolactinoma
PRO   Patient reported outcome
PROM   Patient reported outcome measure
QoL   Quality of life
SAI   Secondary adrenal insufficiency
SMI   Self-management intervention
TRH   Thyrotropin-releasing hormone
TSH   Thyroid-stimulating hormone
VAS   Visual Analogue Scale
VBM   Voxel-based morphormetry
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